data_5sxy_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 5sxy _Structure_validation_residue.Date_analyzed 2017-05-19 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.435 ' H3 ' ' H ' ' A' ' 2' ' ' GLU . 72.3 mtm . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.435 ' H ' ' H3 ' ' A' ' 1' ' ' MET . 17.7 tp10 -167.48 54.77 0.29 Allowed Pre-proline 0 CA--C 1.533 0.297 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.091 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 67.8 Cg_endo -68.01 -18.37 46.17 Favored 'Trans proline' 0 N--CA 1.497 1.706 0 C-N-CA 122.231 1.954 . . . . 0.0 111.73 -179.654 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 26.0 p -77.35 74.67 3.92 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.145 -179.542 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -165.78 62.72 0.11 Allowed 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 115.936 -0.574 . . . . 0.0 111.126 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 51.5 m-85 -89.85 117.59 28.8 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.065 179.482 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 50.9 m -94.18 -179.91 5.1 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.259 179.676 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -64.92 -40.08 96.96 Favored Glycine 0 CA--C 1.528 0.868 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 179.789 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 57.7 m -72.65 -16.57 61.7 Favored 'General case' 0 N--CA 1.462 0.16 0 CA-C-O 120.629 0.252 . . . . 0.0 110.89 -179.728 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 54.0 t0 -71.98 114.53 10.17 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.744 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.419 ' CG2' ' HE ' ' A' ' 54' ' ' ARG . 34.6 m -94.57 126.18 48.72 Favored Pre-proline 0 CA--C 1.548 0.902 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.979 -179.025 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 83.9 Cg_endo -78.82 151.78 24.82 Favored 'Trans proline' 0 N--CA 1.495 1.591 0 C-N-CA 121.27 1.313 . . . . 0.0 111.541 179.591 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 58.2 ttt85 -157.1 130.38 7.89 Favored 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 179.187 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 68.5 mt -70.62 128.62 90.85 Favored Pre-proline 0 CA--C 1.546 0.792 0 CA-C-O 119.245 -0.407 . . . . 0.0 110.674 -179.652 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -73.83 155.9 48.53 Favored 'Trans proline' 0 N--CA 1.496 1.628 0 C-N-CA 121.472 1.448 . . . . 0.0 111.945 179.827 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 35.4 ptt180 -54.26 151.65 7.11 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.832 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 80.55 18.19 71.5 Favored Glycine 0 CA--C 1.525 0.68 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 61.9 t -135.05 133.76 53.34 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 CA-C-O 120.877 0.37 . . . . 0.0 110.321 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 83.4 mtm-85 -136.68 155.78 49.41 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.262 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 41.5 mt -92.26 144.49 25.35 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.983 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 96.7 mtt180 -140.36 141.08 35.66 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.096 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.464 ' O ' ' CD1' ' A' ' 22' ' ' PHE . 50.2 p90 -106.81 121.45 44.42 Favored 'General case' 0 N--CA 1.469 0.495 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.742 -180.0 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.456 ' O ' ' N ' ' A' ' 27' ' ' ASN . 93.8 m-20 -90.19 103.43 16.11 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.042 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.2 tt0 -64.75 -37.88 89.09 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.531 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 3.2 m -63.15 -43.96 99.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.665 -179.487 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 96.5 mtt180 -92.61 -8.13 45.07 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-O 120.684 0.278 . . . . 0.0 110.953 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.456 ' N ' ' O ' ' A' ' 23' ' ' ASP . 15.6 t-20 54.86 37.69 29.03 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.57 179.519 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.477 ' NZ ' ' O ' ' A' ' 40' ' ' LEU . 11.6 ptmm? -145.04 158.51 43.79 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 110.036 -0.357 . . . . 0.0 110.036 179.512 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.4 ' O ' ' O ' ' A' ' 40' ' ' LEU . 69.9 m80 -92.58 148.75 21.83 Favored 'General case' 0 CA--C 1.517 -0.3 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.097 179.79 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 34.1 m -136.76 153.81 30.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.289 0 CA-C-N 116.093 -0.503 . . . . 0.0 109.813 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 41.3 tp -102.37 124.03 47.21 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.779 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 46.7 tp -77.7 101.48 6.65 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 179.046 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -97.27 140.95 22.34 Favored Pre-proline 0 CA--C 1.539 0.521 0 CA-C-O 119.308 -0.377 . . . . 0.0 110.093 -179.779 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 94.3 Cg_exo -43.93 -31.63 3.89 Favored 'Trans proline' 0 N--CA 1.496 1.654 0 C-N-CA 121.316 1.344 . . . . 0.0 112.467 179.029 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -71.36 -51.01 26.54 Favored 'General case' 0 C--N 1.33 -0.269 0 C-N-CA 120.807 -0.357 . . . . 0.0 110.221 -179.292 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 69.0 ttt-85 -172.89 -98.68 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.297 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.019 179.589 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 86.4 m -166.75 151.93 7.78 Favored 'General case' 0 C--N 1.333 -0.145 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 -179.61 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 68.1 m-85 -125.92 136.13 52.68 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-O 120.905 0.383 . . . . 0.0 110.344 -179.846 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 37.3 p-10 -72.07 119.15 15.85 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.943 -0.572 . . . . 0.0 110.194 179.607 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.477 ' O ' ' NZ ' ' A' ' 28' ' ' LYS . 95.4 mt -134.23 157.4 46.36 Favored 'General case' 0 N--CA 1.471 0.58 0 CA-C-O 121.029 0.443 . . . . 0.0 110.329 -179.491 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -84.94 157.43 20.82 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.214 -179.683 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.46 ' OD1' ' N ' ' A' ' 43' ' ' ASN . 38.5 p-10 -61.31 -35.8 78.35 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.757 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . 0.46 ' N ' ' OD1' ' A' ' 42' ' ' ASP . 48.6 t30 -63.04 -39.91 96.15 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.922 -179.507 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -68.75 -36.43 78.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.473 -0.331 . . . . 0.0 110.606 -179.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 46.8 t -87.65 -19.43 7.87 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 CA-C-O 120.726 0.298 . . . . 0.0 110.658 179.635 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.449 ' N ' ' O ' ' A' ' 42' ' ' ASP . . . -58.4 -49.95 75.44 Favored 'General case' 0 CA--C 1.52 -0.173 0 CA-C-O 120.803 0.335 . . . . 0.0 110.394 -179.704 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 30.7 m -62.43 -39.31 83.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.511 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 55.4 mt -69.33 -31.46 69.93 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.372 -0.377 . . . . 0.0 110.309 179.759 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 16.4 ttmm -86.72 -30.58 21.53 Favored 'General case' 0 CA--C 1.534 0.348 0 CA-C-O 120.56 0.219 . . . . 0.0 110.842 179.39 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 57.0 tp -72.47 -32.31 66.13 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 116.472 -0.331 . . . . 0.0 110.824 -179.105 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.6 p -74.86 127.24 36.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-O 121.009 0.433 . . . . 0.0 110.717 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -68.28 -42.68 79.19 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.12 179.371 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -145.97 -99.26 0.25 Allowed Glycine 0 N--CA 1.473 1.132 0 N-CA-C 110.617 -0.993 . . . . 0.0 110.617 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . 0.419 ' HE ' ' CG2' ' A' ' 11' ' ' VAL . 84.1 mtp180 -114.86 104.65 12.15 Favored 'General case' 0 N--CA 1.471 0.615 0 CA-C-N 116.6 0.2 . . . . 0.0 110.525 179.557 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 93.6 m-20 -117.3 155.79 28.91 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 122.684 0.394 . . . . 0.0 110.192 178.205 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 9.6 p -80.51 140.9 35.65 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 178.834 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 17.7 m -55.32 -41.93 64.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 C-N-CA 120.738 -0.385 . . . . 0.0 110.696 -179.537 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 67.1 m -57.71 -42.54 83.97 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.738 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 58.9 tt0 -63.84 -47.62 80.03 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.884 0.374 . . . . 0.0 110.497 -179.757 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 65.8 mt -60.96 -43.09 95.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.158 -0.474 . . . . 0.0 109.839 179.415 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.436 ' O ' ' N ' ' A' ' 65' ' ' GLY . . . -53.62 -38.19 63.8 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.702 -0.681 . . . . 0.0 111.006 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 93.8 mm-40 -64.14 -53.56 47.65 Favored 'General case' 0 C--N 1.331 -0.212 0 C-N-CA 120.694 -0.402 . . . . 0.0 110.582 179.739 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 75.2 mt -63.64 -48.84 84.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 C-N-CA 120.741 -0.383 . . . . 0.0 110.504 -179.255 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 40.3 tp -67.22 -38.91 86.06 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.01 0.433 . . . . 0.0 110.275 179.585 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.439 ' O ' ' N ' ' A' ' 69' ' ' ASP . . . -58.87 -42.17 96.52 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 111.233 -0.747 . . . . 0.0 111.233 -179.453 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 86.4 mt-30 -66.09 -30.37 70.86 Favored 'General case' 0 C--N 1.328 -0.352 0 C-N-CA 120.974 -0.29 . . . . 0.0 110.375 179.568 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 19.8 m -62.36 -49.13 76.78 Favored 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 120.627 -0.429 . . . . 0.0 110.226 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 95.3 m-85 -94.48 -2.43 51.78 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.562 179.301 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . 0.439 ' N ' ' O ' ' A' ' 65' ' ' GLY . 65.7 t0 52.52 62.12 2.85 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.763 0.316 . . . . 0.0 110.83 179.783 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -137.26 158.26 44.83 Favored 'General case' 0 N--CA 1.469 0.517 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.181 -179.652 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 85.6 m-20 -55.85 113.95 6.62 Favored Pre-proline 0 CA--C 1.546 0.798 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.18 -179.501 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 74.9 Cg_exo -48.56 -34.12 25.59 Favored 'Trans proline' 0 N--CA 1.501 1.913 0 C-N-CA 121.672 1.582 . . . . 0.0 112.195 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -52.08 -39.6 59.97 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.043 0.449 . . . . 0.0 110.609 -179.678 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 70.3 mt -71.74 -42.69 70.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.188 179.237 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 33.9 mm -61.35 -49.82 82.94 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.345 -178.616 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -65.0 -43.44 92.54 Favored 'General case' 0 C--O 1.232 0.176 0 C-N-CA 120.595 -0.442 . . . . 0.0 110.155 -179.684 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.418 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -63.9 -21.35 66.42 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.219 179.588 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 65.9 t0 -78.17 -51.91 9.5 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 120.742 0.306 . . . . 0.0 110.912 -179.531 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 30.3 pt -74.01 -37.79 47.98 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.498 -179.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 9.6 mt -42.88 -60.03 2.6 Favored Pre-proline 0 CA--C 1.551 1.017 0 N-CA-C 111.768 0.285 . . . . 0.0 111.768 -179.376 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.418 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 39.1 Cg_endo -61.96 -24.2 76.63 Favored 'Trans proline' 0 N--CA 1.501 1.947 0 C-N-CA 122.089 1.859 . . . . 0.0 112.057 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 9.3 tpt -66.19 -35.5 80.61 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 120.745 0.307 . . . . 0.0 110.659 -179.712 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 43.5 mt -61.19 -41.02 96.07 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.432 -178.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.35 -40.53 96.68 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.849 0.357 . . . . 0.0 110.077 179.469 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -64.31 -40.71 98.12 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 111.091 -0.804 . . . . 0.0 111.091 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 86.3 mt -66.74 -40.77 88.47 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.806 0.336 . . . . 0.0 110.676 -179.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -55.82 -37.13 68.27 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 120.824 -0.351 . . . . 0.0 110.977 -179.526 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 77.8 mt-30 -62.11 -21.43 65.0 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.05 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -91.73 -1.88 57.22 Favored 'General case' 0 N--CA 1.469 0.502 0 CA-C-N 116.476 -0.329 . . . . 0.0 110.549 -179.286 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 64.3 ttt-85 62.25 55.8 2.32 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.459 179.599 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 33.6 m -141.81 5.16 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.516 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.756 179.851 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 55.9 tp -141.81 138.04 31.93 Favored 'General case' 0 N--CA 1.47 0.555 0 CA-C-O 120.937 0.399 . . . . 0.0 110.294 179.673 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -150.77 135.91 17.65 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-N 116.036 -0.529 . . . . 0.0 109.873 179.395 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 60.3 ttp180 . . . . . 0 C--O 1.221 -0.429 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.162 -179.38 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 67.7 mtt . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 108.928 -0.768 . . . . 0.0 108.928 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -71.69 148.9 92.92 Favored Pre-proline 0 CA--C 1.54 0.56 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.466 -179.422 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 64.3 Cg_endo -69.04 -16.3 40.47 Favored 'Trans proline' 0 N--CA 1.495 1.617 0 C-N-CA 122.314 2.01 . . . . 0.0 112.108 179.718 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 19.4 p -75.92 70.11 2.61 Favored 'General case' 0 CA--C 1.52 -0.21 0 CA-C-O 121.057 0.456 . . . . 0.0 110.388 -179.139 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -166.23 53.31 0.09 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.8 179.825 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 75.6 m-85 -83.92 133.99 34.69 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-O 120.817 0.341 . . . . 0.0 110.203 179.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 47.8 m -92.58 -179.91 5.32 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.121 179.665 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -71.86 -30.1 66.33 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.176 -0.77 . . . . 0.0 111.176 179.738 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 34.8 t -69.75 -18.06 63.48 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.84 0.353 . . . . 0.0 110.824 -179.468 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 93.7 m-20 -69.0 150.34 47.78 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 179.756 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.466 ' CG2' ' HE ' ' A' ' 54' ' ' ARG . 19.7 m -129.41 130.47 23.31 Favored Pre-proline 0 N--CA 1.474 0.742 0 CA-C-N 116.568 -0.287 . . . . 0.0 110.786 -179.007 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -77.95 146.85 23.55 Favored 'Trans proline' 0 N--CA 1.49 1.306 0 C-N-CA 121.466 1.444 . . . . 0.0 111.64 179.632 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 62.1 ttp180 -158.12 124.04 4.62 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 179.206 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 72.4 mt -68.72 119.37 68.59 Favored Pre-proline 0 CA--C 1.543 0.707 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.935 -179.437 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.441 ' CD ' ' O ' ' A' ' 91' ' ' VAL . 98.4 Cg_endo -75.11 159.37 41.06 Favored 'Trans proline' 0 N--CA 1.493 1.452 0 C-N-CA 121.821 1.681 . . . . 0.0 112.112 -179.851 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 77.6 mtp85 -55.54 150.83 11.43 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.414 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 82.72 15.02 74.25 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.77 -0.932 . . . . 0.0 110.77 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.3 t -135.05 131.85 52.88 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.525 0 CA-C-O 120.869 0.366 . . . . 0.0 110.145 179.689 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 90.9 mtm180 -138.03 155.94 48.31 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.267 -179.795 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 29.2 mt -93.11 102.68 15.0 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 109.832 -0.432 . . . . 0.0 109.832 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 84.1 mtp180 -89.93 143.67 26.59 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 116.212 -0.449 . . . . 0.0 109.96 179.687 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 87.9 t80 -103.46 110.77 22.92 Favored 'General case' 0 N--CA 1.463 0.207 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.003 179.742 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 95.2 m-20 -89.66 92.97 9.29 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 116.034 -0.53 . . . . 0.0 109.879 179.706 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.5 tt0 -62.16 -33.16 73.98 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.184 -179.805 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 3.0 m -63.19 -42.9 98.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.366 -179.809 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.469 ' NH2' ' OD1' ' A' ' 39' ' ' ASP . 99.8 mtt180 -90.9 -8.51 49.19 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-O 120.67 0.272 . . . . 0.0 110.525 179.693 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 17.0 t-20 55.66 33.36 21.12 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.028 179.737 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 18.2 ptmt -145.08 158.53 43.79 Favored 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 116.319 -0.4 . . . . 0.0 109.957 179.712 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.406 ' O ' ' O ' ' A' ' 40' ' ' LEU . 70.4 m80 -88.48 150.55 23.07 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 179.395 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 21.9 m -137.92 156.49 31.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -179.76 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 36.7 tp -104.53 123.82 48.2 Favored 'General case' 0 CA--C 1.517 -0.319 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.449 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 55.1 tp -78.78 97.16 5.81 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 179.205 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -95.32 147.32 32.84 Favored Pre-proline 0 CA--C 1.54 0.588 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 71.2 Cg_exo -48.24 -36.48 29.51 Favored 'Trans proline' 0 N--CA 1.497 1.724 0 C-N-CA 121.588 1.525 . . . . 0.0 112.557 178.62 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -73.95 -52.06 14.06 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.519 -0.31 . . . . 0.0 111.004 -178.596 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 17.6 ptm180 -176.12 161.69 2.4 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.712 -179.844 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 90.1 m -73.52 124.89 26.75 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.244 178.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 77.2 m-85 -101.5 133.65 45.83 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.156 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.469 ' OD1' ' NH2' ' A' ' 26' ' ' ARG . 82.7 m-20 -73.21 120.53 18.96 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.26 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.406 ' O ' ' O ' ' A' ' 29' ' ' HIS . 84.0 mt -133.16 158.96 41.53 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-O 121.062 0.458 . . . . 0.0 110.343 -179.701 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -82.9 152.14 25.67 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.048 -179.447 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 50.0 t0 -58.48 -37.8 76.27 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.27 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 98.1 m-20 -63.47 -38.96 93.16 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.352 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -68.71 -40.9 79.74 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.67 0.272 . . . . 0.0 110.857 -179.665 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 58.4 t -78.04 -31.45 16.68 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 N-CA-C 110.006 -0.368 . . . . 0.0 110.006 179.693 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -53.55 -38.16 63.58 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.235 -179.591 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 89.9 t -60.57 -46.6 95.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.657 179.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 40.3 mt -76.59 -16.9 59.47 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.842 -178.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 37.5 ttmt -92.37 -32.08 15.09 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.622 179.465 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 5.7 tp -72.51 -32.22 65.96 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.531 -179.123 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 10.4 p -72.51 127.14 34.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 121.049 0.452 . . . . 0.0 110.458 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 95.2 m-20 -69.59 -42.91 73.81 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.35 179.596 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -145.9 -102.47 0.34 Allowed Glycine 0 N--CA 1.472 1.038 0 N-CA-C 110.404 -1.078 . . . . 0.0 110.404 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . 0.466 ' HE ' ' CG2' ' A' ' 11' ' ' VAL . 84.3 mtp180 -114.79 104.98 12.49 Favored 'General case' 0 N--CA 1.471 0.586 0 CA-C-O 120.648 0.261 . . . . 0.0 110.321 179.512 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 97.6 m-20 -117.24 148.86 41.27 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.032 178.541 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 32.1 p -81.14 148.67 29.47 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 179.009 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 32.8 m -56.57 -39.08 60.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-N 116.374 -0.376 . . . . 0.0 110.361 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 69.5 m -57.68 -45.58 85.44 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.656 -179.678 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.3 tt0 -66.52 -45.73 78.55 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.603 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 96.6 mt -61.58 -43.21 96.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.141 -0.481 . . . . 0.0 109.762 -179.536 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.416 ' O ' ' N ' ' A' ' 65' ' ' GLY . . . -53.88 -42.04 68.2 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.9 -179.144 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 98.0 mm-40 -64.53 -56.08 16.36 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.083 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 69.9 mt -64.07 -48.92 83.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-O 120.846 0.355 . . . . 0.0 110.596 -179.096 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 30.6 tp -67.53 -36.53 81.19 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.252 -179.513 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.43 ' O ' ' N ' ' A' ' 69' ' ' ASP . . . -58.65 -39.46 93.45 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 111.011 -0.836 . . . . 0.0 111.011 -179.541 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 97.5 mt-30 -65.8 -34.65 78.66 Favored 'General case' 0 C--N 1.326 -0.434 0 C-N-CA 121.044 -0.262 . . . . 0.0 110.621 179.744 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 96.1 m -61.73 -47.43 85.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.767 0.318 . . . . 0.0 110.393 -179.674 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -93.92 -1.34 54.86 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.633 179.594 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . 0.43 ' N ' ' O ' ' A' ' 65' ' ' GLY . 51.5 t0 50.22 62.12 2.84 Favored 'General case' 0 C--N 1.332 -0.185 0 C-N-CA 120.92 -0.312 . . . . 0.0 110.878 179.756 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -140.45 161.54 37.47 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-N 116.484 -0.325 . . . . 0.0 110.255 -179.584 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 68.6 m-20 -55.85 114.5 7.58 Favored Pre-proline 0 CA--C 1.544 0.736 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.593 -179.193 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_exo -48.52 -35.71 29.54 Favored 'Trans proline' 0 N--CA 1.496 1.664 0 C-N-CA 121.793 1.662 . . . . 0.0 112.329 179.555 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -53.7 -39.97 65.63 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.342 -179.193 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 72.5 mt -72.63 -36.36 53.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.76 179.722 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 42.9 mm -61.01 -48.27 89.84 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.258 -178.506 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -61.71 -43.86 98.05 Favored 'General case' 0 CA--C 1.532 0.252 0 CA-C-O 120.856 0.36 . . . . 0.0 110.197 -179.619 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.454 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -66.85 -19.21 65.69 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.265 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 64.8 t0 -80.64 -46.13 16.13 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-O 120.683 0.278 . . . . 0.0 111.093 -179.637 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 34.0 pt -79.78 -33.88 15.16 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.566 0 CA-C-O 120.916 0.388 . . . . 0.0 111.369 -179.544 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 9.4 mt -47.66 -59.04 6.24 Favored Pre-proline 0 CA--C 1.545 0.768 0 CA-C-N 116.558 -0.292 . . . . 0.0 111.07 179.679 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.454 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 33.3 Cg_endo -60.0 -24.39 76.32 Favored 'Trans proline' 0 N--CA 1.497 1.726 0 C-N-CA 121.964 1.776 . . . . 0.0 111.749 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 13.2 tpt -65.45 -36.18 83.13 Favored 'General case' 0 CA--C 1.532 0.258 0 CA-C-O 120.805 0.335 . . . . 0.0 110.598 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 47.7 mt -61.56 -39.44 91.14 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.294 -179.652 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.0 -40.82 95.01 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 179.746 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -66.48 -40.56 94.38 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 111.51 -0.636 . . . . 0.0 111.51 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 87.2 mt -66.83 -40.59 88.02 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.852 0.358 . . . . 0.0 110.513 -179.601 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -54.73 -37.35 65.78 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.796 0.331 . . . . 0.0 110.542 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 86.7 mt-30 -62.57 -22.95 66.75 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.815 179.721 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 65.1 mttp -91.34 -6.76 52.55 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.199 -179.542 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 14.8 tpt180 62.35 53.13 2.86 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.914 -0.584 . . . . 0.0 110.17 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . 0.441 ' O ' ' CD ' ' A' ' 15' ' ' PRO . 30.2 m -133.09 -1.27 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.312 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.809 -179.619 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 35.1 tp -104.92 145.42 30.43 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-O 121.271 0.557 . . . . 0.0 109.989 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 45.8 tp10 -149.06 115.24 5.78 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.14 -0.936 . . . . 0.0 109.902 -179.302 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 61.3 ttp180 . . . . . 0 C--O 1.221 -0.436 0 CA-C-O 117.901 -1.047 . . . . 0.0 109.989 179.931 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 16.8 ptm . . . . . 0 N--CA 1.489 1.506 0 N-CA-C 109.268 -0.641 . . . . 0.0 109.268 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 52.46 63.76 8.4 Favored Pre-proline 0 CA--C 1.534 0.347 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.457 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -75.36 168.44 24.57 Favored 'Trans proline' 0 N--CA 1.493 1.456 0 C-N-CA 122.472 2.115 . . . . 0.0 111.869 -179.806 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 18.7 p -73.46 -35.28 65.7 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.123 -179.591 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . 45.76 93.12 0.01 OUTLIER 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.797 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 91.4 m-85 -80.01 133.83 36.18 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.378 -179.665 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 34.1 m -94.1 -175.43 3.69 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.506 -179.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -65.21 -37.47 94.07 Favored Glycine 0 CA--C 1.527 0.806 0 N-CA-C 111.348 -0.701 . . . . 0.0 111.348 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 15.5 m -72.81 -25.44 61.15 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.826 0.346 . . . . 0.0 110.734 -179.544 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -68.39 150.41 48.19 Favored 'General case' 0 CA--C 1.515 -0.369 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 -179.806 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.478 ' CG2' ' HE ' ' A' ' 54' ' ' ARG . 27.4 m -128.2 128.94 23.68 Favored Pre-proline 0 CA--C 1.54 0.565 0 CA-C-N 116.422 -0.353 . . . . 0.0 111.178 -179.192 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 95.1 Cg_endo -77.22 145.13 24.01 Favored 'Trans proline' 0 N--CA 1.494 1.551 0 C-N-CA 121.959 1.773 . . . . 0.0 111.742 179.377 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 71.1 ttt-85 -158.09 127.35 5.77 Favored 'General case' 0 C--N 1.332 -0.183 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.216 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 47.0 mt -68.2 131.59 91.99 Favored Pre-proline 0 CA--C 1.542 0.644 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.955 -179.381 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 81.2 Cg_endo -75.29 158.75 40.89 Favored 'Trans proline' 0 N--CA 1.491 1.354 0 C-N-CA 122.006 1.804 . . . . 0.0 111.938 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 60.4 ttt85 -55.95 144.44 28.4 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.074 179.556 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 87.36 12.39 67.51 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 179.679 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 59.9 t -132.83 130.28 58.76 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.52 0 CA-C-O 120.946 0.403 . . . . 0.0 110.155 179.344 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.589 HH11 ' NH1' ' A' ' 21' ' ' ARG . 81.2 mtm-85 -138.81 157.78 45.44 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.079 179.768 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 27.5 mt -92.03 139.9 30.18 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.715 179.846 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.589 ' NH1' HH11 ' A' ' 19' ' ' ARG . 81.7 mtt85 -139.47 146.71 40.38 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.002 -0.544 . . . . 0.0 109.948 -179.677 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 59.2 t80 -102.83 117.6 34.99 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 115.701 -0.682 . . . . 0.0 110.166 179.656 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -89.73 103.9 16.51 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.601 178.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 78.2 tt0 -63.76 -36.47 83.97 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.524 -179.828 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 1.5 m -62.99 -42.67 97.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.342 -179.524 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 100.0 mtt180 -86.67 -18.6 30.88 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 120.743 0.306 . . . . 0.0 110.289 -179.629 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 12.2 m-80 68.03 23.66 8.08 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.116 179.502 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 14.6 ptpt -145.29 163.52 34.25 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.088 179.393 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 77.3 m80 -89.51 151.0 22.21 Favored 'General case' 0 CA--C 1.519 -0.247 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.934 179.67 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 34.7 m -140.74 158.07 23.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.007 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 34.1 tp -100.41 116.46 32.43 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.23 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 44.3 tp -77.02 99.35 5.27 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 179.285 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -97.38 147.27 32.73 Favored Pre-proline 0 CA--C 1.542 0.662 0 C-N-CA 121.107 -0.237 . . . . 0.0 110.395 179.782 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 77.3 Cg_exo -49.17 -37.84 39.78 Favored 'Trans proline' 0 N--CA 1.499 1.804 0 C-N-CA 122.073 1.849 . . . . 0.0 112.502 178.654 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 77.8 tt0 -74.28 -51.93 13.79 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.893 -178.72 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 59.4 ttm-85 -174.87 151.34 1.37 Allowed 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.954 0.407 . . . . 0.0 110.475 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 69.7 m -69.48 132.84 46.93 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.47 179.114 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 85.4 m-85 -103.4 133.99 47.53 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.458 179.895 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 38.5 p-10 -71.59 117.78 13.59 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.364 179.451 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 88.2 mt -133.45 157.48 45.49 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.392 -179.728 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 87.5 m-20 -86.7 152.49 22.5 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.045 -179.726 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 53.9 t0 -58.51 -39.47 80.2 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.716 -179.767 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 5.3 m120 -63.7 -39.97 95.63 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.704 -179.586 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.76 -40.19 76.26 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.865 -179.564 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 57.6 t -78.15 -29.94 15.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.398 -0.364 . . . . 0.0 110.258 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -54.11 -36.06 62.81 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.307 -179.68 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 60.1 t -60.71 -46.19 96.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.693 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 38.2 mt -75.76 -19.01 59.33 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.522 -179.024 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 15.2 ttmm -90.08 -29.42 18.37 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.546 179.639 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 9.0 tp -71.13 -32.7 69.31 Favored 'General case' 0 C--N 1.332 -0.178 0 C-N-CA 120.602 -0.439 . . . . 0.0 110.533 -178.522 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.1 p -74.46 127.37 36.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.456 179.75 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 95.2 m-20 -70.9 -43.75 67.67 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.376 179.536 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -143.51 -101.03 0.36 Allowed Glycine 0 N--CA 1.472 1.044 0 N-CA-C 110.458 -1.057 . . . . 0.0 110.458 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . 0.478 ' HE ' ' CG2' ' A' ' 11' ' ' VAL . 85.1 mtp180 -114.77 104.87 12.39 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-O 120.924 0.393 . . . . 0.0 110.265 179.232 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 97.2 m-20 -117.11 153.77 32.18 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.355 178.072 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 13.7 p -80.09 136.53 36.57 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 178.668 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 29.9 m -54.49 -38.98 43.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.481 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 12.0 t -60.12 -44.63 94.74 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.676 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 56.8 tt0 -64.41 -43.21 95.11 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.842 -179.461 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 96.6 mt -61.2 -43.15 95.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 -179.632 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.42 ' O ' ' N ' ' A' ' 65' ' ' GLY . . . -52.17 -35.42 48.74 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.164 -178.924 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 94.3 mm-40 -63.36 -53.85 46.08 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.674 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 70.2 mt -66.63 -48.43 80.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.924 0.392 . . . . 0.0 110.854 -179.503 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 21.8 tp -67.73 -39.21 84.29 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.545 -178.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 61' ' ' ALA . . . -54.74 -41.0 73.55 Favored Glycine 0 CA--C 1.525 0.662 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 -179.319 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 87.7 mt-30 -65.85 -31.6 72.65 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.63 0.252 . . . . 0.0 110.557 179.706 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 18.8 m -61.99 -45.69 92.53 Favored 'General case' 0 C--N 1.329 -0.283 0 C-N-CA 120.872 -0.331 . . . . 0.0 110.546 -179.437 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -90.6 1.75 56.47 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.466 179.855 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 61.6 t0 54.74 48.65 19.72 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.564 179.767 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -140.94 160.56 39.81 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-O 120.915 0.388 . . . . 0.0 110.313 -179.68 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 95.0 m-20 -55.91 144.39 57.83 Favored Pre-proline 0 CA--C 1.54 0.566 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.678 -179.096 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -68.18 -33.76 23.85 Favored 'Trans proline' 0 N--CA 1.498 1.777 0 C-N-CA 122.462 2.108 . . . . 0.0 112.28 -179.533 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -54.41 -32.22 56.78 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.829 0.347 . . . . 0.0 110.861 -179.348 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 65.6 mt -68.46 -42.03 83.63 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.599 -179.856 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.431 ' N ' ' CD1' ' A' ' 75' ' ' ILE . 1.7 mp -60.82 -39.85 83.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 -179.182 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 7.0 mm-40 -57.31 -66.24 0.49 Allowed 'General case' 0 C--N 1.314 -0.977 0 C-N-CA 120.597 -0.441 . . . . 0.0 110.967 -178.337 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.402 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -55.34 -16.75 3.8 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.742 -178.69 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 58.5 t0 -80.65 -52.59 7.39 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.186 -179.713 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 18.4 pt -80.51 -33.5 13.84 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.425 0 CA-C-O 121.021 0.438 . . . . 0.0 111.485 -178.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.403 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 10.3 mt -44.94 -59.74 3.86 Favored Pre-proline 0 CA--C 1.54 0.578 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.611 179.844 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.403 ' HD2' ' N ' ' A' ' 80' ' ' LEU . 39.6 Cg_endo -61.73 -30.33 84.8 Favored 'Trans proline' 0 N--CA 1.493 1.444 0 C-N-CA 121.451 1.434 . . . . 0.0 111.751 179.793 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 15.1 tpt -65.85 -41.01 92.22 Favored 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 120.781 -0.367 . . . . 0.0 110.752 -179.367 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 82.9 mt -62.86 -41.41 99.37 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.243 -179.483 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.91 -37.87 88.71 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.384 179.647 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -62.43 -39.79 98.24 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 111.122 -0.791 . . . . 0.0 111.122 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 88.2 mt -67.67 -39.54 84.51 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.865 0.364 . . . . 0.0 110.491 -179.768 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -53.8 -36.94 63.01 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.886 0.374 . . . . 0.0 110.69 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 54.6 mt-30 -62.38 -21.76 65.6 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.886 179.734 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -92.26 -1.56 57.02 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 116.515 -0.312 . . . . 0.0 110.242 -179.261 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 63.2 ttt-85 61.56 57.11 2.37 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.345 179.525 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 34.8 m -141.71 11.82 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.216 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 55.3 tp -140.18 140.13 35.84 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.397 179.863 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 16.4 pt-20 -149.31 142.04 24.57 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 115.652 -0.703 . . . . 0.0 110.555 179.386 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 62.2 ttp180 . . . . . 0 C--O 1.22 -0.494 0 CA-C-O 118.057 -0.973 . . . . 0.0 110.263 179.727 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 48.4 ttp . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 26.4 mm-40 48.41 72.73 1.16 Allowed Pre-proline 0 CA--C 1.533 0.305 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.751 -179.81 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_exo -56.77 149.41 60.02 Favored 'Trans proline' 0 N--CA 1.496 1.631 0 C-N-CA 122.575 2.183 . . . . 0.0 111.942 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -79.02 83.64 5.1 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.974 -179.78 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.405 ' O ' ' O ' ' A' ' 6' ' ' PHE . . . -76.21 -4.68 43.12 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.554 -179.906 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.558 ' CE2' ' NH2' ' A' ' 94' ' ' ARG . 97.0 m-85 58.67 146.56 0.01 OUTLIER 'General case' 0 N--CA 1.462 0.161 0 O-C-N 123.608 0.567 . . . . 0.0 110.515 -179.523 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 49.7 m -92.57 -177.57 4.62 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-O 120.833 0.349 . . . . 0.0 110.239 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -71.73 -32.07 64.44 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 110.926 -0.87 . . . . 0.0 110.926 179.604 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 37.1 t -69.41 -17.49 63.66 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.681 0.277 . . . . 0.0 110.841 -179.321 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -68.28 146.16 53.57 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 30.0 m -128.96 102.83 18.94 Favored Pre-proline 0 CA--C 1.541 0.599 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.492 -179.861 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -55.71 143.49 79.86 Favored 'Trans proline' 0 N--CA 1.5 1.91 0 C-N-CA 122.082 1.855 . . . . 0.0 112.11 178.64 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 78.6 ttt-85 -151.33 122.65 7.8 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-O 120.814 0.34 . . . . 0.0 110.15 178.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 71.1 mt -69.61 118.73 65.51 Favored Pre-proline 0 CA--C 1.542 0.639 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.323 -179.265 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.46 ' CD ' ' O ' ' A' ' 91' ' ' VAL . 89.1 Cg_endo -78.61 166.49 23.78 Favored 'Trans proline' 0 N--CA 1.495 1.572 0 C-N-CA 122.257 1.971 . . . . 0.0 112.036 179.763 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 9.3 ptm180 -55.48 154.3 6.57 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.282 179.27 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 84.36 -14.83 43.43 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 111.211 -0.755 . . . . 0.0 111.211 179.442 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 41.4 t -104.65 127.8 58.78 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.498 0 CA-C-O 120.929 0.395 . . . . 0.0 110.06 179.743 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 81.8 mtm-85 -138.38 153.43 48.92 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.269 -179.732 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 19.0 mt -98.47 98.78 9.94 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.079 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 96.0 mtt-85 -93.07 143.2 26.47 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.194 179.596 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 82.1 t80 -102.21 119.16 38.34 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.581 179.408 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 88.5 m-20 -87.73 105.97 17.74 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.127 -179.772 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -64.92 -37.35 87.35 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.766 -179.796 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 3.0 m -62.64 -43.24 98.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.617 -179.223 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.493 ' CD ' ' HZ3' ' A' ' 28' ' ' LYS . 95.3 mtt-85 -90.76 -10.98 40.92 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-O 120.695 0.283 . . . . 0.0 110.589 179.844 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 61.1 t-20 56.36 37.11 28.53 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.591 179.768 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.571 ' HZ2' ' CG1' ' A' ' 30' ' ' VAL . 9.5 pttm -144.91 167.05 23.54 Favored 'General case' 0 N--CA 1.466 0.346 0 N-CA-C 109.648 -0.501 . . . . 0.0 109.648 179.809 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.51 ' CD2' ' HZ3' ' A' ' 49' ' ' LYS . 73.9 m80 -93.32 149.9 20.88 Favored 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 109.652 -0.499 . . . . 0.0 109.652 178.467 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.571 ' CG1' ' HZ2' ' A' ' 28' ' ' LYS . 35.3 m -140.62 152.77 21.04 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.337 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.834 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 35.4 tp -100.56 117.68 35.19 Favored 'General case' 0 N--CA 1.465 0.289 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 179.567 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 56.9 tp -79.16 97.98 6.4 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 179.044 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -93.62 148.07 34.77 Favored Pre-proline 0 CA--C 1.543 0.688 0 C-N-CA 120.985 -0.286 . . . . 0.0 110.321 179.845 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -44.26 -34.75 7.39 Favored 'Trans proline' 0 N--CA 1.497 1.7 0 C-N-CA 122.19 1.927 . . . . 0.0 112.189 178.877 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 -76.17 -52.08 10.81 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-N 116.48 -0.327 . . . . 0.0 111.076 -178.787 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 37.5 ptt180 -176.39 165.75 2.73 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.672 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 61.3 m -77.24 127.86 33.35 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.39 178.845 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 65.1 m-85 -104.23 138.41 40.73 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-O 121.039 0.447 . . . . 0.0 110.074 179.682 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -74.15 119.87 18.95 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.506 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 92.8 mt -135.31 157.58 46.53 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.209 -0.45 . . . . 0.0 109.894 179.826 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 19.9 m-20 -85.05 161.58 19.66 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.973 -179.581 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.471 ' OD1' ' ND1' ' A' ' 29' ' ' HIS . 31.8 m-20 -61.15 -39.9 91.85 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.357 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 8.8 m120 -63.0 -36.8 84.76 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.578 -179.463 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.01 -43.44 74.78 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.468 -0.333 . . . . 0.0 111.119 -179.433 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 60.1 t -79.0 -31.83 15.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-O 120.741 0.305 . . . . 0.0 110.526 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -53.87 -35.84 61.98 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.537 -179.559 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 93.1 t -61.32 -47.75 92.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.943 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 44.9 mt -77.61 -14.76 59.56 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.868 -178.833 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . 0.51 ' HZ3' ' CD2' ' A' ' 29' ' ' HIS . 37.4 ttmt -91.36 -30.66 16.41 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.88 0.371 . . . . 0.0 110.492 179.31 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 7.9 tp -71.15 -32.1 68.51 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.638 -178.451 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.6 p -73.51 125.01 31.85 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.602 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -73.35 -41.42 63.47 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.463 179.372 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -143.51 -99.58 0.31 Allowed Glycine 0 N--CA 1.471 0.968 0 N-CA-C 110.454 -1.059 . . . . 0.0 110.454 -179.635 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -114.83 104.43 11.94 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 110.1 -0.333 . . . . 0.0 110.1 178.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 97.9 m-20 -117.36 146.09 43.63 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.005 178.207 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 42.3 p -79.69 141.43 36.42 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 178.776 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 27.8 m -54.19 -39.52 43.04 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.413 -179.667 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 67.0 m -58.64 -43.1 89.65 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.663 179.596 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 55.9 tt0 -64.97 -47.91 75.91 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.868 -179.701 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 65.2 mt -60.77 -43.04 94.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.307 179.913 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.449 ' O ' ' N ' ' A' ' 65' ' ' GLY . . . -53.24 -41.04 65.03 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.322 -0.399 . . . . 0.0 111.042 -179.286 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 96.0 mm-40 -63.59 -53.86 45.01 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.894 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 65.3 mt -66.06 -46.83 86.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-O 121.02 0.438 . . . . 0.0 110.604 -179.057 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 25.7 tp -68.58 -37.75 80.11 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.093 -179.419 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.449 ' N ' ' O ' ' A' ' 61' ' ' ALA . . . -57.14 -40.41 91.49 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 -179.537 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 73.1 mt-30 -66.03 -32.31 73.71 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.656 0.265 . . . . 0.0 110.46 179.545 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 19.5 m -62.66 -47.96 81.39 Favored 'General case' 0 C--N 1.329 -0.3 0 C-N-CA 120.722 -0.391 . . . . 0.0 110.634 -179.602 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -94.81 -3.04 49.7 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.47 179.73 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . 0.433 ' N ' ' O ' ' A' ' 65' ' ' GLY . 66.4 t0 54.25 62.26 2.66 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.798 179.654 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -140.99 160.52 39.9 Favored 'General case' 0 N--CA 1.469 0.523 0 CA-C-O 120.766 0.317 . . . . 0.0 110.434 -179.723 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 88.2 m-20 -55.73 114.21 7.0 Favored Pre-proline 0 CA--C 1.543 0.693 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.49 -178.774 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 81.9 Cg_exo -49.22 -36.5 37.1 Favored 'Trans proline' 0 N--CA 1.502 1.995 0 C-N-CA 122.099 1.866 . . . . 0.0 112.474 179.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -53.58 -38.58 64.06 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.053 0.454 . . . . 0.0 110.884 -179.274 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 67.4 mt -72.71 -38.2 57.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.53 179.409 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 43.6 mm -60.63 -49.14 85.65 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.122 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.12 -178.039 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -62.01 -44.56 96.45 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.888 0.375 . . . . 0.0 110.436 -179.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.449 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -66.31 -20.71 66.17 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.954 -0.567 . . . . 0.0 111.114 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 65.9 t0 -79.82 -46.39 16.99 Favored 'General case' 0 CA--C 1.533 0.297 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.255 -179.602 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 34.9 pt -79.26 -32.19 14.86 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 CA-C-O 121.074 0.464 . . . . 0.0 111.43 -179.124 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.427 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 8.3 mt -48.56 -59.63 5.82 Favored Pre-proline 0 CA--C 1.543 0.686 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.5 179.722 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.449 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 30.1 Cg_endo -59.22 -25.24 77.44 Favored 'Trans proline' 0 N--CA 1.494 1.523 0 C-N-CA 121.995 1.796 . . . . 0.0 111.988 -179.316 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 44.5 ttp -65.35 -36.39 83.89 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.843 0.354 . . . . 0.0 110.551 -179.7 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 52.2 mt -62.12 -39.32 92.15 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.892 -179.656 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.7 -37.3 83.62 Favored 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 120.763 -0.375 . . . . 0.0 110.376 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -65.47 -41.66 96.21 Favored Glycine 0 CA--C 1.526 0.781 0 N-CA-C 111.122 -0.791 . . . . 0.0 111.122 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 84.6 mt -70.69 -38.36 73.7 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.902 0.382 . . . . 0.0 110.417 -179.714 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -52.68 -24.33 8.36 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.609 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 86.1 mt-30 -61.18 -30.85 70.65 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.566 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 25.6 mtmm -96.64 0.39 49.77 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-O 120.921 0.391 . . . . 0.0 110.462 -179.361 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 66.3 ttt180 56.52 47.73 18.09 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.295 179.588 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . 0.46 ' O ' ' CD ' ' A' ' 15' ' ' PRO . 24.5 m -105.85 2.2 10.26 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.504 0 CA-C-N 116.471 -0.332 . . . . 0.0 110.185 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 97.3 mt -102.31 164.84 11.46 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-O 121.23 0.538 . . . . 0.0 110.505 179.849 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 45.7 tp10 -154.33 129.19 9.43 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.185 -0.916 . . . . 0.0 110.243 -179.534 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . 0.558 ' NH2' ' CE2' ' A' ' 6' ' ' PHE . 73.2 mtt85 . . . . . 0 C--N 1.326 -0.449 0 CA-C-O 117.763 -1.113 . . . . 0.0 109.752 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 69.8 mtm . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 31.3 tt0 57.3 57.15 7.85 Favored Pre-proline 0 CA--C 1.533 0.314 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.376 -179.652 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.543 ' C ' ' H ' ' A' ' 5' ' ' ALA . 66.8 Cg_endo -70.56 -13.05 32.31 Favored 'Trans proline' 0 N--CA 1.496 1.658 0 C-N-CA 122.323 2.015 . . . . 0.0 111.536 -179.866 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.506 ' C ' ' H ' ' A' ' 6' ' ' PHE . 15.7 p 60.76 -4.13 0.13 Allowed 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.889 -179.312 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.543 ' H ' ' C ' ' A' ' 3' ' ' PRO . . . 69.63 -40.52 0.46 Allowed 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 116.476 -0.329 . . . . 0.0 110.907 179.886 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.506 ' H ' ' C ' ' A' ' 4' ' ' THR . 1.3 t80 56.74 107.72 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.111 -0.495 . . . . 0.0 109.928 -179.619 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 16.7 m -90.14 176.61 6.7 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.581 179.848 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -71.31 -27.16 72.11 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 111.125 -0.79 . . . . 0.0 111.125 179.763 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 15.4 m -70.44 -22.03 62.74 Favored 'General case' 0 C--O 1.232 0.156 0 CA-C-O 120.836 0.351 . . . . 0.0 110.522 -179.481 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 -69.09 149.75 48.36 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 179.232 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.442 ' CG2' ' HE ' ' A' ' 54' ' ' ARG . 20.9 m -128.17 127.44 23.78 Favored Pre-proline 0 CA--C 1.548 0.868 0 CA-C-O 119.744 -0.169 . . . . 0.0 110.783 -178.966 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -77.46 147.41 25.42 Favored 'Trans proline' 0 N--CA 1.494 1.538 0 C-N-CA 121.321 1.347 . . . . 0.0 112.279 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 56.7 ttt85 -158.1 124.85 4.88 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 115.728 -0.669 . . . . 0.0 109.364 178.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 67.6 mt -70.09 128.25 91.72 Favored Pre-proline 0 CA--C 1.544 0.743 0 CA-C-O 119.389 -0.339 . . . . 0.0 110.771 -179.531 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -73.33 158.78 47.98 Favored 'Trans proline' 0 N--CA 1.496 1.643 0 C-N-CA 121.748 1.632 . . . . 0.0 111.978 179.834 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 90.7 mtm180 -57.37 148.56 22.77 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.521 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 83.54 12.86 77.31 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 111.031 -0.827 . . . . 0.0 111.031 179.792 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 61.4 t -132.6 132.08 59.93 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.566 0 CA-C-O 121.037 0.446 . . . . 0.0 109.986 179.78 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 89.9 mtm180 -136.81 158.75 43.73 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.207 -179.82 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 47.6 mt -91.06 142.56 27.62 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.092 -179.698 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 83.6 mtp180 -137.58 139.86 40.66 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 121.052 0.453 . . . . 0.0 110.095 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 73.9 t80 -99.28 120.86 40.24 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.286 -179.855 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.481 ' O ' ' N ' ' A' ' 27' ' ' ASN . 94.6 m-20 -87.45 105.98 17.66 Favored 'General case' 0 N--CA 1.462 0.174 0 CA-C-N 116.031 -0.531 . . . . 0.0 109.638 179.84 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.478 ' O ' ' ND2' ' A' ' 27' ' ' ASN . 39.2 tt0 -64.85 -37.24 86.96 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.071 -179.531 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 1.5 p -62.18 -45.39 98.87 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.988 -179.275 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 94.6 mtt-85 -93.88 -9.25 37.85 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.689 -179.263 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.481 ' N ' ' O ' ' A' ' 23' ' ' ASP . 26.2 m120 54.18 41.39 32.03 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.216 179.352 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 13.9 pttm -144.45 163.58 33.4 Favored 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 109.457 -0.572 . . . . 0.0 109.457 179.768 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 78.2 m80 -94.26 148.29 22.35 Favored 'General case' 0 C--N 1.329 -0.284 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 179.158 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 27.4 m -139.6 158.87 27.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.246 -0.434 . . . . 0.0 109.836 -179.765 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 37.8 tp -103.07 120.15 40.16 Favored 'General case' 0 N--CA 1.468 0.467 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.241 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 58.5 tp -80.01 97.3 6.73 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 178.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -97.01 147.13 32.46 Favored Pre-proline 0 CA--C 1.538 0.518 0 N-CA-C 110.172 -0.307 . . . . 0.0 110.172 -179.546 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 80.8 Cg_exo -47.52 -37.75 26.74 Favored 'Trans proline' 0 N--CA 1.496 1.668 0 C-N-CA 121.419 1.412 . . . . 0.0 112.698 179.032 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 82.1 tt0 -72.84 -52.06 16.36 Favored 'General case' 0 C--N 1.331 -0.206 0 C-N-CA 120.785 -0.366 . . . . 0.0 111.205 -178.489 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 44.0 ttm180 -176.66 151.11 0.89 Allowed 'General case' 0 N--CA 1.465 0.295 0 O-C-N 123.462 0.476 . . . . 0.0 110.378 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 91.7 m -69.8 130.22 41.71 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.185 179.092 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.556 ' CD2' ' NZ ' ' A' ' 89' ' ' LYS . 95.5 m-85 -102.81 139.64 38.12 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-O 120.903 0.382 . . . . 0.0 110.504 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 95.4 m-20 -74.88 119.73 19.46 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.066 179.665 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 75.3 mt -131.38 158.66 40.16 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.364 -179.625 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -85.38 152.81 22.96 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.386 -179.727 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 68.2 t0 -58.95 -41.32 87.15 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.648 -179.711 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 43.8 t-20 -63.35 -37.59 87.85 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.537 -179.842 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -67.93 -37.84 82.15 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.75 -179.478 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 43.2 t -86.53 -19.32 8.25 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.344 0 CA-C-O 120.9 0.381 . . . . 0.0 110.543 179.529 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.73 -50.14 73.12 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.01 0.433 . . . . 0.0 110.321 -179.54 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 17.8 m -62.39 -38.06 80.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.714 179.742 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 47.9 mt -68.9 -32.5 72.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.914 0.387 . . . . 0.0 110.338 179.846 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 36.6 ttpt -87.63 -29.23 21.35 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 116.385 -0.371 . . . . 0.0 111.168 179.785 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 58.6 tp -71.47 -32.28 68.11 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-O 120.661 0.267 . . . . 0.0 110.717 -179.108 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.5 p -73.18 129.74 35.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 121.118 0.485 . . . . 0.0 110.644 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 86.6 m-20 -68.8 -43.18 76.19 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.282 179.45 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -145.36 -100.47 0.29 Allowed Glycine 0 N--CA 1.472 1.072 0 N-CA-C 110.493 -1.043 . . . . 0.0 110.493 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . 0.442 ' HE ' ' CG2' ' A' ' 11' ' ' VAL . 84.3 mtp180 -114.92 104.43 11.91 Favored 'General case' 0 N--CA 1.471 0.612 0 CA-C-N 116.897 0.349 . . . . 0.0 110.327 179.348 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 -117.6 152.13 35.77 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.05 178.07 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 71.2 p -79.18 140.32 37.75 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 178.682 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 29.6 m -54.0 -37.61 34.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 C-N-CA 120.725 -0.39 . . . . 0.0 110.456 -179.534 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 56.8 m -57.89 -43.96 86.44 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.772 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 50.6 tt0 -65.4 -46.3 80.56 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.824 0.345 . . . . 0.0 110.955 -179.534 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 66.8 mt -61.35 -42.63 94.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.312 -179.712 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.427 ' O ' ' N ' ' A' ' 65' ' ' GLY . . . -52.33 -38.44 58.58 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.893 -179.394 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 93.4 mm-40 -63.94 -49.57 72.08 Favored 'General case' 0 C--N 1.327 -0.392 0 C-N-CA 120.872 -0.331 . . . . 0.0 110.596 179.825 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 70.4 mt -64.32 -51.08 72.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.918 -179.252 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 30.0 tp -69.79 -35.63 75.04 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.028 0.442 . . . . 0.0 110.334 -179.606 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.427 ' N ' ' O ' ' A' ' 61' ' ' ALA . . . -54.22 -40.09 66.36 Favored Glycine 0 CA--C 1.525 0.698 0 N-CA-C 110.926 -0.87 . . . . 0.0 110.926 -179.487 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 51.6 mt-30 -66.15 -32.2 73.51 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.569 0.223 . . . . 0.0 110.642 179.598 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 20.8 m -62.45 -47.44 84.03 Favored 'General case' 0 C--N 1.33 -0.258 0 C-N-CA 120.752 -0.379 . . . . 0.0 110.654 -179.502 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 87.8 m-85 -92.33 -3.1 55.88 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.5 179.381 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 66.3 t0 51.6 60.96 3.48 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.996 179.649 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -144.65 164.58 30.54 Favored 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.224 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 76.6 m-20 -55.67 112.78 4.64 Favored Pre-proline 0 CA--C 1.545 0.787 0 CA-C-O 119.248 -0.406 . . . . 0.0 110.311 -179.509 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 80.0 Cg_exo -48.33 -34.74 25.8 Favored 'Trans proline' 0 N--CA 1.502 2.02 0 C-N-CA 121.926 1.751 . . . . 0.0 112.949 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -51.3 -36.54 42.94 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.954 0.407 . . . . 0.0 111.086 -179.352 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 67.8 mt -71.32 -40.44 73.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.806 179.747 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.447 ' N ' ' CD1' ' A' ' 75' ' ' ILE . 1.7 mp -60.66 -47.9 91.0 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.711 -178.6 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -61.81 -47.09 86.67 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 120.344 -0.542 . . . . 0.0 110.347 -179.162 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.428 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -65.07 -20.47 66.5 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.514 179.766 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 66.0 t0 -79.44 -52.19 8.38 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-O 120.716 0.293 . . . . 0.0 110.887 -179.628 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 13.2 pt -72.09 -40.62 67.12 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 116.299 -0.409 . . . . 0.0 111.256 -179.658 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 8.0 mt -41.19 -60.11 1.91 Allowed Pre-proline 0 CA--C 1.553 1.065 0 CA-C-O 119.586 -0.245 . . . . 0.0 111.056 -179.809 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.428 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 76.2 Cg_exo -39.53 -42.58 2.75 Favored 'Trans proline' 0 N--CA 1.493 1.471 0 C-N-CA 122.576 2.184 . . . . 0.0 112.363 177.824 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 36.2 tpp -65.76 -41.86 91.57 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.508 -179.496 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 44.7 mt -62.01 -41.71 98.37 Favored 'General case' 0 C--N 1.329 -0.283 0 C-N-CA 120.552 -0.459 . . . . 0.0 110.489 -179.031 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -63.5 -39.54 94.72 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.232 179.665 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -68.23 -40.53 87.62 Favored Glycine 0 CA--C 1.527 0.806 0 N-CA-C 111.512 -0.635 . . . . 0.0 111.512 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 66.7 mt -66.7 -39.86 88.26 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.709 0.29 . . . . 0.0 110.638 -179.608 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -52.67 -34.16 50.5 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.777 0.322 . . . . 0.0 110.516 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 77.2 mt-30 -62.87 -22.6 66.82 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.834 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . 0.556 ' NZ ' ' CD2' ' A' ' 38' ' ' PHE . 98.8 mttt -92.74 -3.75 54.27 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.412 -179.225 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 52.9 ttt180 64.43 26.94 13.56 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.549 179.327 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 26.1 m -100.23 0.58 10.39 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.492 179.795 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 45.8 tp -112.21 147.5 36.07 Favored 'General case' 0 N--CA 1.472 0.646 0 CA-C-O 121.215 0.531 . . . . 0.0 109.861 179.625 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -135.46 153.85 51.62 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.472 -0.786 . . . . 0.0 109.788 -179.307 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 50.5 ptt85 . . . . . 0 C--N 1.324 -0.516 0 CA-C-O 117.843 -1.075 . . . . 0.0 110.143 -179.298 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 81.6 mmm . . . . . 0 N--CA 1.492 1.642 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 8.3 mm-40 53.09 57.38 14.46 Favored Pre-proline 0 CA--C 1.532 0.26 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.424 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -71.23 159.67 51.26 Favored 'Trans proline' 0 N--CA 1.494 1.534 0 C-N-CA 122.317 2.011 . . . . 0.0 111.793 -179.8 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.558 ' C ' ' H ' ' A' ' 6' ' ' PHE . 5.2 p -81.3 -23.69 37.72 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.507 -179.521 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . 69.56 -22.22 0.16 Allowed 'General case' 0 CA--C 1.532 0.266 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.04 -179.778 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.558 ' H ' ' C ' ' A' ' 4' ' ' THR . 96.0 m-85 52.26 175.46 0.02 OUTLIER 'General case' 0 CA--C 1.529 0.142 0 CA-C-N 116.476 -0.329 . . . . 0.0 110.394 -179.544 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 44.3 m -133.68 179.92 5.93 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-O 120.976 0.417 . . . . 0.0 110.526 -179.598 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -65.66 -32.9 84.55 Favored Glycine 0 CA--C 1.526 0.742 0 N-CA-C 110.84 -0.904 . . . . 0.0 110.84 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 78.2 p -70.76 -22.41 62.4 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 120.677 0.275 . . . . 0.0 111.102 -179.256 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 94.9 m-20 -68.85 145.75 53.45 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 179.855 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.461 ' CG2' ' HE ' ' A' ' 54' ' ' ARG . 16.5 m -122.8 125.0 26.49 Favored Pre-proline 0 CA--C 1.545 0.772 0 CA-C-N 116.572 -0.286 . . . . 0.0 110.493 -179.303 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 86.9 Cg_endo -77.96 151.13 27.29 Favored 'Trans proline' 0 N--CA 1.492 1.431 0 C-N-CA 121.161 1.241 . . . . 0.0 111.125 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 77.9 ttt180 -158.4 128.18 5.87 Favored 'General case' 0 N--CA 1.464 0.244 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 179.343 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 30.9 mt -68.53 120.68 77.01 Favored Pre-proline 0 CA--C 1.546 0.806 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.81 -179.414 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -75.55 164.52 32.19 Favored 'Trans proline' 0 N--CA 1.497 1.692 0 C-N-CA 121.678 1.585 . . . . 0.0 111.984 -179.762 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 17.0 ptm180 -53.62 143.53 19.88 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.661 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 85.86 6.41 82.56 Favored Glycine 0 CA--C 1.52 0.384 0 N-CA-C 110.713 -0.955 . . . . 0.0 110.713 179.718 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 42.9 t -132.55 128.84 58.35 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 CA-C-O 120.982 0.42 . . . . 0.0 110.326 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 39.3 ptt180 -145.15 164.72 30.41 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.362 179.679 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 46.0 mt -94.44 138.16 32.71 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.237 -179.737 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 76.6 mtp85 -139.62 148.14 42.06 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.127 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 88.3 t80 -97.17 119.71 36.17 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.266 -179.833 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.405 ' O ' ' N ' ' A' ' 27' ' ' ASN . 87.8 m-20 -90.5 105.85 18.1 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 116.021 -0.536 . . . . 0.0 109.689 179.258 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 82.6 tt0 -64.13 -37.94 89.28 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.321 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -63.43 -43.74 98.58 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.462 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.733 -179.389 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -89.09 -14.5 36.16 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-O 120.815 0.341 . . . . 0.0 110.201 -179.484 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.405 ' N ' ' O ' ' A' ' 23' ' ' ASP . 33.8 m-20 63.08 27.93 15.94 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.753 179.723 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.28 170.9 15.4 Favored 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 179.389 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.457 ' CD2' ' HZ2' ' A' ' 49' ' ' LYS . 79.2 m80 -92.67 150.35 20.75 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.095 179.745 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 35.0 m -138.55 161.71 30.29 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.171 -179.462 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 32.4 tp -98.48 113.66 25.75 Favored 'General case' 0 N--CA 1.464 0.231 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 179.27 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 58.5 tp -77.83 95.07 4.63 Favored 'General case' 0 CA--C 1.517 -0.305 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 179.262 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -97.77 154.1 37.99 Favored Pre-proline 0 CA--C 1.537 0.473 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -63.7 -26.67 68.55 Favored 'Trans proline' 0 N--CA 1.495 1.599 0 C-N-CA 121.977 1.785 . . . . 0.0 111.673 179.789 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 42.2 tp10 -80.85 -51.98 7.99 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.699 -179.485 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 42.7 ttm180 -174.67 146.64 0.99 Allowed 'General case' 0 N--CA 1.463 0.22 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.54 -179.397 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 57.9 m -74.51 129.58 38.02 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.104 178.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 93.7 m-85 -102.79 140.2 37.37 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-N 116.515 -0.312 . . . . 0.0 110.744 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 30.8 t0 -73.89 118.47 16.88 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.288 -0.414 . . . . 0.0 109.926 179.49 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 63.2 mt -131.37 154.1 48.97 Favored 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 116.245 -0.434 . . . . 0.0 109.954 -179.755 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 80.8 m-20 -87.47 159.73 18.55 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.132 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.466 ' OD1' ' N ' ' A' ' 43' ' ' ASN . 36.6 p-10 -60.67 -39.87 90.04 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.693 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . 0.466 ' N ' ' OD1' ' A' ' 42' ' ' ASP . 50.4 t30 -64.02 -39.7 94.67 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.75 -179.747 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -68.63 -34.62 76.06 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.645 -179.671 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 59.9 t -88.83 -17.4 8.32 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 CA-C-O 120.765 0.317 . . . . 0.0 110.267 179.58 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.417 ' O ' ' N ' ' A' ' 50' ' ' LEU . . . -56.98 -47.21 81.33 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.382 -179.515 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 35.0 m -61.42 -42.32 93.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.723 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 56.5 mt -70.09 -30.52 67.76 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.455 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . 0.457 ' HZ2' ' CD2' ' A' ' 29' ' ' HIS . 36.7 ttmt -86.39 -28.85 23.34 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.884 179.778 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . 0.417 ' N ' ' O ' ' A' ' 46' ' ' ALA . 59.3 tp -72.41 -32.43 66.35 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 116.485 -0.325 . . . . 0.0 110.593 -179.239 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.6 p -74.6 129.37 36.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 121.065 0.46 . . . . 0.0 110.654 179.884 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 -72.09 -41.11 67.69 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.204 178.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -144.66 -100.29 0.3 Allowed Glycine 0 N--CA 1.473 1.145 0 N-CA-C 110.605 -0.998 . . . . 0.0 110.605 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . 0.461 ' HE ' ' CG2' ' A' ' 11' ' ' VAL . 85.3 mtp180 -114.9 104.73 12.21 Favored 'General case' 0 N--CA 1.471 0.621 0 CA-C-O 120.583 0.23 . . . . 0.0 110.411 179.462 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 94.8 m-20 -117.41 154.61 31.05 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.137 178.024 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 35.3 p -79.89 136.86 36.77 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 178.626 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 29.8 m -54.31 -37.09 35.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-O 120.935 0.398 . . . . 0.0 110.482 -179.558 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 41.3 t -58.57 -44.54 89.79 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.599 179.808 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 49.4 tt0 -64.45 -44.68 90.35 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.785 -179.587 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 96.9 mt -62.12 -43.39 97.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -53.06 -36.73 60.93 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.148 -179.083 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 70.8 mm-40 -63.25 -52.79 60.67 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.723 -0.391 . . . . 0.0 110.596 179.803 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 73.2 mt -64.46 -49.97 78.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.925 -179.173 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 10.3 tp -67.06 -39.69 86.91 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.652 -179.391 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -56.39 -41.64 88.13 Favored Glycine 0 CA--C 1.526 0.746 0 N-CA-C 111.095 -0.802 . . . . 0.0 111.095 -179.192 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 86.4 mt-30 -65.29 -31.28 72.34 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.656 0.265 . . . . 0.0 110.46 179.511 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 20.3 m -62.16 -46.25 89.81 Favored 'General case' 0 C--N 1.331 -0.212 0 C-N-CA 120.813 -0.355 . . . . 0.0 110.476 -179.666 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -92.99 1.6 57.22 Favored 'General case' 0 N--CA 1.469 0.484 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.706 179.759 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 66.1 t0 54.79 53.23 10.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.506 -0.315 . . . . 0.0 110.961 179.707 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -141.19 159.57 41.94 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 110.122 -0.325 . . . . 0.0 110.122 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 69.6 m-20 -56.02 142.16 66.12 Favored Pre-proline 0 CA--C 1.541 0.622 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.392 -179.361 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -67.65 -30.26 35.06 Favored 'Trans proline' 0 N--CA 1.503 2.045 0 C-N-CA 122.426 2.084 . . . . 0.0 112.42 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -55.34 -34.87 64.6 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.2 0.524 . . . . 0.0 110.432 -179.621 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 63.7 mt -68.87 -44.62 81.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 115.813 -0.63 . . . . 0.0 111.252 -179.566 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.43 ' N ' ' CD1' ' A' ' 75' ' ' ILE . 1.6 mp -61.94 -52.1 64.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.425 0 CA-C-N 116.614 -0.266 . . . . 0.0 111.291 -178.505 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -60.54 -46.98 88.17 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 120.253 -0.579 . . . . 0.0 110.352 -178.048 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.429 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -63.89 -23.64 67.43 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.055 -0.521 . . . . 0.0 111.303 179.827 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 66.7 t0 -78.66 -52.17 8.81 Favored 'General case' 0 N--CA 1.469 0.508 0 CA-C-N 116.531 -0.304 . . . . 0.0 111.545 -179.502 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 12.6 pt -71.14 -41.92 75.75 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.188 -179.093 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 8.3 mt -40.64 -60.56 1.53 Allowed Pre-proline 0 CA--C 1.552 1.049 0 CA-C-O 119.314 -0.374 . . . . 0.0 110.983 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.429 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 50.8 Cg_exo -38.82 -42.71 2.01 Favored 'Trans proline' 0 N--CA 1.493 1.477 0 C-N-CA 122.511 2.141 . . . . 0.0 112.182 178.203 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 41.0 ttm -66.83 -41.64 87.11 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.846 -179.363 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 36.0 mt -62.23 -40.37 95.91 Favored 'General case' 0 C--N 1.328 -0.362 0 C-N-CA 120.689 -0.404 . . . . 0.0 109.987 -178.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -63.03 -40.77 98.72 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.916 -0.583 . . . . 0.0 110.362 179.608 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -66.81 -40.63 93.75 Favored Glycine 0 CA--C 1.526 0.767 0 N-CA-C 111.346 -0.702 . . . . 0.0 111.346 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 78.4 mt -66.34 -41.27 89.8 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.713 0.292 . . . . 0.0 110.808 -179.708 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -54.97 -38.56 67.95 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.969 0.414 . . . . 0.0 110.396 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 85.4 mt-30 -64.06 -22.05 66.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.041 179.477 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -91.27 -2.49 57.41 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-O 120.733 0.301 . . . . 0.0 110.439 -179.068 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 34.3 ttm180 62.14 55.5 2.44 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.656 179.542 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 33.0 m -140.84 3.77 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.472 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.498 179.761 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 54.2 tp -140.86 131.22 25.14 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-O 120.901 0.382 . . . . 0.0 110.067 179.588 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 18.8 pt-20 -153.43 148.22 26.42 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.911 179.164 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 90.6 mtm180 . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 117.968 -1.015 . . . . 0.0 110.399 179.842 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 70.2 mtm . . . . . 0 N--CA 1.489 1.478 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 92.0 mt-10 -71.73 148.12 92.33 Favored Pre-proline 0 CA--C 1.539 0.551 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.657 -179.276 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_exo -42.99 155.45 0.12 Allowed 'Trans proline' 0 N--CA 1.494 1.522 0 C-N-CA 122.045 1.83 . . . . 0.0 112.357 179.068 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 81.9 p -75.02 -27.62 60.16 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.402 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . 51.47 99.34 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.674 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 27.9 m-85 -79.39 128.47 33.38 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.045 -0.525 . . . . 0.0 109.755 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 28.1 m -95.34 177.42 5.84 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.206 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -64.92 -38.36 95.42 Favored Glycine 0 CA--C 1.527 0.817 0 N-CA-C 111.141 -0.784 . . . . 0.0 111.141 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 38.9 m -72.94 -18.23 61.41 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.689 0.281 . . . . 0.0 110.505 -179.738 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 48.5 t0 -71.45 116.24 11.55 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.434 ' CG2' ' NH1' ' A' ' 54' ' ' ARG . 33.5 m -95.05 122.71 59.41 Favored Pre-proline 0 CA--C 1.54 0.587 0 CA-C-N 116.553 -0.294 . . . . 0.0 110.989 -179.32 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -77.58 154.52 31.13 Favored 'Trans proline' 0 N--CA 1.494 1.506 0 C-N-CA 121.531 1.487 . . . . 0.0 111.454 179.767 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 72.3 ttp85 -157.45 133.2 9.27 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 179.623 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 16.3 mt -67.17 123.04 85.37 Favored Pre-proline 0 CA--C 1.541 0.633 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.726 -178.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 92.7 Cg_endo -76.57 155.06 35.67 Favored 'Trans proline' 0 N--CA 1.492 1.397 0 C-N-CA 121.795 1.663 . . . . 0.0 111.99 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 58.4 ttt85 -57.17 151.2 15.97 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.04 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 84.31 15.79 68.28 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 111.047 -0.821 . . . . 0.0 111.047 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 62.0 t -135.55 133.92 51.91 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 CA-C-O 121.062 0.458 . . . . 0.0 110.213 179.66 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 89.5 mtm180 -136.23 153.24 51.27 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.119 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 31.9 mt -95.33 148.62 22.24 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.934 -179.836 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 86.5 mtm180 -140.09 142.61 36.08 Favored 'General case' 0 N--CA 1.463 0.218 0 CA-C-N 116.189 -0.459 . . . . 0.0 109.868 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 86.1 t80 -100.62 109.72 21.81 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.015 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -89.76 91.48 8.65 Favored 'General case' 0 N--CA 1.463 0.207 0 CA-C-N 116.077 -0.511 . . . . 0.0 109.697 179.59 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 42.3 tt0 -60.0 -33.67 72.29 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.162 -179.683 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 1.7 m -64.02 -43.31 97.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.426 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 99.9 mtt180 -86.46 -18.81 30.72 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-O 120.577 0.227 . . . . 0.0 110.522 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 60.8 t30 68.57 24.31 6.98 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.201 179.501 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.584 ' HZ1' ' CG1' ' A' ' 30' ' ' VAL . 2.7 ptmm? -145.17 167.62 22.32 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-O 121.094 0.474 . . . . 0.0 109.899 179.629 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 71.5 m80 -90.73 160.21 15.93 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.864 179.887 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.584 ' CG1' ' HZ1' ' A' ' 28' ' ' LYS . 29.5 m -142.45 147.83 20.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.021 -0.536 . . . . 0.0 109.699 179.933 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 5.8 tp -102.01 111.87 24.29 Favored 'General case' 0 N--CA 1.463 0.207 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 179.487 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 55.9 tp -79.16 95.08 5.5 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 179.169 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -93.97 145.81 30.51 Favored Pre-proline 0 CA--C 1.538 0.502 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 179.864 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 70.9 Cg_exo -45.09 -36.45 11.76 Favored 'Trans proline' 0 N--CA 1.495 1.587 0 C-N-CA 122.03 1.82 . . . . 0.0 112.652 179.088 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 46.5 tp10 -74.81 -51.97 12.65 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.93 -178.755 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 75.2 ttt180 -174.48 150.95 1.47 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.798 -179.553 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 34.4 m -69.26 132.03 45.83 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.063 -0.517 . . . . 0.0 109.954 179.184 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -106.63 128.67 54.35 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.267 -179.473 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -72.8 115.14 11.72 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.167 -0.469 . . . . 0.0 109.914 179.73 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 95.9 mt -133.22 161.09 35.4 Favored 'General case' 0 N--CA 1.469 0.475 0 CA-C-O 121.051 0.453 . . . . 0.0 110.111 -179.58 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 81.6 m-20 -84.03 159.45 21.18 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.163 -179.421 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.46 ' O ' ' N ' ' A' ' 46' ' ' ALA . 38.4 p-10 -61.55 -35.09 76.79 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.856 -179.694 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . 0.459 ' N ' ' OD1' ' A' ' 42' ' ' ASP . 88.4 m-20 -62.9 -39.92 95.99 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.64 -179.578 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -68.78 -35.51 77.15 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.729 -179.703 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 40.0 t -89.12 -20.04 7.3 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.451 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.77 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.46 ' N ' ' O ' ' A' ' 42' ' ' ASP . . . -58.33 -48.67 79.8 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.477 -179.583 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 35.4 m -61.78 -39.0 81.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.703 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 63.1 mt -69.53 -31.61 69.94 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.652 179.866 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 36.6 ttpt -88.68 -27.54 21.18 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.671 179.358 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . 0.41 ' N ' ' O ' ' A' ' 46' ' ' ALA . 55.2 tp -73.1 -32.49 65.01 Favored 'General case' 0 N--CA 1.464 0.265 0 C-N-CA 120.862 -0.335 . . . . 0.0 110.563 -178.941 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.4 p -74.11 125.82 33.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.935 0.398 . . . . 0.0 110.671 -179.822 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 95.4 m-20 -72.92 -42.16 63.79 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.252 179.408 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -143.37 -98.95 0.29 Allowed Glycine 0 N--CA 1.472 1.048 0 N-CA-C 110.477 -1.049 . . . . 0.0 110.477 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . 0.487 HH22 ' C ' ' A' ' 94' ' ' ARG . 78.4 mtp85 -114.86 104.29 11.79 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-O 121.005 0.431 . . . . 0.0 110.389 179.533 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 97.0 m-20 -117.57 152.88 34.22 Favored 'General case' 0 N--CA 1.471 0.598 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.194 178.297 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 11.2 p -82.59 141.11 32.83 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 109.683 -0.488 . . . . 0.0 109.683 178.751 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 18.9 m -56.6 -41.23 73.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.349 -179.703 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 35.4 t -58.64 -44.18 89.96 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.716 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 57.4 tt0 -64.0 -44.39 92.79 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.501 -179.823 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 96.6 mt -62.1 -43.38 97.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.261 -0.427 . . . . 0.0 109.992 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.424 ' O ' ' N ' ' A' ' 65' ' ' GLY . . . -52.12 -38.16 56.56 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.876 -179.364 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 94.1 mm-40 -63.88 -51.18 65.77 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.492 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 69.2 mt -64.72 -49.0 82.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.497 -179.37 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 34.7 tp -68.69 -36.81 78.99 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.362 -179.629 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.455 ' O ' ' N ' ' A' ' 69' ' ' ASP . . . -59.14 -41.89 96.84 Favored Glycine 0 CA--C 1.526 0.754 0 N-CA-C 111.3 -0.72 . . . . 0.0 111.3 -179.206 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 86.4 mt-30 -65.12 -31.97 73.44 Favored 'General case' 0 C--N 1.326 -0.428 0 C-N-CA 121.025 -0.27 . . . . 0.0 110.423 179.751 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 22.1 m -61.94 -48.53 80.0 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 120.682 -0.407 . . . . 0.0 110.474 -179.879 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -94.62 -3.12 50.14 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.45 179.542 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . 0.455 ' N ' ' O ' ' A' ' 65' ' ' GLY . 65.8 t0 54.0 62.26 2.68 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.694 179.698 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -138.7 160.31 39.96 Favored 'General case' 0 N--CA 1.469 0.475 0 CA-C-O 120.897 0.379 . . . . 0.0 110.152 -179.591 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 74.0 m-20 -55.9 114.8 8.13 Favored Pre-proline 0 CA--C 1.543 0.675 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.532 -179.193 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_exo -48.41 -36.39 30.48 Favored 'Trans proline' 0 N--CA 1.497 1.716 0 C-N-CA 121.88 1.72 . . . . 0.0 112.714 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -52.6 -39.24 61.41 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-O 120.968 0.413 . . . . 0.0 111.157 -179.341 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 70.8 mt -71.5 -40.13 71.58 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.699 179.69 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 38.0 mm -59.92 -49.28 84.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.915 -178.374 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 15.6 pt-20 -65.13 -42.38 93.93 Favored 'General case' 0 C--N 1.333 -0.115 0 C-N-CA 120.765 -0.374 . . . . 0.0 110.055 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.457 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -65.92 -19.86 66.02 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.19 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 66.1 t0 -79.27 -48.59 13.89 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-O 120.875 0.369 . . . . 0.0 111.107 -179.566 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 28.5 pt -78.38 -36.47 20.59 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.525 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.235 -179.199 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 9.8 mt -43.99 -60.5 2.68 Favored Pre-proline 0 CA--C 1.543 0.688 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.782 179.857 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.457 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 39.5 Cg_endo -61.71 -31.56 86.21 Favored 'Trans proline' 0 N--CA 1.496 1.67 0 C-N-CA 121.762 1.641 . . . . 0.0 111.575 179.656 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 40.1 tpp -66.72 -42.67 85.97 Favored 'General case' 0 CA--C 1.529 0.166 0 CA-C-O 120.83 0.348 . . . . 0.0 110.775 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 74.7 mt -62.85 -41.9 99.54 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.246 -179.221 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -63.31 -38.85 92.76 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.54 179.779 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -64.62 -41.22 97.89 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 83.2 mt -68.22 -39.66 82.29 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.818 0.342 . . . . 0.0 110.465 -179.764 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -52.73 -35.08 55.34 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.84 0.352 . . . . 0.0 110.639 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 87.5 mt-30 -63.32 -21.09 66.04 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.755 179.775 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -92.58 0.29 57.41 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-O 120.702 0.287 . . . . 0.0 110.402 -179.42 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 33.8 ttm180 61.45 57.93 2.22 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.444 179.818 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 33.1 m -141.54 12.57 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.28 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 50.5 tp -134.26 147.0 50.58 Favored 'General case' 0 N--CA 1.473 0.706 0 CA-C-O 121.503 0.668 . . . . 0.0 110.618 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 44.2 tp10 -147.64 140.13 24.59 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.221 -179.619 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . 0.487 ' C ' HH22 ' A' ' 54' ' ' ARG . 88.2 mtm180 . . . . . 0 C--O 1.219 -0.506 0 CA-C-O 118.101 -0.952 . . . . 0.0 110.207 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.412 ' SD ' ' N ' ' A' ' 2' ' ' GLU . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.527 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 . . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.412 ' N ' ' SD ' ' A' ' 1' ' ' MET . 10.0 pt-20 -170.63 147.35 2.48 Favored Pre-proline 0 CA--C 1.537 0.462 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.504 179.913 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -70.9 161.59 45.57 Favored 'Trans proline' 0 N--CA 1.496 1.624 0 C-N-CA 122.203 1.935 . . . . 0.0 111.874 179.592 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 7.2 p -80.49 166.72 20.93 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.569 -0.741 . . . . 0.0 109.919 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -163.72 106.08 0.96 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.25 -179.726 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 66.6 m-85 -79.9 136.22 36.61 Favored 'General case' 0 N--CA 1.463 0.207 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.391 -179.717 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 63.7 m -93.14 -174.5 3.57 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.614 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -65.96 -40.25 95.23 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 111.18 -0.768 . . . . 0.0 111.18 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 78.2 p -70.95 -24.54 62.45 Favored 'General case' 0 C--O 1.233 0.198 0 CA-C-O 120.736 0.303 . . . . 0.0 110.803 -179.669 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 95.4 m-20 -68.26 148.19 51.14 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 179.676 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 30.1 m -128.99 127.27 23.37 Favored Pre-proline 0 CA--C 1.545 0.753 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.757 -178.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -77.02 155.05 33.63 Favored 'Trans proline' 0 N--CA 1.498 1.78 0 C-N-CA 121.732 1.621 . . . . 0.0 112.243 179.731 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 71.7 ttt-85 -156.0 131.11 9.31 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.285 179.261 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 55.1 mt -69.03 113.58 17.35 Favored Pre-proline 0 CA--C 1.538 0.517 0 CA-C-O 119.074 -0.489 . . . . 0.0 111.098 -179.455 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_exo -60.77 154.06 58.14 Favored 'Trans proline' 0 N--CA 1.507 2.278 0 C-N-CA 121.903 1.735 . . . . 0.0 113.799 179.493 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 68.5 ttt-85 -51.96 132.45 32.34 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.877 178.802 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.57 -6.34 67.77 Favored Glycine 0 N--CA 1.467 0.719 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 39.2 t -106.77 127.85 61.97 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.613 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 179.252 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 33.2 ptt180 -142.24 158.85 43.27 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.44 -0.8 . . . . 0.0 110.365 -179.299 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 15.9 mt -95.32 107.62 19.75 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.693 -179.109 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 84.6 mtp180 -98.46 137.97 36.36 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.406 179.23 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.468 ' O ' ' CD1' ' A' ' 22' ' ' PHE . 38.3 p90 -100.34 114.81 28.61 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.163 179.623 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -88.09 92.02 8.99 Favored 'General case' 0 N--CA 1.464 0.239 0 CA-C-N 116.207 -0.451 . . . . 0.0 109.914 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -60.56 -34.11 73.68 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.18 -179.796 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -63.5 -43.61 98.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.416 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -88.77 -7.43 56.24 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-O 120.776 0.322 . . . . 0.0 110.269 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 65.2 t30 60.3 30.32 19.73 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.83 179.645 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.494 ' NZ ' ' OD1' ' A' ' 39' ' ' ASP . 15.9 ptpt -145.34 168.74 19.76 Favored 'General case' 0 N--CA 1.47 0.553 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 178.774 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 69.8 m80 -99.39 150.15 22.44 Favored 'General case' 0 CA--C 1.518 -0.261 0 CA-C-N 116.017 -0.538 . . . . 0.0 109.829 178.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 34.2 m -137.66 155.46 30.89 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.206 -179.602 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 35.1 tp -102.47 121.94 43.34 Favored 'General case' 0 N--CA 1.468 0.447 0 CA-C-N 116.263 -0.426 . . . . 0.0 109.901 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 48.2 tp -77.26 100.5 5.87 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 179.151 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -95.7 145.21 29.15 Favored Pre-proline 0 CA--C 1.537 0.461 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_exo -47.17 -37.46 23.64 Favored 'Trans proline' 0 N--CA 1.493 1.447 0 C-N-CA 121.28 1.32 . . . . 0.0 112.243 179.183 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 9.5 tm-20 -74.62 -52.28 12.16 Favored 'General case' 0 N--CA 1.462 0.164 0 C-N-CA 120.812 -0.355 . . . . 0.0 111.863 -178.718 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 58.1 ttt85 -175.67 153.6 1.45 Allowed 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 120.798 0.332 . . . . 0.0 110.518 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 75.8 m -67.19 133.42 49.73 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.431 -0.35 . . . . 0.0 110.381 179.315 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 69.8 m-85 -108.84 141.43 40.89 Favored 'General case' 0 N--CA 1.472 0.642 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.954 -179.516 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.494 ' OD1' ' NZ ' ' A' ' 28' ' ' LYS . 37.1 t0 -73.18 121.01 19.59 Favored 'General case' 0 C--N 1.333 -0.13 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.148 179.144 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 72.3 mt -136.42 157.47 46.72 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-N 115.973 -0.558 . . . . 0.0 109.777 179.712 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 95.3 m-20 -85.47 154.06 22.05 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.382 -179.659 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 68.1 t0 -59.7 -38.4 81.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.982 -0.553 . . . . 0.0 110.545 -179.79 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 97.7 m-20 -63.1 -39.15 93.85 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.636 -179.687 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.26 -41.05 77.44 Favored 'General case' 0 C--N 1.329 -0.284 0 C-N-CA 120.899 -0.321 . . . . 0.0 110.886 -179.605 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 44.0 t -79.59 -27.87 12.83 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-O 120.714 0.293 . . . . 0.0 110.385 179.878 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.44 ' O ' ' N ' ' A' ' 50' ' ' LEU . . . -54.72 -39.1 67.88 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.016 -179.61 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 90.5 t -60.67 -48.07 90.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.355 179.824 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 49.7 mt -70.43 -29.54 66.16 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.234 -179.688 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 3.1 ttmp? -82.07 -29.05 32.04 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.701 179.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . 0.44 ' N ' ' O ' ' A' ' 46' ' ' ALA . 50.2 tp -71.78 -32.61 67.83 Favored 'General case' 0 N--CA 1.465 0.276 0 C-N-CA 121.012 -0.275 . . . . 0.0 110.704 -178.926 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.7 p -77.55 128.47 38.06 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.345 0 CA-C-O 121.078 0.466 . . . . 0.0 110.604 179.567 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 -68.61 -43.12 77.08 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.351 179.218 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -146.84 -97.16 0.19 Allowed Glycine 0 N--CA 1.471 0.992 0 N-CA-C 110.488 -1.045 . . . . 0.0 110.488 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 89.2 mtm180 -114.9 104.86 12.35 Favored 'General case' 0 N--CA 1.471 0.6 0 CA-C-O 120.66 0.267 . . . . 0.0 110.658 179.286 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 93.9 m-20 -117.07 147.92 41.96 Favored 'General case' 0 N--CA 1.472 0.66 0 CA-C-N 116.156 -0.475 . . . . 0.0 109.862 177.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 15.3 p -78.74 142.15 37.27 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.057 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 33.0 m -55.76 -38.45 51.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.789 0.328 . . . . 0.0 110.461 -179.578 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 38.7 t -58.88 -44.83 91.19 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.691 179.789 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 10.6 tp-100 -65.32 -45.59 83.69 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.917 -179.588 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 85.3 mt -60.93 -42.65 93.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 121.062 0.458 . . . . 0.0 109.911 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.413 ' O ' ' N ' ' A' ' 65' ' ' GLY . . . -51.93 -40.06 60.17 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.249 -179.192 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 97.1 mm-40 -63.41 -51.38 66.02 Favored 'General case' 0 C--N 1.325 -0.469 0 C-N-CA 120.577 -0.449 . . . . 0.0 110.593 179.757 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 73.5 mt -65.09 -50.68 73.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.162 -179.312 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . 0.411 ' O ' ' OG1' ' A' ' 67' ' ' THR . 23.9 tp -69.62 -34.74 74.5 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.095 0.474 . . . . 0.0 110.611 -179.061 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.413 ' N ' ' O ' ' A' ' 61' ' ' ALA . . . -58.54 -43.22 96.16 Favored Glycine 0 CA--C 1.527 0.824 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 -179.584 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 87.8 mt-30 -67.31 -38.66 85.3 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.664 0.269 . . . . 0.0 110.981 179.709 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.411 ' OG1' ' O ' ' A' ' 64' ' ' LEU . 38.6 p -63.42 -38.29 90.57 Favored 'General case' 0 C--N 1.332 -0.188 0 C-N-CA 120.888 -0.325 . . . . 0.0 110.566 -179.411 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 30.4 m-85 -93.83 0.91 56.48 Favored 'General case' 0 N--CA 1.47 0.528 0 N-CA-C 110.057 -0.349 . . . . 0.0 110.057 179.515 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 66.6 t0 52.47 48.36 22.74 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.769 0.318 . . . . 0.0 110.881 179.556 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -140.86 158.49 43.87 Favored 'General case' 0 N--CA 1.469 0.502 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.43 -179.457 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 22.0 m-20 -56.07 144.14 60.29 Favored Pre-proline 0 CA--C 1.54 0.575 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.501 -179.374 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -67.82 -31.39 31.87 Favored 'Trans proline' 0 N--CA 1.501 1.937 0 C-N-CA 122.419 2.079 . . . . 0.0 112.097 -179.791 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -54.42 -33.67 59.89 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.076 0.465 . . . . 0.0 110.575 -179.712 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 65.4 mt -69.35 -43.45 81.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.423 -179.577 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.439 ' N ' ' CD1' ' A' ' 75' ' ' ILE . 1.7 mp -62.65 -48.34 88.65 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 C-N-CA 120.482 -0.487 . . . . 0.0 111.186 -178.131 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -60.61 -45.83 92.56 Favored 'General case' 0 C--N 1.325 -0.467 0 C-N-CA 119.94 -0.704 . . . . 0.0 110.097 -178.468 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.42 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -65.59 -23.44 66.84 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.25 179.445 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 64.2 t0 -78.5 -49.47 13.32 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.541 -0.3 . . . . 0.0 111.36 -179.301 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 15.3 pt -75.72 -37.27 35.54 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.41 0 CA-C-N 116.412 -0.358 . . . . 0.0 111.544 -179.224 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 8.9 mt -43.35 -59.74 3.04 Favored Pre-proline 0 CA--C 1.547 0.835 0 CA-C-O 119.748 -0.168 . . . . 0.0 111.137 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.42 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 43.0 Cg_endo -62.46 -31.46 80.66 Favored 'Trans proline' 0 N--CA 1.498 1.743 0 C-N-CA 121.954 1.769 . . . . 0.0 111.759 179.656 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 42.8 tpp -66.91 -43.1 84.22 Favored 'General case' 0 C--N 1.333 -0.112 0 C-N-CA 120.773 -0.371 . . . . 0.0 110.014 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 87.2 mt -62.67 -42.05 99.41 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.185 -179.547 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -63.78 -37.39 87.19 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.36 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -64.19 -38.35 95.81 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 111.089 -0.805 . . . . 0.0 111.089 -179.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 87.3 mt -68.07 -36.65 80.19 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.787 0.327 . . . . 0.0 110.291 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -53.29 -27.41 22.77 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.827 -179.672 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 86.2 mt-30 -61.89 -26.24 68.04 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.491 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 46.7 mtmt -94.08 -1.87 53.7 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.092 -179.672 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 59.7 ttt180 60.24 38.92 19.68 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.783 -0.644 . . . . 0.0 109.911 179.638 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 31.7 m -109.86 -3.75 10.58 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.585 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.354 179.858 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 38.3 tp -113.95 143.68 44.33 Favored 'General case' 0 N--CA 1.475 0.814 0 CA-C-O 121.274 0.559 . . . . 0.0 110.775 -179.369 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 40.1 tp10 -151.67 150.11 29.88 Favored 'General case' 0 CA--C 1.519 -0.245 0 CA-C-N 115.231 -0.895 . . . . 0.0 109.731 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 91.4 mtm180 . . . . . 0 C--N 1.314 -0.971 0 CA-C-O 118.062 -0.97 . . . . 0.0 110.284 179.011 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 72.2 mtm . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 57.8 mm-40 45.5 73.58 0.95 Allowed Pre-proline 0 CA--C 1.533 0.293 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.952 -179.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_exo -57.81 142.48 96.23 Favored 'Trans proline' 0 N--CA 1.497 1.681 0 C-N-CA 122.333 2.022 . . . . 0.0 112.009 -179.739 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.459 ' OG1' ' CE1' ' A' ' 6' ' ' PHE . 24.5 p -84.52 112.6 20.55 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.061 179.722 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -76.16 108.33 9.01 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.62 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.459 ' CE1' ' OG1' ' A' ' 4' ' ' THR . 95.4 m-85 -81.72 135.6 35.49 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.284 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 44.3 m -91.87 178.57 5.86 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.693 -179.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -65.8 -33.12 84.95 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 111.157 -0.777 . . . . 0.0 111.157 179.799 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 31.7 t -71.22 -20.57 62.24 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.7 0.286 . . . . 0.0 111.427 -178.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . 0.412 ' CG ' ' NH2' ' A' ' 94' ' ' ARG . 92.6 m-20 -71.67 124.97 25.92 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 -179.732 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.466 HG23 ' HE ' ' A' ' 54' ' ' ARG . 27.4 m -101.69 116.32 63.63 Favored Pre-proline 0 CA--C 1.56 1.351 0 N-CA-C 113.525 0.935 . . . . 0.0 113.525 -177.523 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_endo -58.79 143.31 99.14 Favored 'Trans proline' 0 N--CA 1.511 2.508 0 C-N-CA 121.52 1.48 . . . . 0.0 113.595 178.186 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.457 ' NH1' ' OE2' ' A' ' 93' ' ' GLU . 70.0 ttp85 -158.27 121.77 3.95 Favored 'General case' 0 N--CA 1.47 0.539 0 CA-C-N 115.637 -0.711 . . . . 0.0 109.559 177.074 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 53.1 mt -66.82 122.04 80.49 Favored Pre-proline 0 CA--C 1.543 0.708 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.594 -179.523 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 96.9 Cg_endo -78.11 160.8 29.8 Favored 'Trans proline' 0 N--CA 1.491 1.374 0 C-N-CA 121.893 1.729 . . . . 0.0 111.743 -179.554 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 17.2 ptm180 -53.54 150.98 6.23 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.759 179.571 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 82.15 6.41 88.84 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.975 -0.85 . . . . 0.0 110.975 179.562 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 45.8 t -129.48 126.05 62.7 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.582 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 83.5 mtp180 -138.24 158.18 44.81 Favored 'General case' 0 N--CA 1.468 0.436 0 CA-C-N 116.085 -0.507 . . . . 0.0 109.939 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 21.9 mt -94.15 103.35 15.4 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.139 -179.653 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 96.8 mtt180 -92.81 139.69 30.28 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.122 179.456 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.472 ' O ' ' CD1' ' A' ' 22' ' ' PHE . 38.3 p90 -102.85 116.19 32.08 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.024 179.635 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.454 ' O ' ' N ' ' A' ' 27' ' ' ASN . 87.9 m-20 -87.5 95.04 9.89 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 116.234 -0.439 . . . . 0.0 109.896 -179.816 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 42.0 tt0 -61.21 -35.59 77.61 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.414 -179.634 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 3.4 m -63.77 -43.35 97.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.556 -179.788 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -92.1 -7.43 48.61 Favored 'General case' 0 N--CA 1.469 0.484 0 CA-C-O 120.742 0.306 . . . . 0.0 110.493 179.735 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.454 ' N ' ' O ' ' A' ' 23' ' ' ASP . 18.3 t-20 55.42 37.17 28.51 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.3 179.638 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -145.14 158.03 43.93 Favored 'General case' 0 N--CA 1.469 0.519 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 179.55 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 77.9 m80 -94.06 148.69 21.92 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.121 179.637 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 33.6 m -136.89 157.19 35.8 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.247 -179.857 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 41.0 tp -100.36 123.44 44.59 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.16 -179.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 38.9 tp -77.36 98.99 5.41 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 179.067 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -93.89 148.18 34.82 Favored Pre-proline 0 CA--C 1.54 0.56 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 -179.601 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_exo -46.74 -33.64 14.15 Favored 'Trans proline' 0 N--CA 1.497 1.73 0 C-N-CA 121.551 1.501 . . . . 0.0 112.292 179.013 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -71.24 -51.68 23.21 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.772 -179.086 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 60.3 ttt85 -172.26 -96.64 0.01 OUTLIER 'General case' 0 CA--C 1.531 0.245 0 CA-C-N 116.598 -0.273 . . . . 0.0 110.543 179.827 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 90.1 m -165.95 151.81 9.05 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.292 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 53.2 m-85 -125.99 137.7 53.69 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-O 120.967 0.413 . . . . 0.0 110.593 -179.641 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 38.8 p-10 -71.04 117.92 13.15 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.357 179.643 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 89.1 mt -134.25 155.98 49.2 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.021 -179.769 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 86.2 m-20 -85.09 154.78 21.83 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.976 0.417 . . . . 0.0 110.201 -179.74 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.462 ' OD1' ' N ' ' A' ' 43' ' ' ASN . 36.6 p-10 -59.96 -37.66 80.23 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.64 -179.867 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . 0.462 ' N ' ' OD1' ' A' ' 42' ' ' ASP . 5.4 m120 -64.2 -39.63 94.39 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.472 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.06 -39.99 78.78 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.468 -0.333 . . . . 0.0 110.917 -179.457 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 66.0 t -78.7 -26.52 13.68 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.239 0 CA-C-O 120.74 0.305 . . . . 0.0 110.271 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.428 ' O ' ' N ' ' A' ' 50' ' ' LEU . . . -58.1 -36.08 72.35 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.355 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 84.0 t -59.93 -47.71 90.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.42 -179.684 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 47.2 mt -70.95 -29.53 65.57 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.373 -179.634 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 36.0 ttpt -83.38 -23.5 32.4 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.651 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . 0.428 ' N ' ' O ' ' A' ' 46' ' ' ALA . 60.4 tp -70.4 -32.55 70.24 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-O 120.735 0.302 . . . . 0.0 110.586 -179.477 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 2.4 p -75.17 130.1 36.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-O 121.047 0.451 . . . . 0.0 110.638 179.78 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 -70.12 -44.86 68.07 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.612 179.291 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -143.32 -96.96 0.24 Allowed Glycine 0 N--CA 1.473 1.152 0 N-CA-C 110.341 -1.104 . . . . 0.0 110.341 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . 0.466 ' HE ' HG23 ' A' ' 11' ' ' VAL . 83.9 mtp180 -114.85 104.68 12.18 Favored 'General case' 0 N--CA 1.472 0.661 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 179.06 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 96.9 m-20 -117.28 145.49 43.94 Favored 'General case' 0 N--CA 1.476 0.86 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.16 178.465 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 48.4 p -78.3 140.18 38.83 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 178.528 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 33.0 m -53.44 -38.22 32.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 120.837 0.351 . . . . 0.0 110.325 -179.358 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 38.5 t -59.93 -44.3 94.42 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.892 179.395 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 50.8 tt0 -64.69 -45.88 84.75 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.534 -0.303 . . . . 0.0 110.862 -179.266 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 66.5 mt -60.76 -42.73 93.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 120.88 0.372 . . . . 0.0 110.021 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.467 ' O ' ' N ' ' A' ' 65' ' ' GLY . . . -52.71 -38.41 60.69 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.679 -179.585 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 98.4 mm-40 -63.7 -51.13 66.38 Favored 'General case' 0 C--N 1.329 -0.297 0 C-N-CA 120.583 -0.447 . . . . 0.0 110.683 179.816 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 73.7 mt -64.63 -48.84 83.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.776 0.322 . . . . 0.0 110.677 -179.396 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . 0.435 ' O ' ' OG1' ' A' ' 67' ' ' THR . 28.7 tp -69.95 -32.49 70.77 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.169 0.509 . . . . 0.0 110.19 -179.771 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.467 ' N ' ' O ' ' A' ' 61' ' ' ALA . . . -61.84 -41.64 99.65 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.871 -0.892 . . . . 0.0 110.871 -179.719 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 93.8 mt-30 -66.74 -38.43 86.64 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 121.049 -0.26 . . . . 0.0 110.339 179.551 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.435 ' OG1' ' O ' ' A' ' 64' ' ' LEU . 37.3 p -64.05 -39.9 95.11 Favored 'General case' 0 C--N 1.329 -0.283 0 C-N-CA 120.779 -0.368 . . . . 0.0 110.361 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 40.3 m-85 -95.97 -1.3 49.35 Favored 'General case' 0 N--CA 1.472 0.651 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 179.359 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . 0.451 ' N ' ' O ' ' A' ' 65' ' ' GLY . 50.7 t0 47.97 61.85 2.78 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.737 0.304 . . . . 0.0 111.159 179.749 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -144.24 160.49 40.89 Favored 'General case' 0 N--CA 1.468 0.425 0 CA-C-N 116.378 -0.373 . . . . 0.0 110.484 -179.762 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 56.2 m-20 -55.37 113.99 6.47 Favored Pre-proline 0 CA--C 1.542 0.646 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.578 -179.708 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_exo -48.76 -37.61 35.86 Favored 'Trans proline' 0 N--CA 1.5 1.889 0 C-N-CA 121.784 1.656 . . . . 0.0 112.928 179.765 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -52.8 -39.99 62.85 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.817 0.342 . . . . 0.0 111.244 -179.104 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 75.0 mt -70.65 -39.31 75.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-O 120.796 0.331 . . . . 0.0 110.315 179.378 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 42.9 mm -60.31 -48.57 87.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.351 -178.638 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -62.21 -45.21 94.36 Favored 'General case' 0 C--N 1.331 -0.201 0 C-N-CA 120.083 -0.647 . . . . 0.0 109.77 -179.776 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.437 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -65.76 -20.7 66.36 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.261 179.584 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 65.6 t0 -79.74 -49.58 11.84 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-O 120.823 0.344 . . . . 0.0 111.551 -179.396 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 17.1 pt -72.17 -39.27 64.67 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.483 -179.423 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 6.8 mt -43.93 -59.68 3.39 Favored Pre-proline 0 CA--C 1.545 0.762 0 CA-C-O 119.509 -0.281 . . . . 0.0 111.039 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.437 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 62.3 Cg_exo -39.82 -42.81 3.18 Favored 'Trans proline' 0 N--CA 1.493 1.444 0 C-N-CA 122.451 2.101 . . . . 0.0 112.186 177.901 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 40.3 tpp -64.77 -41.21 96.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.191 -179.277 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 44.5 mt -62.5 -40.75 97.71 Favored 'General case' 0 C--N 1.327 -0.392 0 C-N-CA 120.585 -0.446 . . . . 0.0 110.027 -179.609 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -63.57 -40.92 98.21 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.325 179.542 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -67.54 -41.75 89.63 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 111.125 -0.79 . . . . 0.0 111.125 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 76.5 mt -66.89 -39.82 87.56 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.673 0.273 . . . . 0.0 110.618 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -52.58 -35.94 55.04 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 120.785 -0.366 . . . . 0.0 110.746 -179.771 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 86.5 mt-30 -63.28 -19.14 64.31 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.78 179.831 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 61.0 mttp -93.65 1.28 56.66 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.41 -179.12 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 65.8 ttt-85 60.23 58.74 2.53 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.542 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 35.4 m -141.78 16.42 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.156 179.71 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 42.6 tp -139.64 143.54 37.24 Favored 'General case' 0 N--CA 1.471 0.578 0 CA-C-O 120.988 0.423 . . . . 0.0 110.218 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.457 ' OE2' ' NH1' ' A' ' 13' ' ' ARG . 20.9 pt-20 -148.42 173.6 12.92 Favored 'General case' 0 N--CA 1.462 0.16 0 CA-C-N 115.626 -0.715 . . . . 0.0 110.312 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . 0.412 ' NH2' ' CG ' ' A' ' 10' ' ' ASP . 0.3 OUTLIER . . . . . 0 C--O 1.22 -0.466 0 CA-C-O 118.025 -0.988 . . . . 0.0 110.573 -179.46 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 72.2 mtm . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 109.091 -0.707 . . . . 0.0 109.091 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 -166.53 62.04 0.69 Allowed Pre-proline 0 CA--C 1.533 0.316 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.236 179.631 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 75.8 Cg_endo -74.13 165.77 31.17 Favored 'Trans proline' 0 N--CA 1.494 1.522 0 C-N-CA 122.389 2.059 . . . . 0.0 111.877 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 11.2 p -79.05 90.09 4.81 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.27 -179.689 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.51 120.57 21.11 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.046 -179.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -80.67 144.84 31.96 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.33 -0.396 . . . . 0.0 110.022 -179.89 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 16.5 m -88.58 175.04 7.73 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-O 120.85 0.357 . . . . 0.0 110.469 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -66.5 -37.89 92.99 Favored Glycine 0 CA--C 1.527 0.813 0 N-CA-C 111.272 -0.731 . . . . 0.0 111.272 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 74.6 m -71.77 -16.75 62.2 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.729 0.299 . . . . 0.0 110.479 -179.661 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 17.6 t70 -66.85 152.66 45.18 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 179.633 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 28.9 m -129.15 123.56 21.77 Favored Pre-proline 0 N--CA 1.474 0.757 0 CA-C-O 119.607 -0.235 . . . . 0.0 110.716 -179.731 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_endo -76.94 150.5 30.15 Favored 'Trans proline' 0 N--CA 1.494 1.5 0 C-N-CA 121.39 1.393 . . . . 0.0 111.578 -179.882 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 72.7 ttp85 -158.12 130.94 7.3 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.467 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 61.8 mt -68.0 121.68 80.86 Favored Pre-proline 0 CA--C 1.544 0.738 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.913 -179.222 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 91.3 Cg_endo -76.42 160.96 35.09 Favored 'Trans proline' 0 N--CA 1.493 1.456 0 C-N-CA 121.757 1.638 . . . . 0.0 112.028 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 9.5 ptm180 -54.83 153.35 6.22 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.513 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 79.31 12.91 83.39 Favored Glycine 0 CA--C 1.523 0.545 0 N-CA-C 111.218 -0.753 . . . . 0.0 111.218 179.609 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 46.4 t -134.05 130.06 54.7 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.593 0 CA-C-O 120.927 0.394 . . . . 0.0 110.173 179.655 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 83.5 mtm-85 -140.12 157.2 46.0 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.097 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 23.4 mt -95.79 104.96 16.91 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.215 -0.448 . . . . 0.0 109.866 179.864 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 85.1 mtp180 -90.48 141.35 28.84 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 116.095 -0.502 . . . . 0.0 109.931 179.777 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 78.4 t80 -98.95 104.04 16.05 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.236 -0.438 . . . . 0.0 109.875 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 86.8 m-20 -88.81 93.3 9.53 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-N 115.964 -0.562 . . . . 0.0 109.922 179.742 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -62.38 -34.13 76.1 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.226 -179.913 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 1.8 m -63.81 -42.05 94.6 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.366 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 99.9 mtt180 -82.24 -16.63 48.9 Favored 'General case' 0 N--CA 1.465 0.296 0 N-CA-C 110.276 -0.268 . . . . 0.0 110.276 -179.792 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 64.8 t30 66.72 19.78 10.72 Favored 'General case' 0 N--CA 1.467 0.387 0 O-C-N 123.56 0.537 . . . . 0.0 111.014 179.685 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 14.8 ptpt -145.03 165.13 29.09 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-O 121.019 0.438 . . . . 0.0 110.097 179.331 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.487 ' ND1' ' OD1' ' A' ' 42' ' ' ASP . 79.7 m80 -87.89 154.32 20.61 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.808 -0.633 . . . . 0.0 109.502 179.382 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 25.8 m -137.9 157.34 32.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.083 -0.508 . . . . 0.0 109.865 -179.625 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 37.7 tp -109.48 120.84 43.72 Favored 'General case' 0 N--CA 1.467 0.399 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 178.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 61.4 tp -78.26 95.78 5.09 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 178.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -94.66 146.37 31.31 Favored Pre-proline 0 CA--C 1.54 0.586 0 N-CA-C 109.673 -0.491 . . . . 0.0 109.673 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 78.8 Cg_exo -46.34 -35.7 16.25 Favored 'Trans proline' 0 N--CA 1.497 1.702 0 C-N-CA 121.784 1.656 . . . . 0.0 112.658 179.068 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -74.56 -52.04 12.93 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.638 -0.255 . . . . 0.0 111.069 -178.451 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 17.7 ptp180 -176.59 162.72 2.3 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-O 120.861 0.362 . . . . 0.0 110.646 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 58.2 m -73.67 125.16 27.42 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.171 179.048 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 78.6 m-85 -103.54 130.01 50.86 Favored 'General case' 0 N--CA 1.472 0.647 0 CA-C-O 120.864 0.364 . . . . 0.0 110.099 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -71.71 120.3 17.11 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.138 179.82 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 90.2 mt -130.52 158.96 38.52 Favored 'General case' 0 N--CA 1.468 0.464 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.042 -179.532 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 16.7 m-20 -84.22 160.03 20.88 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.165 -179.518 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.487 ' OD1' ' ND1' ' A' ' 29' ' ' HIS . 84.8 m-20 -61.32 -40.71 95.2 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.529 -179.847 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 49.9 t30 -62.38 -37.61 86.39 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.789 -179.249 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -68.64 -41.91 78.76 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.497 -0.32 . . . . 0.0 110.963 -179.51 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 49.0 t -80.4 -27.12 11.63 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.183 0 CA-C-O 120.678 0.275 . . . . 0.0 110.423 179.803 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.47 ' O ' ' N ' ' A' ' 50' ' ' LEU . . . -57.31 -41.47 79.97 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.436 -179.85 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 94.5 t -60.62 -47.34 93.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.367 -179.824 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 49.5 mt -70.16 -32.2 70.05 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.508 -179.612 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 37.9 ttmt -82.17 -26.22 33.62 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.458 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . 0.47 ' N ' ' O ' ' A' ' 46' ' ' ALA . 53.6 tp -69.29 -32.92 72.4 Favored 'General case' 0 N--CA 1.462 0.171 0 C-N-CA 120.531 -0.468 . . . . 0.0 110.08 -179.299 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 2.7 p -76.92 129.72 37.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.99 0.424 . . . . 0.0 110.501 179.803 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -72.98 -45.49 57.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.112 179.258 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -140.23 -99.21 0.4 Allowed Glycine 0 N--CA 1.473 1.146 0 N-CA-C 110.633 -0.987 . . . . 0.0 110.633 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 95.2 mtt180 -114.87 104.82 12.31 Favored 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 179.147 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 -116.95 144.51 44.47 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.002 178.68 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 21.6 p -79.15 141.3 37.37 Favored 'General case' 0 C--N 1.327 -0.398 0 N-CA-C 109.664 -0.495 . . . . 0.0 109.664 179.05 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 34.1 m -53.95 -37.68 34.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.252 -179.66 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 69.9 m -58.38 -44.64 88.99 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.639 179.704 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 54.0 tt0 -65.08 -46.99 78.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.518 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 66.1 mt -61.91 -43.06 96.93 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.192 179.801 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.443 ' O ' ' N ' ' A' ' 65' ' ' GLY . . . -53.39 -38.39 63.35 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.143 -179.204 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 80.6 mm-40 -63.51 -52.34 61.64 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.637 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 70.0 mt -64.67 -50.67 74.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.941 -179.046 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 20.9 tp -69.37 -38.46 78.07 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.596 -179.334 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.443 ' N ' ' O ' ' A' ' 61' ' ' ALA . . . -54.71 -42.19 77.09 Favored Glycine 0 CA--C 1.524 0.612 0 N-CA-C 111.131 -0.788 . . . . 0.0 111.131 -179.279 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 87.0 mt-30 -64.65 -31.85 73.25 Favored 'General case' 0 C--N 1.327 -0.37 0 C-N-CA 120.984 -0.286 . . . . 0.0 110.546 179.656 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 19.4 m -62.04 -46.52 88.78 Favored 'General case' 0 C--N 1.33 -0.25 0 C-N-CA 120.764 -0.374 . . . . 0.0 110.627 -179.835 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 90.7 m-85 -91.08 -0.6 57.76 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.451 179.652 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 64.8 t0 54.26 51.85 13.64 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.744 179.687 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -140.13 157.29 45.86 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.18 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 16.6 m-20 -56.77 141.96 73.02 Favored Pre-proline 0 CA--C 1.545 0.771 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.078 -178.846 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -66.46 -28.46 45.97 Favored 'Trans proline' 0 N--CA 1.503 2.072 0 C-N-CA 122.618 2.212 . . . . 0.0 112.752 -179.171 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -54.93 -29.51 56.56 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.945 0.402 . . . . 0.0 110.748 -179.242 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.523 ' N ' ' CD1' ' A' ' 74' ' ' ILE . 1.6 mp -78.58 -44.61 26.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.111 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.446 ' N ' ' CD1' ' A' ' 75' ' ' ILE . 1.7 mp -62.46 -47.72 91.69 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.641 -178.046 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 14.9 pt-20 -60.34 -46.35 90.22 Favored 'General case' 0 C--N 1.324 -0.526 0 C-N-CA 120.416 -0.514 . . . . 0.0 110.443 -178.502 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.44 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -67.6 -20.6 65.38 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.096 179.759 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 66.0 t0 -80.74 -47.59 13.73 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 120.727 0.298 . . . . 0.0 111.508 -179.47 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 18.0 pt -71.46 -41.03 72.94 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 CA-C-N 116.385 -0.371 . . . . 0.0 111.136 -179.117 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 7.2 mt -43.0 -61.13 1.89 Allowed Pre-proline 0 CA--C 1.548 0.894 0 CA-C-N 116.522 -0.308 . . . . 0.0 110.843 179.544 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.44 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 61.9 Cg_exo -38.94 -41.54 1.79 Allowed 'Trans proline' 0 N--CA 1.492 1.435 0 C-N-CA 122.707 2.272 . . . . 0.0 112.264 177.845 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 14.2 tpt -65.63 -40.71 92.85 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.6 -179.191 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 47.2 mt -61.42 -40.41 94.32 Favored 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 120.59 -0.444 . . . . 0.0 110.3 -179.293 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -63.71 -40.02 95.73 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 120.839 0.352 . . . . 0.0 110.335 179.469 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -67.82 -39.78 89.74 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 111.405 -0.678 . . . . 0.0 111.405 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 73.8 mt -67.01 -38.51 86.11 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.752 0.311 . . . . 0.0 110.525 -179.605 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -53.93 -36.3 62.63 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.89 0.376 . . . . 0.0 110.459 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 83.7 mt-30 -63.06 -23.9 67.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.795 179.764 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -90.7 -3.18 57.67 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-O 120.684 0.278 . . . . 0.0 110.342 -179.382 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 14.5 tpt180 63.97 51.35 2.31 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.992 179.498 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 30.8 m -139.29 10.53 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.283 179.889 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -141.53 123.23 15.18 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-O 121.14 0.495 . . . . 0.0 109.755 -179.901 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -153.29 137.93 16.92 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.24 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 49.0 ptt85 . . . . . 0 C--N 1.325 -0.48 0 CA-C-O 117.901 -1.047 . . . . 0.0 110.597 179.787 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.52 ' SD ' ' N ' ' A' ' 1' ' ' MET . 2.0 mpt? . . . . . 0 N--CA 1.491 1.593 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -168.24 71.6 0.85 Allowed Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.28 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -54.07 165.37 2.08 Favored 'Trans proline' 0 N--CA 1.495 1.566 0 C-N-CA 122.574 2.183 . . . . 0.0 111.885 179.523 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 5.2 t -149.9 178.0 9.32 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.111 -179.626 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -158.15 120.11 3.64 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.059 -179.483 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 64.1 m-85 -77.58 139.02 39.47 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.175 179.866 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 15.9 m -94.41 179.48 5.27 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-O 120.786 0.327 . . . . 0.0 110.228 179.888 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -65.0 -43.06 96.4 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.691 -0.963 . . . . 0.0 110.691 179.761 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 27.9 t -72.84 -25.39 61.1 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.864 0.364 . . . . 0.0 110.605 179.826 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . 0.44 ' OD1' ' N ' ' A' ' 11' ' ' VAL . 60.5 t0 -67.82 135.95 53.37 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 179.848 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.44 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 15.5 m -117.59 129.6 25.24 Favored Pre-proline 0 CA--C 1.546 0.822 0 CA-C-O 119.621 -0.228 . . . . 0.0 111.123 -179.091 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -79.56 157.58 25.17 Favored 'Trans proline' 0 N--CA 1.493 1.494 0 C-N-CA 121.899 1.733 . . . . 0.0 111.133 179.005 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 58.3 ttt85 -157.99 127.52 5.9 Favored 'General case' 0 N--CA 1.466 0.346 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 179.162 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 58.9 mt -67.39 118.21 54.35 Favored Pre-proline 0 CA--C 1.541 0.61 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.937 -179.328 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -76.58 160.68 34.79 Favored 'Trans proline' 0 N--CA 1.49 1.292 0 C-N-CA 121.731 1.621 . . . . 0.0 111.789 -179.723 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 78.3 ttt180 -54.52 141.0 32.8 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.423 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 92.96 6.29 63.53 Favored Glycine 0 N--CA 1.465 0.585 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 179.896 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 51.2 t -130.63 129.76 64.4 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.535 0 CA-C-O 120.915 0.388 . . . . 0.0 110.0 179.505 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 63.3 mtt-85 -143.42 155.93 44.52 Favored 'General case' 0 N--CA 1.462 0.131 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.064 -179.568 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 16.2 mt -94.67 100.13 12.12 Favored 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.582 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.401 ' HE ' ' CD2' ' A' ' 32' ' ' LEU . 96.2 mtt-85 -93.82 139.47 30.83 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.134 179.821 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.468 ' O ' ' CD1' ' A' ' 22' ' ' PHE . 41.9 p90 -100.11 117.43 34.34 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.331 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 86.0 m-20 -89.74 99.44 12.45 Favored 'General case' 0 N--CA 1.463 0.218 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 179.729 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 82.9 tt0 -63.38 -35.22 79.69 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.323 -179.782 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 1.6 m -63.4 -42.9 97.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.61 -179.776 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -84.09 -16.04 45.15 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 110.383 -0.229 . . . . 0.0 110.383 -179.847 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 57.6 t30 68.77 21.53 7.7 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 115.945 -0.571 . . . . 0.0 111.094 179.714 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -145.05 164.68 30.46 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 116.124 -0.489 . . . . 0.0 109.93 179.396 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 73.2 m80 -92.49 152.9 19.41 Favored 'General case' 0 CA--C 1.514 -0.42 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.281 179.855 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 30.2 m -139.33 154.1 24.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.837 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 50.7 tp -98.89 116.14 30.44 Favored 'General case' 0 CA--C 1.517 -0.314 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 179.216 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.401 ' CD2' ' HE ' ' A' ' 21' ' ' ARG . 57.8 tp -79.11 102.06 8.23 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 179.21 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -97.65 142.03 23.91 Favored Pre-proline 0 CA--C 1.538 0.503 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.858 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_exo -43.37 -34.55 4.87 Favored 'Trans proline' 0 N--CA 1.495 1.614 0 C-N-CA 121.898 1.732 . . . . 0.0 112.569 179.297 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.445 ' CG ' ' N ' ' A' ' 36' ' ' ARG . 14.2 pt-20 -75.66 -51.61 12.4 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.393 -178.673 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.445 ' N ' ' CG ' ' A' ' 35' ' ' GLU . 77.0 ttt-85 -177.16 151.59 0.82 Allowed 'General case' 0 C--N 1.332 -0.193 0 O-C-N 123.293 0.371 . . . . 0.0 110.124 -179.368 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 51.6 m -69.32 135.11 49.95 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.661 179.106 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 78.1 m-85 -108.58 137.41 46.57 Favored 'General case' 0 N--CA 1.472 0.636 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.288 179.857 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 38.8 p-10 -72.69 117.71 14.71 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.352 179.698 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 83.8 mt -134.71 157.38 46.83 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-O 121.042 0.448 . . . . 0.0 110.153 -179.594 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 95.0 m-20 -86.07 155.22 20.9 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.942 -179.691 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -59.39 -37.74 78.75 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.564 -179.614 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -62.98 -39.78 95.75 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.542 -179.765 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.26 -41.74 76.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.554 -0.294 . . . . 0.0 110.882 -179.659 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 44.6 t -78.79 -26.2 13.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 120.856 0.36 . . . . 0.0 110.141 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.65 -35.61 68.57 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.088 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 66.8 t -60.47 -47.45 92.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.67 -179.685 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 41.4 mt -77.61 -16.48 58.56 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.856 -179.239 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 2.8 ttmp? -89.08 -32.17 17.68 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.593 179.224 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 5.6 tp -71.06 -32.25 68.88 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.791 -178.557 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.5 p -73.55 126.02 33.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 121.001 0.429 . . . . 0.0 110.375 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 94.5 m-20 -71.04 -41.13 71.19 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.259 179.475 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -147.68 -97.8 0.2 Allowed Glycine 0 N--CA 1.471 0.998 0 N-CA-C 110.578 -1.009 . . . . 0.0 110.578 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 83.4 mtp180 -114.77 104.84 12.36 Favored 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 110.16 -0.311 . . . . 0.0 110.16 179.78 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 92.6 m-20 -117.12 148.86 41.18 Favored 'General case' 0 N--CA 1.473 0.696 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.156 178.429 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 41.3 p -81.04 139.95 35.43 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.73 178.836 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 19.5 m -54.81 -39.75 49.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.385 -179.657 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 70.9 m -57.17 -43.95 83.04 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.521 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 49.2 tt0 -65.55 -47.93 74.16 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.825 0.345 . . . . 0.0 110.593 -179.839 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 66.5 mt -59.63 -40.75 83.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.14 179.488 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.419 ' O ' ' N ' ' A' ' 65' ' ' GLY . . . -55.36 -42.95 74.58 Favored 'General case' 0 C--N 1.325 -0.492 0 C-N-CA 120.664 -0.414 . . . . 0.0 110.612 -179.778 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 90.4 mm-40 -64.13 -55.99 17.99 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.034 179.902 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 72.5 mt -64.41 -48.94 83.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.829 -179.141 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 28.0 tp -67.83 -36.96 81.28 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.407 -179.528 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.419 ' N ' ' O ' ' A' ' 61' ' ' ALA . . . -56.93 -40.72 91.1 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -179.645 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 75.5 mt-30 -64.4 -31.67 72.97 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 121.011 -0.275 . . . . 0.0 110.35 179.797 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 20.5 m -63.08 -46.59 86.69 Favored 'General case' 0 C--N 1.331 -0.198 0 C-N-CA 120.842 -0.343 . . . . 0.0 110.526 -179.749 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -91.13 -1.08 57.81 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.324 179.782 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 55.6 t0 53.17 54.06 10.9 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.464 -0.335 . . . . 0.0 110.65 179.605 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -140.44 162.48 35.23 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.11 -179.65 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 79.0 m-20 -56.7 134.89 78.28 Favored Pre-proline 0 CA--C 1.541 0.629 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.307 -179.098 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -66.35 -31.25 43.65 Favored 'Trans proline' 0 N--CA 1.502 1.989 0 C-N-CA 122.456 2.104 . . . . 0.0 112.659 -179.309 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -55.25 -37.76 67.66 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.04 0.448 . . . . 0.0 110.785 -179.368 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 64.8 mt -70.92 -39.54 75.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.48 179.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 36.9 mm -59.74 -48.79 86.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.981 -177.896 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -62.13 -45.26 94.25 Favored 'General case' 0 N--CA 1.461 0.094 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.132 -179.673 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.452 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -66.63 -19.02 65.67 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.166 179.779 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 64.7 t0 -80.64 -47.54 13.94 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 116.617 -0.265 . . . . 0.0 111.03 -179.525 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 33.5 pt -79.6 -33.24 14.97 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.624 0 CA-C-O 121.054 0.454 . . . . 0.0 111.251 -179.399 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 9.7 mt -47.38 -59.63 5.23 Favored Pre-proline 0 CA--C 1.545 0.76 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.836 179.719 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.452 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 39.8 Cg_endo -61.39 -29.38 85.46 Favored 'Trans proline' 0 N--CA 1.496 1.64 0 C-N-CA 121.988 1.792 . . . . 0.0 111.612 179.86 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 40.2 ttm -67.07 -39.31 86.82 Favored 'General case' 0 N--CA 1.461 0.125 0 CA-C-O 120.772 0.32 . . . . 0.0 110.784 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 84.5 mt -62.56 -39.92 95.2 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.396 -179.714 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -60.91 -38.6 86.3 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.256 179.808 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -65.2 -40.81 96.99 Favored Glycine 0 CA--C 1.527 0.812 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 88.1 mt -69.74 -35.34 74.9 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.799 0.333 . . . . 0.0 110.583 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -52.68 -38.12 59.98 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.886 0.374 . . . . 0.0 110.443 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 87.6 mt-30 -61.45 -21.18 63.92 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.432 179.564 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 62.9 mttp -95.05 -1.44 52.22 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.109 -179.47 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 67.3 ttp85 55.83 67.82 0.95 Allowed 'General case' 0 N--CA 1.453 -0.318 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.73 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 24.4 m -141.46 16.2 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.507 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 95.1 mt -129.83 155.96 45.14 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-O 121.311 0.577 . . . . 0.0 110.251 179.629 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 80.2 tt0 -146.19 113.69 6.33 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.08 -0.964 . . . . 0.0 110.497 -179.228 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 90.3 mtm180 . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 118.159 -0.924 . . . . 0.0 110.218 179.32 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 79.0 mmm . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.454 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 0.0 OUTLIER -166.86 51.14 0.22 Allowed Pre-proline 0 CA--C 1.536 0.408 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.321 -179.885 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.454 ' CD ' ' N ' ' A' ' 2' ' ' GLU . 55.8 Cg_endo -66.81 -19.03 53.31 Favored 'Trans proline' 0 N--CA 1.497 1.685 0 C-N-CA 122.236 1.957 . . . . 0.0 111.785 179.781 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 81.6 p 49.13 94.16 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.229 0 CA-C-O 120.788 0.327 . . . . 0.0 110.643 -179.392 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.61 -11.09 60.31 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.562 -179.641 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 69.2 m-85 52.44 174.96 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.813 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 69.5 m -133.58 -171.88 2.82 Favored 'General case' 0 N--CA 1.471 0.6 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.63 -179.515 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -66.16 -38.39 93.85 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 95.0 p -71.75 -14.0 61.88 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-O 120.614 0.245 . . . . 0.0 111.099 -179.492 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -66.2 136.69 56.25 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.745 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -130.13 114.63 17.45 Favored Pre-proline 0 CA--C 1.545 0.78 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.069 -179.736 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -79.27 144.01 17.96 Favored 'Trans proline' 0 N--CA 1.489 1.264 0 C-N-CA 121.001 1.134 . . . . 0.0 111.492 179.805 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 76.2 ttt180 -153.14 139.3 18.34 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.758 -0.655 . . . . 0.0 109.722 179.348 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 52.6 mt -69.33 123.91 89.35 Favored Pre-proline 0 CA--C 1.545 0.78 0 CA-C-N 115.655 -0.702 . . . . 0.0 111.35 -179.239 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_endo -73.57 159.47 45.99 Favored 'Trans proline' 0 N--CA 1.497 1.708 0 C-N-CA 121.842 1.695 . . . . 0.0 111.902 179.341 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 78.7 ttt180 -54.81 150.5 9.75 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.337 179.728 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 81.7 18.69 67.52 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.837 -0.905 . . . . 0.0 110.837 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 58.7 t -133.98 133.65 56.08 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 CA-C-O 120.931 0.396 . . . . 0.0 110.183 179.831 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 89.6 mtm-85 -136.82 155.91 49.18 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.244 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 44.5 mt -92.81 138.0 31.87 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.742 179.853 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 25.2 mtp-105 -135.46 142.45 45.55 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.121 -179.601 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 43.4 t80 -101.53 115.71 31.14 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.203 179.739 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 87.6 m-20 -91.65 94.4 9.38 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.485 178.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -60.45 -35.17 75.21 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.193 -179.682 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -63.13 -42.96 98.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.285 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.579 ' NH1' ' HZ1' ' A' ' 28' ' ' LYS . 76.1 mtp180 -84.24 -13.54 52.35 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-O 120.767 0.318 . . . . 0.0 110.482 -179.873 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 58.1 t30 66.19 19.84 11.11 Favored 'General case' 0 CA--C 1.532 0.278 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.366 179.639 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.579 ' HZ1' ' NH1' ' A' ' 26' ' ' ARG . 20.8 pttp -145.1 162.58 36.66 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-O 120.679 0.276 . . . . 0.0 110.282 179.184 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.473 ' ND1' ' OD1' ' A' ' 42' ' ' ASP . 78.4 m80 -90.5 153.13 20.6 Favored 'General case' 0 N--CA 1.464 0.238 0 N-CA-C 109.622 -0.51 . . . . 0.0 109.622 178.932 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 27.4 m -140.26 156.75 24.61 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.359 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.214 -179.721 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 34.5 tp -100.63 118.22 36.33 Favored 'General case' 0 N--CA 1.467 0.409 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 179.496 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 50.5 tp -78.22 97.27 5.46 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 179.276 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -96.05 145.01 28.81 Favored Pre-proline 0 CA--C 1.539 0.551 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.097 -179.506 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_exo -46.23 -37.08 18.05 Favored 'Trans proline' 0 N--CA 1.493 1.449 0 C-N-CA 121.266 1.311 . . . . 0.0 112.517 179.319 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 41.2 tp10 -72.66 -52.04 16.97 Favored 'General case' 0 C--N 1.331 -0.201 0 C-N-CA 120.986 -0.286 . . . . 0.0 111.204 -178.444 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 9.0 ptm180 -176.59 161.2 2.1 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.863 0.363 . . . . 0.0 110.603 -179.732 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 59.3 m -74.87 128.75 36.31 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.374 178.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -100.82 140.64 34.82 Favored 'General case' 0 N--CA 1.472 0.652 0 CA-C-O 120.943 0.401 . . . . 0.0 110.666 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 36.4 p-10 -72.84 115.13 11.77 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.25 179.243 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 41.1 mt -131.05 152.41 50.39 Favored 'General case' 0 N--CA 1.472 0.657 0 CA-C-O 120.939 0.4 . . . . 0.0 110.198 -179.478 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 29.6 m-20 -88.2 165.87 14.76 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.121 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.473 ' OD1' ' ND1' ' A' ' 29' ' ' HIS . 98.7 m-20 -60.7 -43.58 97.6 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.247 179.783 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . 0.464 ' OD1' ' N ' ' A' ' 44' ' ' ALA . 23.6 p30 -65.02 -32.83 74.74 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.053 -0.522 . . . . 0.0 110.663 -179.705 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.464 ' N ' ' OD1' ' A' ' 43' ' ' ASN . . . -69.87 -42.71 73.14 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 120.853 -0.339 . . . . 0.0 111.014 -179.601 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 58.9 t -80.32 -33.53 14.13 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 CA-C-N 116.533 -0.303 . . . . 0.0 110.779 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -53.29 -44.86 68.62 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.863 0.363 . . . . 0.0 110.565 -179.432 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 96.4 t -61.01 -45.66 98.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.318 179.629 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 50.4 mt -73.2 -17.87 61.31 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.102 -179.282 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 36.5 ttpt -91.18 -27.94 18.18 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.567 179.312 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 36.1 tp -71.15 -32.22 68.68 Favored 'General case' 0 N--CA 1.461 0.113 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.547 -179.198 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.3 p -73.74 120.34 22.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-O 121.122 0.487 . . . . 0.0 110.561 179.824 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 95.2 m-20 -71.12 -44.05 66.4 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.48 179.553 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -141.8 -98.31 0.31 Allowed Glycine 0 N--CA 1.472 1.053 0 N-CA-C 110.2 -1.16 . . . . 0.0 110.2 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 90.2 mtm180 -114.8 104.78 12.29 Favored 'General case' 0 N--CA 1.472 0.652 0 CA-C-O 120.734 0.302 . . . . 0.0 110.21 179.003 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 -117.27 138.2 51.89 Favored 'General case' 0 N--CA 1.473 0.706 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.199 178.17 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 44.0 p -78.07 141.65 38.67 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 178.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 28.7 m -51.26 -39.42 21.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-O 120.886 0.374 . . . . 0.0 110.557 -179.536 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 55.9 m -58.62 -44.94 90.13 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.54 179.223 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 44.7 tt0 -65.18 -46.7 79.72 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.789 -179.783 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 67.0 mt -61.23 -42.91 95.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.173 -0.467 . . . . 0.0 109.861 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.445 ' O ' ' N ' ' A' ' 65' ' ' GLY . . . -53.69 -41.63 67.13 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.829 -179.317 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 95.9 mm-40 -63.81 -52.88 58.21 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.823 179.855 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 72.9 mt -64.0 -49.77 80.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.822 0.344 . . . . 0.0 110.967 -178.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 25.3 tp -69.95 -36.19 75.07 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.967 0.413 . . . . 0.0 110.477 -179.414 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.445 ' N ' ' O ' ' A' ' 61' ' ' ALA . . . -55.58 -40.23 77.74 Favored Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.985 -0.846 . . . . 0.0 110.985 -179.65 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 85.0 mt-30 -65.6 -32.08 73.47 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.717 0.294 . . . . 0.0 110.338 179.727 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 19.5 m -62.71 -47.03 85.37 Favored 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 120.816 -0.354 . . . . 0.0 110.331 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 90.5 m-85 -92.68 -2.3 56.17 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.565 179.591 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 65.5 t0 49.25 61.23 3.24 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.801 0.334 . . . . 0.0 111.135 179.666 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -144.31 164.5 30.6 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.126 -179.68 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 81.7 m-20 -55.65 112.79 4.65 Favored Pre-proline 0 CA--C 1.545 0.76 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.234 -179.667 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 76.3 Cg_exo -48.37 -36.33 30.12 Favored 'Trans proline' 0 N--CA 1.503 2.038 0 C-N-CA 121.995 1.797 . . . . 0.0 112.94 -179.746 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -50.68 -35.9 33.17 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.869 0.366 . . . . 0.0 111.011 -179.489 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 68.5 mt -70.92 -41.44 77.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.646 179.473 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.439 ' N ' ' CD1' ' A' ' 75' ' ' ILE . 1.7 mp -60.61 -47.81 91.28 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.698 -178.336 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 8.6 pt-20 -61.82 -45.78 92.35 Favored 'General case' 0 C--N 1.329 -0.322 0 C-N-CA 120.164 -0.614 . . . . 0.0 109.993 -179.222 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.427 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -66.51 -20.54 66.06 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.17 179.771 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 65.7 t0 -80.97 -48.9 11.64 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-O 120.775 0.321 . . . . 0.0 111.275 -179.529 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 14.8 pt -71.08 -40.72 75.85 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.279 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.889 -179.525 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 6.6 mt -42.55 -60.8 1.97 Allowed Pre-proline 0 CA--C 1.549 0.933 0 CA-C-O 119.487 -0.292 . . . . 0.0 111.113 -179.884 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.427 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 59.4 Cg_exo -39.88 -41.5 2.86 Favored 'Trans proline' 0 N--CA 1.495 1.609 0 C-N-CA 122.617 2.211 . . . . 0.0 112.286 178.01 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 13.0 tpt -65.61 -39.53 91.63 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.506 -179.038 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 45.0 mt -61.83 -36.64 81.77 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.117 -179.437 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -60.9 -42.14 97.45 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.318 179.574 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -70.56 -39.88 67.69 Favored Glycine 0 CA--C 1.529 0.956 0 N-CA-C 111.73 -0.548 . . . . 0.0 111.73 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 79.4 mt -67.6 -39.98 84.76 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.887 0.375 . . . . 0.0 110.573 -179.268 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -54.56 -40.02 68.33 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.666 -179.723 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 78.4 mt-30 -61.69 -22.26 65.17 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.545 179.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -94.24 -3.78 50.06 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.076 -179.662 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 36.7 ttm180 55.83 68.03 0.92 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.343 179.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 33.7 m -140.07 16.61 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.667 -179.755 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 78.0 mt -122.18 159.67 26.76 Favored 'General case' 0 N--CA 1.471 0.6 0 CA-C-O 121.51 0.672 . . . . 0.0 110.582 179.853 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 79.6 tt0 -140.93 144.97 35.47 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 114.651 -1.159 . . . . 0.0 110.326 179.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 52.6 ptt85 . . . . . 0 C--N 1.324 -0.54 0 CA-C-N 115.07 -0.968 . . . . 0.0 110.397 179.733 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.536 ' SD ' ' N ' ' A' ' 1' ' ' MET . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.619 0 CA-C-O 121.236 0.541 . . . . 0.0 109.936 . . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.429 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 5.9 tp10 -176.91 -57.92 0.0 OUTLIER Pre-proline 0 CA--C 1.54 0.585 0 CA-C-N 115.265 -0.88 . . . . 0.0 110.109 -179.484 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.429 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 32.7 Cg_endo -58.07 -86.85 0.01 OUTLIER 'Trans proline' 0 N--CA 1.5 1.897 0 C-N-CA 121.935 1.757 . . . . 0.0 111.81 -179.858 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -161.92 67.32 0.26 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.058 -179.542 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -72.94 111.28 7.91 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.158 -179.685 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 62.8 m-85 -78.13 139.98 39.02 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.405 -179.323 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.431 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 17.5 m -88.29 175.01 7.85 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.469 179.9 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -65.17 -31.36 80.44 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 111.231 -0.748 . . . . 0.0 111.231 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 68.8 m -72.0 -6.75 44.42 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.495 0.188 . . . . 0.0 111.303 -179.249 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . 0.431 ' OD2' ' O ' ' A' ' 7' ' ' SER . 0.2 OUTLIER -68.42 153.09 44.43 Favored 'General case' 0 C--N 1.332 -0.192 0 N-CA-C 109.587 -0.523 . . . . 0.0 109.587 179.798 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 33.0 m -131.21 116.89 16.72 Favored Pre-proline 0 CA--C 1.54 0.574 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 179.266 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -77.02 151.3 30.6 Favored 'Trans proline' 0 N--CA 1.492 1.438 0 C-N-CA 121.114 1.209 . . . . 0.0 111.958 -178.828 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 72.5 ttp85 -154.97 133.94 12.26 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.615 -0.721 . . . . 0.0 109.631 179.7 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 65.7 mt -67.68 115.25 25.45 Favored Pre-proline 0 CA--C 1.542 0.636 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.776 -179.57 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -78.75 159.65 27.98 Favored 'Trans proline' 0 N--CA 1.494 1.515 0 C-N-CA 121.682 1.588 . . . . 0.0 111.827 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 85.3 mtp180 -57.93 148.54 25.41 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.76 179.68 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 82.21 13.23 79.42 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 179.669 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 61.9 t -134.32 132.11 55.14 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 CA-C-O 120.966 0.412 . . . . 0.0 110.167 179.697 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 90.0 mtm180 -136.66 153.44 50.91 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.233 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 19.2 mt -98.81 97.67 8.86 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.173 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 84.2 mtp180 -96.18 139.63 32.05 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.12 179.611 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.481 ' O ' ' CD1' ' A' ' 22' ' ' PHE . 38.7 p90 -97.71 115.22 27.54 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-O 121.001 0.429 . . . . 0.0 110.161 179.873 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -89.86 96.72 10.81 Favored 'General case' 0 N--CA 1.464 0.268 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.736 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -61.82 -34.11 75.35 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.212 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 2.4 m -63.63 -40.95 90.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.359 -179.854 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -84.43 -15.9 44.55 Favored 'General case' 0 N--CA 1.467 0.402 0 CA-C-O 120.692 0.282 . . . . 0.0 110.439 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.4 ' O ' ' ND2' ' A' ' 27' ' ' ASN . 0.1 OUTLIER 71.96 12.85 6.05 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.773 179.69 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 47.2 pttt -144.83 161.01 40.34 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 121.071 0.462 . . . . 0.0 109.885 179.731 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 72.0 m80 -86.88 154.48 20.82 Favored 'General case' 0 CA--C 1.513 -0.462 0 CA-C-N 115.717 -0.674 . . . . 0.0 109.989 -179.888 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 34.5 m -136.6 157.25 36.58 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.257 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.108 -179.632 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 6.7 tp -98.95 110.23 22.87 Favored 'General case' 0 N--CA 1.464 0.256 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 179.612 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 55.9 tp -75.32 101.3 4.67 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 109.222 -0.659 . . . . 0.0 109.222 179.479 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -94.62 144.48 27.98 Favored Pre-proline 0 CA--C 1.537 0.48 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.031 -179.619 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 89.3 Cg_exo -45.05 -38.28 13.62 Favored 'Trans proline' 0 N--CA 1.495 1.575 0 C-N-CA 121.494 1.463 . . . . 0.0 112.315 179.313 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 -71.72 -44.32 64.36 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.951 -178.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 50.4 ttp180 -171.51 -122.28 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.523 0 N-CA-C 110.083 -0.34 . . . . 0.0 110.083 -179.64 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 91.8 m -161.05 153.09 19.89 Favored 'General case' 0 C--O 1.232 0.167 0 N-CA-C 109.508 -0.552 . . . . 0.0 109.508 -179.523 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.464 ' CB ' ' HZ3' ' A' ' 89' ' ' LYS . 95.5 m-85 -126.2 139.84 53.03 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.441 -179.432 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -72.32 115.57 11.73 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.129 -0.487 . . . . 0.0 109.872 179.791 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 16.0 mt -128.52 156.88 42.58 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.117 -179.422 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -84.67 153.73 22.94 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.077 -179.716 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 68.1 t0 -59.01 -36.72 75.41 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.189 -179.613 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -63.59 -38.48 91.29 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.322 179.934 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -68.01 -40.39 82.99 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.724 -179.437 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 49.1 t -79.64 -28.15 12.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 120.809 0.338 . . . . 0.0 110.153 179.793 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.45 ' O ' ' N ' ' A' ' 50' ' ' LEU . . . -57.58 -41.63 81.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.365 -179.671 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 97.3 t -61.03 -47.15 94.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.482 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 38.6 mt -70.0 -30.46 67.78 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.022 -179.589 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 36.9 ttmt -82.66 -29.41 30.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.687 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . 0.45 ' N ' ' O ' ' A' ' 46' ' ' ALA . 58.8 tp -72.49 -32.74 66.44 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 120.984 -0.286 . . . . 0.0 110.661 -179.121 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.5 p -79.25 128.67 38.4 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.251 0 CA-C-O 120.966 0.413 . . . . 0.0 110.592 179.676 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 94.8 m-20 -76.43 -86.81 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.166 -0.47 . . . . 0.0 109.738 179.343 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -88.56 -117.08 1.4 Allowed Glycine 0 CA--C 1.524 0.633 0 N-CA-C 110.332 -1.107 . . . . 0.0 110.332 179.328 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 83.2 mtm-85 -111.37 105.3 13.89 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-O 120.802 0.334 . . . . 0.0 110.295 179.746 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 95.1 m-20 -116.75 150.05 38.9 Favored 'General case' 0 N--CA 1.471 0.604 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.084 178.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 48.1 p -80.13 149.2 30.66 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 178.893 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 29.9 m -55.4 -37.87 46.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 120.858 0.361 . . . . 0.0 110.409 -179.796 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 7.7 t -58.09 -44.86 87.83 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.669 179.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 50.7 tt0 -64.58 -49.57 70.65 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.836 0.35 . . . . 0.0 110.712 -179.686 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 66.2 mt -61.19 -42.2 92.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.205 -0.452 . . . . 0.0 109.95 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -51.42 -39.61 57.65 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.029 -179.541 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 92.2 mm-40 -63.22 -47.57 81.92 Favored 'General case' 0 C--N 1.327 -0.389 0 C-N-CA 120.7 -0.4 . . . . 0.0 110.135 179.524 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 69.9 mt -64.82 -48.94 82.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.626 -179.369 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 23.7 tp -68.65 -37.84 79.99 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.986 0.422 . . . . 0.0 110.478 -179.284 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.427 ' O ' ' N ' ' A' ' 69' ' ' ASP . . . -56.17 -41.78 86.74 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 -179.194 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 87.8 mt-30 -66.4 -31.79 72.77 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 121.06 -0.256 . . . . 0.0 110.522 179.834 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 21.5 m -62.33 -49.01 77.29 Favored 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 120.84 -0.344 . . . . 0.0 110.436 -179.756 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -95.14 -0.88 52.94 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.552 179.535 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . 0.427 ' N ' ' O ' ' A' ' 65' ' ' GLY . 50.2 t0 52.16 62.08 2.88 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.506 -0.315 . . . . 0.0 110.834 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -141.97 163.14 33.7 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.226 -179.78 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 72.3 m-20 -55.79 113.09 5.1 Favored Pre-proline 0 CA--C 1.543 0.683 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.46 -179.691 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 78.2 Cg_exo -49.35 -36.37 38.02 Favored 'Trans proline' 0 N--CA 1.5 1.891 0 C-N-CA 121.854 1.702 . . . . 0.0 112.68 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -52.85 -37.13 59.82 Favored 'General case' 0 C--N 1.326 -0.445 0 C-N-CA 120.864 -0.334 . . . . 0.0 111.091 -179.267 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 97.6 mt -67.02 -42.27 88.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.574 -179.77 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.416 ' N ' ' CD1' ' A' ' 75' ' ' ILE . 1.7 mp -55.09 -31.48 25.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 -178.403 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 23.2 mt-10 -61.8 -58.87 6.3 Favored 'General case' 0 C--N 1.324 -0.512 0 C-N-CA 120.373 -0.531 . . . . 0.0 110.428 -179.494 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.401 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -56.39 -20.18 18.26 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.16 -179.376 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 65.3 t0 -78.74 -55.55 5.09 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.554 -0.294 . . . . 0.0 110.789 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 21.7 pt -77.74 -32.22 17.83 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 N-CA-C 111.721 0.267 . . . . 0.0 111.721 -179.517 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 15.6 mt -44.92 -60.03 3.54 Favored Pre-proline 0 CA--C 1.545 0.769 0 CA-C-O 119.658 -0.211 . . . . 0.0 111.051 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.401 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 52.4 Cg_endo -63.04 -26.54 73.64 Favored 'Trans proline' 0 N--CA 1.499 1.845 0 C-N-CA 122.072 1.848 . . . . 0.0 112.142 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 43.1 tpp -65.79 -39.99 91.49 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.86 0.362 . . . . 0.0 110.265 -179.514 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 91.7 mt -62.34 -41.64 98.73 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.081 -179.558 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -63.8 -37.29 86.82 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.515 179.606 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -62.93 -37.75 95.44 Favored Glycine 0 CA--C 1.525 0.682 0 N-CA-C 111.031 -0.828 . . . . 0.0 111.031 -179.88 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 89.7 mt -67.41 -38.56 84.8 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.882 0.372 . . . . 0.0 110.243 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -54.86 -37.2 65.93 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.658 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 87.2 mt-30 -61.39 -23.66 65.95 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.584 -179.867 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . 0.464 ' HZ3' ' CB ' ' A' ' 38' ' ' PHE . 99.3 mttt -93.24 -6.7 47.05 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.311 -179.462 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 55.8 ttm-85 61.63 58.06 2.12 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.314 179.767 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 33.6 m -141.79 6.1 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.644 -179.867 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 55.2 tp -113.5 145.6 40.94 Favored 'General case' 0 N--CA 1.474 0.755 0 CA-C-O 121.306 0.574 . . . . 0.0 110.302 179.942 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 45.6 tp10 -153.27 127.98 9.45 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.054 -179.432 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 96.4 mtt180 . . . . . 0 C--N 1.325 -0.485 0 CA-C-O 118.143 -0.932 . . . . 0.0 110.368 179.856 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 71.7 mtm . . . . . 0 N--CA 1.49 1.561 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 9.4 tp10 -168.0 62.71 0.58 Allowed Pre-proline 0 CA--C 1.532 0.274 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.261 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_endo -76.02 -170.27 0.82 Allowed 'Trans proline' 0 N--CA 1.492 1.405 0 C-N-CA 122.268 1.979 . . . . 0.0 111.599 -179.648 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.461 ' OG1' ' CE1' ' A' ' 6' ' ' PHE . 48.8 p -77.14 -16.83 58.99 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.509 -179.425 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . 52.38 88.08 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.838 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.461 ' CE1' ' OG1' ' A' ' 4' ' ' THR . 76.0 m-85 -79.93 141.52 35.97 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.229 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 49.4 m -90.55 -177.62 5.09 Favored 'General case' 0 N--CA 1.47 0.535 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.463 -179.88 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -66.54 -35.0 89.36 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 111.388 -0.685 . . . . 0.0 111.388 179.858 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 33.9 t -71.36 -2.82 17.72 Favored 'General case' 0 C--N 1.329 -0.305 0 O-C-N 122.569 -0.371 . . . . 0.0 110.747 -179.453 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -66.66 135.6 54.31 Favored 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 120.746 -0.382 . . . . 0.0 110.037 179.749 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 7.3 p -131.36 110.19 15.07 Favored Pre-proline 0 CA--C 1.539 0.551 0 N-CA-C 110.086 -0.338 . . . . 0.0 110.086 179.026 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -78.11 156.24 29.94 Favored 'Trans proline' 0 N--CA 1.489 1.216 0 C-N-CA 121.459 1.439 . . . . 0.0 111.891 -179.112 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 73.4 ttp85 -155.68 132.23 10.37 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 115.892 -0.594 . . . . 0.0 109.562 179.835 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 59.8 mt -67.92 115.41 27.89 Favored Pre-proline 0 CA--C 1.543 0.691 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.535 -179.642 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -78.93 167.23 22.38 Favored 'Trans proline' 0 N--CA 1.495 1.605 0 C-N-CA 121.84 1.693 . . . . 0.0 112.286 -179.671 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 62.1 ttp180 -54.66 139.87 37.36 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.396 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.76 3.63 73.8 Favored Glycine 0 N--CA 1.465 0.595 0 N-CA-C 110.971 -0.851 . . . . 0.0 110.971 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 62.0 t -127.06 127.29 69.46 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 CA-C-O 120.931 0.396 . . . . 0.0 109.971 179.596 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 34.7 ptt180 -144.38 161.49 38.87 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.19 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 25.0 mt -94.76 136.24 35.3 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.254 -179.608 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 83.5 mtp180 -139.86 144.76 37.39 Favored 'General case' 0 N--CA 1.469 0.496 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.233 179.914 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.473 ' O ' ' CD1' ' A' ' 22' ' ' PHE . 38.5 p90 -98.9 117.32 33.12 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.415 -179.718 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 29.5 m-20 -92.43 104.13 16.48 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.678 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 82.3 tt0 -64.22 -37.37 87.21 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.335 -179.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 1.5 m -63.31 -42.17 95.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.382 -179.732 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 75.0 mtp85 -81.43 -16.82 50.91 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 120.543 0.211 . . . . 0.0 110.622 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 61.4 t30 69.81 13.06 8.06 Favored 'General case' 0 N--CA 1.468 0.466 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.048 179.77 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 22.0 pttm -145.0 165.67 27.52 Favored 'General case' 0 N--CA 1.469 0.477 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.225 179.457 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.48 ' ND1' ' OD1' ' A' ' 42' ' ' ASP . 80.6 m80 -88.48 149.67 23.53 Favored 'General case' 0 CA--C 1.517 -0.31 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.152 179.892 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 31.0 m -137.68 158.82 34.32 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.103 -179.714 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 37.0 tp -97.54 120.97 38.89 Favored 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 109.651 -0.5 . . . . 0.0 109.651 179.837 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 34.3 tp -81.29 95.69 7.05 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 109.192 -0.669 . . . . 0.0 109.192 179.384 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -94.75 153.21 40.14 Favored Pre-proline 0 CA--C 1.535 0.369 0 N-CA-C 108.995 -0.742 . . . . 0.0 108.995 -179.869 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -63.66 -28.16 69.06 Favored 'Trans proline' 0 C--N 1.312 -1.382 0 C-N-CA 121.538 1.492 . . . . 0.0 111.206 -179.624 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 43.3 tp10 -78.78 -52.16 8.75 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.625 -179.93 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 61.1 ttp180 -176.32 149.07 0.81 Allowed 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.333 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 61.6 m -70.44 136.46 49.54 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.53 179.164 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -109.24 140.87 42.31 Favored 'General case' 0 N--CA 1.471 0.62 0 CA-C-O 120.909 0.385 . . . . 0.0 110.958 -179.647 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 39.5 p-10 -72.98 117.62 14.93 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.397 179.401 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 95.4 mt -135.53 155.93 49.7 Favored 'General case' 0 N--CA 1.47 0.556 0 CA-C-O 121.046 0.45 . . . . 0.0 110.313 -179.714 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 22.1 m-20 -86.58 163.07 17.66 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.145 -179.768 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.48 ' OD1' ' ND1' ' A' ' 29' ' ' HIS . 87.4 m-20 -60.92 -40.95 95.11 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 115.783 -0.644 . . . . 0.0 109.99 179.539 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 5.5 m120 -63.4 -38.59 91.74 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.38 -179.574 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -67.96 -40.23 83.24 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.742 -179.524 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 58.7 t -80.42 -26.24 11.48 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 CA-C-O 120.748 0.309 . . . . 0.0 110.252 179.43 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.78 -39.96 75.03 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.032 0.444 . . . . 0.0 109.948 -179.846 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 87.2 t -61.01 -46.57 96.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.425 179.561 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 42.7 mt -76.08 -16.25 59.95 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.607 -179.161 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . 0.452 ' HZ2' ' CD2' ' A' ' 29' ' ' HIS . 36.7 ttmt -90.29 -34.7 15.64 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-O 120.904 0.383 . . . . 0.0 110.467 179.259 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 5.7 tp -70.37 -32.16 69.72 Favored 'General case' 0 N--CA 1.463 0.182 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.256 -179.306 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.1 p -71.85 121.8 22.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 120.958 0.409 . . . . 0.0 110.62 -179.7 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 95.2 m-20 -70.08 -44.42 69.1 Favored 'General case' 0 CA--C 1.532 0.254 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.369 179.691 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -144.14 -98.38 0.26 Allowed Glycine 0 N--CA 1.472 1.077 0 N-CA-C 110.408 -1.077 . . . . 0.0 110.408 179.88 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 89.3 mtm180 -114.73 104.3 11.83 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-N 116.747 0.273 . . . . 0.0 110.447 179.241 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -117.5 133.85 55.51 Favored 'General case' 0 N--CA 1.472 0.672 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.127 178.32 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 71.2 p -74.69 141.25 44.56 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.665 -0.494 . . . . 0.0 109.665 179.199 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 23.7 m -47.31 -40.35 6.21 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.248 0 CA-C-O 120.901 0.381 . . . . 0.0 110.702 -179.366 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 58.0 m -58.42 -44.93 89.28 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.298 179.351 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 55.2 tt0 -65.94 -46.87 76.58 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.698 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 63.1 mt -60.96 -43.23 95.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.066 -179.654 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -53.33 -40.31 64.75 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.988 -179.365 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 95.7 mm-40 -63.57 -54.31 38.05 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.524 -0.307 . . . . 0.0 110.971 179.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 73.7 mt -65.31 -48.5 83.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.819 0.342 . . . . 0.0 110.97 -179.069 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 26.0 tp -69.33 -37.6 77.8 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.657 -179.21 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -56.05 -41.96 86.26 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 110.94 -0.864 . . . . 0.0 110.94 -179.671 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 84.7 mt-30 -65.55 -31.16 72.06 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.601 0.239 . . . . 0.0 110.433 179.754 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 19.6 m -62.62 -46.68 87.15 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.704 0.287 . . . . 0.0 110.541 -179.734 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 88.1 m-85 -91.45 0.87 57.45 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.493 179.678 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 61.7 t0 51.98 53.19 12.96 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.482 -0.326 . . . . 0.0 110.838 179.585 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -139.93 162.6 34.78 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.182 -179.701 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -56.27 134.94 75.59 Favored Pre-proline 0 CA--C 1.545 0.787 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.725 -179.099 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -68.42 -29.27 31.53 Favored 'Trans proline' 0 N--CA 1.503 2.087 0 C-N-CA 122.523 2.149 . . . . 0.0 112.661 -179.387 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -55.34 -38.98 69.47 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.152 0.501 . . . . 0.0 110.865 -179.303 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 65.4 mt -71.1 -38.34 70.9 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.444 -179.884 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 37.3 mm -60.71 -46.2 96.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.07 -177.725 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -62.49 -45.34 93.47 Favored 'General case' 0 C--N 1.334 -0.101 0 C-N-CA 120.283 -0.567 . . . . 0.0 109.637 -179.614 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.421 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -65.56 -20.09 66.18 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.725 -0.67 . . . . 0.0 111.063 179.561 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 65.0 t0 -78.97 -50.01 11.82 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-O 120.813 0.339 . . . . 0.0 110.933 -179.466 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 25.5 pt -76.66 -37.81 29.59 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.515 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.468 -179.698 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 9.7 mt -43.06 -60.29 2.48 Favored Pre-proline 0 CA--C 1.548 0.9 0 CA-C-O 119.603 -0.237 . . . . 0.0 111.233 -179.65 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.421 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 36.7 Cg_endo -60.43 -32.2 93.54 Favored 'Trans proline' 0 N--CA 1.499 1.84 0 C-N-CA 121.847 1.698 . . . . 0.0 111.43 179.788 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 5.4 tpt -67.22 -43.14 82.8 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.786 0.327 . . . . 0.0 110.395 -179.937 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 78.1 mt -63.13 -39.63 95.24 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.411 -179.54 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.15 -38.72 87.45 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.144 179.904 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -65.5 -39.6 95.71 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.821 -0.911 . . . . 0.0 110.821 179.644 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 94.6 mt -68.12 -39.01 82.86 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.773 0.321 . . . . 0.0 110.422 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -53.29 -35.12 59.75 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.816 0.341 . . . . 0.0 110.754 -179.487 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 76.7 mt-30 -62.49 -20.28 64.42 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.828 179.692 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -93.46 -0.26 56.5 Favored 'General case' 0 N--CA 1.469 0.479 0 CA-C-O 120.86 0.362 . . . . 0.0 110.299 -179.451 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 16.2 tpp180 59.49 67.27 0.91 Allowed 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.614 179.739 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 7.5 m -139.78 6.62 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.476 -179.695 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 76.3 mt -138.04 141.18 40.35 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-O 121.03 0.443 . . . . 0.0 110.42 179.823 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -151.8 113.13 4.32 Favored 'General case' 0 CA--C 1.531 0.222 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.195 178.835 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 89.5 mtm180 . . . . . 0 C--O 1.22 -0.481 0 CA-C-O 117.975 -1.012 . . . . 0.0 110.353 179.521 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.523 ' SD ' ' N ' ' A' ' 1' ' ' MET . 2.1 mpt? . . . . . 0 N--CA 1.491 1.59 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 36.6 mt-10 48.16 55.76 17.26 Favored Pre-proline 0 CA--C 1.534 0.334 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.556 -179.642 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -70.1 153.33 67.45 Favored 'Trans proline' 0 N--CA 1.495 1.565 0 C-N-CA 122.607 2.205 . . . . 0.0 111.782 -179.528 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 59.8 p -152.87 34.59 0.48 Allowed 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.096 -179.929 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -163.72 -34.92 0.03 OUTLIER 'General case' 0 N--CA 1.463 0.175 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.419 179.79 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 50.7 m-85 50.7 -172.81 0.02 OUTLIER 'General case' 0 CA--C 1.531 0.225 0 CA-C-N 116.567 -0.288 . . . . 0.0 110.36 -179.714 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 17.3 m -133.57 -161.76 1.17 Allowed 'General case' 0 N--CA 1.468 0.464 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.304 -179.659 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -87.0 -28.38 25.95 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 111.161 -0.775 . . . . 0.0 111.161 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 67.6 m -76.92 -7.69 56.01 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-O 120.649 0.262 . . . . 0.0 110.714 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 42.8 p-10 -67.68 146.14 54.1 Favored 'General case' 0 C--N 1.331 -0.217 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 27.6 m -130.56 128.29 22.52 Favored Pre-proline 0 CA--C 1.542 0.662 0 CA-C-N 116.656 -0.247 . . . . 0.0 110.694 179.584 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_endo -77.43 145.57 23.82 Favored 'Trans proline' 0 N--CA 1.498 1.751 0 C-N-CA 121.795 1.663 . . . . 0.0 111.608 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 78.5 ttt-85 -157.9 123.88 4.68 Favored 'General case' 0 N--CA 1.464 0.246 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.185 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 24.9 mt -68.9 119.59 70.55 Favored Pre-proline 0 CA--C 1.541 0.616 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.048 -179.322 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -76.86 162.0 32.74 Favored 'Trans proline' 0 N--CA 1.491 1.367 0 C-N-CA 121.783 1.655 . . . . 0.0 111.745 -179.78 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 77.4 ttt-85 -55.52 142.88 31.51 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.083 179.905 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 86.14 8.93 77.75 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 111.18 -0.768 . . . . 0.0 111.18 179.704 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 53.3 t -134.69 124.63 44.68 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 CA-C-O 120.893 0.378 . . . . 0.0 110.111 179.372 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 83.8 mtp180 -140.42 157.29 45.74 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.026 179.662 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 54.0 mt -91.55 138.47 31.54 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 116.043 -0.526 . . . . 0.0 109.915 -179.698 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 83.2 mtp180 -141.93 151.04 42.23 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.453 -179.488 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 72.4 t80 -100.89 114.33 28.09 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.977 179.606 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 13.5 m-20 -90.08 99.17 12.23 Favored 'General case' 0 N--CA 1.464 0.261 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 179.174 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -57.94 -31.61 67.01 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.038 179.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -65.55 -43.68 94.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.423 -179.341 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 88.9 mtt-85 -84.84 -16.41 41.44 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.304 -178.766 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 3.2 m120 69.5 15.4 8.29 Favored 'General case' 0 CA--C 1.531 0.214 0 CA-C-N 115.531 -0.758 . . . . 0.0 110.89 179.548 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 59.5 pttt -144.85 170.01 16.94 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 116.077 -0.51 . . . . 0.0 109.872 179.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 76.4 m80 -89.39 153.6 20.72 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.619 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 27.3 m -141.65 163.01 20.42 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.283 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.058 -179.853 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 34.1 tp -97.23 116.69 29.91 Favored 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 179.561 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 57.0 tp -80.01 92.73 5.62 Favored 'General case' 0 CA--C 1.517 -0.311 0 N-CA-C 109.211 -0.662 . . . . 0.0 109.211 178.886 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -96.83 154.9 38.17 Favored Pre-proline 0 CA--C 1.543 0.688 0 N-CA-C 110.007 -0.368 . . . . 0.0 110.007 -179.884 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -63.6 -29.75 70.25 Favored 'Trans proline' 0 N--CA 1.496 1.674 0 C-N-CA 122.46 2.107 . . . . 0.0 111.53 179.799 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 -80.4 -51.84 8.37 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 116.548 -0.296 . . . . 0.0 110.775 -179.582 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 61.7 ttp180 -173.46 148.68 1.61 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.269 -179.669 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 76.6 m -71.66 131.37 43.07 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.377 179.322 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 79.1 m-85 -100.92 137.85 38.76 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-O 120.935 0.397 . . . . 0.0 110.833 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 38.5 p-10 -74.7 116.63 15.62 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.424 179.32 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 81.4 mt -132.42 156.61 46.39 Favored 'General case' 0 N--CA 1.469 0.498 0 CA-C-O 121.076 0.465 . . . . 0.0 110.394 -179.63 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 95.9 m-20 -85.88 153.04 22.51 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.899 -179.847 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 68.3 t0 -58.23 -41.3 83.85 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.551 -179.429 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . 0.448 ' OD1' ' N ' ' A' ' 44' ' ' ALA . 21.0 p30 -64.2 -36.21 83.33 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.709 -179.767 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.448 ' N ' ' OD1' ' A' ' 43' ' ' ASN . . . -69.4 -41.07 76.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.341 -0.391 . . . . 0.0 111.053 -179.537 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 60.6 t -77.45 -27.71 15.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 N-CA-C 110.101 -0.333 . . . . 0.0 110.101 179.84 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.43 ' O ' ' N ' ' A' ' 50' ' ' LEU . . . -55.72 -39.02 70.52 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.33 -179.882 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 58.3 t -60.54 -45.1 97.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.136 179.739 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 49.6 mt -69.62 -32.12 70.63 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.457 -179.646 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 35.4 ttpt -82.93 -26.54 31.34 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.429 179.667 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . 0.43 ' N ' ' O ' ' A' ' 46' ' ' ALA . 59.3 tp -72.19 -32.87 67.2 Favored 'General case' 0 N--CA 1.461 0.114 0 C-N-CA 120.429 -0.508 . . . . 0.0 110.353 -179.106 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.3 p -79.64 132.19 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.241 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.587 179.573 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 93.3 m-20 -73.34 -69.94 0.4 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.916 0.389 . . . . 0.0 109.985 179.63 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -114.31 -110.22 2.86 Favored Glycine 0 N--CA 1.474 1.198 0 N-CA-C 110.48 -1.048 . . . . 0.0 110.48 179.552 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 89.9 mtm180 -109.27 105.17 14.48 Favored 'General case' 0 N--CA 1.47 0.539 0 CA-C-O 120.864 0.364 . . . . 0.0 110.27 179.418 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 -116.68 150.24 38.48 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-N 115.828 -0.624 . . . . 0.0 109.923 178.801 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 35.7 p -78.24 139.68 38.91 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 179.214 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 32.0 m -53.82 -38.17 35.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.958 0.409 . . . . 0.0 110.323 -179.711 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 53.4 m -58.69 -43.88 90.1 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.745 179.489 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 55.7 tt0 -64.8 -46.49 81.81 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.601 -179.556 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 65.0 mt -61.22 -42.93 95.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.228 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.443 ' O ' ' N ' ' A' ' 65' ' ' GLY . . . -53.68 -39.36 65.07 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.068 -179.258 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 92.2 mm-40 -63.7 -51.6 64.3 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.818 179.746 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 72.9 mt -65.21 -48.96 81.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 120.914 0.388 . . . . 0.0 110.862 -179.348 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 26.5 tp -70.31 -33.91 72.08 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.267 -179.349 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.443 ' N ' ' O ' ' A' ' 61' ' ' ALA . . . -57.72 -39.54 91.41 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 -179.391 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 -65.48 -32.0 73.37 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 121.001 -0.28 . . . . 0.0 110.339 179.706 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 19.7 m -62.58 -47.13 85.16 Favored 'General case' 0 C--N 1.329 -0.314 0 C-N-CA 120.755 -0.378 . . . . 0.0 110.57 -179.714 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -92.95 -2.41 55.82 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.441 179.817 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 49.4 t0 50.23 61.68 3.07 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.805 179.783 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -145.59 163.45 34.75 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 120.729 0.299 . . . . 0.0 110.352 -179.475 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 15.2 m-20 -55.65 112.88 4.76 Favored Pre-proline 0 CA--C 1.542 0.639 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.168 -179.074 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_exo -48.16 -35.02 25.4 Favored 'Trans proline' 0 N--CA 1.502 1.985 0 C-N-CA 121.964 1.776 . . . . 0.0 112.704 -179.492 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -51.45 -35.45 39.64 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-O 121.024 0.44 . . . . 0.0 110.885 -179.32 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 72.9 mt -72.11 -40.36 66.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.817 179.098 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.456 ' N ' ' CD1' ' A' ' 75' ' ' ILE . 1.7 mp -61.77 -47.9 91.14 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.134 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.006 -178.213 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -59.93 -45.47 92.48 Favored 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 120.385 -0.526 . . . . 0.0 110.461 -178.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.45 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -67.9 -20.44 65.11 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.037 179.729 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -80.52 -47.35 14.38 Favored 'General case' 0 CA--C 1.534 0.362 0 CA-C-N 116.55 -0.295 . . . . 0.0 111.004 -179.563 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 16.5 pt -72.61 -41.2 63.11 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.437 -179.765 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 6.9 mt -42.11 -60.72 1.88 Allowed Pre-proline 0 CA--C 1.546 0.801 0 CA-C-O 119.514 -0.279 . . . . 0.0 110.407 179.461 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.45 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 76.2 Cg_exo -41.12 -45.24 5.34 Favored 'Trans proline' 0 N--CA 1.494 1.529 0 C-N-CA 122.232 1.955 . . . . 0.0 111.815 177.522 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 13.2 tmm? -67.33 -42.76 83.06 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.018 -179.228 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 91.6 mt -63.55 -43.79 96.04 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.993 0.425 . . . . 0.0 110.215 -179.459 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -64.89 -35.98 82.89 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.592 179.74 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -61.8 -38.62 96.25 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.974 -0.85 . . . . 0.0 110.974 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 89.2 mt -66.9 -39.96 87.59 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 110.021 -0.363 . . . . 0.0 110.021 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -54.91 -39.09 68.42 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.314 179.852 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 78.3 mt-30 -63.12 -22.59 66.96 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.897 179.751 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 65.3 mttp -91.95 -3.89 55.34 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-O 120.784 0.326 . . . . 0.0 110.229 -179.548 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 59.7 ttm-85 62.39 55.07 2.39 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.597 179.583 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 32.4 m -141.47 5.91 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.206 179.855 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 56.1 tp -139.87 131.01 26.43 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-O 121.144 0.497 . . . . 0.0 110.411 179.714 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 14.9 pt-20 -155.18 135.62 13.31 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.525 179.282 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 16.8 ptm180 . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 117.83 -1.081 . . . . 0.0 110.335 179.674 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 28.3 ttt . . . . . 0 N--CA 1.49 1.532 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 21.4 tp10 -169.35 72.36 0.71 Allowed Pre-proline 0 CA--C 1.531 0.244 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.881 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_exo -56.38 169.83 1.46 Allowed 'Trans proline' 0 N--CA 1.496 1.674 0 C-N-CA 122.467 2.111 . . . . 0.0 111.965 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 51.2 p -75.3 -19.9 59.41 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.344 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . 51.82 91.65 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.948 179.722 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -78.62 142.64 37.08 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 115.998 -0.546 . . . . 0.0 109.909 179.64 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 42.6 m -89.29 -178.66 5.68 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 115.694 -0.685 . . . . 0.0 110.057 179.753 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -78.73 -25.44 60.48 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 111.211 -0.756 . . . . 0.0 111.211 179.87 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 78.5 p -76.27 -4.81 44.0 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.619 0.247 . . . . 0.0 110.65 -179.497 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 41.1 p-10 -66.55 143.67 56.91 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 120.693 -0.403 . . . . 0.0 109.966 -179.834 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 35.5 m -130.5 103.07 16.45 Favored Pre-proline 0 N--CA 1.47 0.528 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.647 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_endo -76.22 145.8 27.8 Favored 'Trans proline' 0 N--CA 1.488 1.149 0 C-N-CA 121.142 1.228 . . . . 0.0 111.986 -179.545 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 77.8 ttt-85 -155.16 144.07 20.78 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.797 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 60.4 mt -64.26 114.94 15.83 Favored Pre-proline 0 CA--C 1.541 0.624 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.828 -179.303 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -79.5 155.78 24.77 Favored 'Trans proline' 0 N--CA 1.49 1.286 0 C-N-CA 121.798 1.666 . . . . 0.0 111.705 -179.442 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 59.7 ttm-85 -57.75 139.25 54.36 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.172 179.683 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 90.81 2.63 71.85 Favored Glycine 0 CA--C 1.523 0.563 0 N-CA-C 110.956 -0.858 . . . . 0.0 110.956 179.657 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 49.4 t -131.13 129.84 63.22 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 179.548 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 83.3 mtp180 -136.91 155.86 49.21 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 115.943 -0.571 . . . . 0.0 109.965 179.811 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 30.7 mt -90.75 139.18 30.97 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.847 -0.615 . . . . 0.0 109.931 -179.596 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 75.6 mtp85 -137.26 138.62 40.29 Favored 'General case' 0 N--CA 1.466 0.372 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.717 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.47 ' O ' ' CD1' ' A' ' 22' ' ' PHE . 43.2 p90 -98.24 117.98 33.85 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.08 -179.863 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 87.0 m-20 -89.78 104.94 17.45 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.16 -0.473 . . . . 0.0 109.826 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -65.16 -36.29 83.78 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.161 179.882 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 2.2 m -63.45 -42.8 97.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.645 -179.607 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 95.4 mtt-85 -83.08 -18.59 39.1 Favored 'General case' 0 N--CA 1.466 0.334 0 N-CA-C 110.406 -0.22 . . . . 0.0 110.406 -179.842 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 70.32 19.63 6.42 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.996 179.762 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -145.06 165.93 26.82 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.34 179.63 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.478 ' ND1' ' OD1' ' A' ' 42' ' ' ASP . 79.2 m80 -90.78 150.65 21.51 Favored 'General case' 0 CA--C 1.516 -0.343 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.307 179.889 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 33.7 m -139.86 160.05 26.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.153 -179.647 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 43.0 tp -102.38 121.58 42.59 Favored 'General case' 0 CA--C 1.517 -0.311 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 179.141 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 43.5 tp -79.7 100.59 7.96 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 178.852 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -96.55 146.36 31.17 Favored Pre-proline 0 CA--C 1.54 0.572 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -179.833 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_exo -47.17 -38.37 25.11 Favored 'Trans proline' 0 N--CA 1.495 1.615 0 C-N-CA 121.843 1.696 . . . . 0.0 112.67 178.907 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -74.07 -52.07 13.8 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.01 -178.579 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 58.5 ttt85 -175.32 152.17 1.35 Allowed 'General case' 0 C--N 1.333 -0.142 0 CA-C-O 120.89 0.376 . . . . 0.0 110.664 -179.784 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 37.9 m -68.18 133.92 49.66 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.547 179.456 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 78.5 m-85 -107.79 139.56 42.18 Favored 'General case' 0 N--CA 1.472 0.641 0 CA-C-O 120.977 0.418 . . . . 0.0 110.52 -179.624 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 36.6 p-10 -73.48 121.33 20.38 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.493 179.629 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 93.5 mt -136.09 158.12 45.17 Favored 'General case' 0 N--CA 1.471 0.583 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 179.738 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -85.16 163.14 18.91 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.405 -179.604 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.478 ' OD1' ' ND1' ' A' ' 29' ' ' HIS . 90.8 m-20 -60.59 -44.67 95.98 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.643 179.866 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 15.1 p-10 -65.54 -27.49 68.48 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.693 -179.417 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -72.52 -44.46 62.15 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.552 -0.295 . . . . 0.0 110.756 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 48.9 t -79.21 -35.72 17.54 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.629 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -51.83 -36.54 48.48 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.786 -179.101 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 91.6 t -60.89 -47.57 92.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.606 179.677 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 45.1 mt -72.83 -24.06 60.85 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.435 -179.076 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 17.1 ttmm -84.44 -34.59 23.44 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.035 179.755 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 5.9 tp -71.16 -33.03 69.65 Favored 'General case' 0 N--CA 1.463 0.207 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.845 -178.464 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.2 p -76.68 126.11 37.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 121.01 0.433 . . . . 0.0 110.722 179.483 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 -78.6 -86.59 0.07 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.096 -0.502 . . . . 0.0 109.775 179.137 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -85.07 -116.55 0.79 Allowed Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.167 -1.173 . . . . 0.0 110.167 179.278 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 89.0 mtm180 -113.73 105.31 13.14 Favored 'General case' 0 N--CA 1.471 0.578 0 N-CA-C 110.037 -0.357 . . . . 0.0 110.037 179.484 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 88.3 m-20 -116.55 153.04 32.9 Favored 'General case' 0 N--CA 1.473 0.721 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.099 179.083 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 10.2 p -81.75 152.95 26.76 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.026 179.185 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 33.5 m -59.21 -43.15 89.0 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.309 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 51.4 m -58.2 -43.77 87.78 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.719 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 57.6 tt0 -64.76 -46.13 83.49 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.54 -179.79 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 96.7 mt -61.76 -43.42 97.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 -179.92 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.457 ' O ' ' N ' ' A' ' 65' ' ' GLY . . . -52.97 -37.83 61.6 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.173 -179.011 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 97.4 mm-40 -63.6 -52.95 58.67 Favored 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 120.588 -0.445 . . . . 0.0 110.776 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 68.0 mt -66.28 -46.82 86.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 C-N-CA 120.869 -0.332 . . . . 0.0 110.644 -179.906 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 34.7 tp -68.04 -37.67 81.6 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.417 -179.645 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.457 ' N ' ' O ' ' A' ' 61' ' ' ALA . . . -58.3 -41.0 94.78 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 111.018 -0.833 . . . . 0.0 111.018 -179.434 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 87.3 mt-30 -66.13 -30.88 71.45 Favored 'General case' 0 C--N 1.327 -0.408 0 C-N-CA 121.086 -0.245 . . . . 0.0 110.456 179.734 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 20.9 m -62.18 -48.71 78.82 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.799 -0.361 . . . . 0.0 110.531 -179.747 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -95.37 -2.14 49.72 Favored 'General case' 0 N--CA 1.469 0.51 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.565 179.489 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . 0.42 ' N ' ' O ' ' A' ' 65' ' ' GLY . 63.4 t0 53.86 62.19 2.73 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.809 179.792 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -138.53 160.63 39.08 Favored 'General case' 0 N--CA 1.469 0.491 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 -179.738 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 64.8 m-20 -55.8 114.06 6.77 Favored Pre-proline 0 CA--C 1.545 0.763 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.491 -179.201 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_exo -49.33 -36.89 39.33 Favored 'Trans proline' 0 N--CA 1.497 1.684 0 C-N-CA 121.725 1.617 . . . . 0.0 112.655 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -52.03 -39.31 59.36 Favored 'General case' 0 N--CA 1.464 0.227 0 CA-C-O 120.996 0.427 . . . . 0.0 111.158 -179.148 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 73.1 mt -71.96 -40.22 67.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.555 179.5 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 41.8 mm -59.56 -49.1 84.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.996 -178.225 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -63.08 -43.59 98.12 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 -179.859 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.445 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -66.04 -20.76 66.28 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.089 179.714 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 52.4 t0 -79.56 -48.22 14.19 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-O 120.642 0.258 . . . . 0.0 111.218 -179.418 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 34.4 pt -78.18 -35.01 19.41 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.575 0 CA-C-O 120.955 0.407 . . . . 0.0 111.496 -179.416 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 9.8 mt -45.74 -60.11 3.82 Favored Pre-proline 0 CA--C 1.544 0.747 0 CA-C-N 116.49 -0.323 . . . . 0.0 110.935 179.745 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.445 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 42.1 Cg_endo -61.97 -28.37 80.65 Favored 'Trans proline' 0 N--CA 1.497 1.703 0 C-N-CA 121.902 1.734 . . . . 0.0 111.713 179.814 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 40.8 tpp -65.89 -39.75 90.92 Favored 'General case' 0 CA--C 1.53 0.202 0 CA-C-O 120.811 0.339 . . . . 0.0 110.457 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 84.6 mt -62.13 -39.8 93.79 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.307 -179.522 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.03 -38.92 87.85 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.42 -0.354 . . . . 0.0 110.287 179.698 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -65.5 -40.96 96.48 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 111.146 -0.782 . . . . 0.0 111.146 179.777 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 92.1 mt -70.04 -35.53 74.35 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.785 0.326 . . . . 0.0 110.431 -179.865 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -54.86 -34.25 62.71 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.725 -179.883 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 87.5 mt-30 -56.21 -28.76 59.52 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.175 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -96.96 -7.99 31.72 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.253 179.795 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 18.6 tpt85 57.79 51.4 9.28 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.693 179.763 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 35.4 m -108.1 11.19 8.98 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.584 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.657 -179.58 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -138.37 179.71 6.3 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.478 -179.418 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 16.5 pt-20 -152.37 173.8 14.62 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.516 -179.875 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 8.9 ptm180 . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 117.905 -1.045 . . . . 0.0 110.49 -179.878 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 66.5 mtt . . . . . 0 N--CA 1.491 1.589 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 4.5 mp0 -71.62 148.87 93.09 Favored Pre-proline 0 CA--C 1.538 0.516 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.632 -178.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -71.7 42.88 0.51 Allowed 'Trans proline' 0 N--CA 1.499 1.796 0 C-N-CA 122.232 1.954 . . . . 0.0 111.514 179.518 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 13.1 p 52.58 68.57 0.8 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.042 0.449 . . . . 0.0 110.419 179.759 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.11 107.83 5.67 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.106 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 91.6 m-85 -79.38 138.46 37.66 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.154 -179.701 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.411 ' H ' ' CG ' ' A' ' 10' ' ' ASP . 15.4 m -93.65 -173.6 3.22 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 120.948 0.404 . . . . 0.0 110.814 -179.85 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -67.21 -35.49 88.39 Favored Glycine 0 CA--C 1.529 0.916 0 N-CA-C 111.379 -0.688 . . . . 0.0 111.379 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 33.6 t -69.08 -16.98 63.81 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.897 0.38 . . . . 0.0 110.897 -179.415 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . 0.474 ' OD2' ' NH2' ' A' ' 94' ' ' ARG . 0.7 OUTLIER -68.79 149.7 48.69 Favored 'General case' 0 CA--C 1.515 -0.393 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 179.595 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 27.6 m -130.13 129.61 22.96 Favored Pre-proline 0 N--CA 1.472 0.644 0 CA-C-N 116.693 -0.23 . . . . 0.0 110.939 -179.835 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -77.6 151.79 29.03 Favored 'Trans proline' 0 N--CA 1.493 1.48 0 C-N-CA 121.637 1.558 . . . . 0.0 111.333 179.566 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 76.1 ttt180 -157.79 121.71 4.14 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 179.475 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 17.4 mt -69.77 121.96 84.32 Favored Pre-proline 0 CA--C 1.543 0.71 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.969 -179.133 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.413 ' CD ' ' O ' ' A' ' 91' ' ' VAL . 89.6 Cg_endo -75.07 157.4 42.49 Favored 'Trans proline' 0 N--CA 1.492 1.429 0 C-N-CA 121.805 1.67 . . . . 0.0 112.24 179.837 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 89.8 mtm180 -59.28 152.98 19.68 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.355 179.603 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 85.98 11.42 73.34 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 111.223 -0.751 . . . . 0.0 111.223 179.732 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 61.6 t -128.0 133.74 66.6 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 CA-C-O 120.871 0.367 . . . . 0.0 110.085 179.784 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 90.2 mtm180 -134.3 153.98 51.57 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.089 -179.819 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 31.0 mt -98.13 140.74 31.99 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.941 -179.776 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 84.3 mtp180 -140.34 144.76 36.48 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.117 -0.492 . . . . 0.0 109.933 -179.802 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 89.9 t80 -96.7 114.41 26.05 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.15 -0.477 . . . . 0.0 109.882 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 28.2 m-20 -90.05 99.17 12.23 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.919 179.776 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -64.74 -34.29 77.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.117 0.484 . . . . 0.0 109.879 179.83 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 2.0 m -61.97 -40.88 88.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.86 -179.858 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 95.1 mtt-85 -87.82 -20.5 25.99 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.541 179.7 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 6.2 m-80 71.8 19.9 4.72 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.83 179.701 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -144.96 170.07 16.86 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.077 179.707 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 72.5 m80 -87.24 156.13 19.79 Favored 'General case' 0 CA--C 1.517 -0.289 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.536 179.828 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 34.4 m -140.26 158.11 25.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.818 -179.785 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 6.4 tp -103.21 107.92 18.92 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 179.727 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 53.4 tp -77.2 95.44 4.3 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 179.228 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -96.7 147.64 33.23 Favored Pre-proline 0 CA--C 1.54 0.571 0 N-CA-C 110.029 -0.359 . . . . 0.0 110.029 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 80.4 Cg_exo -44.99 -32.96 7.03 Favored 'Trans proline' 0 N--CA 1.496 1.62 0 C-N-CA 122.054 1.836 . . . . 0.0 112.267 178.716 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -72.52 -48.88 36.89 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.789 -179.014 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 51.3 ttp180 -171.81 -123.76 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.49 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.248 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 86.1 m -161.88 124.23 2.92 Favored 'General case' 0 N--CA 1.456 -0.142 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 -179.411 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -100.73 137.19 39.46 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.58 -179.809 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 38.1 p-10 -72.72 120.58 18.54 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.419 179.696 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 94.3 mt -133.0 158.49 42.57 Favored 'General case' 0 N--CA 1.469 0.51 0 CA-C-O 121.006 0.431 . . . . 0.0 110.073 -179.77 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 83.8 m-20 -82.84 159.95 22.31 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.009 -0.542 . . . . 0.0 110.084 -179.347 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.436 ' OD1' ' N ' ' A' ' 43' ' ' ASN . 35.7 p-10 -60.28 -41.91 94.3 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.852 -179.544 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . 0.499 ' OD1' ' N ' ' A' ' 44' ' ' ALA . 24.8 p30 -66.72 -28.41 68.4 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.691 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.499 ' N ' ' OD1' ' A' ' 43' ' ' ASN . . . -72.9 -42.59 63.4 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.893 -179.786 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 48.0 t -79.8 -34.53 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.494 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -53.76 -42.38 68.15 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.536 -179.654 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 74.1 t -60.32 -45.1 96.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.47 -0.332 . . . . 0.0 110.47 179.707 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 39.4 mt -71.62 -20.69 61.94 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.347 -179.225 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 35.8 ttpt -92.4 -29.38 16.33 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.734 179.559 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 5.3 tp -70.35 -32.32 69.97 Favored 'General case' 0 N--CA 1.462 0.155 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.953 -179.047 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.5 p -72.15 120.77 21.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.547 -179.915 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 95.0 m-20 -71.9 -44.54 63.53 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.185 179.643 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -142.58 -97.57 0.27 Allowed Glycine 0 N--CA 1.472 1.091 0 N-CA-C 110.261 -1.135 . . . . 0.0 110.261 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . 0.475 HH12 ' C ' ' A' ' 94' ' ' ARG . 95.2 mtt-85 -114.64 104.52 12.08 Favored 'General case' 0 N--CA 1.469 0.492 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 179.084 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 97.8 m-20 -117.42 145.59 44.02 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.866 178.632 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 18.2 p -80.83 137.11 36.2 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 179.092 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 30.0 m -55.61 -39.94 57.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.293 -179.753 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 78.2 p -58.29 -43.52 88.08 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.53 179.697 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 55.4 tt0 -65.93 -44.28 85.59 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.889 -179.91 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 96.8 mt -61.39 -43.25 96.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 -179.412 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.422 ' O ' ' N ' ' A' ' 65' ' ' GLY . . . -50.7 -36.18 34.81 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.921 -179.072 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 96.6 mm-40 -64.11 -49.96 70.16 Favored 'General case' 0 C--N 1.325 -0.485 0 C-N-CA 120.654 -0.418 . . . . 0.0 110.403 179.809 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 72.2 mt -65.2 -49.31 79.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.376 -0.374 . . . . 0.0 110.619 -179.661 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 31.3 tp -68.88 -36.24 77.84 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.284 -179.472 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.422 ' N ' ' O ' ' A' ' 61' ' ' ALA . . . -54.54 -39.54 66.58 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 111.114 -0.795 . . . . 0.0 111.114 -179.36 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 76.0 mt-30 -65.39 -32.34 73.92 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.665 0.269 . . . . 0.0 110.671 179.842 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 21.1 m -61.83 -48.46 80.46 Favored 'General case' 0 C--N 1.33 -0.264 0 C-N-CA 120.767 -0.373 . . . . 0.0 110.559 -179.774 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 95.5 m-85 -92.86 -3.14 55.14 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.43 179.6 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 61.8 t0 51.88 62.02 2.92 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.824 179.721 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -144.38 164.07 31.88 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-O 120.757 0.313 . . . . 0.0 110.282 -179.632 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 65.9 m-20 -55.8 113.65 6.07 Favored Pre-proline 0 CA--C 1.545 0.777 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.221 -179.408 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_exo -49.21 -36.79 37.89 Favored 'Trans proline' 0 N--CA 1.497 1.692 0 C-N-CA 121.937 1.758 . . . . 0.0 112.601 -179.739 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -52.23 -38.07 56.97 Favored 'General case' 0 C--N 1.323 -0.554 0 C-N-CA 120.806 -0.357 . . . . 0.0 111.076 -179.029 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 97.7 mt -66.7 -42.34 89.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.67 -179.481 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.412 ' N ' ' CD1' ' A' ' 75' ' ' ILE . 1.7 mp -54.67 -33.1 26.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 -178.394 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 21.9 mt-10 -61.37 -58.3 8.77 Favored 'General case' 0 C--N 1.321 -0.662 0 C-N-CA 120.302 -0.559 . . . . 0.0 110.4 -179.406 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.427 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -55.56 -19.9 11.56 Favored 'General case' 0 C--N 1.328 -0.328 0 O-C-N 123.543 0.527 . . . . 0.0 111.282 -179.375 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 58.3 t0 -79.23 -53.81 6.59 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-O 120.601 0.239 . . . . 0.0 111.02 -179.851 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 29.4 pt -80.29 -30.09 12.53 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 CA-C-O 121.146 0.498 . . . . 0.0 111.647 -179.452 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 13.2 mt -47.19 -59.71 5.03 Favored Pre-proline 0 CA--C 1.543 0.698 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.102 179.734 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.427 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 36.3 Cg_endo -61.84 -30.4 84.2 Favored 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 121.505 1.47 . . . . 0.0 111.216 179.293 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 38.6 tpp -65.0 -40.58 95.16 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.133 -179.859 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 83.9 mt -62.77 -41.76 99.39 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.22 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -63.84 -38.36 90.81 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.623 179.753 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -62.1 -38.86 96.83 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 111.004 -0.839 . . . . 0.0 111.004 -179.853 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 91.6 mt -66.8 -39.5 87.78 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 120.821 0.343 . . . . 0.0 110.551 -179.865 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -53.82 -38.43 64.59 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 120.758 0.313 . . . . 0.0 110.485 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 77.5 mt-30 -64.14 -20.24 65.85 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.024 179.864 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 64.4 mttp -92.22 -3.5 55.44 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-N 116.584 -0.28 . . . . 0.0 110.504 -179.199 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 32.3 ttm180 61.55 57.81 2.21 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.284 179.676 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . 0.413 ' O ' ' CD ' ' A' ' 15' ' ' PRO . 33.8 m -140.99 6.52 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.577 -179.886 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 45.9 tp -110.7 146.57 36.03 Favored 'General case' 0 N--CA 1.473 0.709 0 CA-C-O 121.109 0.481 . . . . 0.0 110.046 179.862 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 77.1 tt0 -146.85 162.24 39.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.276 -0.874 . . . . 0.0 110.459 -179.308 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . 0.475 ' C ' HH12 ' A' ' 54' ' ' ARG . 33.7 ptt180 . . . . . 0 C--O 1.22 -0.472 0 CA-C-O 118.008 -0.996 . . . . 0.0 110.371 -179.747 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 66.5 mtt . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.448 ' OE1' ' N ' ' A' ' 2' ' ' GLU . 1.1 mp0 49.5 63.0 11.01 Favored Pre-proline 0 CA--C 1.534 0.341 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.623 -179.996 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 86.8 Cg_endo -76.67 10.63 2.18 Favored 'Trans proline' 0 N--CA 1.495 1.561 0 C-N-CA 122.501 2.134 . . . . 0.0 111.72 -179.818 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 20.8 p -76.45 72.24 3.15 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.041 0.448 . . . . 0.0 110.18 -179.537 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.405 ' O ' ' O ' ' A' ' 6' ' ' PHE . . . -165.39 -84.13 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.802 179.641 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.405 ' O ' ' O ' ' A' ' 5' ' ' ALA . 6.2 m-85 55.62 110.51 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.324 0 CA-C-O 121.025 0.44 . . . . 0.0 110.116 -179.891 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 70.0 m -87.29 -177.9 6.07 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.203 179.647 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.06 -33.41 87.18 Favored Glycine 0 CA--C 1.527 0.841 0 N-CA-C 111.367 -0.693 . . . . 0.0 111.367 -179.76 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 22.9 t -71.65 -3.21 20.37 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.561 0.22 . . . . 0.0 111.072 -179.325 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 21.9 p-10 -67.18 147.92 52.46 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.685 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 29.7 m -131.32 120.26 17.94 Favored Pre-proline 0 CA--C 1.542 0.647 0 N-CA-C 110.105 -0.331 . . . . 0.0 110.105 179.671 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 87.0 Cg_endo -76.57 148.26 29.2 Favored 'Trans proline' 0 N--CA 1.49 1.274 0 CA-C-N 120.371 1.168 . . . . 0.0 112.103 -179.822 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 73.0 ttp85 -154.58 121.51 5.55 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.556 179.888 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 89.2 mt -69.47 121.61 82.81 Favored Pre-proline 0 CA--C 1.543 0.676 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.781 -179.331 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_endo -76.3 159.84 36.3 Favored 'Trans proline' 0 N--CA 1.495 1.575 0 C-N-CA 121.557 1.505 . . . . 0.0 112.009 -179.802 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 90.9 mtt-85 -57.14 153.47 11.67 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.738 -179.828 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 80.49 16.5 75.69 Favored Glycine 0 CA--C 1.523 0.576 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 179.786 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 58.1 t -133.82 132.46 56.69 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 CA-C-O 120.849 0.357 . . . . 0.0 110.099 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 90.8 mtm180 -135.11 155.88 49.96 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.296 -179.703 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 25.0 mt -96.3 101.28 12.9 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.072 -179.835 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.472 ' NH1' ' OG1' ' A' ' 37' ' ' THR . 82.4 mtm180 -92.1 139.95 30.12 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.108 179.514 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.474 ' O ' ' CD1' ' A' ' 22' ' ' PHE . 44.2 p90 -105.0 118.09 35.65 Favored 'General case' 0 N--CA 1.469 0.48 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.129 179.751 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 93.7 m-20 -89.26 100.17 13.01 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.003 -179.768 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -63.9 -37.37 87.16 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.508 -179.885 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 3.1 m -62.9 -43.57 99.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.598 -179.484 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 96.5 mtt180 -90.33 -7.68 52.7 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-O 120.921 0.391 . . . . 0.0 110.403 179.68 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 54.62 36.59 26.35 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.088 179.681 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 19.2 ptmt -145.12 158.47 43.81 Favored 'General case' 0 N--CA 1.468 0.442 0 N-CA-C 110.015 -0.365 . . . . 0.0 110.015 179.57 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 80.3 m80 -93.66 149.49 21.19 Favored 'General case' 0 C--N 1.329 -0.284 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 179.584 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 30.4 m -137.17 156.9 34.65 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-N 116.077 -0.51 . . . . 0.0 109.907 -179.911 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 37.9 tp -102.28 121.3 42.01 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.157 179.841 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 51.4 tp -76.87 99.85 5.34 Favored 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 179.226 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -96.52 144.84 28.53 Favored Pre-proline 0 CA--C 1.538 0.491 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.417 -179.489 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_exo -46.27 -37.46 18.74 Favored 'Trans proline' 0 N--CA 1.495 1.564 0 C-N-CA 121.26 1.307 . . . . 0.0 112.435 179.129 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -71.17 -42.64 68.83 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.887 -178.644 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 15.8 ptm180 -174.95 -120.03 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.504 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.536 -179.765 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.472 ' OG1' ' NH1' ' A' ' 21' ' ' ARG . 93.2 m -155.14 128.64 8.46 Favored 'General case' 0 C--N 1.333 -0.138 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 179.678 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -100.55 132.2 46.06 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.543 -179.355 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 40.3 p-10 -70.9 120.5 16.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.354 179.664 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 93.0 mt -133.67 159.52 40.26 Favored 'General case' 0 N--CA 1.472 0.673 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.261 -179.799 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -85.46 154.97 21.45 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.363 -179.66 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 48.9 t0 -57.98 -40.48 80.75 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.25 -179.847 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 97.6 m-20 -63.86 -39.32 93.93 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.39 -179.773 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.03 -40.16 78.78 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.66 -0.245 . . . . 0.0 111.307 -179.159 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 56.8 t -79.09 -29.94 14.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 CA-C-O 120.708 0.29 . . . . 0.0 110.662 -179.834 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -55.17 -35.67 65.04 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.388 -179.558 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 96.1 t -60.85 -46.57 96.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.528 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 42.6 mt -74.97 -17.87 60.47 Favored 'General case' 0 N--CA 1.462 0.152 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.633 -178.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 35.6 ttpt -90.54 -34.37 15.55 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.679 179.265 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 6.2 tp -70.35 -32.17 69.76 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.942 -178.753 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 10.2 p -73.31 126.34 33.83 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-O 120.879 0.371 . . . . 0.0 110.583 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -71.77 -45.32 62.02 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.6 179.608 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -142.49 -102.73 0.45 Allowed Glycine 0 N--CA 1.472 1.048 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 89.6 mtm180 -114.63 105.01 12.56 Favored 'General case' 0 N--CA 1.471 0.585 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 179.052 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 96.4 m-20 -116.84 149.72 39.57 Favored 'General case' 0 N--CA 1.473 0.721 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.37 178.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 39.5 p -79.69 140.9 36.85 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 178.727 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 31.1 m -53.8 -38.8 36.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.755 0.312 . . . . 0.0 110.6 -179.765 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 54.2 m -57.47 -44.39 84.8 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.719 179.706 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 50.7 tt0 -65.36 -47.38 76.61 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.695 -179.708 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 66.5 mt -60.78 -42.57 92.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.195 -0.457 . . . . 0.0 109.773 179.846 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -53.53 -41.99 66.96 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.272 -179.33 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 96.4 mm-40 -63.29 -54.62 34.35 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 120.762 -0.375 . . . . 0.0 111.035 -179.742 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 69.3 mt -66.15 -49.04 79.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.767 0.318 . . . . 0.0 111.436 -179.03 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 24.8 tp -69.61 -37.72 76.98 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.903 -178.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -55.71 -42.12 84.38 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 110.796 -0.921 . . . . 0.0 110.796 -179.562 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 85.2 mt-30 -66.1 -30.19 70.65 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.605 0.24 . . . . 0.0 110.68 179.768 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 19.5 m -62.2 -45.35 93.75 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.758 0.313 . . . . 0.0 110.551 -179.644 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -90.26 1.96 55.95 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.541 179.674 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 66.1 t0 54.22 50.43 16.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.881 179.693 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -141.37 162.2 36.06 Favored 'General case' 0 N--CA 1.469 0.505 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.3 -179.729 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 72.7 m-20 -55.94 143.18 62.67 Favored Pre-proline 0 CA--C 1.54 0.583 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.555 -179.414 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -69.78 -31.58 20.17 Favored 'Trans proline' 0 N--CA 1.503 2.083 0 C-N-CA 122.51 2.14 . . . . 0.0 112.255 -179.603 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -53.74 -34.04 57.64 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.062 0.458 . . . . 0.0 110.613 -179.646 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 64.3 mt -68.58 -44.34 82.84 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.203 -179.569 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.437 ' N ' ' CD1' ' A' ' 75' ' ' ILE . 1.7 mp -62.07 -49.55 83.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 C-N-CA 120.933 -0.307 . . . . 0.0 111.26 -178.286 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -62.21 -45.59 92.67 Favored 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 120.143 -0.623 . . . . 0.0 110.225 -178.528 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.405 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -65.16 -24.07 67.29 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.36 179.55 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 65.8 t0 -78.41 -49.69 13.06 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-O 120.823 0.344 . . . . 0.0 111.157 -179.356 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 13.1 pt -74.31 -39.81 49.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.463 -179.407 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 9.1 mt -41.37 -60.41 1.82 Allowed Pre-proline 0 CA--C 1.549 0.919 0 CA-C-O 119.622 -0.228 . . . . 0.0 111.26 -179.693 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.405 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 46.8 Cg_endo -62.84 -29.98 77.07 Favored 'Trans proline' 0 N--CA 1.499 1.82 0 C-N-CA 122.0 1.8 . . . . 0.0 111.459 179.483 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 9.5 tpt -66.78 -40.6 88.24 Favored 'General case' 0 N--CA 1.462 0.168 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.483 -179.705 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 80.9 mt -62.2 -41.18 98.12 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.365 -179.129 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.22 -38.6 87.19 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 179.363 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -65.75 -40.22 95.6 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 111.166 -0.774 . . . . 0.0 111.166 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 92.6 mt -67.02 -38.59 86.2 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.843 0.354 . . . . 0.0 110.321 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -53.15 -35.91 60.27 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.839 0.352 . . . . 0.0 110.81 -179.671 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 86.9 mt-30 -61.73 -21.52 64.59 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.637 179.876 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 62.2 mttp -93.08 -5.17 50.99 Favored 'General case' 0 N--CA 1.467 0.419 0 CA-C-O 120.899 0.38 . . . . 0.0 110.048 -179.304 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 23.0 ttm180 65.54 22.46 11.79 Favored 'General case' 0 CA--C 1.531 0.229 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.597 179.5 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 19.5 m -96.1 -14.98 7.7 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.521 0 CA-C-O 120.777 0.322 . . . . 0.0 110.589 -179.748 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 39.6 tp -102.2 149.02 24.73 Favored 'General case' 0 N--CA 1.47 0.531 0 CA-C-O 121.253 0.549 . . . . 0.0 109.824 179.748 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -142.76 147.4 35.49 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.422 -0.808 . . . . 0.0 109.689 -178.829 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 7.8 tmm_? . . . . . 0 C--N 1.326 -0.451 0 CA-C-O 117.93 -1.033 . . . . 0.0 110.046 -179.407 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 15.6 ptt? . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -169.89 72.3 0.65 Allowed Pre-proline 0 C--N 1.326 -0.426 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.624 179.862 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.425 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 36.2 Cg_exo -59.82 155.21 44.85 Favored 'Trans proline' 0 N--CA 1.497 1.698 0 C-N-CA 122.544 2.163 . . . . 0.0 112.079 179.866 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 14.6 t -76.17 -27.78 57.07 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.152 -179.87 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -162.55 -31.18 0.04 OUTLIER 'General case' 0 CA--C 1.528 0.114 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.419 -179.57 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.425 ' O ' ' CB ' ' A' ' 3' ' ' PRO . 36.0 m-85 -81.17 104.89 11.96 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-O 121.15 0.5 . . . . 0.0 110.653 -179.485 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 72.9 m -91.99 -172.89 3.31 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.581 179.417 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -66.83 -42.41 93.0 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 78.4 p -71.92 -21.21 61.66 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.78 0.324 . . . . 0.0 110.855 -179.691 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . 0.466 ' OD2' ' NH2' ' A' ' 94' ' ' ARG . 91.3 m-20 -69.7 154.48 41.92 Favored 'General case' 0 C--O 1.233 0.188 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 179.863 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 28.6 m -128.82 128.63 23.46 Favored Pre-proline 0 N--CA 1.474 0.739 0 CA-C-O 119.67 -0.205 . . . . 0.0 110.728 -178.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -79.47 153.24 23.69 Favored 'Trans proline' 0 N--CA 1.494 1.528 0 C-N-CA 121.684 1.589 . . . . 0.0 111.81 179.743 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.421 ' NH1' ' OE2' ' A' ' 93' ' ' GLU . 60.8 ttp180 -154.28 128.55 9.06 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 116.037 -0.529 . . . . 0.0 109.707 178.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 93.0 mt -69.45 120.34 76.49 Favored Pre-proline 0 CA--C 1.545 0.77 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.205 -179.167 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.428 ' CD ' ' O ' ' A' ' 91' ' ' VAL . 95.1 Cg_endo -77.36 160.03 32.55 Favored 'Trans proline' 0 N--CA 1.498 1.75 0 C-N-CA 121.988 1.792 . . . . 0.0 112.074 179.444 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 43.1 ttm180 -57.31 151.57 15.76 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.132 179.276 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 82.59 14.79 75.12 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 111.108 -0.797 . . . . 0.0 111.108 179.719 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.2 t -133.2 131.16 58.26 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.444 0 CA-C-O 120.89 0.376 . . . . 0.0 109.998 179.682 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 81.3 mtm-85 -137.37 158.69 43.87 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.038 -179.651 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 15.1 mt -94.6 97.64 10.26 Favored 'General case' 0 N--CA 1.463 0.206 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.063 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 83.8 mtp180 -90.77 142.46 27.74 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.239 179.588 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 69.4 t80 -102.81 119.68 39.27 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.227 -0.442 . . . . 0.0 109.867 179.495 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.48 ' O ' ' N ' ' A' ' 27' ' ' ASN . 96.2 m-20 -86.72 96.28 10.1 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.998 -0.546 . . . . 0.0 109.712 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -62.65 -34.65 77.51 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.665 -179.76 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 1.7 p -60.63 -46.39 95.81 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.638 -179.361 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 94.3 mtt-85 -95.47 -6.17 41.29 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.69 -179.844 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.48 ' N ' ' O ' ' A' ' 23' ' ' ASP . 15.8 t-20 55.66 43.69 27.68 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.542 179.552 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -144.78 160.99 40.35 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-O 120.716 0.293 . . . . 0.0 110.571 178.905 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.483 ' ND1' ' OD1' ' A' ' 42' ' ' ASP . 77.2 m80 -94.12 143.85 26.01 Favored 'General case' 0 CA--C 1.519 -0.229 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 178.486 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 33.5 m -137.11 159.45 36.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.141 -0.481 . . . . 0.0 109.879 -179.447 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 6.0 tp -102.73 122.24 44.06 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 116.205 -0.452 . . . . 0.0 109.846 -179.902 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 44.4 tp -77.79 100.03 6.13 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 178.762 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -96.6 147.09 32.42 Favored Pre-proline 0 CA--C 1.539 0.532 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 -179.825 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_exo -48.62 -38.25 36.0 Favored 'Trans proline' 0 N--CA 1.497 1.682 0 C-N-CA 121.233 1.289 . . . . 0.0 112.743 179.217 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 79.3 tt0 -73.65 -52.15 14.33 Favored 'General case' 0 C--N 1.332 -0.186 0 C-N-CA 120.962 -0.295 . . . . 0.0 111.307 -178.394 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 43.6 ttm180 -175.87 151.99 1.18 Allowed 'General case' 0 N--CA 1.465 0.28 0 CA-C-O 120.964 0.412 . . . . 0.0 110.622 -179.788 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 58.0 m -68.79 133.34 48.19 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.407 179.267 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.484 ' CE2' ' NZ ' ' A' ' 89' ' ' LYS . 81.7 m-85 -106.49 137.62 44.15 Favored 'General case' 0 N--CA 1.472 0.629 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.596 -179.588 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 22.0 t0 -72.76 119.58 17.18 Favored 'General case' 0 C--N 1.333 -0.132 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.932 179.642 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 89.2 mt -134.53 157.37 46.7 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.007 -179.743 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 25.8 m-20 -84.86 161.41 19.9 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.421 -179.596 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.483 ' OD1' ' ND1' ' A' ' 29' ' ' HIS . 87.4 m-20 -60.59 -44.73 95.9 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.425 179.837 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 47.0 t30 -63.7 -35.66 81.28 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.625 -179.574 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -68.98 -44.86 72.04 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.185 -179.438 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 48.7 t -78.06 -25.32 14.2 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.197 0 CA-C-O 120.839 0.352 . . . . 0.0 110.333 -179.914 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.85 -31.55 64.9 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.194 -179.776 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 6.0 t -60.99 -46.34 96.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.893 -179.486 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 30.9 mt -76.37 -19.4 58.21 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.71 -179.027 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 33.6 ttpt -87.98 -34.54 18.03 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.671 179.509 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 5.4 tp -70.15 -32.55 70.58 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.03 -179.275 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 8.5 p -75.88 125.01 35.09 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-O 120.916 0.389 . . . . 0.0 110.696 179.849 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 97.5 m-20 -70.95 -45.64 63.81 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.384 179.579 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -139.89 -101.66 0.5 Allowed Glycine 0 N--CA 1.471 1.015 0 N-CA-C 110.448 -1.061 . . . . 0.0 110.448 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 90.7 mtm180 -115.02 104.69 12.15 Favored 'General case' 0 N--CA 1.47 0.572 0 CA-C-O 120.523 0.201 . . . . 0.0 110.527 179.252 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 96.7 m-20 -117.24 146.91 42.97 Favored 'General case' 0 N--CA 1.472 0.64 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 178.054 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 32.3 p -79.36 149.63 31.64 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 179.099 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 19.8 m -52.66 -40.32 33.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.829 0.347 . . . . 0.0 110.593 -179.559 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 33.5 t -59.36 -45.16 92.17 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.886 179.891 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 50.5 tt0 -64.48 -48.13 76.36 Favored 'General case' 0 N--CA 1.463 0.182 0 CA-C-O 120.804 0.335 . . . . 0.0 110.894 -179.355 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 65.5 mt -61.09 -42.64 93.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.002 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -53.38 -40.39 64.98 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.932 -0.576 . . . . 0.0 111.224 -179.336 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 94.7 mm-40 -63.26 -55.39 25.2 Favored 'General case' 0 C--N 1.33 -0.275 0 C-N-CA 120.813 -0.355 . . . . 0.0 110.98 -179.541 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 66.1 mt -66.75 -45.13 88.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.843 0.354 . . . . 0.0 110.652 -179.267 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 36.0 tp -66.77 -38.6 86.9 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.445 -179.537 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.462 ' O ' ' N ' ' A' ' 69' ' ' ASP . . . -57.64 -39.22 90.74 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 111.103 -0.799 . . . . 0.0 111.103 -179.667 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 87.7 mt-30 -65.84 -33.14 75.16 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.972 -0.291 . . . . 0.0 110.408 179.688 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 25.2 m -62.24 -47.24 85.25 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 120.789 -0.364 . . . . 0.0 110.547 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -94.66 -3.58 49.2 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.565 179.45 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . 0.462 ' N ' ' O ' ' A' ' 65' ' ' GLY . 61.6 t0 51.51 62.12 2.87 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.972 179.726 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -141.35 160.96 39.04 Favored 'General case' 0 N--CA 1.467 0.408 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.103 -179.735 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 58.7 m-20 -55.79 113.42 5.66 Favored Pre-proline 0 CA--C 1.546 0.802 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.364 -179.37 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_exo -49.06 -32.42 23.76 Favored 'Trans proline' 0 N--CA 1.5 1.877 0 C-N-CA 121.807 1.671 . . . . 0.0 112.656 179.56 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -52.05 -37.82 54.92 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.934 0.397 . . . . 0.0 111.61 -178.793 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 19.9 mm -80.24 -34.59 14.98 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.609 -179.785 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 46.5 mm -62.01 -46.56 96.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.963 -179.396 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -62.89 -44.53 95.86 Favored 'General case' 0 C--N 1.333 -0.124 0 C-N-CA 120.547 -0.461 . . . . 0.0 109.783 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.431 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -67.32 -18.45 65.18 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.758 -0.655 . . . . 0.0 111.147 179.472 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 61.1 t0 -80.8 -46.84 14.75 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-O 120.753 0.311 . . . . 0.0 111.031 -179.709 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 22.0 pt -78.16 -34.12 18.59 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.434 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.017 -179.665 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 7.9 mt -46.07 -60.26 3.78 Favored Pre-proline 0 CA--C 1.547 0.839 0 C-N-CA 121.015 -0.274 . . . . 0.0 111.097 179.639 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.431 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 38.6 Cg_endo -61.92 -28.84 81.44 Favored 'Trans proline' 0 N--CA 1.499 1.812 0 C-N-CA 122.126 1.884 . . . . 0.0 111.845 179.516 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 45.1 ttp -66.15 -42.34 89.16 Favored 'General case' 0 C--N 1.333 -0.114 0 C-N-CA 120.858 -0.337 . . . . 0.0 110.14 -179.855 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 91.8 mt -63.06 -42.78 99.78 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.486 -179.742 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.82 -38.34 90.32 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.048 -0.524 . . . . 0.0 109.913 179.633 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -64.75 -41.01 97.82 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 111.206 -0.758 . . . . 0.0 111.206 -179.763 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 88.5 mt -68.4 -36.99 79.93 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.036 0.446 . . . . 0.0 110.128 179.788 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -53.1 -36.83 61.14 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.582 -179.785 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 26.5 mt-30 -61.23 -23.3 65.54 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.529 179.659 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . 0.484 ' NZ ' ' CE2' ' A' ' 38' ' ' PHE . 68.2 mttm -93.73 -3.89 51.42 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.086 -179.742 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 35.3 ttm180 57.14 67.97 0.92 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.568 179.909 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . 0.428 ' O ' ' CD ' ' A' ' 15' ' ' PRO . 33.4 m -136.7 -0.38 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.985 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 95.0 mt -106.66 173.47 6.31 Favored 'General case' 0 CA--C 1.511 -0.534 0 CA-C-O 121.413 0.625 . . . . 0.0 110.333 179.525 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.421 ' OE2' ' NH1' ' A' ' 13' ' ' ARG . 79.9 tt0 -149.09 145.8 27.41 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 114.852 -1.067 . . . . 0.0 110.653 179.873 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . 0.466 ' NH2' ' OD2' ' A' ' 10' ' ' ASP . 16.6 ptm180 . . . . . 0 C--N 1.324 -0.533 0 CA-C-O 118.1 -0.952 . . . . 0.0 110.059 179.777 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 4.3 mmt . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 109.063 -0.718 . . . . 0.0 109.063 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 54.6 tt0 50.44 64.15 8.8 Favored Pre-proline 0 CA--C 1.534 0.34 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.598 -179.571 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 77.1 Cg_endo -74.93 169.55 22.37 Favored 'Trans proline' 0 N--CA 1.495 1.59 0 C-N-CA 122.374 2.05 . . . . 0.0 111.928 -179.572 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 16.2 p -78.5 86.07 4.55 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.273 -179.668 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.21 100.96 4.47 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.463 -179.837 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -79.48 139.59 37.57 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.436 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 67.0 m -93.32 -175.12 3.72 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.696 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -68.41 -38.8 87.35 Favored Glycine 0 CA--C 1.528 0.876 0 N-CA-C 111.277 -0.729 . . . . 0.0 111.277 179.764 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 18.1 m -71.3 -17.04 62.48 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.75 0.31 . . . . 0.0 110.832 -179.48 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -66.93 142.71 57.19 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 179.573 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 1.4 p -129.73 120.78 19.73 Favored Pre-proline 0 CA--C 1.547 0.828 0 O-C-N 123.167 0.292 . . . . 0.0 110.264 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_endo -77.31 150.2 28.56 Favored 'Trans proline' 0 N--CA 1.492 1.435 0 C-N-CA 121.389 1.393 . . . . 0.0 111.472 179.407 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.436 HH22 ' CA ' ' A' ' 53' ' ' GLY . 59.4 ttt85 -149.57 139.68 22.11 Favored 'General case' 0 N--CA 1.467 0.422 0 N-CA-C 109.624 -0.509 . . . . 0.0 109.624 179.085 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 65.6 mt -71.32 118.15 63.4 Favored Pre-proline 0 CA--C 1.541 0.633 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.78 -179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo -77.12 160.66 33.05 Favored 'Trans proline' 0 N--CA 1.494 1.507 0 C-N-CA 121.633 1.555 . . . . 0.0 111.994 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 9.4 ptm180 -53.94 148.46 10.5 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.627 179.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 82.71 8.28 86.22 Favored Glycine 0 CA--C 1.521 0.444 0 N-CA-C 110.913 -0.875 . . . . 0.0 110.913 179.593 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 43.6 t -132.9 124.3 50.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.46 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.655 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 84.2 mtp180 -138.22 157.96 45.24 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.153 179.563 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 33.2 mt -94.36 109.16 21.02 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.222 -179.69 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 91.5 mtt-85 -90.89 137.76 32.11 Favored 'General case' 0 CA--C 1.52 -0.194 0 CA-C-N 116.114 -0.493 . . . . 0.0 109.888 179.786 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 35.0 t80 -95.99 100.06 11.77 Favored 'General case' 0 C--N 1.332 -0.187 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 94.5 m-20 -89.16 90.18 8.26 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.022 -179.904 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -61.77 -34.68 76.3 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.144 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 1.7 m -63.26 -41.22 91.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.285 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -80.68 -17.3 51.57 Favored 'General case' 0 N--CA 1.463 0.195 0 N-CA-C 110.222 -0.288 . . . . 0.0 110.222 -179.71 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 6.7 t-20 71.0 12.5 7.01 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.044 -0.526 . . . . 0.0 111.135 179.568 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 20.9 pttp -145.03 163.09 35.28 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-O 120.989 0.424 . . . . 0.0 110.187 179.461 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 62.1 m80 -89.14 160.55 16.95 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.053 179.865 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 27.7 m -141.91 156.83 20.28 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.1 179.846 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 44.5 tp -100.67 124.62 46.53 Favored 'General case' 0 N--CA 1.465 0.297 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 179.296 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 38.8 tp -79.65 96.27 6.15 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 179.031 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -94.08 147.67 33.83 Favored Pre-proline 0 CA--C 1.538 0.504 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.767 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 77.6 Cg_exo -50.05 -37.58 47.89 Favored 'Trans proline' 0 N--CA 1.496 1.652 0 C-N-CA 121.527 1.485 . . . . 0.0 112.721 179.143 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 47.6 tp10 -74.33 -52.14 13.09 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.409 -0.36 . . . . 0.0 111.117 -178.253 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 60.8 ttp180 -175.5 153.79 1.54 Allowed 'General case' 0 N--CA 1.462 0.155 0 CA-C-O 120.848 0.356 . . . . 0.0 110.608 -179.591 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 68.3 m -67.54 130.83 44.28 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.219 178.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 76.7 m-85 -105.53 142.55 35.08 Favored 'General case' 0 N--CA 1.471 0.578 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.522 -179.733 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 38.4 t0 -73.71 117.25 15.27 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.758 179.257 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 20.6 mt -131.8 155.85 47.04 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.189 -179.527 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 26.0 m-20 -83.72 147.06 27.86 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.216 -179.552 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.467 ' OD1' ' N ' ' A' ' 43' ' ' ASN . 36.8 p-10 -60.07 -35.79 75.95 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.744 -179.773 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . 0.467 ' N ' ' OD1' ' A' ' 42' ' ' ASP . 16.1 p30 -63.73 -40.85 97.75 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.776 -179.73 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.462 ' N ' ' OD1' ' A' ' 43' ' ' ASN . . . -70.96 -38.97 72.8 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.702 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 94.9 t -78.09 -28.96 15.34 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.157 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -55.81 -36.8 67.84 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.238 -179.65 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 65.8 t -59.71 -47.17 92.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.462 -179.671 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 47.6 mt -71.27 -28.71 64.34 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.682 -179.354 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 34.8 ttpt -82.16 -28.33 32.2 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.126 -179.678 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 7.0 tp -69.63 -32.53 71.26 Favored 'General case' 0 N--CA 1.463 0.19 0 C-N-CA 120.647 -0.421 . . . . 0.0 110.359 -179.005 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 2.6 p -76.33 129.27 37.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 121.122 0.487 . . . . 0.0 110.354 179.184 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -69.39 -43.96 72.42 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.374 179.049 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.436 ' CA ' HH22 ' A' ' 13' ' ' ARG . . . -145.48 -95.24 0.18 Allowed Glycine 0 N--CA 1.473 1.103 0 N-CA-C 110.511 -1.036 . . . . 0.0 110.511 179.632 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 82.7 mtm-85 -114.9 104.84 12.32 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-O 120.865 0.365 . . . . 0.0 110.256 179.347 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 96.6 m-20 -117.51 142.75 46.79 Favored 'General case' 0 N--CA 1.472 0.633 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.214 177.348 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 65.2 p -78.78 141.58 37.68 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 178.548 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 28.3 m -51.09 -38.31 18.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.893 0.378 . . . . 0.0 110.671 -179.492 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 60.2 m -58.47 -45.08 89.37 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.452 179.655 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 50.3 tt0 -66.21 -46.66 76.49 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.769 -179.777 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 66.7 mt -61.11 -42.91 95.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.058 -179.771 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.435 ' O ' ' N ' ' A' ' 65' ' ' GLY . . . -53.53 -39.19 64.48 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.206 -179.342 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 85.1 mm-40 -62.96 -53.44 54.05 Favored 'General case' 0 C--N 1.325 -0.467 0 C-N-CA 120.845 -0.342 . . . . 0.0 110.769 179.858 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 72.4 mt -65.16 -49.79 77.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.259 -179.203 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 23.3 tp -69.84 -37.06 76.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.691 -179.11 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.435 ' N ' ' O ' ' A' ' 61' ' ' ALA . . . -55.85 -42.2 85.42 Favored Glycine 0 CA--C 1.526 0.759 0 N-CA-C 110.945 -0.862 . . . . 0.0 110.945 -179.708 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 74.6 mt-30 -65.2 -31.0 71.95 Favored 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 121.106 -0.238 . . . . 0.0 110.535 179.711 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 19.4 m -62.27 -46.26 89.62 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.788 0.327 . . . . 0.0 110.544 -179.583 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -91.37 1.66 56.96 Favored 'General case' 0 N--CA 1.468 0.461 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.534 179.815 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 66.2 t0 53.94 51.97 13.76 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.784 179.689 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -142.19 159.0 43.1 Favored 'General case' 0 N--CA 1.468 0.459 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.212 -179.794 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 26.2 m-20 -55.95 143.83 60.31 Favored Pre-proline 0 CA--C 1.538 0.485 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.364 -179.321 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -66.34 -29.45 46.07 Favored 'Trans proline' 0 N--CA 1.502 1.971 0 C-N-CA 122.561 2.174 . . . . 0.0 112.307 -179.564 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -55.16 -36.41 65.8 Favored 'General case' 0 CA--C 1.515 -0.384 0 CA-C-O 121.218 0.533 . . . . 0.0 110.95 -179.106 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 34.5 mm -70.18 -44.26 78.09 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.868 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.157 -179.43 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.425 ' N ' ' CD1' ' A' ' 75' ' ' ILE . 1.7 mp -62.06 -51.89 67.07 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 CA-C-N 116.496 -0.32 . . . . 0.0 111.264 -178.704 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 15.9 pt-20 -59.49 -44.37 93.08 Favored 'General case' 0 C--N 1.326 -0.416 0 C-N-CA 120.402 -0.519 . . . . 0.0 110.079 -177.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.419 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -67.52 -23.26 65.44 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.992 179.577 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 66.0 t0 -80.1 -46.82 15.81 Favored 'General case' 0 N--CA 1.471 0.612 0 CA-C-N 116.587 -0.279 . . . . 0.0 111.741 -179.318 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 15.8 pt -71.32 -41.14 74.13 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.455 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.054 -179.15 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 7.0 mt -42.31 -60.98 1.78 Allowed Pre-proline 0 CA--C 1.55 0.955 0 CA-C-O 119.621 -0.228 . . . . 0.0 110.863 179.445 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.419 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 53.4 Cg_exo -40.22 -41.18 3.16 Favored 'Trans proline' 0 N--CA 1.491 1.374 0 C-N-CA 122.633 2.222 . . . . 0.0 112.204 177.773 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 10.8 tpt -65.37 -39.83 92.78 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.627 -178.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 41.6 mt -61.4 -39.44 90.72 Favored 'General case' 0 C--N 1.325 -0.499 0 C-N-CA 120.577 -0.449 . . . . 0.0 110.051 -179.303 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -63.31 -38.65 91.97 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.944 0.402 . . . . 0.0 110.063 179.211 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -69.07 -38.95 84.47 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 111.408 -0.677 . . . . 0.0 111.408 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 86.0 mt -66.42 -40.51 89.6 Favored 'General case' 0 C--N 1.326 -0.417 0 O-C-N 122.745 -0.268 . . . . 0.0 110.888 -179.668 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -53.74 -28.12 32.47 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.48 -0.327 . . . . 0.0 110.725 -179.768 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 94.7 mt-30 -63.08 -26.53 68.88 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.68 -179.858 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 46.1 mtmt -94.11 -1.98 53.47 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.497 -179.451 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 50.0 ttt180 65.29 23.01 12.13 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.567 179.385 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 23.8 m -95.18 -4.74 10.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.222 -179.891 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -109.06 121.58 45.44 Favored 'General case' 0 CA--C 1.533 0.324 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 -179.36 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -101.31 174.49 5.96 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 115.869 -0.605 . . . . 0.0 109.992 179.539 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 73.1 ttp85 . . . . . 0 C--N 1.322 -0.592 0 CA-C-O 117.96 -1.019 . . . . 0.0 109.351 -179.853 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 72.3 mtm . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 17.7 tp10 -167.48 54.77 0.29 Allowed Pre-proline 0 CA--C 1.533 0.297 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.091 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 67.8 Cg_endo -68.01 -18.37 46.17 Favored 'Trans proline' 0 N--CA 1.497 1.706 0 C-N-CA 122.231 1.954 . . . . 0.0 111.73 -179.654 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 26.0 p -77.35 74.67 3.92 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.145 -179.542 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -165.78 62.72 0.11 Allowed 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 115.936 -0.574 . . . . 0.0 111.126 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 51.5 m-85 -89.85 117.59 28.8 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.065 179.482 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 50.9 m -94.18 -179.91 5.1 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.259 179.676 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -64.92 -40.08 96.96 Favored Glycine 0 CA--C 1.528 0.868 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 179.789 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 57.7 m -72.65 -16.57 61.7 Favored 'General case' 0 N--CA 1.462 0.16 0 CA-C-O 120.629 0.252 . . . . 0.0 110.89 -179.728 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 54.0 t0 -71.98 114.53 10.17 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.744 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.463 HG21 ' HE ' ' A' ' 54' ' ' ARG . 34.6 m -94.57 126.18 48.72 Favored Pre-proline 0 CA--C 1.548 0.902 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.979 -179.025 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 83.9 Cg_endo -78.82 151.78 24.82 Favored 'Trans proline' 0 N--CA 1.495 1.591 0 C-N-CA 121.27 1.313 . . . . 0.0 111.541 179.591 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 58.2 ttt85 -157.1 130.38 7.89 Favored 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 179.187 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 68.5 mt -70.62 128.62 90.85 Favored Pre-proline 0 CA--C 1.546 0.792 0 CA-C-O 119.245 -0.407 . . . . 0.0 110.674 -179.652 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -73.83 155.9 48.53 Favored 'Trans proline' 0 N--CA 1.496 1.628 0 C-N-CA 121.472 1.448 . . . . 0.0 111.945 179.827 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 35.4 ptt180 -54.26 151.65 7.11 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.832 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 80.55 18.19 71.5 Favored Glycine 0 CA--C 1.525 0.68 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.503 ' CG1' HD11 ' A' ' 31' ' ' LEU . 61.9 t -135.05 133.76 53.34 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 CA-C-O 120.877 0.37 . . . . 0.0 110.321 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 83.4 mtm-85 -136.68 155.78 49.41 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.262 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 41.5 mt -92.26 144.49 25.35 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.983 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 96.7 mtt180 -140.36 141.08 35.66 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.096 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.464 ' O ' ' CD1' ' A' ' 22' ' ' PHE . 50.2 p90 -106.81 121.45 44.42 Favored 'General case' 0 N--CA 1.469 0.495 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.742 -180.0 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.456 ' O ' ' N ' ' A' ' 27' ' ' ASN . 93.8 m-20 -90.19 103.43 16.11 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.042 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.2 tt0 -64.75 -37.88 89.09 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.531 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 3.2 m -63.15 -43.96 99.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.665 -179.487 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 96.5 mtt180 -92.61 -8.13 45.07 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-O 120.684 0.278 . . . . 0.0 110.953 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.456 ' N ' ' O ' ' A' ' 23' ' ' ASP . 15.6 t-20 54.86 37.69 29.03 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.57 179.519 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.439 ' NZ ' ' O ' ' A' ' 40' ' ' LEU . 11.6 ptmm? -145.04 158.51 43.79 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 110.036 -0.357 . . . . 0.0 110.036 179.512 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.4 ' O ' ' O ' ' A' ' 40' ' ' LEU . 69.9 m80 -92.58 148.75 21.83 Favored 'General case' 0 CA--C 1.517 -0.3 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.097 179.79 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 34.1 m -136.76 153.81 30.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.289 0 CA-C-N 116.093 -0.503 . . . . 0.0 109.813 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.503 HD11 ' CG1' ' A' ' 18' ' ' VAL . 41.3 tp -102.37 124.03 47.21 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.779 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 46.7 tp -77.7 101.48 6.65 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 179.046 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -97.27 140.95 22.34 Favored Pre-proline 0 CA--C 1.539 0.521 0 CA-C-O 119.308 -0.377 . . . . 0.0 110.093 -179.779 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 94.3 Cg_exo -43.93 -31.63 3.89 Favored 'Trans proline' 0 N--CA 1.496 1.654 0 C-N-CA 121.316 1.344 . . . . 0.0 112.467 179.029 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -71.36 -51.01 26.54 Favored 'General case' 0 C--N 1.33 -0.269 0 C-N-CA 120.807 -0.357 . . . . 0.0 110.221 -179.292 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 69.0 ttt-85 -172.89 -98.68 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.297 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.019 179.589 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 86.4 m -166.75 151.93 7.78 Favored 'General case' 0 C--N 1.333 -0.145 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 -179.61 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 68.1 m-85 -125.92 136.13 52.68 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-O 120.905 0.383 . . . . 0.0 110.344 -179.846 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 37.3 p-10 -72.07 119.15 15.85 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.943 -0.572 . . . . 0.0 110.194 179.607 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.439 ' O ' ' NZ ' ' A' ' 28' ' ' LYS . 95.4 mt -134.23 157.4 46.36 Favored 'General case' 0 N--CA 1.471 0.58 0 CA-C-O 121.029 0.443 . . . . 0.0 110.329 -179.491 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -84.94 157.43 20.82 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.214 -179.683 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.475 ' OD1' ' N ' ' A' ' 43' ' ' ASN . 38.5 p-10 -61.31 -35.8 78.35 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.757 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' ASN . . . . . 0.475 ' N ' ' OD1' ' A' ' 42' ' ' ASP . 48.6 t30 -63.04 -39.91 96.15 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.922 -179.507 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -68.75 -36.43 78.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.473 -0.331 . . . . 0.0 110.606 -179.785 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 46.8 t -87.65 -19.43 7.87 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 CA-C-O 120.726 0.298 . . . . 0.0 110.658 179.635 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.449 ' N ' ' O ' ' A' ' 42' ' ' ASP . . . -58.4 -49.95 75.44 Favored 'General case' 0 CA--C 1.52 -0.173 0 CA-C-O 120.803 0.335 . . . . 0.0 110.394 -179.704 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 30.7 m -62.43 -39.31 83.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.511 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 55.4 mt -69.33 -31.46 69.93 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.372 -0.377 . . . . 0.0 110.309 179.759 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 16.4 ttmm -86.72 -30.58 21.53 Favored 'General case' 0 CA--C 1.534 0.348 0 CA-C-O 120.56 0.219 . . . . 0.0 110.842 179.39 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 57.0 tp -72.47 -32.31 66.13 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 116.472 -0.331 . . . . 0.0 110.824 -179.105 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.6 p -74.86 127.24 36.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-O 121.009 0.433 . . . . 0.0 110.717 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -68.28 -42.68 79.19 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.12 179.371 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -145.97 -99.26 0.25 Allowed Glycine 0 N--CA 1.473 1.132 0 N-CA-C 110.617 -0.993 . . . . 0.0 110.617 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ARG . . . . . 0.463 ' HE ' HG21 ' A' ' 11' ' ' VAL . 84.1 mtp180 -114.86 104.65 12.15 Favored 'General case' 0 N--CA 1.471 0.615 0 CA-C-N 116.6 0.2 . . . . 0.0 110.525 179.557 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 93.6 m-20 -117.3 155.79 28.91 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 122.684 0.394 . . . . 0.0 110.192 178.205 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 9.6 p -80.51 140.9 35.65 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 178.834 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.46 HG23 ' N ' ' A' ' 58' ' ' SER . 17.7 m -55.32 -41.93 64.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 C-N-CA 120.738 -0.385 . . . . 0.0 110.696 -179.537 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' SER . . . . . 0.46 ' N ' HG23 ' A' ' 57' ' ' VAL . 67.1 m -57.71 -42.54 83.97 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.738 179.902 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 58.9 tt0 -63.84 -47.62 80.03 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.884 0.374 . . . . 0.0 110.497 -179.757 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 65.8 mt -60.96 -43.09 95.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.158 -0.474 . . . . 0.0 109.839 179.415 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.418 ' O ' ' N ' ' A' ' 65' ' ' GLY . . . -53.62 -38.19 63.8 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.702 -0.681 . . . . 0.0 111.006 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 24.9 mm100 -64.14 -53.56 47.65 Favored 'General case' 0 C--N 1.331 -0.212 0 C-N-CA 120.694 -0.402 . . . . 0.0 110.582 179.739 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 75.2 mt -63.64 -48.84 84.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 C-N-CA 120.741 -0.383 . . . . 0.0 110.504 -179.255 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 40.3 tp -67.22 -38.91 86.06 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.01 0.433 . . . . 0.0 110.275 179.585 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.439 ' O ' ' N ' ' A' ' 69' ' ' ASP . . . -58.87 -42.17 96.52 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 111.233 -0.747 . . . . 0.0 111.233 -179.453 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 86.4 mt-30 -66.09 -30.37 70.86 Favored 'General case' 0 C--N 1.328 -0.352 0 C-N-CA 120.974 -0.29 . . . . 0.0 110.375 179.568 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 19.8 m -62.36 -49.13 76.78 Favored 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 120.627 -0.429 . . . . 0.0 110.226 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 95.3 m-85 -94.48 -2.43 51.78 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.562 179.301 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' ASP . . . . . 0.439 ' N ' ' O ' ' A' ' 65' ' ' GLY . 65.7 t0 52.52 62.12 2.85 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.763 0.316 . . . . 0.0 110.83 179.783 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -137.26 158.26 44.83 Favored 'General case' 0 N--CA 1.469 0.517 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.181 -179.652 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 85.6 m-20 -55.85 113.95 6.62 Favored Pre-proline 0 CA--C 1.546 0.798 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.18 -179.501 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 74.9 Cg_exo -48.56 -34.12 25.59 Favored 'Trans proline' 0 N--CA 1.501 1.913 0 C-N-CA 121.672 1.582 . . . . 0.0 112.195 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -52.08 -39.6 59.97 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.043 0.449 . . . . 0.0 110.609 -179.678 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 70.3 mt -71.74 -42.69 70.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.188 179.237 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 33.9 mm -61.35 -49.82 82.94 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.345 -178.616 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -65.0 -43.44 92.54 Favored 'General case' 0 C--O 1.232 0.176 0 C-N-CA 120.595 -0.442 . . . . 0.0 110.155 -179.684 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.418 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -63.9 -21.35 66.42 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.219 179.588 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 65.9 t0 -78.17 -51.91 9.5 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 120.742 0.306 . . . . 0.0 110.912 -179.531 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 30.3 pt -74.01 -37.79 47.98 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.498 -179.838 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 9.6 mt -42.88 -60.03 2.6 Favored Pre-proline 0 CA--C 1.551 1.017 0 N-CA-C 111.768 0.285 . . . . 0.0 111.768 -179.376 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.418 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 39.1 Cg_endo -61.96 -24.2 76.63 Favored 'Trans proline' 0 N--CA 1.501 1.947 0 C-N-CA 122.089 1.859 . . . . 0.0 112.057 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 9.3 tpt -66.19 -35.5 80.61 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 120.745 0.307 . . . . 0.0 110.659 -179.712 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 43.5 mt -61.19 -41.02 96.07 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.432 -178.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.35 -40.53 96.68 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.849 0.357 . . . . 0.0 110.077 179.469 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -64.31 -40.71 98.12 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 111.091 -0.804 . . . . 0.0 111.091 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 86.3 mt -66.74 -40.77 88.47 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.806 0.336 . . . . 0.0 110.676 -179.828 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -55.82 -37.13 68.27 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 120.824 -0.351 . . . . 0.0 110.977 -179.526 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 77.8 mt-30 -62.11 -21.43 65.0 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.05 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -91.73 -1.88 57.22 Favored 'General case' 0 N--CA 1.469 0.502 0 CA-C-N 116.476 -0.329 . . . . 0.0 110.549 -179.286 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 64.3 ttt-85 62.25 55.8 2.32 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.459 179.599 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 33.6 m -141.81 5.16 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.516 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.756 179.851 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 55.9 tp -141.81 138.04 31.93 Favored 'General case' 0 N--CA 1.47 0.555 0 CA-C-O 120.937 0.399 . . . . 0.0 110.294 179.673 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -150.77 135.91 17.65 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-N 116.036 -0.529 . . . . 0.0 109.873 179.395 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 60.3 ttp180 . . . . . 0 C--O 1.221 -0.429 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.162 -179.38 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 67.7 mtt . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 108.928 -0.768 . . . . 0.0 108.928 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -71.69 148.9 92.92 Favored Pre-proline 0 CA--C 1.54 0.56 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.466 -179.422 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 64.3 Cg_endo -69.04 -16.3 40.47 Favored 'Trans proline' 0 N--CA 1.495 1.617 0 C-N-CA 122.314 2.01 . . . . 0.0 112.108 179.718 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 19.4 p -75.92 70.11 2.61 Favored 'General case' 0 CA--C 1.52 -0.21 0 CA-C-O 121.057 0.456 . . . . 0.0 110.388 -179.139 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -166.23 53.31 0.09 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.8 179.825 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 75.6 m-85 -83.92 133.99 34.69 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-O 120.817 0.341 . . . . 0.0 110.203 179.818 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 47.8 m -92.58 -179.91 5.32 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.121 179.665 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -71.86 -30.1 66.33 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.176 -0.77 . . . . 0.0 111.176 179.738 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 34.8 t -69.75 -18.06 63.48 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.84 0.353 . . . . 0.0 110.824 -179.468 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 93.7 m-20 -69.0 150.34 47.78 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 179.756 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.534 HG21 ' HE ' ' A' ' 54' ' ' ARG . 19.7 m -129.41 130.47 23.31 Favored Pre-proline 0 N--CA 1.474 0.742 0 CA-C-N 116.568 -0.287 . . . . 0.0 110.786 -179.007 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -77.95 146.85 23.55 Favored 'Trans proline' 0 N--CA 1.49 1.306 0 C-N-CA 121.466 1.444 . . . . 0.0 111.64 179.632 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 62.1 ttp180 -158.12 124.04 4.62 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 179.206 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 72.4 mt -68.72 119.37 68.59 Favored Pre-proline 0 CA--C 1.543 0.707 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.935 -179.437 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.441 ' CD ' ' O ' ' A' ' 91' ' ' VAL . 98.4 Cg_endo -75.11 159.37 41.06 Favored 'Trans proline' 0 N--CA 1.493 1.452 0 C-N-CA 121.821 1.681 . . . . 0.0 112.112 -179.851 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 77.6 mtp85 -55.54 150.83 11.43 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.414 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 82.72 15.02 74.25 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.77 -0.932 . . . . 0.0 110.77 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.54 ' CG1' HD11 ' A' ' 31' ' ' LEU . 60.3 t -135.05 131.85 52.88 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.525 0 CA-C-O 120.869 0.366 . . . . 0.0 110.145 179.689 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 90.9 mtm180 -138.03 155.94 48.31 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.267 -179.795 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 29.2 mt -93.11 102.68 15.0 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 109.832 -0.432 . . . . 0.0 109.832 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 84.1 mtp180 -89.93 143.67 26.59 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 116.212 -0.449 . . . . 0.0 109.96 179.687 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 87.9 t80 -103.46 110.77 22.92 Favored 'General case' 0 N--CA 1.463 0.207 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.003 179.742 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 95.2 m-20 -89.66 92.97 9.29 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 116.034 -0.53 . . . . 0.0 109.879 179.706 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.5 tt0 -62.16 -33.16 73.98 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.184 -179.805 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.402 HG22 ' H ' ' A' ' 25' ' ' VAL . 3.0 m -63.19 -42.9 98.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.366 -179.809 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.469 ' NH2' ' OD1' ' A' ' 39' ' ' ASP . 99.8 mtt180 -90.9 -8.51 49.19 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-O 120.67 0.272 . . . . 0.0 110.525 179.693 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 17.0 t-20 55.66 33.36 21.12 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.028 179.737 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 18.2 ptmt -145.08 158.53 43.79 Favored 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 116.319 -0.4 . . . . 0.0 109.957 179.712 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.406 ' O ' ' O ' ' A' ' 40' ' ' LEU . 70.4 m80 -88.48 150.55 23.07 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 179.395 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 21.9 m -137.92 156.49 31.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -179.76 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.54 HD11 ' CG1' ' A' ' 18' ' ' VAL . 36.7 tp -104.53 123.82 48.2 Favored 'General case' 0 CA--C 1.517 -0.319 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.449 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 55.1 tp -78.78 97.16 5.81 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 179.205 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -95.32 147.32 32.84 Favored Pre-proline 0 CA--C 1.54 0.588 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 71.2 Cg_exo -48.24 -36.48 29.51 Favored 'Trans proline' 0 N--CA 1.497 1.724 0 C-N-CA 121.588 1.525 . . . . 0.0 112.557 178.62 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -73.95 -52.06 14.06 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.519 -0.31 . . . . 0.0 111.004 -178.596 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 17.6 ptm180 -176.12 161.69 2.4 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.712 -179.844 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 90.1 m -73.52 124.89 26.75 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.244 178.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 77.2 m-85 -101.5 133.65 45.83 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.156 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.469 ' OD1' ' NH2' ' A' ' 26' ' ' ARG . 82.7 m-20 -73.21 120.53 18.96 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.26 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.406 ' O ' ' O ' ' A' ' 29' ' ' HIS . 84.0 mt -133.16 158.96 41.53 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-O 121.062 0.458 . . . . 0.0 110.343 -179.701 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -82.9 152.14 25.67 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.048 -179.447 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 50.0 t0 -58.48 -37.8 76.27 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.27 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 98.1 m-20 -63.47 -38.96 93.16 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.352 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -68.71 -40.9 79.74 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.67 0.272 . . . . 0.0 110.857 -179.665 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 58.4 t -78.04 -31.45 16.68 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 N-CA-C 110.006 -0.368 . . . . 0.0 110.006 179.693 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -53.55 -38.16 63.58 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.235 -179.591 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 89.9 t -60.57 -46.6 95.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.657 179.857 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 40.3 mt -76.59 -16.9 59.47 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.842 -178.958 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 37.5 ttmt -92.37 -32.08 15.09 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.622 179.465 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 5.7 tp -72.51 -32.22 65.96 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.531 -179.123 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.409 HG13 ' O ' ' A' ' 51' ' ' VAL . 10.4 p -72.51 127.14 34.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 121.049 0.452 . . . . 0.0 110.458 -179.908 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 95.2 m-20 -69.59 -42.91 73.81 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.35 179.596 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -145.9 -102.47 0.34 Allowed Glycine 0 N--CA 1.472 1.038 0 N-CA-C 110.404 -1.078 . . . . 0.0 110.404 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' ARG . . . . . 0.534 ' HE ' HG21 ' A' ' 11' ' ' VAL . 84.3 mtp180 -114.79 104.98 12.49 Favored 'General case' 0 N--CA 1.471 0.586 0 CA-C-O 120.648 0.261 . . . . 0.0 110.321 179.512 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 97.6 m-20 -117.24 148.86 41.27 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.032 178.541 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 32.1 p -81.14 148.67 29.47 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 179.009 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.426 HG23 ' N ' ' A' ' 58' ' ' SER . 32.8 m -56.57 -39.08 60.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-N 116.374 -0.376 . . . . 0.0 110.361 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' SER . . . . . 0.426 ' N ' HG23 ' A' ' 57' ' ' VAL . 69.5 m -57.68 -45.58 85.44 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.656 -179.678 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.3 tt0 -66.52 -45.73 78.55 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.603 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 96.6 mt -61.58 -43.21 96.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.141 -0.481 . . . . 0.0 109.762 -179.536 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.416 ' O ' ' N ' ' A' ' 65' ' ' GLY . . . -53.88 -42.04 68.2 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.9 -179.144 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 28.6 mm100 -64.53 -56.08 16.36 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.083 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 69.9 mt -64.07 -48.92 83.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-O 120.846 0.355 . . . . 0.0 110.596 -179.096 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 30.6 tp -67.53 -36.53 81.19 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.252 -179.513 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.43 ' O ' ' N ' ' A' ' 69' ' ' ASP . . . -58.65 -39.46 93.45 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 111.011 -0.836 . . . . 0.0 111.011 -179.541 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 97.5 mt-30 -65.8 -34.65 78.66 Favored 'General case' 0 C--N 1.326 -0.434 0 C-N-CA 121.044 -0.262 . . . . 0.0 110.621 179.744 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 96.1 m -61.73 -47.43 85.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.767 0.318 . . . . 0.0 110.393 -179.674 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -93.92 -1.34 54.86 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.633 179.594 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' ASP . . . . . 0.43 ' N ' ' O ' ' A' ' 65' ' ' GLY . 51.5 t0 50.22 62.12 2.84 Favored 'General case' 0 C--N 1.332 -0.185 0 C-N-CA 120.92 -0.312 . . . . 0.0 110.878 179.756 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -140.45 161.54 37.47 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-N 116.484 -0.325 . . . . 0.0 110.255 -179.584 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 68.6 m-20 -55.85 114.5 7.58 Favored Pre-proline 0 CA--C 1.544 0.736 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.593 -179.193 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_exo -48.52 -35.71 29.54 Favored 'Trans proline' 0 N--CA 1.496 1.664 0 C-N-CA 121.793 1.662 . . . . 0.0 112.329 179.555 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -53.7 -39.97 65.63 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.342 -179.193 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 72.5 mt -72.63 -36.36 53.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.76 179.722 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 42.9 mm -61.01 -48.27 89.84 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.258 -178.506 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -61.71 -43.86 98.05 Favored 'General case' 0 CA--C 1.532 0.252 0 CA-C-O 120.856 0.36 . . . . 0.0 110.197 -179.619 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.454 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -66.85 -19.21 65.69 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.265 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 64.8 t0 -80.64 -46.13 16.13 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-O 120.683 0.278 . . . . 0.0 111.093 -179.637 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 34.0 pt -79.78 -33.88 15.16 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.566 0 CA-C-O 120.916 0.388 . . . . 0.0 111.369 -179.544 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.413 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 9.4 mt -47.66 -59.04 6.24 Favored Pre-proline 0 CA--C 1.545 0.768 0 CA-C-N 116.558 -0.292 . . . . 0.0 111.07 179.679 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.454 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 33.3 Cg_endo -60.0 -24.39 76.32 Favored 'Trans proline' 0 N--CA 1.497 1.726 0 C-N-CA 121.964 1.776 . . . . 0.0 111.749 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 13.2 tpt -65.45 -36.18 83.13 Favored 'General case' 0 CA--C 1.532 0.258 0 CA-C-O 120.805 0.335 . . . . 0.0 110.598 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 47.7 mt -61.56 -39.44 91.14 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.294 -179.652 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.0 -40.82 95.01 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 179.746 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -66.48 -40.56 94.38 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 111.51 -0.636 . . . . 0.0 111.51 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 87.2 mt -66.83 -40.59 88.02 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.852 0.358 . . . . 0.0 110.513 -179.601 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -54.73 -37.35 65.78 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.796 0.331 . . . . 0.0 110.542 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 86.7 mt-30 -62.57 -22.95 66.75 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.815 179.721 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 65.1 mttp -91.34 -6.76 52.55 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.199 -179.542 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 14.8 tpt180 62.35 53.13 2.86 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.914 -0.584 . . . . 0.0 110.17 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' VAL . . . . . 0.441 ' O ' ' CD ' ' A' ' 15' ' ' PRO . 30.2 m -133.09 -1.27 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.312 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.809 -179.619 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 35.1 tp -104.92 145.42 30.43 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-O 121.271 0.557 . . . . 0.0 109.989 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 45.8 tp10 -149.06 115.24 5.78 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.14 -0.936 . . . . 0.0 109.902 -179.302 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 61.3 ttp180 . . . . . 0 C--O 1.221 -0.436 0 CA-C-O 117.901 -1.047 . . . . 0.0 109.989 179.931 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 16.8 ptm . . . . . 0 N--CA 1.489 1.506 0 N-CA-C 109.268 -0.641 . . . . 0.0 109.268 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 52.46 63.76 8.4 Favored Pre-proline 0 CA--C 1.534 0.347 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.457 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -75.36 168.44 24.57 Favored 'Trans proline' 0 N--CA 1.493 1.456 0 C-N-CA 122.472 2.115 . . . . 0.0 111.869 -179.806 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 18.7 p -73.46 -35.28 65.7 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.123 -179.591 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . 45.76 93.12 0.01 OUTLIER 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.797 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 91.4 m-85 -80.01 133.83 36.18 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.378 -179.665 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 34.1 m -94.1 -175.43 3.69 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.506 -179.836 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -65.21 -37.47 94.07 Favored Glycine 0 CA--C 1.527 0.806 0 N-CA-C 111.348 -0.701 . . . . 0.0 111.348 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 15.5 m -72.81 -25.44 61.15 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.826 0.346 . . . . 0.0 110.734 -179.544 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -68.39 150.41 48.19 Favored 'General case' 0 CA--C 1.515 -0.369 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 -179.806 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.578 HG21 ' HE ' ' A' ' 54' ' ' ARG . 27.4 m -128.2 128.94 23.68 Favored Pre-proline 0 CA--C 1.54 0.565 0 CA-C-N 116.422 -0.353 . . . . 0.0 111.178 -179.192 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 95.1 Cg_endo -77.22 145.13 24.01 Favored 'Trans proline' 0 N--CA 1.494 1.551 0 C-N-CA 121.959 1.773 . . . . 0.0 111.742 179.377 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 71.1 ttt-85 -158.09 127.35 5.77 Favored 'General case' 0 C--N 1.332 -0.183 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.216 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 47.0 mt -68.2 131.59 91.99 Favored Pre-proline 0 CA--C 1.542 0.644 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.955 -179.381 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 81.2 Cg_endo -75.29 158.75 40.89 Favored 'Trans proline' 0 N--CA 1.491 1.354 0 C-N-CA 122.006 1.804 . . . . 0.0 111.938 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 60.4 ttt85 -55.95 144.44 28.4 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.074 179.556 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 87.36 12.39 67.51 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 179.679 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.519 ' CG1' HD11 ' A' ' 31' ' ' LEU . 59.9 t -132.83 130.28 58.76 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.52 0 CA-C-O 120.946 0.403 . . . . 0.0 110.155 179.344 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.598 HH11 ' NH1' ' A' ' 21' ' ' ARG . 81.2 mtm-85 -138.81 157.78 45.44 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.079 179.768 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 27.5 mt -92.03 139.9 30.18 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.715 179.846 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.598 ' NH1' HH11 ' A' ' 19' ' ' ARG . 81.7 mtt85 -139.47 146.71 40.38 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.002 -0.544 . . . . 0.0 109.948 -179.677 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 59.2 t80 -102.83 117.6 34.99 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 115.701 -0.682 . . . . 0.0 110.166 179.656 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -89.73 103.9 16.51 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.601 178.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 78.2 tt0 -63.76 -36.47 83.97 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.524 -179.828 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.418 HG22 ' H ' ' A' ' 25' ' ' VAL . 1.5 m -62.99 -42.67 97.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.342 -179.524 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 100.0 mtt180 -86.67 -18.6 30.88 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 120.743 0.306 . . . . 0.0 110.289 -179.629 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 12.2 m-80 68.03 23.66 8.08 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.116 179.502 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 14.6 ptpt -145.29 163.52 34.25 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.088 179.393 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 77.3 m80 -89.51 151.0 22.21 Favored 'General case' 0 CA--C 1.519 -0.247 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.934 179.67 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 34.7 m -140.74 158.07 23.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.007 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.519 HD11 ' CG1' ' A' ' 18' ' ' VAL . 34.1 tp -100.41 116.46 32.43 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.23 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 44.3 tp -77.02 99.35 5.27 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 179.285 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -97.38 147.27 32.73 Favored Pre-proline 0 CA--C 1.542 0.662 0 C-N-CA 121.107 -0.237 . . . . 0.0 110.395 179.782 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 77.3 Cg_exo -49.17 -37.84 39.78 Favored 'Trans proline' 0 N--CA 1.499 1.804 0 C-N-CA 122.073 1.849 . . . . 0.0 112.502 178.654 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 77.8 tt0 -74.28 -51.93 13.79 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.893 -178.72 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 59.4 ttm-85 -174.87 151.34 1.37 Allowed 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.954 0.407 . . . . 0.0 110.475 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 69.7 m -69.48 132.84 46.93 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.47 179.114 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 85.4 m-85 -103.4 133.99 47.53 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.458 179.895 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 38.5 p-10 -71.59 117.78 13.59 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.364 179.451 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 88.2 mt -133.45 157.48 45.49 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.392 -179.728 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 87.5 m-20 -86.7 152.49 22.5 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.045 -179.726 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 53.9 t0 -58.51 -39.47 80.2 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.716 -179.767 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 70.9 m-20 -63.7 -39.97 95.63 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.704 -179.586 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.76 -40.19 76.26 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.865 -179.564 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 57.6 t -78.15 -29.94 15.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.398 -0.364 . . . . 0.0 110.258 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -54.11 -36.06 62.81 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.307 -179.68 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 60.1 t -60.71 -46.19 96.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.693 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 38.2 mt -75.76 -19.01 59.33 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.522 -179.024 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 15.2 ttmm -90.08 -29.42 18.37 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.546 179.639 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 9.0 tp -71.13 -32.7 69.31 Favored 'General case' 0 C--N 1.332 -0.178 0 C-N-CA 120.602 -0.439 . . . . 0.0 110.533 -178.522 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.1 p -74.46 127.37 36.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.456 179.75 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 95.2 m-20 -70.9 -43.75 67.67 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.376 179.536 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -143.51 -101.03 0.36 Allowed Glycine 0 N--CA 1.472 1.044 0 N-CA-C 110.458 -1.057 . . . . 0.0 110.458 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' ARG . . . . . 0.578 ' HE ' HG21 ' A' ' 11' ' ' VAL . 85.1 mtp180 -114.77 104.87 12.39 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-O 120.924 0.393 . . . . 0.0 110.265 179.232 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 97.2 m-20 -117.11 153.77 32.18 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.355 178.072 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 13.7 p -80.09 136.53 36.57 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 178.668 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 29.9 m -54.49 -38.98 43.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.481 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 12.0 t -60.12 -44.63 94.74 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.676 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 56.8 tt0 -64.41 -43.21 95.11 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.842 -179.461 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 96.6 mt -61.2 -43.15 95.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 -179.632 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -52.17 -35.42 48.74 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.164 -178.924 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 94.3 mm-40 -63.36 -53.85 46.08 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.674 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 70.2 mt -66.63 -48.43 80.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.924 0.392 . . . . 0.0 110.854 -179.503 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 21.8 tp -67.73 -39.21 84.29 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.545 -178.946 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -54.74 -41.0 73.55 Favored Glycine 0 CA--C 1.525 0.662 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 -179.319 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 87.7 mt-30 -65.85 -31.6 72.65 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.63 0.252 . . . . 0.0 110.557 179.706 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 18.8 m -61.99 -45.69 92.53 Favored 'General case' 0 C--N 1.329 -0.283 0 C-N-CA 120.872 -0.331 . . . . 0.0 110.546 -179.437 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -90.6 1.75 56.47 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.466 179.855 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 61.6 t0 54.74 48.65 19.72 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.564 179.767 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -140.94 160.56 39.81 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-O 120.915 0.388 . . . . 0.0 110.313 -179.68 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 95.0 m-20 -55.91 144.39 57.83 Favored Pre-proline 0 CA--C 1.54 0.566 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.678 -179.096 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -68.18 -33.76 23.85 Favored 'Trans proline' 0 N--CA 1.498 1.777 0 C-N-CA 122.462 2.108 . . . . 0.0 112.28 -179.533 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -54.41 -32.22 56.78 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.829 0.347 . . . . 0.0 110.861 -179.348 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 65.6 mt -68.46 -42.03 83.63 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.599 -179.856 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.544 ' N ' HD12 ' A' ' 75' ' ' ILE . 1.7 mp -60.82 -39.85 83.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 -179.182 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 7.0 mm-40 -57.31 -66.24 0.49 Allowed 'General case' 0 C--N 1.314 -0.977 0 C-N-CA 120.597 -0.441 . . . . 0.0 110.967 -178.337 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.402 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -55.34 -16.75 3.8 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.742 -178.69 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 58.5 t0 -80.65 -52.59 7.39 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.186 -179.713 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 18.4 pt -80.51 -33.5 13.84 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.425 0 CA-C-O 121.021 0.438 . . . . 0.0 111.485 -178.953 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.416 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 10.3 mt -44.94 -59.74 3.86 Favored Pre-proline 0 CA--C 1.54 0.578 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.611 179.844 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.416 ' HD2' ' N ' ' A' ' 80' ' ' LEU . 39.6 Cg_endo -61.73 -30.33 84.8 Favored 'Trans proline' 0 N--CA 1.493 1.444 0 C-N-CA 121.451 1.434 . . . . 0.0 111.751 179.793 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 15.1 tpt -65.85 -41.01 92.22 Favored 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 120.781 -0.367 . . . . 0.0 110.752 -179.367 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 82.9 mt -62.86 -41.41 99.37 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.243 -179.483 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.91 -37.87 88.71 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.384 179.647 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -62.43 -39.79 98.24 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 111.122 -0.791 . . . . 0.0 111.122 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 88.2 mt -67.67 -39.54 84.51 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.865 0.364 . . . . 0.0 110.491 -179.768 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -53.8 -36.94 63.01 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.886 0.374 . . . . 0.0 110.69 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 49.0 mt-30 -62.38 -21.76 65.6 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.886 179.734 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -92.26 -1.56 57.02 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 116.515 -0.312 . . . . 0.0 110.242 -179.261 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 63.2 ttt-85 61.56 57.11 2.37 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.345 179.525 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 34.8 m -141.71 11.82 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.216 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 55.3 tp -140.18 140.13 35.84 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.397 179.863 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 16.4 pt-20 -149.31 142.04 24.57 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 115.652 -0.703 . . . . 0.0 110.555 179.386 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 62.2 ttp180 . . . . . 0 C--O 1.22 -0.494 0 CA-C-O 118.057 -0.973 . . . . 0.0 110.263 179.727 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 48.4 ttp . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 26.4 mm-40 48.41 72.73 1.16 Allowed Pre-proline 0 CA--C 1.533 0.305 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.751 -179.81 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_exo -56.77 149.41 60.02 Favored 'Trans proline' 0 N--CA 1.496 1.631 0 C-N-CA 122.575 2.183 . . . . 0.0 111.942 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.429 HG22 ' H ' ' A' ' 4' ' ' THR . 0.0 OUTLIER -79.02 83.64 5.1 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.974 -179.78 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.405 ' O ' ' O ' ' A' ' 6' ' ' PHE . . . -76.21 -4.68 43.12 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.554 -179.906 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.558 ' CE2' ' NH2' ' A' ' 94' ' ' ARG . 97.0 m-85 58.67 146.56 0.01 OUTLIER 'General case' 0 N--CA 1.462 0.161 0 O-C-N 123.608 0.567 . . . . 0.0 110.515 -179.523 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 49.7 m -92.57 -177.57 4.62 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-O 120.833 0.349 . . . . 0.0 110.239 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -71.73 -32.07 64.44 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 110.926 -0.87 . . . . 0.0 110.926 179.604 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 37.1 t -69.41 -17.49 63.66 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.681 0.277 . . . . 0.0 110.841 -179.321 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -68.28 146.16 53.57 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.536 HG23 ' O ' ' A' ' 11' ' ' VAL . 30.0 m -128.96 102.83 18.94 Favored Pre-proline 0 CA--C 1.541 0.599 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.492 -179.861 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -55.71 143.49 79.86 Favored 'Trans proline' 0 N--CA 1.5 1.91 0 C-N-CA 122.082 1.855 . . . . 0.0 112.11 178.64 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.41 ' HD2' ' HE ' ' A' ' 54' ' ' ARG . 78.6 ttt-85 -151.33 122.65 7.8 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-O 120.814 0.34 . . . . 0.0 110.15 178.992 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 71.1 mt -69.61 118.73 65.51 Favored Pre-proline 0 CA--C 1.542 0.639 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.323 -179.265 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.46 ' CD ' ' O ' ' A' ' 91' ' ' VAL . 89.1 Cg_endo -78.61 166.49 23.78 Favored 'Trans proline' 0 N--CA 1.495 1.572 0 C-N-CA 122.257 1.971 . . . . 0.0 112.036 179.763 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 9.3 ptm180 -55.48 154.3 6.57 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.282 179.27 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 84.36 -14.83 43.43 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 111.211 -0.755 . . . . 0.0 111.211 179.442 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.587 ' CG1' HD11 ' A' ' 31' ' ' LEU . 41.4 t -104.65 127.8 58.78 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.498 0 CA-C-O 120.929 0.395 . . . . 0.0 110.06 179.743 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 81.8 mtm-85 -138.38 153.43 48.92 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.269 -179.732 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 19.0 mt -98.47 98.78 9.94 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.079 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.496 ' HE ' HD22 ' A' ' 32' ' ' LEU . 96.0 mtt-85 -93.07 143.2 26.47 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.194 179.596 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 82.1 t80 -102.21 119.16 38.34 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.581 179.408 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 88.5 m-20 -87.73 105.97 17.74 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.127 -179.772 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -64.92 -37.35 87.35 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.766 -179.796 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 3.0 m -62.64 -43.24 98.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.617 -179.223 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.431 ' CD ' ' HZ2' ' A' ' 28' ' ' LYS . 95.3 mtt-85 -90.76 -10.98 40.92 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-O 120.695 0.283 . . . . 0.0 110.589 179.844 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 61.1 t-20 56.36 37.11 28.53 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.591 179.768 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.623 ' HZ3' ' CG1' ' A' ' 30' ' ' VAL . 9.5 pttm -144.91 167.05 23.54 Favored 'General case' 0 N--CA 1.466 0.346 0 N-CA-C 109.648 -0.501 . . . . 0.0 109.648 179.809 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.471 ' ND1' ' OD1' ' A' ' 42' ' ' ASP . 73.9 m80 -93.32 149.9 20.88 Favored 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 109.652 -0.499 . . . . 0.0 109.652 178.467 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.623 ' CG1' ' HZ3' ' A' ' 28' ' ' LYS . 35.3 m -140.62 152.77 21.04 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.337 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.834 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.587 HD11 ' CG1' ' A' ' 18' ' ' VAL . 35.4 tp -100.56 117.68 35.19 Favored 'General case' 0 N--CA 1.465 0.289 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 179.567 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.496 HD22 ' HE ' ' A' ' 21' ' ' ARG . 56.9 tp -79.16 97.98 6.4 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 179.044 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -93.62 148.07 34.77 Favored Pre-proline 0 CA--C 1.543 0.688 0 C-N-CA 120.985 -0.286 . . . . 0.0 110.321 179.845 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -44.26 -34.75 7.39 Favored 'Trans proline' 0 N--CA 1.497 1.7 0 C-N-CA 122.19 1.927 . . . . 0.0 112.189 178.877 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 -76.17 -52.08 10.81 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-N 116.48 -0.327 . . . . 0.0 111.076 -178.787 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 37.5 ptt180 -176.39 165.75 2.73 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.672 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 61.3 m -77.24 127.86 33.35 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.39 178.845 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 65.1 m-85 -104.23 138.41 40.73 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-O 121.039 0.447 . . . . 0.0 110.074 179.682 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -74.15 119.87 18.95 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.506 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 92.8 mt -135.31 157.58 46.53 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.209 -0.45 . . . . 0.0 109.894 179.826 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 19.9 m-20 -85.05 161.58 19.66 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.973 -179.581 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.471 ' OD1' ' ND1' ' A' ' 29' ' ' HIS . 31.8 m-20 -61.15 -39.9 91.85 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.357 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' ASN . . . . . 0.403 ' O ' HG23 ' A' ' 47' ' ' VAL . 55.6 m-20 -63.0 -36.8 84.76 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.578 -179.463 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.01 -43.44 74.78 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.468 -0.333 . . . . 0.0 111.119 -179.433 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 60.1 t -79.0 -31.83 15.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-O 120.741 0.305 . . . . 0.0 110.526 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -53.87 -35.84 61.98 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.537 -179.559 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.403 HG23 ' O ' ' A' ' 43' ' ' ASN . 93.1 t -61.32 -47.75 92.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.943 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 44.9 mt -77.61 -14.76 59.56 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.868 -178.833 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 37.4 ttmt -91.36 -30.66 16.41 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.88 0.371 . . . . 0.0 110.492 179.31 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 7.9 tp -71.15 -32.1 68.51 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.638 -178.451 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.6 p -73.51 125.01 31.85 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.602 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -73.35 -41.42 63.47 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.463 179.372 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -143.51 -99.58 0.31 Allowed Glycine 0 N--CA 1.471 0.968 0 N-CA-C 110.454 -1.059 . . . . 0.0 110.454 -179.635 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' ARG . . . . . 0.41 ' HE ' ' HD2' ' A' ' 13' ' ' ARG . 99.5 mtt180 -114.83 104.43 11.94 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 110.1 -0.333 . . . . 0.0 110.1 178.927 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 97.9 m-20 -117.36 146.09 43.63 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.005 178.207 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 42.3 p -79.69 141.43 36.42 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 178.776 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.442 HG23 ' N ' ' A' ' 58' ' ' SER . 27.8 m -54.19 -39.52 43.04 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.413 -179.667 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' SER . . . . . 0.442 ' N ' HG23 ' A' ' 57' ' ' VAL . 67.0 m -58.64 -43.1 89.65 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.663 179.596 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 55.9 tt0 -64.97 -47.91 75.91 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.868 -179.701 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 65.2 mt -60.77 -43.04 94.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.307 179.913 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -53.24 -41.04 65.03 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.322 -0.399 . . . . 0.0 111.042 -179.286 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 96.0 mm-40 -63.59 -53.86 45.01 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.894 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 65.3 mt -66.06 -46.83 86.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-O 121.02 0.438 . . . . 0.0 110.604 -179.057 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 25.7 tp -68.58 -37.75 80.11 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.093 -179.419 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.433 ' O ' ' N ' ' A' ' 69' ' ' ASP . . . -57.14 -40.41 91.49 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 -179.537 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 73.1 mt-30 -66.03 -32.31 73.71 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.656 0.265 . . . . 0.0 110.46 179.545 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 19.5 m -62.66 -47.96 81.39 Favored 'General case' 0 C--N 1.329 -0.3 0 C-N-CA 120.722 -0.391 . . . . 0.0 110.634 -179.602 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -94.81 -3.04 49.7 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.47 179.73 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' ASP . . . . . 0.433 ' N ' ' O ' ' A' ' 65' ' ' GLY . 66.4 t0 54.25 62.26 2.66 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.798 179.654 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -140.99 160.52 39.9 Favored 'General case' 0 N--CA 1.469 0.523 0 CA-C-O 120.766 0.317 . . . . 0.0 110.434 -179.723 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 88.2 m-20 -55.73 114.21 7.0 Favored Pre-proline 0 CA--C 1.543 0.693 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.49 -178.774 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 81.9 Cg_exo -49.22 -36.5 37.1 Favored 'Trans proline' 0 N--CA 1.502 1.995 0 C-N-CA 122.099 1.866 . . . . 0.0 112.474 179.887 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -53.58 -38.58 64.06 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.053 0.454 . . . . 0.0 110.884 -179.274 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 67.4 mt -72.71 -38.2 57.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.53 179.409 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 43.6 mm -60.63 -49.14 85.65 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.122 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.12 -178.039 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -62.01 -44.56 96.45 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.888 0.375 . . . . 0.0 110.436 -179.914 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.449 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -66.31 -20.71 66.17 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.954 -0.567 . . . . 0.0 111.114 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 65.9 t0 -79.82 -46.39 16.99 Favored 'General case' 0 CA--C 1.533 0.297 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.255 -179.602 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 34.9 pt -79.26 -32.19 14.86 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 CA-C-O 121.074 0.464 . . . . 0.0 111.43 -179.124 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.438 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 8.3 mt -48.56 -59.63 5.82 Favored Pre-proline 0 CA--C 1.543 0.686 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.5 179.722 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.449 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 30.1 Cg_endo -59.22 -25.24 77.44 Favored 'Trans proline' 0 N--CA 1.494 1.523 0 C-N-CA 121.995 1.796 . . . . 0.0 111.988 -179.316 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 44.5 ttp -65.35 -36.39 83.89 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.843 0.354 . . . . 0.0 110.551 -179.7 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 52.2 mt -62.12 -39.32 92.15 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.892 -179.656 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.7 -37.3 83.62 Favored 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 120.763 -0.375 . . . . 0.0 110.376 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -65.47 -41.66 96.21 Favored Glycine 0 CA--C 1.526 0.781 0 N-CA-C 111.122 -0.791 . . . . 0.0 111.122 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.414 HD23 ' HZ1' ' A' ' 89' ' ' LYS . 84.6 mt -70.69 -38.36 73.7 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.902 0.382 . . . . 0.0 110.417 -179.714 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -52.68 -24.33 8.36 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.609 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 86.1 mt-30 -61.18 -30.85 70.65 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.566 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' LYS . . . . . 0.414 ' HZ1' HD23 ' A' ' 86' ' ' LEU . 25.6 mtmm -96.64 0.39 49.77 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-O 120.921 0.391 . . . . 0.0 110.462 -179.361 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 66.3 ttt180 56.52 47.73 18.09 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.295 179.588 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' VAL . . . . . 0.46 ' O ' ' CD ' ' A' ' 15' ' ' PRO . 24.5 m -105.85 2.2 10.26 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.504 0 CA-C-N 116.471 -0.332 . . . . 0.0 110.185 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.567 HD13 HH12 ' A' ' 94' ' ' ARG . 97.3 mt -102.31 164.84 11.46 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-O 121.23 0.538 . . . . 0.0 110.505 179.849 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 45.7 tp10 -154.33 129.19 9.43 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.185 -0.916 . . . . 0.0 110.243 -179.534 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' ARG . . . . . 0.567 HH12 HD13 ' A' ' 92' ' ' LEU . 73.2 mtt85 . . . . . 0 C--N 1.326 -0.449 0 CA-C-O 117.763 -1.113 . . . . 0.0 109.752 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 69.8 mtm . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 31.3 tt0 57.3 57.15 7.85 Favored Pre-proline 0 CA--C 1.533 0.314 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.376 -179.652 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.519 ' C ' ' H ' ' A' ' 5' ' ' ALA . 66.8 Cg_endo -70.56 -13.05 32.31 Favored 'Trans proline' 0 N--CA 1.496 1.658 0 C-N-CA 122.323 2.015 . . . . 0.0 111.536 -179.866 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.474 ' C ' ' H ' ' A' ' 6' ' ' PHE . 15.7 p 60.76 -4.13 0.13 Allowed 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.889 -179.312 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.519 ' H ' ' C ' ' A' ' 3' ' ' PRO . . . 69.63 -40.52 0.46 Allowed 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 116.476 -0.329 . . . . 0.0 110.907 179.886 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.474 ' H ' ' C ' ' A' ' 4' ' ' THR . 1.3 t80 56.74 107.72 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.111 -0.495 . . . . 0.0 109.928 -179.619 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 16.7 m -90.14 176.61 6.7 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.581 179.848 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -71.31 -27.16 72.11 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 111.125 -0.79 . . . . 0.0 111.125 179.763 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 15.4 m -70.44 -22.03 62.74 Favored 'General case' 0 C--O 1.232 0.156 0 CA-C-O 120.836 0.351 . . . . 0.0 110.522 -179.481 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 -69.09 149.75 48.36 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 179.232 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.479 ' CG2' ' HE ' ' A' ' 54' ' ' ARG . 20.9 m -128.17 127.44 23.78 Favored Pre-proline 0 CA--C 1.548 0.868 0 CA-C-O 119.744 -0.169 . . . . 0.0 110.783 -178.966 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -77.46 147.41 25.42 Favored 'Trans proline' 0 N--CA 1.494 1.538 0 C-N-CA 121.321 1.347 . . . . 0.0 112.279 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 56.7 ttt85 -158.1 124.85 4.88 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 115.728 -0.669 . . . . 0.0 109.364 178.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 67.6 mt -70.09 128.25 91.72 Favored Pre-proline 0 CA--C 1.544 0.743 0 CA-C-O 119.389 -0.339 . . . . 0.0 110.771 -179.531 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -73.33 158.78 47.98 Favored 'Trans proline' 0 N--CA 1.496 1.643 0 C-N-CA 121.748 1.632 . . . . 0.0 111.978 179.834 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 90.7 mtm180 -57.37 148.56 22.77 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.521 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 83.54 12.86 77.31 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 111.031 -0.827 . . . . 0.0 111.031 179.792 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.476 ' CG1' HD11 ' A' ' 31' ' ' LEU . 61.4 t -132.6 132.08 59.93 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.566 0 CA-C-O 121.037 0.446 . . . . 0.0 109.986 179.78 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 89.9 mtm180 -136.81 158.75 43.73 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.207 -179.82 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 47.6 mt -91.06 142.56 27.62 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.092 -179.698 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 83.6 mtp180 -137.58 139.86 40.66 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 121.052 0.453 . . . . 0.0 110.095 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 73.9 t80 -99.28 120.86 40.24 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.286 -179.855 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.481 ' O ' ' N ' ' A' ' 27' ' ' ASN . 94.6 m-20 -87.45 105.98 17.66 Favored 'General case' 0 N--CA 1.462 0.174 0 CA-C-N 116.031 -0.531 . . . . 0.0 109.638 179.84 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -64.85 -37.24 86.96 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.071 -179.531 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 1.5 p -62.18 -45.39 98.87 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.988 -179.275 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 94.6 mtt-85 -93.88 -9.25 37.85 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.689 -179.263 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.481 ' N ' ' O ' ' A' ' 23' ' ' ASP . 70.5 m-20 54.18 41.39 32.03 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.216 179.352 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 13.9 pttm -144.45 163.58 33.4 Favored 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 109.457 -0.572 . . . . 0.0 109.457 179.768 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 78.2 m80 -94.26 148.29 22.35 Favored 'General case' 0 C--N 1.329 -0.284 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 179.158 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 27.4 m -139.6 158.87 27.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.246 -0.434 . . . . 0.0 109.836 -179.765 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.476 HD11 ' CG1' ' A' ' 18' ' ' VAL . 37.8 tp -103.07 120.15 40.16 Favored 'General case' 0 N--CA 1.468 0.467 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.241 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 58.5 tp -80.01 97.3 6.73 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 178.875 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -97.01 147.13 32.46 Favored Pre-proline 0 CA--C 1.538 0.518 0 N-CA-C 110.172 -0.307 . . . . 0.0 110.172 -179.546 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 80.8 Cg_exo -47.52 -37.75 26.74 Favored 'Trans proline' 0 N--CA 1.496 1.668 0 C-N-CA 121.419 1.412 . . . . 0.0 112.698 179.032 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 82.1 tt0 -72.84 -52.06 16.36 Favored 'General case' 0 C--N 1.331 -0.206 0 C-N-CA 120.785 -0.366 . . . . 0.0 111.205 -178.489 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 44.0 ttm180 -176.66 151.11 0.89 Allowed 'General case' 0 N--CA 1.465 0.295 0 O-C-N 123.462 0.476 . . . . 0.0 110.378 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 91.7 m -69.8 130.22 41.71 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.185 179.092 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.491 ' CD2' ' NZ ' ' A' ' 89' ' ' LYS . 95.5 m-85 -102.81 139.64 38.12 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-O 120.903 0.382 . . . . 0.0 110.504 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 95.4 m-20 -74.88 119.73 19.46 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.066 179.665 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 75.3 mt -131.38 158.66 40.16 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.364 -179.625 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -85.38 152.81 22.96 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.386 -179.727 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 68.2 t0 -58.95 -41.32 87.15 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.648 -179.711 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 43.8 t-20 -63.35 -37.59 87.85 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.537 -179.842 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -67.93 -37.84 82.15 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.75 -179.478 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 43.2 t -86.53 -19.32 8.25 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.344 0 CA-C-O 120.9 0.381 . . . . 0.0 110.543 179.529 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.73 -50.14 73.12 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.01 0.433 . . . . 0.0 110.321 -179.54 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 17.8 m -62.39 -38.06 80.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.714 179.742 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 47.9 mt -68.9 -32.5 72.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.914 0.387 . . . . 0.0 110.338 179.846 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 36.6 ttpt -87.63 -29.23 21.35 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 116.385 -0.371 . . . . 0.0 111.168 179.785 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 58.6 tp -71.47 -32.28 68.11 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-O 120.661 0.267 . . . . 0.0 110.717 -179.108 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.5 p -73.18 129.74 35.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 121.118 0.485 . . . . 0.0 110.644 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 86.6 m-20 -68.8 -43.18 76.19 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.282 179.45 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -145.36 -100.47 0.29 Allowed Glycine 0 N--CA 1.472 1.072 0 N-CA-C 110.493 -1.043 . . . . 0.0 110.493 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' ARG . . . . . 0.479 ' HE ' ' CG2' ' A' ' 11' ' ' VAL . 84.3 mtp180 -114.92 104.43 11.91 Favored 'General case' 0 N--CA 1.471 0.612 0 CA-C-N 116.897 0.349 . . . . 0.0 110.327 179.348 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 -117.6 152.13 35.77 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.05 178.07 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 71.2 p -79.18 140.32 37.75 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 178.682 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 29.6 m -54.0 -37.61 34.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 C-N-CA 120.725 -0.39 . . . . 0.0 110.456 -179.534 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 56.8 m -57.89 -43.96 86.44 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.772 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 50.6 tt0 -65.4 -46.3 80.56 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.824 0.345 . . . . 0.0 110.955 -179.534 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 66.8 mt -61.35 -42.63 94.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.312 -179.712 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.406 ' O ' ' N ' ' A' ' 65' ' ' GLY . . . -52.33 -38.44 58.58 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.893 -179.394 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 93.4 mm-40 -63.94 -49.57 72.08 Favored 'General case' 0 C--N 1.327 -0.392 0 C-N-CA 120.872 -0.331 . . . . 0.0 110.596 179.825 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 70.4 mt -64.32 -51.08 72.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.918 -179.252 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 30.0 tp -69.79 -35.63 75.04 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.028 0.442 . . . . 0.0 110.334 -179.606 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.406 ' N ' ' O ' ' A' ' 61' ' ' ALA . . . -54.22 -40.09 66.36 Favored Glycine 0 CA--C 1.525 0.698 0 N-CA-C 110.926 -0.87 . . . . 0.0 110.926 -179.487 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 51.6 mt-30 -66.15 -32.2 73.51 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.569 0.223 . . . . 0.0 110.642 179.598 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 20.8 m -62.45 -47.44 84.03 Favored 'General case' 0 C--N 1.33 -0.258 0 C-N-CA 120.752 -0.379 . . . . 0.0 110.654 -179.502 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 87.8 m-85 -92.33 -3.1 55.88 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.5 179.381 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 66.3 t0 51.6 60.96 3.48 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.996 179.649 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -144.65 164.58 30.54 Favored 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.224 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 76.6 m-20 -55.67 112.78 4.64 Favored Pre-proline 0 CA--C 1.545 0.787 0 CA-C-O 119.248 -0.406 . . . . 0.0 110.311 -179.509 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 80.0 Cg_exo -48.33 -34.74 25.8 Favored 'Trans proline' 0 N--CA 1.502 2.02 0 C-N-CA 121.926 1.751 . . . . 0.0 112.949 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -51.3 -36.54 42.94 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.954 0.407 . . . . 0.0 111.086 -179.352 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 67.8 mt -71.32 -40.44 73.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.806 179.747 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.558 ' N ' HD12 ' A' ' 75' ' ' ILE . 1.7 mp -60.66 -47.9 91.0 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.711 -178.6 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -61.81 -47.09 86.67 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 120.344 -0.542 . . . . 0.0 110.347 -179.162 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.428 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -65.07 -20.47 66.5 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.514 179.766 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 66.0 t0 -79.44 -52.19 8.38 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-O 120.716 0.293 . . . . 0.0 110.887 -179.628 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 13.2 pt -72.09 -40.62 67.12 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 116.299 -0.409 . . . . 0.0 111.256 -179.658 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 8.0 mt -41.19 -60.11 1.91 Allowed Pre-proline 0 CA--C 1.553 1.065 0 CA-C-O 119.586 -0.245 . . . . 0.0 111.056 -179.809 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.428 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 76.2 Cg_exo -39.53 -42.58 2.75 Favored 'Trans proline' 0 N--CA 1.493 1.471 0 C-N-CA 122.576 2.184 . . . . 0.0 112.363 177.824 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 36.2 tpp -65.76 -41.86 91.57 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.508 -179.496 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 44.7 mt -62.01 -41.71 98.37 Favored 'General case' 0 C--N 1.329 -0.283 0 C-N-CA 120.552 -0.459 . . . . 0.0 110.489 -179.031 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -63.5 -39.54 94.72 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.232 179.665 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -68.23 -40.53 87.62 Favored Glycine 0 CA--C 1.527 0.806 0 N-CA-C 111.512 -0.635 . . . . 0.0 111.512 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 66.7 mt -66.7 -39.86 88.26 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.709 0.29 . . . . 0.0 110.638 -179.608 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -52.67 -34.16 50.5 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.777 0.322 . . . . 0.0 110.516 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 77.2 mt-30 -62.87 -22.6 66.82 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.834 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' LYS . . . . . 0.491 ' NZ ' ' CD2' ' A' ' 38' ' ' PHE . 98.8 mttt -92.74 -3.75 54.27 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.412 -179.225 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 52.9 ttt180 64.43 26.94 13.56 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.549 179.327 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 26.1 m -100.23 0.58 10.39 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.492 179.795 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 45.8 tp -112.21 147.5 36.07 Favored 'General case' 0 N--CA 1.472 0.646 0 CA-C-O 121.215 0.531 . . . . 0.0 109.861 179.625 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -135.46 153.85 51.62 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.472 -0.786 . . . . 0.0 109.788 -179.307 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 50.5 ptt85 . . . . . 0 C--N 1.324 -0.516 0 CA-C-O 117.843 -1.075 . . . . 0.0 110.143 -179.298 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 81.6 mmm . . . . . 0 N--CA 1.492 1.642 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 8.3 mm-40 53.09 57.38 14.46 Favored Pre-proline 0 CA--C 1.532 0.26 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.424 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -71.23 159.67 51.26 Favored 'Trans proline' 0 N--CA 1.494 1.534 0 C-N-CA 122.317 2.011 . . . . 0.0 111.793 -179.8 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.528 ' C ' ' H ' ' A' ' 6' ' ' PHE . 5.2 p -81.3 -23.69 37.72 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.507 -179.521 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.413 ' HB3' ' O ' ' A' ' 4' ' ' THR . . . 69.56 -22.22 0.16 Allowed 'General case' 0 CA--C 1.532 0.266 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.04 -179.778 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.528 ' H ' ' C ' ' A' ' 4' ' ' THR . 96.0 m-85 52.26 175.46 0.02 OUTLIER 'General case' 0 CA--C 1.529 0.142 0 CA-C-N 116.476 -0.329 . . . . 0.0 110.394 -179.544 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 44.3 m -133.68 179.92 5.93 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-O 120.976 0.417 . . . . 0.0 110.526 -179.598 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -65.66 -32.9 84.55 Favored Glycine 0 CA--C 1.526 0.742 0 N-CA-C 110.84 -0.904 . . . . 0.0 110.84 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 78.2 p -70.76 -22.41 62.4 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 120.677 0.275 . . . . 0.0 111.102 -179.256 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 94.9 m-20 -68.85 145.75 53.45 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 179.855 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.499 ' CG2' ' HE ' ' A' ' 54' ' ' ARG . 16.5 m -122.8 125.0 26.49 Favored Pre-proline 0 CA--C 1.545 0.772 0 CA-C-N 116.572 -0.286 . . . . 0.0 110.493 -179.303 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 86.9 Cg_endo -77.96 151.13 27.29 Favored 'Trans proline' 0 N--CA 1.492 1.431 0 C-N-CA 121.161 1.241 . . . . 0.0 111.125 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 77.9 ttt180 -158.4 128.18 5.87 Favored 'General case' 0 N--CA 1.464 0.244 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 179.343 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 30.9 mt -68.53 120.68 77.01 Favored Pre-proline 0 CA--C 1.546 0.806 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.81 -179.414 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -75.55 164.52 32.19 Favored 'Trans proline' 0 N--CA 1.497 1.692 0 C-N-CA 121.678 1.585 . . . . 0.0 111.984 -179.762 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 17.0 ptm180 -53.62 143.53 19.88 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.661 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 85.86 6.41 82.56 Favored Glycine 0 CA--C 1.52 0.384 0 N-CA-C 110.713 -0.955 . . . . 0.0 110.713 179.718 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.5 ' CG1' HD11 ' A' ' 31' ' ' LEU . 42.9 t -132.55 128.84 58.35 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 CA-C-O 120.982 0.42 . . . . 0.0 110.326 179.925 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 39.3 ptt180 -145.15 164.72 30.41 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.362 179.679 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 46.0 mt -94.44 138.16 32.71 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.237 -179.737 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 76.6 mtp85 -139.62 148.14 42.06 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.127 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 88.3 t80 -97.17 119.71 36.17 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.266 -179.833 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.405 ' O ' ' N ' ' A' ' 27' ' ' ASN . 87.8 m-20 -90.5 105.85 18.1 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 116.021 -0.536 . . . . 0.0 109.689 179.258 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 82.6 tt0 -64.13 -37.94 89.28 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.321 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.461 HG22 ' H ' ' A' ' 25' ' ' VAL . 0.7 OUTLIER -63.43 -43.74 98.58 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.462 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.733 -179.389 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -89.09 -14.5 36.16 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-O 120.815 0.341 . . . . 0.0 110.201 -179.484 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.405 ' N ' ' O ' ' A' ' 23' ' ' ASP . 33.8 m-20 63.08 27.93 15.94 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.753 179.723 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.28 170.9 15.4 Favored 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 179.389 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 89.6 m-70 -92.67 150.35 20.75 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.095 179.745 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 35.0 m -138.55 161.71 30.29 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.171 -179.462 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.5 HD11 ' CG1' ' A' ' 18' ' ' VAL . 32.4 tp -98.48 113.66 25.75 Favored 'General case' 0 N--CA 1.464 0.231 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 179.27 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 58.5 tp -77.83 95.07 4.63 Favored 'General case' 0 CA--C 1.517 -0.305 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 179.262 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -97.77 154.1 37.99 Favored Pre-proline 0 CA--C 1.537 0.473 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -63.7 -26.67 68.55 Favored 'Trans proline' 0 N--CA 1.495 1.599 0 C-N-CA 121.977 1.785 . . . . 0.0 111.673 179.789 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 42.2 tp10 -80.85 -51.98 7.99 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.699 -179.485 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 42.7 ttm180 -174.67 146.64 0.99 Allowed 'General case' 0 N--CA 1.463 0.22 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.54 -179.397 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 57.9 m -74.51 129.58 38.02 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.104 178.979 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 93.7 m-85 -102.79 140.2 37.37 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-N 116.515 -0.312 . . . . 0.0 110.744 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 30.8 t0 -73.89 118.47 16.88 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.288 -0.414 . . . . 0.0 109.926 179.49 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 63.2 mt -131.37 154.1 48.97 Favored 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 116.245 -0.434 . . . . 0.0 109.954 -179.755 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 80.8 m-20 -87.47 159.73 18.55 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.132 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.466 ' OD1' ' N ' ' A' ' 43' ' ' ASN . 36.6 p-10 -60.67 -39.87 90.04 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.693 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' ASN . . . . . 0.466 ' N ' ' OD1' ' A' ' 42' ' ' ASP . 50.4 t30 -64.02 -39.7 94.67 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.75 -179.747 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -68.63 -34.62 76.06 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.645 -179.671 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 59.9 t -88.83 -17.4 8.32 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 CA-C-O 120.765 0.317 . . . . 0.0 110.267 179.58 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.417 ' O ' ' N ' ' A' ' 50' ' ' LEU . . . -56.98 -47.21 81.33 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.382 -179.515 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.44 HG23 ' N ' ' A' ' 48' ' ' LEU . 35.0 m -61.42 -42.32 93.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.723 179.897 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.44 ' N ' HG23 ' A' ' 47' ' ' VAL . 56.5 mt -70.09 -30.52 67.76 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.455 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 36.7 ttmt -86.39 -28.85 23.34 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.884 179.778 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.417 ' N ' ' O ' ' A' ' 46' ' ' ALA . 59.3 tp -72.41 -32.43 66.35 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 116.485 -0.325 . . . . 0.0 110.593 -179.239 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.6 p -74.6 129.37 36.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 121.065 0.46 . . . . 0.0 110.654 179.884 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 -72.09 -41.11 67.69 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.204 178.961 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -144.66 -100.29 0.3 Allowed Glycine 0 N--CA 1.473 1.145 0 N-CA-C 110.605 -0.998 . . . . 0.0 110.605 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' ARG . . . . . 0.499 ' HE ' ' CG2' ' A' ' 11' ' ' VAL . 85.3 mtp180 -114.9 104.73 12.21 Favored 'General case' 0 N--CA 1.471 0.621 0 CA-C-O 120.583 0.23 . . . . 0.0 110.411 179.462 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 94.8 m-20 -117.41 154.61 31.05 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.137 178.024 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 35.3 p -79.89 136.86 36.77 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 178.626 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.407 HG23 ' N ' ' A' ' 58' ' ' SER . 29.8 m -54.31 -37.09 35.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-O 120.935 0.398 . . . . 0.0 110.482 -179.558 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 58' ' ' SER . . . . . 0.407 ' N ' HG23 ' A' ' 57' ' ' VAL . 41.3 t -58.57 -44.54 89.79 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.599 179.808 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 49.4 tt0 -64.45 -44.68 90.35 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.785 -179.587 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 96.9 mt -62.12 -43.39 97.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -53.06 -36.73 60.93 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.148 -179.083 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 70.8 mm-40 -63.25 -52.79 60.67 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.723 -0.391 . . . . 0.0 110.596 179.803 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 73.2 mt -64.46 -49.97 78.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.925 -179.173 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 10.3 tp -67.06 -39.69 86.91 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.652 -179.391 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -56.39 -41.64 88.13 Favored Glycine 0 CA--C 1.526 0.746 0 N-CA-C 111.095 -0.802 . . . . 0.0 111.095 -179.192 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 86.4 mt-30 -65.29 -31.28 72.34 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.656 0.265 . . . . 0.0 110.46 179.511 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 20.3 m -62.16 -46.25 89.81 Favored 'General case' 0 C--N 1.331 -0.212 0 C-N-CA 120.813 -0.355 . . . . 0.0 110.476 -179.666 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -92.99 1.6 57.22 Favored 'General case' 0 N--CA 1.469 0.484 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.706 179.759 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 66.1 t0 54.79 53.23 10.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.506 -0.315 . . . . 0.0 110.961 179.707 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -141.19 159.57 41.94 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 110.122 -0.325 . . . . 0.0 110.122 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 69.6 m-20 -56.02 142.16 66.12 Favored Pre-proline 0 CA--C 1.541 0.622 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.392 -179.361 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -67.65 -30.26 35.06 Favored 'Trans proline' 0 N--CA 1.503 2.045 0 C-N-CA 122.426 2.084 . . . . 0.0 112.42 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -55.34 -34.87 64.6 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.2 0.524 . . . . 0.0 110.432 -179.621 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 63.7 mt -68.87 -44.62 81.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 115.813 -0.63 . . . . 0.0 111.252 -179.566 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.523 ' N ' HD12 ' A' ' 75' ' ' ILE . 1.6 mp -61.94 -52.1 64.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.425 0 CA-C-N 116.614 -0.266 . . . . 0.0 111.291 -178.505 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -60.54 -46.98 88.17 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 120.253 -0.579 . . . . 0.0 110.352 -178.048 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.429 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -63.89 -23.64 67.43 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.055 -0.521 . . . . 0.0 111.303 179.827 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 66.7 t0 -78.66 -52.17 8.81 Favored 'General case' 0 N--CA 1.469 0.508 0 CA-C-N 116.531 -0.304 . . . . 0.0 111.545 -179.502 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 12.6 pt -71.14 -41.92 75.75 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.188 -179.093 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 8.3 mt -40.64 -60.56 1.53 Allowed Pre-proline 0 CA--C 1.552 1.049 0 CA-C-O 119.314 -0.374 . . . . 0.0 110.983 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.429 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 50.8 Cg_exo -38.82 -42.71 2.01 Favored 'Trans proline' 0 N--CA 1.493 1.477 0 C-N-CA 122.511 2.141 . . . . 0.0 112.182 178.203 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 41.0 ttm -66.83 -41.64 87.11 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.846 -179.363 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 36.0 mt -62.23 -40.37 95.91 Favored 'General case' 0 C--N 1.328 -0.362 0 C-N-CA 120.689 -0.404 . . . . 0.0 109.987 -178.952 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -63.03 -40.77 98.72 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.916 -0.583 . . . . 0.0 110.362 179.608 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -66.81 -40.63 93.75 Favored Glycine 0 CA--C 1.526 0.767 0 N-CA-C 111.346 -0.702 . . . . 0.0 111.346 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 78.4 mt -66.34 -41.27 89.8 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.713 0.292 . . . . 0.0 110.808 -179.708 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -54.97 -38.56 67.95 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.969 0.414 . . . . 0.0 110.396 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 85.4 mt-30 -64.06 -22.05 66.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.041 179.477 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -91.27 -2.49 57.41 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-O 120.733 0.301 . . . . 0.0 110.439 -179.068 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 34.3 ttm180 62.14 55.5 2.44 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.656 179.542 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 33.0 m -140.84 3.77 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.472 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.498 179.761 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 54.2 tp -140.86 131.22 25.14 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-O 120.901 0.382 . . . . 0.0 110.067 179.588 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 18.8 pt-20 -153.43 148.22 26.42 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.911 179.164 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 90.6 mtm180 . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 117.968 -1.015 . . . . 0.0 110.399 179.842 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 70.2 mtm . . . . . 0 N--CA 1.489 1.478 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 92.0 mt-10 -71.73 148.12 92.33 Favored Pre-proline 0 CA--C 1.539 0.551 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.657 -179.276 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_exo -42.99 155.45 0.12 Allowed 'Trans proline' 0 N--CA 1.494 1.522 0 C-N-CA 122.045 1.83 . . . . 0.0 112.357 179.068 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 81.9 p -75.02 -27.62 60.16 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.402 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . 51.47 99.34 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.674 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 27.9 m-85 -79.39 128.47 33.38 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.045 -0.525 . . . . 0.0 109.755 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 28.1 m -95.34 177.42 5.84 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.206 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -64.92 -38.36 95.42 Favored Glycine 0 CA--C 1.527 0.817 0 N-CA-C 111.141 -0.784 . . . . 0.0 111.141 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 38.9 m -72.94 -18.23 61.41 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.689 0.281 . . . . 0.0 110.505 -179.738 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 48.5 t0 -71.45 116.24 11.55 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.492 HG23 ' O ' ' A' ' 11' ' ' VAL . 33.5 m -95.05 122.71 59.41 Favored Pre-proline 0 CA--C 1.54 0.587 0 CA-C-N 116.553 -0.294 . . . . 0.0 110.989 -179.32 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -77.58 154.52 31.13 Favored 'Trans proline' 0 N--CA 1.494 1.506 0 C-N-CA 121.531 1.487 . . . . 0.0 111.454 179.767 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 72.3 ttp85 -157.45 133.2 9.27 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 179.623 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 16.3 mt -67.17 123.04 85.37 Favored Pre-proline 0 CA--C 1.541 0.633 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.726 -178.899 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 92.7 Cg_endo -76.57 155.06 35.67 Favored 'Trans proline' 0 N--CA 1.492 1.397 0 C-N-CA 121.795 1.663 . . . . 0.0 111.99 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 58.4 ttt85 -57.17 151.2 15.97 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.04 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 84.31 15.79 68.28 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 111.047 -0.821 . . . . 0.0 111.047 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 62.0 t -135.55 133.92 51.91 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 CA-C-O 121.062 0.458 . . . . 0.0 110.213 179.66 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 89.5 mtm180 -136.23 153.24 51.27 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.119 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 31.9 mt -95.33 148.62 22.24 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.934 -179.836 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 86.5 mtm180 -140.09 142.61 36.08 Favored 'General case' 0 N--CA 1.463 0.218 0 CA-C-N 116.189 -0.459 . . . . 0.0 109.868 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 86.1 t80 -100.62 109.72 21.81 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.015 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -89.76 91.48 8.65 Favored 'General case' 0 N--CA 1.463 0.207 0 CA-C-N 116.077 -0.511 . . . . 0.0 109.697 179.59 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 42.3 tt0 -60.0 -33.67 72.29 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.162 -179.683 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.407 ' H ' HG22 ' A' ' 25' ' ' VAL . 1.7 m -64.02 -43.31 97.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.426 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.513 ' HD3' ' HZ2' ' A' ' 28' ' ' LYS . 99.9 mtt180 -86.46 -18.81 30.72 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-O 120.577 0.227 . . . . 0.0 110.522 179.941 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 60.8 t30 68.57 24.31 6.98 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.201 179.501 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.513 ' HZ2' ' HD3' ' A' ' 26' ' ' ARG . 2.7 ptmm? -145.17 167.62 22.32 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-O 121.094 0.474 . . . . 0.0 109.899 179.629 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 71.5 m80 -90.73 160.21 15.93 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.864 179.887 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 29.5 m -142.45 147.83 20.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.021 -0.536 . . . . 0.0 109.699 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 5.8 tp -102.01 111.87 24.29 Favored 'General case' 0 N--CA 1.463 0.207 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 179.487 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 55.9 tp -79.16 95.08 5.5 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 179.169 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -93.97 145.81 30.51 Favored Pre-proline 0 CA--C 1.538 0.502 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 179.864 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 70.9 Cg_exo -45.09 -36.45 11.76 Favored 'Trans proline' 0 N--CA 1.495 1.587 0 C-N-CA 122.03 1.82 . . . . 0.0 112.652 179.088 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 46.5 tp10 -74.81 -51.97 12.65 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.93 -178.755 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 75.2 ttt180 -174.48 150.95 1.47 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.798 -179.553 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 34.4 m -69.26 132.03 45.83 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.063 -0.517 . . . . 0.0 109.954 179.184 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -106.63 128.67 54.35 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.267 -179.473 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -72.8 115.14 11.72 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.167 -0.469 . . . . 0.0 109.914 179.73 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 95.9 mt -133.22 161.09 35.4 Favored 'General case' 0 N--CA 1.469 0.475 0 CA-C-O 121.051 0.453 . . . . 0.0 110.111 -179.58 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 81.6 m-20 -84.03 159.45 21.18 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.163 -179.421 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.464 ' OD1' ' N ' ' A' ' 43' ' ' ASN . 38.4 p-10 -61.55 -35.09 76.79 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.856 -179.694 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' ASN . . . . . 0.464 ' N ' ' OD1' ' A' ' 42' ' ' ASP . 88.4 m-20 -62.9 -39.92 95.99 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.64 -179.578 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -68.78 -35.51 77.15 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.729 -179.703 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 40.0 t -89.12 -20.04 7.3 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.451 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.77 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.46 ' N ' ' O ' ' A' ' 42' ' ' ASP . . . -58.33 -48.67 79.8 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.477 -179.583 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 35.4 m -61.78 -39.0 81.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.703 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 63.1 mt -69.53 -31.61 69.94 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.652 179.866 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 36.6 ttpt -88.68 -27.54 21.18 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.671 179.358 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.41 ' N ' ' O ' ' A' ' 46' ' ' ALA . 55.2 tp -73.1 -32.49 65.01 Favored 'General case' 0 N--CA 1.464 0.265 0 C-N-CA 120.862 -0.335 . . . . 0.0 110.563 -178.941 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.4 p -74.11 125.82 33.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.935 0.398 . . . . 0.0 110.671 -179.822 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 95.4 m-20 -72.92 -42.16 63.79 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.252 179.408 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -143.37 -98.95 0.29 Allowed Glycine 0 N--CA 1.472 1.048 0 N-CA-C 110.477 -1.049 . . . . 0.0 110.477 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' ARG . . . . . 0.508 HH22 ' C ' ' A' ' 94' ' ' ARG . 78.4 mtp85 -114.86 104.29 11.79 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-O 121.005 0.431 . . . . 0.0 110.389 179.533 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 97.0 m-20 -117.57 152.88 34.22 Favored 'General case' 0 N--CA 1.471 0.598 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.194 178.297 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 11.2 p -82.59 141.11 32.83 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 109.683 -0.488 . . . . 0.0 109.683 178.751 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.47 HG23 ' N ' ' A' ' 58' ' ' SER . 18.9 m -56.6 -41.23 73.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.349 -179.703 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' SER . . . . . 0.47 ' N ' HG23 ' A' ' 57' ' ' VAL . 35.4 t -58.64 -44.18 89.96 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.716 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 57.4 tt0 -64.0 -44.39 92.79 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.501 -179.823 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 96.6 mt -62.1 -43.38 97.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.261 -0.427 . . . . 0.0 109.992 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.409 ' O ' ' N ' ' A' ' 65' ' ' GLY . . . -52.12 -38.16 56.56 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.876 -179.364 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 94.1 mm-40 -63.88 -51.18 65.77 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.492 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 69.2 mt -64.72 -49.0 82.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.497 -179.37 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 34.7 tp -68.69 -36.81 78.99 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.362 -179.629 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.455 ' O ' ' N ' ' A' ' 69' ' ' ASP . . . -59.14 -41.89 96.84 Favored Glycine 0 CA--C 1.526 0.754 0 N-CA-C 111.3 -0.72 . . . . 0.0 111.3 -179.206 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 86.4 mt-30 -65.12 -31.97 73.44 Favored 'General case' 0 C--N 1.326 -0.428 0 C-N-CA 121.025 -0.27 . . . . 0.0 110.423 179.751 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 22.1 m -61.94 -48.53 80.0 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 120.682 -0.407 . . . . 0.0 110.474 -179.879 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -94.62 -3.12 50.14 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.45 179.542 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' ASP . . . . . 0.455 ' N ' ' O ' ' A' ' 65' ' ' GLY . 65.8 t0 54.0 62.26 2.68 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.694 179.698 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -138.7 160.31 39.96 Favored 'General case' 0 N--CA 1.469 0.475 0 CA-C-O 120.897 0.379 . . . . 0.0 110.152 -179.591 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 74.0 m-20 -55.9 114.8 8.13 Favored Pre-proline 0 CA--C 1.543 0.675 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.532 -179.193 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_exo -48.41 -36.39 30.48 Favored 'Trans proline' 0 N--CA 1.497 1.716 0 C-N-CA 121.88 1.72 . . . . 0.0 112.714 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -52.6 -39.24 61.41 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-O 120.968 0.413 . . . . 0.0 111.157 -179.341 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 70.8 mt -71.5 -40.13 71.58 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.699 179.69 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 38.0 mm -59.92 -49.28 84.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.915 -178.374 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 15.6 pt-20 -65.13 -42.38 93.93 Favored 'General case' 0 C--N 1.333 -0.115 0 C-N-CA 120.765 -0.374 . . . . 0.0 110.055 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.457 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -65.92 -19.86 66.02 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.19 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 66.1 t0 -79.27 -48.59 13.89 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-O 120.875 0.369 . . . . 0.0 111.107 -179.566 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 28.5 pt -78.38 -36.47 20.59 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.525 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.235 -179.199 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 9.8 mt -43.99 -60.5 2.68 Favored Pre-proline 0 CA--C 1.543 0.688 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.782 179.857 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.457 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 39.5 Cg_endo -61.71 -31.56 86.21 Favored 'Trans proline' 0 N--CA 1.496 1.67 0 C-N-CA 121.762 1.641 . . . . 0.0 111.575 179.656 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 40.1 tpp -66.72 -42.67 85.97 Favored 'General case' 0 CA--C 1.529 0.166 0 CA-C-O 120.83 0.348 . . . . 0.0 110.775 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 74.7 mt -62.85 -41.9 99.54 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.246 -179.221 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -63.31 -38.85 92.76 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.54 179.779 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -64.62 -41.22 97.89 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 83.2 mt -68.22 -39.66 82.29 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.818 0.342 . . . . 0.0 110.465 -179.764 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -52.73 -35.08 55.34 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.84 0.352 . . . . 0.0 110.639 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 87.5 mt-30 -63.32 -21.09 66.04 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.755 179.775 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -92.58 0.29 57.41 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-O 120.702 0.287 . . . . 0.0 110.402 -179.42 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 33.8 ttm180 61.45 57.93 2.22 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.444 179.818 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 33.1 m -141.54 12.57 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.28 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 50.5 tp -134.26 147.0 50.58 Favored 'General case' 0 N--CA 1.473 0.706 0 CA-C-O 121.503 0.668 . . . . 0.0 110.618 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 44.2 tp10 -147.64 140.13 24.59 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.221 -179.619 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' ARG . . . . . 0.508 ' C ' HH22 ' A' ' 54' ' ' ARG . 88.2 mtm180 . . . . . 0 C--O 1.219 -0.506 0 CA-C-O 118.101 -0.952 . . . . 0.0 110.207 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.412 ' SD ' ' N ' ' A' ' 2' ' ' GLU . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.527 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 . . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.412 ' N ' ' SD ' ' A' ' 1' ' ' MET . 10.0 pt-20 -170.63 147.35 2.48 Favored Pre-proline 0 CA--C 1.537 0.462 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.504 179.913 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -70.9 161.59 45.57 Favored 'Trans proline' 0 N--CA 1.496 1.624 0 C-N-CA 122.203 1.935 . . . . 0.0 111.874 179.592 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 7.2 p -80.49 166.72 20.93 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.569 -0.741 . . . . 0.0 109.919 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -163.72 106.08 0.96 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.25 -179.726 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 66.6 m-85 -79.9 136.22 36.61 Favored 'General case' 0 N--CA 1.463 0.207 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.391 -179.717 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 63.7 m -93.14 -174.5 3.57 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.614 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -65.96 -40.25 95.23 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 111.18 -0.768 . . . . 0.0 111.18 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 78.2 p -70.95 -24.54 62.45 Favored 'General case' 0 C--O 1.233 0.198 0 CA-C-O 120.736 0.303 . . . . 0.0 110.803 -179.669 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 95.4 m-20 -68.26 148.19 51.14 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 179.676 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 30.1 m -128.99 127.27 23.37 Favored Pre-proline 0 CA--C 1.545 0.753 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.757 -178.913 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -77.02 155.05 33.63 Favored 'Trans proline' 0 N--CA 1.498 1.78 0 C-N-CA 121.732 1.621 . . . . 0.0 112.243 179.731 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 71.7 ttt-85 -156.0 131.11 9.31 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.285 179.261 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 55.1 mt -69.03 113.58 17.35 Favored Pre-proline 0 CA--C 1.538 0.517 0 CA-C-O 119.074 -0.489 . . . . 0.0 111.098 -179.455 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_exo -60.77 154.06 58.14 Favored 'Trans proline' 0 N--CA 1.507 2.278 0 C-N-CA 121.903 1.735 . . . . 0.0 113.799 179.493 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 68.5 ttt-85 -51.96 132.45 32.34 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.877 178.802 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.57 -6.34 67.77 Favored Glycine 0 N--CA 1.467 0.719 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.44 ' CG1' HD11 ' A' ' 31' ' ' LEU . 39.2 t -106.77 127.85 61.97 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.613 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 179.252 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.434 ' HE ' HD22 ' A' ' 32' ' ' LEU . 33.2 ptt180 -142.24 158.85 43.27 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.44 -0.8 . . . . 0.0 110.365 -179.299 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 15.9 mt -95.32 107.62 19.75 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.693 -179.109 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 84.6 mtp180 -98.46 137.97 36.36 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.406 179.23 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.468 ' O ' ' CD1' ' A' ' 22' ' ' PHE . 38.3 p90 -100.34 114.81 28.61 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.163 179.623 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -88.09 92.02 8.99 Favored 'General case' 0 N--CA 1.464 0.239 0 CA-C-N 116.207 -0.451 . . . . 0.0 109.914 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -60.56 -34.11 73.68 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.18 -179.796 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.455 HG22 ' H ' ' A' ' 25' ' ' VAL . 1.0 OUTLIER -63.5 -43.61 98.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.416 179.978 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -88.77 -7.43 56.24 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-O 120.776 0.322 . . . . 0.0 110.269 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 65.2 t30 60.3 30.32 19.73 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.83 179.645 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.494 ' NZ ' ' OD1' ' A' ' 39' ' ' ASP . 15.9 ptpt -145.34 168.74 19.76 Favored 'General case' 0 N--CA 1.47 0.553 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 178.774 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 69.8 m80 -99.39 150.15 22.44 Favored 'General case' 0 CA--C 1.518 -0.261 0 CA-C-N 116.017 -0.538 . . . . 0.0 109.829 178.989 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 34.2 m -137.66 155.46 30.89 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.206 -179.602 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.44 HD11 ' CG1' ' A' ' 18' ' ' VAL . 35.1 tp -102.47 121.94 43.34 Favored 'General case' 0 N--CA 1.468 0.447 0 CA-C-N 116.263 -0.426 . . . . 0.0 109.901 179.792 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.434 HD22 ' HE ' ' A' ' 19' ' ' ARG . 48.2 tp -77.26 100.5 5.87 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 179.151 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -95.7 145.21 29.15 Favored Pre-proline 0 CA--C 1.537 0.461 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_exo -47.17 -37.46 23.64 Favored 'Trans proline' 0 N--CA 1.493 1.447 0 C-N-CA 121.28 1.32 . . . . 0.0 112.243 179.183 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 9.5 tm-20 -74.62 -52.28 12.16 Favored 'General case' 0 N--CA 1.462 0.164 0 C-N-CA 120.812 -0.355 . . . . 0.0 111.863 -178.718 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 58.1 ttt85 -175.67 153.6 1.45 Allowed 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 120.798 0.332 . . . . 0.0 110.518 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 75.8 m -67.19 133.42 49.73 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.431 -0.35 . . . . 0.0 110.381 179.315 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 69.8 m-85 -108.84 141.43 40.89 Favored 'General case' 0 N--CA 1.472 0.642 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.954 -179.516 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.494 ' OD1' ' NZ ' ' A' ' 28' ' ' LYS . 37.1 t0 -73.18 121.01 19.59 Favored 'General case' 0 C--N 1.333 -0.13 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.148 179.144 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 72.3 mt -136.42 157.47 46.72 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-N 115.973 -0.558 . . . . 0.0 109.777 179.712 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 95.3 m-20 -85.47 154.06 22.05 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.382 -179.659 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 68.1 t0 -59.7 -38.4 81.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.982 -0.553 . . . . 0.0 110.545 -179.79 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 97.7 m-20 -63.1 -39.15 93.85 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.636 -179.687 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.26 -41.05 77.44 Favored 'General case' 0 C--N 1.329 -0.284 0 C-N-CA 120.899 -0.321 . . . . 0.0 110.886 -179.605 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 44.0 t -79.59 -27.87 12.83 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-O 120.714 0.293 . . . . 0.0 110.385 179.878 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.44 ' O ' ' N ' ' A' ' 50' ' ' LEU . . . -54.72 -39.1 67.88 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.016 -179.61 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 90.5 t -60.67 -48.07 90.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.355 179.824 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 49.7 mt -70.43 -29.54 66.16 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.234 -179.688 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' LYS . . . . . 0.437 ' HZ2' ' HB2' ' A' ' 49' ' ' LYS . 3.1 ttmp? -82.07 -29.05 32.04 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.701 179.933 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.44 ' N ' ' O ' ' A' ' 46' ' ' ALA . 50.2 tp -71.78 -32.61 67.83 Favored 'General case' 0 N--CA 1.465 0.276 0 C-N-CA 121.012 -0.275 . . . . 0.0 110.704 -178.926 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.7 p -77.55 128.47 38.06 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.345 0 CA-C-O 121.078 0.466 . . . . 0.0 110.604 179.567 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 -68.61 -43.12 77.08 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.351 179.218 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -146.84 -97.16 0.19 Allowed Glycine 0 N--CA 1.471 0.992 0 N-CA-C 110.488 -1.045 . . . . 0.0 110.488 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 89.2 mtm180 -114.9 104.86 12.35 Favored 'General case' 0 N--CA 1.471 0.6 0 CA-C-O 120.66 0.267 . . . . 0.0 110.658 179.286 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 93.9 m-20 -117.07 147.92 41.96 Favored 'General case' 0 N--CA 1.472 0.66 0 CA-C-N 116.156 -0.475 . . . . 0.0 109.862 177.942 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 15.3 p -78.74 142.15 37.27 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.057 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.406 HG23 ' N ' ' A' ' 58' ' ' SER . 33.0 m -55.76 -38.45 51.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.789 0.328 . . . . 0.0 110.461 -179.578 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' SER . . . . . 0.406 ' N ' HG23 ' A' ' 57' ' ' VAL . 38.7 t -58.88 -44.83 91.19 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.691 179.789 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 10.6 tp-100 -65.32 -45.59 83.69 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.917 -179.588 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 85.3 mt -60.93 -42.65 93.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 121.062 0.458 . . . . 0.0 109.911 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.413 ' O ' ' N ' ' A' ' 65' ' ' GLY . . . -51.93 -40.06 60.17 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.249 -179.192 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 97.1 mm-40 -63.41 -51.38 66.02 Favored 'General case' 0 C--N 1.325 -0.469 0 C-N-CA 120.577 -0.449 . . . . 0.0 110.593 179.757 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 73.5 mt -65.09 -50.68 73.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.162 -179.312 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 23.9 tp -69.62 -34.74 74.5 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.095 0.474 . . . . 0.0 110.611 -179.061 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.413 ' N ' ' O ' ' A' ' 61' ' ' ALA . . . -58.54 -43.22 96.16 Favored Glycine 0 CA--C 1.527 0.824 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 -179.584 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 87.8 mt-30 -67.31 -38.66 85.3 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.664 0.269 . . . . 0.0 110.981 179.709 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 38.6 p -63.42 -38.29 90.57 Favored 'General case' 0 C--N 1.332 -0.188 0 C-N-CA 120.888 -0.325 . . . . 0.0 110.566 -179.411 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 30.4 m-85 -93.83 0.91 56.48 Favored 'General case' 0 N--CA 1.47 0.528 0 N-CA-C 110.057 -0.349 . . . . 0.0 110.057 179.515 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 66.6 t0 52.47 48.36 22.74 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.769 0.318 . . . . 0.0 110.881 179.556 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -140.86 158.49 43.87 Favored 'General case' 0 N--CA 1.469 0.502 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.43 -179.457 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 22.0 m-20 -56.07 144.14 60.29 Favored Pre-proline 0 CA--C 1.54 0.575 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.501 -179.374 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -67.82 -31.39 31.87 Favored 'Trans proline' 0 N--CA 1.501 1.937 0 C-N-CA 122.419 2.079 . . . . 0.0 112.097 -179.791 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -54.42 -33.67 59.89 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.076 0.465 . . . . 0.0 110.575 -179.712 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 65.4 mt -69.35 -43.45 81.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.423 -179.577 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.57 ' N ' HD12 ' A' ' 75' ' ' ILE . 1.7 mp -62.65 -48.34 88.65 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 C-N-CA 120.482 -0.487 . . . . 0.0 111.186 -178.131 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -60.61 -45.83 92.56 Favored 'General case' 0 C--N 1.325 -0.467 0 C-N-CA 119.94 -0.704 . . . . 0.0 110.097 -178.468 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.42 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -65.59 -23.44 66.84 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.25 179.445 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 64.2 t0 -78.5 -49.47 13.32 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.541 -0.3 . . . . 0.0 111.36 -179.301 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 15.3 pt -75.72 -37.27 35.54 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.41 0 CA-C-N 116.412 -0.358 . . . . 0.0 111.544 -179.224 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 8.9 mt -43.35 -59.74 3.04 Favored Pre-proline 0 CA--C 1.547 0.835 0 CA-C-O 119.748 -0.168 . . . . 0.0 111.137 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.42 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 43.0 Cg_endo -62.46 -31.46 80.66 Favored 'Trans proline' 0 N--CA 1.498 1.743 0 C-N-CA 121.954 1.769 . . . . 0.0 111.759 179.656 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 42.8 tpp -66.91 -43.1 84.22 Favored 'General case' 0 C--N 1.333 -0.112 0 C-N-CA 120.773 -0.371 . . . . 0.0 110.014 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 87.2 mt -62.67 -42.05 99.41 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.185 -179.547 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -63.78 -37.39 87.19 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.36 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -64.19 -38.35 95.81 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 111.089 -0.805 . . . . 0.0 111.089 -179.871 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 87.3 mt -68.07 -36.65 80.19 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.787 0.327 . . . . 0.0 110.291 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -53.29 -27.41 22.77 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.827 -179.672 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 86.2 mt-30 -61.89 -26.24 68.04 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.491 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 46.7 mtmt -94.08 -1.87 53.7 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.092 -179.672 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 59.7 ttt180 60.24 38.92 19.68 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.783 -0.644 . . . . 0.0 109.911 179.638 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 31.7 m -109.86 -3.75 10.58 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.585 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.354 179.858 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 38.3 tp -113.95 143.68 44.33 Favored 'General case' 0 N--CA 1.475 0.814 0 CA-C-O 121.274 0.559 . . . . 0.0 110.775 -179.369 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 40.1 tp10 -151.67 150.11 29.88 Favored 'General case' 0 CA--C 1.519 -0.245 0 CA-C-N 115.231 -0.895 . . . . 0.0 109.731 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 91.4 mtm180 . . . . . 0 C--N 1.314 -0.971 0 CA-C-O 118.062 -0.97 . . . . 0.0 110.284 179.011 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 72.2 mtm . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 57.8 mm-40 45.5 73.58 0.95 Allowed Pre-proline 0 CA--C 1.533 0.293 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.952 -179.841 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_exo -57.81 142.48 96.23 Favored 'Trans proline' 0 N--CA 1.497 1.681 0 C-N-CA 122.333 2.022 . . . . 0.0 112.009 -179.739 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.459 ' OG1' ' CE1' ' A' ' 6' ' ' PHE . 24.5 p -84.52 112.6 20.55 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.061 179.722 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -76.16 108.33 9.01 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.62 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.459 ' CE1' ' OG1' ' A' ' 4' ' ' THR . 95.4 m-85 -81.72 135.6 35.49 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.284 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 44.3 m -91.87 178.57 5.86 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.693 -179.904 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -65.8 -33.12 84.95 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 111.157 -0.777 . . . . 0.0 111.157 179.799 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 31.7 t -71.22 -20.57 62.24 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.7 0.286 . . . . 0.0 111.427 -178.965 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.412 ' CG ' ' NH2' ' A' ' 94' ' ' ARG . 92.6 m-20 -71.67 124.97 25.92 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 -179.732 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.472 ' CG2' ' HE ' ' A' ' 54' ' ' ARG . 27.4 m -101.69 116.32 63.63 Favored Pre-proline 0 CA--C 1.56 1.351 0 N-CA-C 113.525 0.935 . . . . 0.0 113.525 -177.523 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_endo -58.79 143.31 99.14 Favored 'Trans proline' 0 N--CA 1.511 2.508 0 C-N-CA 121.52 1.48 . . . . 0.0 113.595 178.186 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.457 ' NH1' ' OE2' ' A' ' 93' ' ' GLU . 70.0 ttp85 -158.27 121.77 3.95 Favored 'General case' 0 N--CA 1.47 0.539 0 CA-C-N 115.637 -0.711 . . . . 0.0 109.559 177.074 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 53.1 mt -66.82 122.04 80.49 Favored Pre-proline 0 CA--C 1.543 0.708 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.594 -179.523 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 96.9 Cg_endo -78.11 160.8 29.8 Favored 'Trans proline' 0 N--CA 1.491 1.374 0 C-N-CA 121.893 1.729 . . . . 0.0 111.743 -179.554 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 17.2 ptm180 -53.54 150.98 6.23 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.759 179.571 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 82.15 6.41 88.84 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.975 -0.85 . . . . 0.0 110.975 179.562 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.511 ' CG1' HD11 ' A' ' 31' ' ' LEU . 45.8 t -129.48 126.05 62.7 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.582 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 83.5 mtp180 -138.24 158.18 44.81 Favored 'General case' 0 N--CA 1.468 0.436 0 CA-C-N 116.085 -0.507 . . . . 0.0 109.939 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 21.9 mt -94.15 103.35 15.4 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.139 -179.653 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 96.8 mtt180 -92.81 139.69 30.28 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.122 179.456 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.472 ' O ' ' CD1' ' A' ' 22' ' ' PHE . 38.3 p90 -102.85 116.19 32.08 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.024 179.635 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.454 ' O ' ' N ' ' A' ' 27' ' ' ASN . 87.9 m-20 -87.5 95.04 9.89 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 116.234 -0.439 . . . . 0.0 109.896 -179.816 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 42.0 tt0 -61.21 -35.59 77.61 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.414 -179.634 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 3.4 m -63.77 -43.35 97.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.556 -179.788 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -92.1 -7.43 48.61 Favored 'General case' 0 N--CA 1.469 0.484 0 CA-C-O 120.742 0.306 . . . . 0.0 110.493 179.735 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.454 ' N ' ' O ' ' A' ' 23' ' ' ASP . 18.3 t-20 55.42 37.17 28.51 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.3 179.638 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -145.14 158.03 43.93 Favored 'General case' 0 N--CA 1.469 0.519 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 179.55 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 77.9 m80 -94.06 148.69 21.92 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.121 179.637 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 33.6 m -136.89 157.19 35.8 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.247 -179.857 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.511 HD11 ' CG1' ' A' ' 18' ' ' VAL . 41.0 tp -100.36 123.44 44.59 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.16 -179.828 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 38.9 tp -77.36 98.99 5.41 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 179.067 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -93.89 148.18 34.82 Favored Pre-proline 0 CA--C 1.54 0.56 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 -179.601 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_exo -46.74 -33.64 14.15 Favored 'Trans proline' 0 N--CA 1.497 1.73 0 C-N-CA 121.551 1.501 . . . . 0.0 112.292 179.013 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -71.24 -51.68 23.21 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.772 -179.086 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 60.3 ttt85 -172.26 -96.64 0.01 OUTLIER 'General case' 0 CA--C 1.531 0.245 0 CA-C-N 116.598 -0.273 . . . . 0.0 110.543 179.827 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 90.1 m -165.95 151.81 9.05 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.292 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 53.2 m-85 -125.99 137.7 53.69 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-O 120.967 0.413 . . . . 0.0 110.593 -179.641 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 38.8 p-10 -71.04 117.92 13.15 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.357 179.643 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 89.1 mt -134.25 155.98 49.2 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.021 -179.769 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 86.2 m-20 -85.09 154.78 21.83 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.976 0.417 . . . . 0.0 110.201 -179.74 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.462 ' OD1' ' N ' ' A' ' 43' ' ' ASN . 36.6 p-10 -59.96 -37.66 80.23 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.64 -179.867 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' ASN . . . . . 0.462 ' N ' ' OD1' ' A' ' 42' ' ' ASP . 74.5 m-20 -64.2 -39.63 94.39 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.472 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.06 -39.99 78.78 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.468 -0.333 . . . . 0.0 110.917 -179.457 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 66.0 t -78.7 -26.52 13.68 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.239 0 CA-C-O 120.74 0.305 . . . . 0.0 110.271 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.428 ' O ' ' N ' ' A' ' 50' ' ' LEU . . . -58.1 -36.08 72.35 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.355 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 84.0 t -59.93 -47.71 90.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.42 -179.684 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 47.2 mt -70.95 -29.53 65.57 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.373 -179.634 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 36.0 ttpt -83.38 -23.5 32.4 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.651 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.428 ' N ' ' O ' ' A' ' 46' ' ' ALA . 60.4 tp -70.4 -32.55 70.24 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-O 120.735 0.302 . . . . 0.0 110.586 -179.477 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 2.4 p -75.17 130.1 36.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-O 121.047 0.451 . . . . 0.0 110.638 179.78 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 -70.12 -44.86 68.07 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.612 179.291 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -143.32 -96.96 0.24 Allowed Glycine 0 N--CA 1.473 1.152 0 N-CA-C 110.341 -1.104 . . . . 0.0 110.341 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' ARG . . . . . 0.472 ' HE ' ' CG2' ' A' ' 11' ' ' VAL . 83.9 mtp180 -114.85 104.68 12.18 Favored 'General case' 0 N--CA 1.472 0.661 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 179.06 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 96.9 m-20 -117.28 145.49 43.94 Favored 'General case' 0 N--CA 1.476 0.86 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.16 178.465 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 48.4 p -78.3 140.18 38.83 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 178.528 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.4 HG23 ' N ' ' A' ' 58' ' ' SER . 33.0 m -53.44 -38.22 32.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 120.837 0.351 . . . . 0.0 110.325 -179.358 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' SER . . . . . 0.4 ' N ' HG23 ' A' ' 57' ' ' VAL . 38.5 t -59.93 -44.3 94.42 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.892 179.395 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 50.8 tt0 -64.69 -45.88 84.75 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.534 -0.303 . . . . 0.0 110.862 -179.266 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 66.5 mt -60.76 -42.73 93.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 120.88 0.372 . . . . 0.0 110.021 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.432 ' O ' ' N ' ' A' ' 65' ' ' GLY . . . -52.71 -38.41 60.69 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.679 -179.585 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 27.2 mm100 -63.7 -51.13 66.38 Favored 'General case' 0 C--N 1.329 -0.297 0 C-N-CA 120.583 -0.447 . . . . 0.0 110.683 179.816 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 73.7 mt -64.63 -48.84 83.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.776 0.322 . . . . 0.0 110.677 -179.396 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' LEU . . . . . 0.416 ' O ' ' OG1' ' A' ' 67' ' ' THR . 28.7 tp -69.95 -32.49 70.77 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.169 0.509 . . . . 0.0 110.19 -179.771 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.451 ' O ' ' N ' ' A' ' 69' ' ' ASP . . . -61.84 -41.64 99.65 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.871 -0.892 . . . . 0.0 110.871 -179.719 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 93.8 mt-30 -66.74 -38.43 86.64 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 121.049 -0.26 . . . . 0.0 110.339 179.551 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.416 ' OG1' ' O ' ' A' ' 64' ' ' LEU . 37.3 p -64.05 -39.9 95.11 Favored 'General case' 0 C--N 1.329 -0.283 0 C-N-CA 120.779 -0.368 . . . . 0.0 110.361 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 40.3 m-85 -95.97 -1.3 49.35 Favored 'General case' 0 N--CA 1.472 0.651 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 179.359 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' ASP . . . . . 0.451 ' N ' ' O ' ' A' ' 65' ' ' GLY . 50.7 t0 47.97 61.85 2.78 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.737 0.304 . . . . 0.0 111.159 179.749 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -144.24 160.49 40.89 Favored 'General case' 0 N--CA 1.468 0.425 0 CA-C-N 116.378 -0.373 . . . . 0.0 110.484 -179.762 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 56.2 m-20 -55.37 113.99 6.47 Favored Pre-proline 0 CA--C 1.542 0.646 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.578 -179.708 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_exo -48.76 -37.61 35.86 Favored 'Trans proline' 0 N--CA 1.5 1.889 0 C-N-CA 121.784 1.656 . . . . 0.0 112.928 179.765 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -52.8 -39.99 62.85 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.817 0.342 . . . . 0.0 111.244 -179.104 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 75.0 mt -70.65 -39.31 75.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-O 120.796 0.331 . . . . 0.0 110.315 179.378 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 42.9 mm -60.31 -48.57 87.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.351 -178.638 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -62.21 -45.21 94.36 Favored 'General case' 0 C--N 1.331 -0.201 0 C-N-CA 120.083 -0.647 . . . . 0.0 109.77 -179.776 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.437 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -65.76 -20.7 66.36 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.261 179.584 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 65.6 t0 -79.74 -49.58 11.84 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-O 120.823 0.344 . . . . 0.0 111.551 -179.396 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 17.1 pt -72.17 -39.27 64.67 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.483 -179.423 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 6.8 mt -43.93 -59.68 3.39 Favored Pre-proline 0 CA--C 1.545 0.762 0 CA-C-O 119.509 -0.281 . . . . 0.0 111.039 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.437 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 62.3 Cg_exo -39.82 -42.81 3.18 Favored 'Trans proline' 0 N--CA 1.493 1.444 0 C-N-CA 122.451 2.101 . . . . 0.0 112.186 177.901 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 40.3 tpp -64.77 -41.21 96.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.191 -179.277 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 44.5 mt -62.5 -40.75 97.71 Favored 'General case' 0 C--N 1.327 -0.392 0 C-N-CA 120.585 -0.446 . . . . 0.0 110.027 -179.609 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -63.57 -40.92 98.21 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.325 179.542 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -67.54 -41.75 89.63 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 111.125 -0.79 . . . . 0.0 111.125 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 76.5 mt -66.89 -39.82 87.56 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.673 0.273 . . . . 0.0 110.618 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -52.58 -35.94 55.04 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 120.785 -0.366 . . . . 0.0 110.746 -179.771 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 86.5 mt-30 -63.28 -19.14 64.31 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.78 179.831 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 61.0 mttp -93.65 1.28 56.66 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.41 -179.12 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 65.8 ttt-85 60.23 58.74 2.53 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.542 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 35.4 m -141.78 16.42 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.156 179.71 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 42.6 tp -139.64 143.54 37.24 Favored 'General case' 0 N--CA 1.471 0.578 0 CA-C-O 120.988 0.423 . . . . 0.0 110.218 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.457 ' OE2' ' NH1' ' A' ' 13' ' ' ARG . 20.9 pt-20 -148.42 173.6 12.92 Favored 'General case' 0 N--CA 1.462 0.16 0 CA-C-N 115.626 -0.715 . . . . 0.0 110.312 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 94' ' ' ARG . . . . . 0.412 ' NH2' ' CG ' ' A' ' 10' ' ' ASP . 0.3 OUTLIER . . . . . 0 C--O 1.22 -0.466 0 CA-C-O 118.025 -0.988 . . . . 0.0 110.573 -179.46 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 72.2 mtm . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 109.091 -0.707 . . . . 0.0 109.091 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 -166.53 62.04 0.69 Allowed Pre-proline 0 CA--C 1.533 0.316 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.236 179.631 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 75.8 Cg_endo -74.13 165.77 31.17 Favored 'Trans proline' 0 N--CA 1.494 1.522 0 C-N-CA 122.389 2.059 . . . . 0.0 111.877 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 11.2 p -79.05 90.09 4.81 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.27 -179.689 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.51 120.57 21.11 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.046 -179.834 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -80.67 144.84 31.96 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.33 -0.396 . . . . 0.0 110.022 -179.89 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 16.5 m -88.58 175.04 7.73 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-O 120.85 0.357 . . . . 0.0 110.469 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -66.5 -37.89 92.99 Favored Glycine 0 CA--C 1.527 0.813 0 N-CA-C 111.272 -0.731 . . . . 0.0 111.272 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 74.6 m -71.77 -16.75 62.2 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.729 0.299 . . . . 0.0 110.479 -179.661 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 17.6 t70 -66.85 152.66 45.18 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 179.633 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 28.9 m -129.15 123.56 21.77 Favored Pre-proline 0 N--CA 1.474 0.757 0 CA-C-O 119.607 -0.235 . . . . 0.0 110.716 -179.731 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_endo -76.94 150.5 30.15 Favored 'Trans proline' 0 N--CA 1.494 1.5 0 C-N-CA 121.39 1.393 . . . . 0.0 111.578 -179.882 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 72.7 ttp85 -158.12 130.94 7.3 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.467 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 61.8 mt -68.0 121.68 80.86 Favored Pre-proline 0 CA--C 1.544 0.738 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.913 -179.222 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 91.3 Cg_endo -76.42 160.96 35.09 Favored 'Trans proline' 0 N--CA 1.493 1.456 0 C-N-CA 121.757 1.638 . . . . 0.0 112.028 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 9.5 ptm180 -54.83 153.35 6.22 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.513 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 79.31 12.91 83.39 Favored Glycine 0 CA--C 1.523 0.545 0 N-CA-C 111.218 -0.753 . . . . 0.0 111.218 179.609 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.557 ' CG1' HD11 ' A' ' 31' ' ' LEU . 46.4 t -134.05 130.06 54.7 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.593 0 CA-C-O 120.927 0.394 . . . . 0.0 110.173 179.655 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 83.5 mtm-85 -140.12 157.2 46.0 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.097 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 23.4 mt -95.79 104.96 16.91 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.215 -0.448 . . . . 0.0 109.866 179.864 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 85.1 mtp180 -90.48 141.35 28.84 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 116.095 -0.502 . . . . 0.0 109.931 179.777 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 78.4 t80 -98.95 104.04 16.05 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.236 -0.438 . . . . 0.0 109.875 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 86.8 m-20 -88.81 93.3 9.53 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-N 115.964 -0.562 . . . . 0.0 109.922 179.742 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -62.38 -34.13 76.1 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.226 -179.913 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.433 HG22 ' H ' ' A' ' 25' ' ' VAL . 1.8 m -63.81 -42.05 94.6 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.366 -179.853 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 99.9 mtt180 -82.24 -16.63 48.9 Favored 'General case' 0 N--CA 1.465 0.296 0 N-CA-C 110.276 -0.268 . . . . 0.0 110.276 -179.792 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 64.8 t30 66.72 19.78 10.72 Favored 'General case' 0 N--CA 1.467 0.387 0 O-C-N 123.56 0.537 . . . . 0.0 111.014 179.685 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 14.8 ptpt -145.03 165.13 29.09 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-O 121.019 0.438 . . . . 0.0 110.097 179.331 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 79.7 m80 -87.89 154.32 20.61 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.808 -0.633 . . . . 0.0 109.502 179.382 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 25.8 m -137.9 157.34 32.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.083 -0.508 . . . . 0.0 109.865 -179.625 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.557 HD11 ' CG1' ' A' ' 18' ' ' VAL . 37.7 tp -109.48 120.84 43.72 Favored 'General case' 0 N--CA 1.467 0.399 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 178.978 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 61.4 tp -78.26 95.78 5.09 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 178.97 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -94.66 146.37 31.31 Favored Pre-proline 0 CA--C 1.54 0.586 0 N-CA-C 109.673 -0.491 . . . . 0.0 109.673 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 78.8 Cg_exo -46.34 -35.7 16.25 Favored 'Trans proline' 0 N--CA 1.497 1.702 0 C-N-CA 121.784 1.656 . . . . 0.0 112.658 179.068 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -74.56 -52.04 12.93 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.638 -0.255 . . . . 0.0 111.069 -178.451 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 17.7 ptp180 -176.59 162.72 2.3 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-O 120.861 0.362 . . . . 0.0 110.646 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 58.2 m -73.67 125.16 27.42 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.171 179.048 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 78.6 m-85 -103.54 130.01 50.86 Favored 'General case' 0 N--CA 1.472 0.647 0 CA-C-O 120.864 0.364 . . . . 0.0 110.099 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -71.71 120.3 17.11 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.138 179.82 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 90.2 mt -130.52 158.96 38.52 Favored 'General case' 0 N--CA 1.468 0.464 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.042 -179.532 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 16.7 m-20 -84.22 160.03 20.88 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.165 -179.518 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 84.8 m-20 -61.32 -40.71 95.2 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.529 -179.847 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 49.9 t30 -62.38 -37.61 86.39 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.789 -179.249 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -68.64 -41.91 78.76 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.497 -0.32 . . . . 0.0 110.963 -179.51 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 49.0 t -80.4 -27.12 11.63 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.183 0 CA-C-O 120.678 0.275 . . . . 0.0 110.423 179.803 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.459 ' O ' ' N ' ' A' ' 50' ' ' LEU . . . -57.31 -41.47 79.97 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.436 -179.85 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 94.5 t -60.62 -47.34 93.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.367 -179.824 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 49.5 mt -70.16 -32.2 70.05 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.508 -179.612 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 37.9 ttmt -82.17 -26.22 33.62 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.458 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.459 ' N ' ' O ' ' A' ' 46' ' ' ALA . 53.6 tp -69.29 -32.92 72.4 Favored 'General case' 0 N--CA 1.462 0.171 0 C-N-CA 120.531 -0.468 . . . . 0.0 110.08 -179.299 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 2.7 p -76.92 129.72 37.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.99 0.424 . . . . 0.0 110.501 179.803 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -72.98 -45.49 57.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.112 179.258 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -140.23 -99.21 0.4 Allowed Glycine 0 N--CA 1.473 1.146 0 N-CA-C 110.633 -0.987 . . . . 0.0 110.633 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 95.2 mtt180 -114.87 104.82 12.31 Favored 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 179.147 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 -116.95 144.51 44.47 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.002 178.68 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 21.6 p -79.15 141.3 37.37 Favored 'General case' 0 C--N 1.327 -0.398 0 N-CA-C 109.664 -0.495 . . . . 0.0 109.664 179.05 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.417 HG23 ' N ' ' A' ' 58' ' ' SER . 34.1 m -53.95 -37.68 34.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.252 -179.66 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 58' ' ' SER . . . . . 0.417 ' N ' HG23 ' A' ' 57' ' ' VAL . 69.9 m -58.38 -44.64 88.99 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.639 179.704 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 54.0 tt0 -65.08 -46.99 78.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.518 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 66.1 mt -61.91 -43.06 96.93 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.192 179.801 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.443 ' O ' ' N ' ' A' ' 65' ' ' GLY . . . -53.39 -38.39 63.35 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.143 -179.204 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 80.6 mm-40 -63.51 -52.34 61.64 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.637 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 70.0 mt -64.67 -50.67 74.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.941 -179.046 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 20.9 tp -69.37 -38.46 78.07 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.596 -179.334 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.443 ' N ' ' O ' ' A' ' 61' ' ' ALA . . . -54.71 -42.19 77.09 Favored Glycine 0 CA--C 1.524 0.612 0 N-CA-C 111.131 -0.788 . . . . 0.0 111.131 -179.279 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 87.0 mt-30 -64.65 -31.85 73.25 Favored 'General case' 0 C--N 1.327 -0.37 0 C-N-CA 120.984 -0.286 . . . . 0.0 110.546 179.656 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 19.4 m -62.04 -46.52 88.78 Favored 'General case' 0 C--N 1.33 -0.25 0 C-N-CA 120.764 -0.374 . . . . 0.0 110.627 -179.835 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 90.7 m-85 -91.08 -0.6 57.76 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.451 179.652 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 64.8 t0 54.26 51.85 13.64 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.744 179.687 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -140.13 157.29 45.86 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.18 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 16.6 m-20 -56.77 141.96 73.02 Favored Pre-proline 0 CA--C 1.545 0.771 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.078 -178.846 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -66.46 -28.46 45.97 Favored 'Trans proline' 0 N--CA 1.503 2.072 0 C-N-CA 122.618 2.212 . . . . 0.0 112.752 -179.171 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -54.93 -29.51 56.56 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.945 0.402 . . . . 0.0 110.748 -179.242 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.688 ' N ' HD12 ' A' ' 74' ' ' ILE . 1.6 mp -78.58 -44.61 26.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.111 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.551 ' N ' HD12 ' A' ' 75' ' ' ILE . 1.7 mp -62.46 -47.72 91.69 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.641 -178.046 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 14.9 pt-20 -60.34 -46.35 90.22 Favored 'General case' 0 C--N 1.324 -0.526 0 C-N-CA 120.416 -0.514 . . . . 0.0 110.443 -178.502 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.44 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -67.6 -20.6 65.38 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.096 179.759 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 66.0 t0 -80.74 -47.59 13.73 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 120.727 0.298 . . . . 0.0 111.508 -179.47 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 18.0 pt -71.46 -41.03 72.94 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 CA-C-N 116.385 -0.371 . . . . 0.0 111.136 -179.117 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 7.2 mt -43.0 -61.13 1.89 Allowed Pre-proline 0 CA--C 1.548 0.894 0 CA-C-N 116.522 -0.308 . . . . 0.0 110.843 179.544 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.44 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 61.9 Cg_exo -38.94 -41.54 1.79 Allowed 'Trans proline' 0 N--CA 1.492 1.435 0 C-N-CA 122.707 2.272 . . . . 0.0 112.264 177.845 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 14.2 tpt -65.63 -40.71 92.85 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.6 -179.191 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 47.2 mt -61.42 -40.41 94.32 Favored 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 120.59 -0.444 . . . . 0.0 110.3 -179.293 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -63.71 -40.02 95.73 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 120.839 0.352 . . . . 0.0 110.335 179.469 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -67.82 -39.78 89.74 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 111.405 -0.678 . . . . 0.0 111.405 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 73.8 mt -67.01 -38.51 86.11 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.752 0.311 . . . . 0.0 110.525 -179.605 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -53.93 -36.3 62.63 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.89 0.376 . . . . 0.0 110.459 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 83.7 mt-30 -63.06 -23.9 67.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.795 179.764 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -90.7 -3.18 57.67 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-O 120.684 0.278 . . . . 0.0 110.342 -179.382 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 14.5 tpt180 63.97 51.35 2.31 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.992 179.498 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 30.8 m -139.29 10.53 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.283 179.889 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.569 HD13 ' N ' ' A' ' 93' ' ' GLU . 0.2 OUTLIER -141.53 123.23 15.18 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-O 121.14 0.495 . . . . 0.0 109.755 -179.901 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.569 ' N ' HD13 ' A' ' 92' ' ' LEU . 11.4 pt-20 -153.29 137.93 16.92 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.24 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 49.0 ptt85 . . . . . 0 C--N 1.325 -0.48 0 CA-C-O 117.901 -1.047 . . . . 0.0 110.597 179.787 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.418 ' SD ' ' N ' ' A' ' 1' ' ' MET . 2.0 mpt? . . . . . 0 N--CA 1.491 1.593 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -168.24 71.6 0.85 Allowed Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.28 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -54.07 165.37 2.08 Favored 'Trans proline' 0 N--CA 1.495 1.566 0 C-N-CA 122.574 2.183 . . . . 0.0 111.885 179.523 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 5.2 t -149.9 178.0 9.32 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.111 -179.626 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -158.15 120.11 3.64 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.059 -179.483 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 64.1 m-85 -77.58 139.02 39.47 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.175 179.866 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 15.9 m -94.41 179.48 5.27 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-O 120.786 0.327 . . . . 0.0 110.228 179.888 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -65.0 -43.06 96.4 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.691 -0.963 . . . . 0.0 110.691 179.761 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 27.9 t -72.84 -25.39 61.1 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.864 0.364 . . . . 0.0 110.605 179.826 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.44 ' OD1' ' N ' ' A' ' 11' ' ' VAL . 60.5 t0 -67.82 135.95 53.37 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 179.848 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.44 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 15.5 m -117.59 129.6 25.24 Favored Pre-proline 0 CA--C 1.546 0.822 0 CA-C-O 119.621 -0.228 . . . . 0.0 111.123 -179.091 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -79.56 157.58 25.17 Favored 'Trans proline' 0 N--CA 1.493 1.494 0 C-N-CA 121.899 1.733 . . . . 0.0 111.133 179.005 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 58.3 ttt85 -157.99 127.52 5.9 Favored 'General case' 0 N--CA 1.466 0.346 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 179.162 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 58.9 mt -67.39 118.21 54.35 Favored Pre-proline 0 CA--C 1.541 0.61 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.937 -179.328 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -76.58 160.68 34.79 Favored 'Trans proline' 0 N--CA 1.49 1.292 0 C-N-CA 121.731 1.621 . . . . 0.0 111.789 -179.723 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 78.3 ttt180 -54.52 141.0 32.8 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.423 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 92.96 6.29 63.53 Favored Glycine 0 N--CA 1.465 0.585 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 179.896 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.532 ' CG1' HD11 ' A' ' 31' ' ' LEU . 51.2 t -130.63 129.76 64.4 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.535 0 CA-C-O 120.915 0.388 . . . . 0.0 110.0 179.505 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 63.3 mtt-85 -143.42 155.93 44.52 Favored 'General case' 0 N--CA 1.462 0.131 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.064 -179.568 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 16.2 mt -94.67 100.13 12.12 Favored 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.582 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.486 ' HE ' HD22 ' A' ' 32' ' ' LEU . 96.2 mtt-85 -93.82 139.47 30.83 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.134 179.821 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.468 ' O ' ' CD1' ' A' ' 22' ' ' PHE . 41.9 p90 -100.11 117.43 34.34 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.331 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 86.0 m-20 -89.74 99.44 12.45 Favored 'General case' 0 N--CA 1.463 0.218 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 179.729 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 82.9 tt0 -63.38 -35.22 79.69 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.323 -179.782 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.433 ' H ' HG22 ' A' ' 25' ' ' VAL . 1.6 m -63.4 -42.9 97.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.61 -179.776 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -84.09 -16.04 45.15 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 110.383 -0.229 . . . . 0.0 110.383 -179.847 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 57.6 t30 68.77 21.53 7.7 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 115.945 -0.571 . . . . 0.0 111.094 179.714 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -145.05 164.68 30.46 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 116.124 -0.489 . . . . 0.0 109.93 179.396 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 73.2 m80 -92.49 152.9 19.41 Favored 'General case' 0 CA--C 1.514 -0.42 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.281 179.855 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 30.2 m -139.33 154.1 24.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.837 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.532 HD11 ' CG1' ' A' ' 18' ' ' VAL . 50.7 tp -98.89 116.14 30.44 Favored 'General case' 0 CA--C 1.517 -0.314 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 179.216 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.486 HD22 ' HE ' ' A' ' 21' ' ' ARG . 57.8 tp -79.11 102.06 8.23 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 179.21 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -97.65 142.03 23.91 Favored Pre-proline 0 CA--C 1.538 0.503 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.858 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_exo -43.37 -34.55 4.87 Favored 'Trans proline' 0 N--CA 1.495 1.614 0 C-N-CA 121.898 1.732 . . . . 0.0 112.569 179.297 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.445 ' CG ' ' N ' ' A' ' 36' ' ' ARG . 14.2 pt-20 -75.66 -51.61 12.4 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.393 -178.673 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.445 ' N ' ' CG ' ' A' ' 35' ' ' GLU . 77.0 ttt-85 -177.16 151.59 0.82 Allowed 'General case' 0 C--N 1.332 -0.193 0 O-C-N 123.293 0.371 . . . . 0.0 110.124 -179.368 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 51.6 m -69.32 135.11 49.95 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.661 179.106 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 78.1 m-85 -108.58 137.41 46.57 Favored 'General case' 0 N--CA 1.472 0.636 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.288 179.857 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 38.8 p-10 -72.69 117.71 14.71 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.352 179.698 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 83.8 mt -134.71 157.38 46.83 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-O 121.042 0.448 . . . . 0.0 110.153 -179.594 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 95.0 m-20 -86.07 155.22 20.9 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.942 -179.691 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -59.39 -37.74 78.75 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.564 -179.614 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -62.98 -39.78 95.75 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.542 -179.765 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.26 -41.74 76.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.554 -0.294 . . . . 0.0 110.882 -179.659 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 44.6 t -78.79 -26.2 13.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 120.856 0.36 . . . . 0.0 110.141 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.65 -35.61 68.57 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.088 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 66.8 t -60.47 -47.45 92.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.67 -179.685 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 41.4 mt -77.61 -16.48 58.56 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.856 -179.239 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 2.8 ttmp? -89.08 -32.17 17.68 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.593 179.224 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 5.6 tp -71.06 -32.25 68.88 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.791 -178.557 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.5 p -73.55 126.02 33.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 121.001 0.429 . . . . 0.0 110.375 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 94.5 m-20 -71.04 -41.13 71.19 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.259 179.475 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -147.68 -97.8 0.2 Allowed Glycine 0 N--CA 1.471 0.998 0 N-CA-C 110.578 -1.009 . . . . 0.0 110.578 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 83.4 mtp180 -114.77 104.84 12.36 Favored 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 110.16 -0.311 . . . . 0.0 110.16 179.78 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 92.6 m-20 -117.12 148.86 41.18 Favored 'General case' 0 N--CA 1.473 0.696 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.156 178.429 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 41.3 p -81.04 139.95 35.43 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.73 178.836 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.461 HG23 ' N ' ' A' ' 58' ' ' SER . 19.5 m -54.81 -39.75 49.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.385 -179.657 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' SER . . . . . 0.461 ' N ' HG23 ' A' ' 57' ' ' VAL . 70.9 m -57.17 -43.95 83.04 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.521 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 49.2 tt0 -65.55 -47.93 74.16 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.825 0.345 . . . . 0.0 110.593 -179.839 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 66.5 mt -59.63 -40.75 83.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.14 179.488 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.419 ' O ' ' N ' ' A' ' 65' ' ' GLY . . . -55.36 -42.95 74.58 Favored 'General case' 0 C--N 1.325 -0.492 0 C-N-CA 120.664 -0.414 . . . . 0.0 110.612 -179.778 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 90.4 mm-40 -64.13 -55.99 17.99 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.034 179.902 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 72.5 mt -64.41 -48.94 83.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.829 -179.141 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 28.0 tp -67.83 -36.96 81.28 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.407 -179.528 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.419 ' N ' ' O ' ' A' ' 61' ' ' ALA . . . -56.93 -40.72 91.1 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -179.645 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 75.5 mt-30 -64.4 -31.67 72.97 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 121.011 -0.275 . . . . 0.0 110.35 179.797 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 20.5 m -63.08 -46.59 86.69 Favored 'General case' 0 C--N 1.331 -0.198 0 C-N-CA 120.842 -0.343 . . . . 0.0 110.526 -179.749 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -91.13 -1.08 57.81 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.324 179.782 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 55.6 t0 53.17 54.06 10.9 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.464 -0.335 . . . . 0.0 110.65 179.605 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -140.44 162.48 35.23 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.11 -179.65 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 79.0 m-20 -56.7 134.89 78.28 Favored Pre-proline 0 CA--C 1.541 0.629 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.307 -179.098 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -66.35 -31.25 43.65 Favored 'Trans proline' 0 N--CA 1.502 1.989 0 C-N-CA 122.456 2.104 . . . . 0.0 112.659 -179.309 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -55.25 -37.76 67.66 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.04 0.448 . . . . 0.0 110.785 -179.368 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 64.8 mt -70.92 -39.54 75.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.48 179.938 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 36.9 mm -59.74 -48.79 86.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.981 -177.896 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -62.13 -45.26 94.25 Favored 'General case' 0 N--CA 1.461 0.094 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.132 -179.673 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.452 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -66.63 -19.02 65.67 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.166 179.779 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 64.7 t0 -80.64 -47.54 13.94 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 116.617 -0.265 . . . . 0.0 111.03 -179.525 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 33.5 pt -79.6 -33.24 14.97 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.624 0 CA-C-O 121.054 0.454 . . . . 0.0 111.251 -179.399 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.405 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 9.7 mt -47.38 -59.63 5.23 Favored Pre-proline 0 CA--C 1.545 0.76 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.836 179.719 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.452 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 39.8 Cg_endo -61.39 -29.38 85.46 Favored 'Trans proline' 0 N--CA 1.496 1.64 0 C-N-CA 121.988 1.792 . . . . 0.0 111.612 179.86 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 40.2 ttm -67.07 -39.31 86.82 Favored 'General case' 0 N--CA 1.461 0.125 0 CA-C-O 120.772 0.32 . . . . 0.0 110.784 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 84.5 mt -62.56 -39.92 95.2 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.396 -179.714 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -60.91 -38.6 86.3 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.256 179.808 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -65.2 -40.81 96.99 Favored Glycine 0 CA--C 1.527 0.812 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 88.1 mt -69.74 -35.34 74.9 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.799 0.333 . . . . 0.0 110.583 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -52.68 -38.12 59.98 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.886 0.374 . . . . 0.0 110.443 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 87.6 mt-30 -61.45 -21.18 63.92 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.432 179.564 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 62.9 mttp -95.05 -1.44 52.22 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.109 -179.47 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 67.3 ttp85 55.83 67.82 0.95 Allowed 'General case' 0 N--CA 1.453 -0.318 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.73 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 24.4 m -141.46 16.2 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.507 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 95.1 mt -129.83 155.96 45.14 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-O 121.311 0.577 . . . . 0.0 110.251 179.629 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 80.2 tt0 -146.19 113.69 6.33 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.08 -0.964 . . . . 0.0 110.497 -179.228 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 90.3 mtm180 . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 118.159 -0.924 . . . . 0.0 110.218 179.32 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 79.0 mmm . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.454 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 0.0 OUTLIER -166.86 51.14 0.22 Allowed Pre-proline 0 CA--C 1.536 0.408 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.321 -179.885 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.454 ' CD ' ' N ' ' A' ' 2' ' ' GLU . 55.8 Cg_endo -66.81 -19.03 53.31 Favored 'Trans proline' 0 N--CA 1.497 1.685 0 C-N-CA 122.236 1.957 . . . . 0.0 111.785 179.781 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 81.6 p 49.13 94.16 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.229 0 CA-C-O 120.788 0.327 . . . . 0.0 110.643 -179.392 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.61 -11.09 60.31 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.562 -179.641 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 69.2 m-85 52.44 174.96 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.813 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 69.5 m -133.58 -171.88 2.82 Favored 'General case' 0 N--CA 1.471 0.6 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.63 -179.515 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -66.16 -38.39 93.85 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 95.0 p -71.75 -14.0 61.88 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-O 120.614 0.245 . . . . 0.0 111.099 -179.492 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -66.2 136.69 56.25 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.745 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.432 HG23 ' O ' ' A' ' 55' ' ' ASN . 1.0 OUTLIER -130.13 114.63 17.45 Favored Pre-proline 0 CA--C 1.545 0.78 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.069 -179.736 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -79.27 144.01 17.96 Favored 'Trans proline' 0 N--CA 1.489 1.264 0 C-N-CA 121.001 1.134 . . . . 0.0 111.492 179.805 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 76.2 ttt180 -153.14 139.3 18.34 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.758 -0.655 . . . . 0.0 109.722 179.348 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 52.6 mt -69.33 123.91 89.35 Favored Pre-proline 0 CA--C 1.545 0.78 0 CA-C-N 115.655 -0.702 . . . . 0.0 111.35 -179.239 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_endo -73.57 159.47 45.99 Favored 'Trans proline' 0 N--CA 1.497 1.708 0 C-N-CA 121.842 1.695 . . . . 0.0 111.902 179.341 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 78.7 ttt180 -54.81 150.5 9.75 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.337 179.728 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 81.7 18.69 67.52 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.837 -0.905 . . . . 0.0 110.837 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.578 ' CG1' HD11 ' A' ' 31' ' ' LEU . 58.7 t -133.98 133.65 56.08 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 CA-C-O 120.931 0.396 . . . . 0.0 110.183 179.831 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 89.6 mtm-85 -136.82 155.91 49.18 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.244 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 44.5 mt -92.81 138.0 31.87 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.742 179.853 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 25.2 mtp-105 -135.46 142.45 45.55 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.121 -179.601 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 43.4 t80 -101.53 115.71 31.14 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.203 179.739 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 87.6 m-20 -91.65 94.4 9.38 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.485 178.995 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -60.45 -35.17 75.21 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.193 -179.682 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.402 ' H ' HG22 ' A' ' 25' ' ' VAL . 0.6 OUTLIER -63.13 -42.96 98.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.285 179.977 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 76.1 mtp180 -84.24 -13.54 52.35 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-O 120.767 0.318 . . . . 0.0 110.482 -179.873 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 58.1 t30 66.19 19.84 11.11 Favored 'General case' 0 CA--C 1.532 0.278 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.366 179.639 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.512 ' HZ1' ' HA ' ' A' ' 39' ' ' ASP . 20.8 pttp -145.1 162.58 36.66 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-O 120.679 0.276 . . . . 0.0 110.282 179.184 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 78.4 m80 -90.5 153.13 20.6 Favored 'General case' 0 N--CA 1.464 0.238 0 N-CA-C 109.622 -0.51 . . . . 0.0 109.622 178.932 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 27.4 m -140.26 156.75 24.61 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.359 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.214 -179.721 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.578 HD11 ' CG1' ' A' ' 18' ' ' VAL . 34.5 tp -100.63 118.22 36.33 Favored 'General case' 0 N--CA 1.467 0.409 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 179.496 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 50.5 tp -78.22 97.27 5.46 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 179.276 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -96.05 145.01 28.81 Favored Pre-proline 0 CA--C 1.539 0.551 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.097 -179.506 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_exo -46.23 -37.08 18.05 Favored 'Trans proline' 0 N--CA 1.493 1.449 0 C-N-CA 121.266 1.311 . . . . 0.0 112.517 179.319 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 41.2 tp10 -72.66 -52.04 16.97 Favored 'General case' 0 C--N 1.331 -0.201 0 C-N-CA 120.986 -0.286 . . . . 0.0 111.204 -178.444 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 9.0 ptm180 -176.59 161.2 2.1 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.863 0.363 . . . . 0.0 110.603 -179.732 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 59.3 m -74.87 128.75 36.31 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.374 178.964 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -100.82 140.64 34.82 Favored 'General case' 0 N--CA 1.472 0.652 0 CA-C-O 120.943 0.401 . . . . 0.0 110.666 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.512 ' HA ' ' HZ1' ' A' ' 28' ' ' LYS . 36.4 p-10 -72.84 115.13 11.77 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.25 179.243 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 41.1 mt -131.05 152.41 50.39 Favored 'General case' 0 N--CA 1.472 0.657 0 CA-C-O 120.939 0.4 . . . . 0.0 110.198 -179.478 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 29.6 m-20 -88.2 165.87 14.76 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.121 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -60.7 -43.58 97.6 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.247 179.783 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' ASN . . . . . 0.464 ' OD1' ' N ' ' A' ' 44' ' ' ALA . 23.6 p30 -65.02 -32.83 74.74 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.053 -0.522 . . . . 0.0 110.663 -179.705 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.464 ' N ' ' OD1' ' A' ' 43' ' ' ASN . . . -69.87 -42.71 73.14 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 120.853 -0.339 . . . . 0.0 111.014 -179.601 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 58.9 t -80.32 -33.53 14.13 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 CA-C-N 116.533 -0.303 . . . . 0.0 110.779 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -53.29 -44.86 68.62 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.863 0.363 . . . . 0.0 110.565 -179.432 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 96.4 t -61.01 -45.66 98.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.318 179.629 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 50.4 mt -73.2 -17.87 61.31 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.102 -179.282 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 36.5 ttpt -91.18 -27.94 18.18 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.567 179.312 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 36.1 tp -71.15 -32.22 68.68 Favored 'General case' 0 N--CA 1.461 0.113 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.547 -179.198 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.3 p -73.74 120.34 22.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-O 121.122 0.487 . . . . 0.0 110.561 179.824 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 95.2 m-20 -71.12 -44.05 66.4 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.48 179.553 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -141.8 -98.31 0.31 Allowed Glycine 0 N--CA 1.472 1.053 0 N-CA-C 110.2 -1.16 . . . . 0.0 110.2 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 90.2 mtm180 -114.8 104.78 12.29 Favored 'General case' 0 N--CA 1.472 0.652 0 CA-C-O 120.734 0.302 . . . . 0.0 110.21 179.003 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.432 ' O ' HG23 ' A' ' 11' ' ' VAL . 99.3 m-20 -117.27 138.2 51.89 Favored 'General case' 0 N--CA 1.473 0.706 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.199 178.17 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 44.0 p -78.07 141.65 38.67 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 178.963 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.439 HG23 ' N ' ' A' ' 58' ' ' SER . 28.7 m -51.26 -39.42 21.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-O 120.886 0.374 . . . . 0.0 110.557 -179.536 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 58' ' ' SER . . . . . 0.439 ' N ' HG23 ' A' ' 57' ' ' VAL . 55.9 m -58.62 -44.94 90.13 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.54 179.223 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 44.7 tt0 -65.18 -46.7 79.72 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.789 -179.783 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 67.0 mt -61.23 -42.91 95.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.173 -0.467 . . . . 0.0 109.861 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.409 ' O ' ' N ' ' A' ' 65' ' ' GLY . . . -53.69 -41.63 67.13 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.829 -179.317 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 95.9 mm-40 -63.81 -52.88 58.21 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.823 179.855 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 72.9 mt -64.0 -49.77 80.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.822 0.344 . . . . 0.0 110.967 -178.938 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 25.3 tp -69.95 -36.19 75.07 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.967 0.413 . . . . 0.0 110.477 -179.414 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.409 ' N ' ' O ' ' A' ' 61' ' ' ALA . . . -55.58 -40.23 77.74 Favored Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.985 -0.846 . . . . 0.0 110.985 -179.65 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 85.0 mt-30 -65.6 -32.08 73.47 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.717 0.294 . . . . 0.0 110.338 179.727 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 19.5 m -62.71 -47.03 85.37 Favored 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 120.816 -0.354 . . . . 0.0 110.331 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 90.5 m-85 -92.68 -2.3 56.17 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.565 179.591 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 65.5 t0 49.25 61.23 3.24 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.801 0.334 . . . . 0.0 111.135 179.666 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -144.31 164.5 30.6 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.126 -179.68 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 81.7 m-20 -55.65 112.79 4.65 Favored Pre-proline 0 CA--C 1.545 0.76 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.234 -179.667 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 76.3 Cg_exo -48.37 -36.33 30.12 Favored 'Trans proline' 0 N--CA 1.503 2.038 0 C-N-CA 121.995 1.797 . . . . 0.0 112.94 -179.746 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -50.68 -35.9 33.17 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.869 0.366 . . . . 0.0 111.011 -179.489 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 68.5 mt -70.92 -41.44 77.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.646 179.473 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.555 ' N ' HD12 ' A' ' 75' ' ' ILE . 1.7 mp -60.61 -47.81 91.28 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.698 -178.336 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 8.6 pt-20 -61.82 -45.78 92.35 Favored 'General case' 0 C--N 1.329 -0.322 0 C-N-CA 120.164 -0.614 . . . . 0.0 109.993 -179.222 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.427 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -66.51 -20.54 66.06 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.17 179.771 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 65.7 t0 -80.97 -48.9 11.64 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-O 120.775 0.321 . . . . 0.0 111.275 -179.529 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 14.8 pt -71.08 -40.72 75.85 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.279 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.889 -179.525 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 6.6 mt -42.55 -60.8 1.97 Allowed Pre-proline 0 CA--C 1.549 0.933 0 CA-C-O 119.487 -0.292 . . . . 0.0 111.113 -179.884 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.427 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 59.4 Cg_exo -39.88 -41.5 2.86 Favored 'Trans proline' 0 N--CA 1.495 1.609 0 C-N-CA 122.617 2.211 . . . . 0.0 112.286 178.01 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 13.0 tpt -65.61 -39.53 91.63 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.506 -179.038 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 45.0 mt -61.83 -36.64 81.77 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.117 -179.437 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -60.9 -42.14 97.45 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.318 179.574 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -70.56 -39.88 67.69 Favored Glycine 0 CA--C 1.529 0.956 0 N-CA-C 111.73 -0.548 . . . . 0.0 111.73 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 79.4 mt -67.6 -39.98 84.76 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.887 0.375 . . . . 0.0 110.573 -179.268 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -54.56 -40.02 68.33 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.666 -179.723 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 78.4 mt-30 -61.69 -22.26 65.17 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.545 179.874 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -94.24 -3.78 50.06 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.076 -179.662 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 36.7 ttm180 55.83 68.03 0.92 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.343 179.937 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 33.7 m -140.07 16.61 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.667 -179.755 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 78.0 mt -122.18 159.67 26.76 Favored 'General case' 0 N--CA 1.471 0.6 0 CA-C-O 121.51 0.672 . . . . 0.0 110.582 179.853 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 79.6 tt0 -140.93 144.97 35.47 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 114.651 -1.159 . . . . 0.0 110.326 179.938 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 52.6 ptt85 . . . . . 0 C--N 1.324 -0.54 0 CA-C-N 115.07 -0.968 . . . . 0.0 110.397 179.733 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.536 ' SD ' ' N ' ' A' ' 1' ' ' MET . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.619 0 CA-C-O 121.236 0.541 . . . . 0.0 109.936 . . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.451 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 5.9 tp10 -176.91 -57.92 0.0 OUTLIER Pre-proline 0 CA--C 1.54 0.585 0 CA-C-N 115.265 -0.88 . . . . 0.0 110.109 -179.484 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.451 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 32.7 Cg_endo -58.07 -86.85 0.01 OUTLIER 'Trans proline' 0 N--CA 1.5 1.897 0 C-N-CA 121.935 1.757 . . . . 0.0 111.81 -179.858 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -161.92 67.32 0.26 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.058 -179.542 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -72.94 111.28 7.91 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.158 -179.685 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 62.8 m-85 -78.13 139.98 39.02 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.405 -179.323 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.431 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 17.5 m -88.29 175.01 7.85 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.469 179.9 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -65.17 -31.36 80.44 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 111.231 -0.748 . . . . 0.0 111.231 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 68.8 m -72.0 -6.75 44.42 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.495 0.188 . . . . 0.0 111.303 -179.249 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.431 ' OD2' ' O ' ' A' ' 7' ' ' SER . 0.2 OUTLIER -68.42 153.09 44.43 Favored 'General case' 0 C--N 1.332 -0.192 0 N-CA-C 109.587 -0.523 . . . . 0.0 109.587 179.798 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.521 HG23 ' O ' ' A' ' 11' ' ' VAL . 33.0 m -131.21 116.89 16.72 Favored Pre-proline 0 CA--C 1.54 0.574 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 179.266 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -77.02 151.3 30.6 Favored 'Trans proline' 0 N--CA 1.492 1.438 0 C-N-CA 121.114 1.209 . . . . 0.0 111.958 -178.828 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 72.5 ttp85 -154.97 133.94 12.26 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.615 -0.721 . . . . 0.0 109.631 179.7 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 65.7 mt -67.68 115.25 25.45 Favored Pre-proline 0 CA--C 1.542 0.636 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.776 -179.57 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -78.75 159.65 27.98 Favored 'Trans proline' 0 N--CA 1.494 1.515 0 C-N-CA 121.682 1.588 . . . . 0.0 111.827 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 85.3 mtp180 -57.93 148.54 25.41 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.76 179.68 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 82.21 13.23 79.42 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 179.669 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 61.9 t -134.32 132.11 55.14 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 CA-C-O 120.966 0.412 . . . . 0.0 110.167 179.697 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 90.0 mtm180 -136.66 153.44 50.91 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.233 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 19.2 mt -98.81 97.67 8.86 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.173 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 84.2 mtp180 -96.18 139.63 32.05 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.12 179.611 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.481 ' O ' ' CD1' ' A' ' 22' ' ' PHE . 38.7 p90 -97.71 115.22 27.54 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-O 121.001 0.429 . . . . 0.0 110.161 179.873 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -89.86 96.72 10.81 Favored 'General case' 0 N--CA 1.464 0.268 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.736 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -61.82 -34.11 75.35 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.212 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.434 ' H ' HG22 ' A' ' 25' ' ' VAL . 2.4 m -63.63 -40.95 90.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.359 -179.854 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.534 ' O ' ' ND2' ' A' ' 27' ' ' ASN . 99.8 mtt180 -84.43 -15.9 44.55 Favored 'General case' 0 N--CA 1.467 0.402 0 CA-C-O 120.692 0.282 . . . . 0.0 110.439 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.534 ' ND2' ' O ' ' A' ' 26' ' ' ARG . 0.0 OUTLIER 71.96 12.85 6.05 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.773 179.69 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 47.2 pttt -144.83 161.01 40.34 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 121.071 0.462 . . . . 0.0 109.885 179.731 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 72.0 m80 -86.88 154.48 20.82 Favored 'General case' 0 CA--C 1.513 -0.462 0 CA-C-N 115.717 -0.674 . . . . 0.0 109.989 -179.888 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 34.5 m -136.6 157.25 36.58 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.257 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.108 -179.632 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 6.7 tp -98.95 110.23 22.87 Favored 'General case' 0 N--CA 1.464 0.256 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 179.612 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 55.9 tp -75.32 101.3 4.67 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 109.222 -0.659 . . . . 0.0 109.222 179.479 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -94.62 144.48 27.98 Favored Pre-proline 0 CA--C 1.537 0.48 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.031 -179.619 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 89.3 Cg_exo -45.05 -38.28 13.62 Favored 'Trans proline' 0 N--CA 1.495 1.575 0 C-N-CA 121.494 1.463 . . . . 0.0 112.315 179.313 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 -71.72 -44.32 64.36 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.951 -178.973 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 50.4 ttp180 -171.51 -122.28 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.523 0 N-CA-C 110.083 -0.34 . . . . 0.0 110.083 -179.64 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 91.8 m -161.05 153.09 19.89 Favored 'General case' 0 C--O 1.232 0.167 0 N-CA-C 109.508 -0.552 . . . . 0.0 109.508 -179.523 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 -126.2 139.84 53.03 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.441 -179.432 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -72.32 115.57 11.73 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.129 -0.487 . . . . 0.0 109.872 179.791 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 16.0 mt -128.52 156.88 42.58 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.117 -179.422 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -84.67 153.73 22.94 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.077 -179.716 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 68.1 t0 -59.01 -36.72 75.41 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.189 -179.613 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -63.59 -38.48 91.29 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.322 179.934 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -68.01 -40.39 82.99 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.724 -179.437 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 49.1 t -79.64 -28.15 12.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 120.809 0.338 . . . . 0.0 110.153 179.793 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.45 ' O ' ' N ' ' A' ' 50' ' ' LEU . . . -57.58 -41.63 81.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.365 -179.671 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 97.3 t -61.03 -47.15 94.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.482 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 38.6 mt -70.0 -30.46 67.78 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.022 -179.589 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 36.9 ttmt -82.66 -29.41 30.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.687 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.45 ' N ' ' O ' ' A' ' 46' ' ' ALA . 58.8 tp -72.49 -32.74 66.44 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 120.984 -0.286 . . . . 0.0 110.661 -179.121 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.5 p -79.25 128.67 38.4 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.251 0 CA-C-O 120.966 0.413 . . . . 0.0 110.592 179.676 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 94.8 m-20 -76.43 -86.81 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.166 -0.47 . . . . 0.0 109.738 179.343 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -88.56 -117.08 1.4 Allowed Glycine 0 CA--C 1.524 0.633 0 N-CA-C 110.332 -1.107 . . . . 0.0 110.332 179.328 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 83.2 mtm-85 -111.37 105.3 13.89 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-O 120.802 0.334 . . . . 0.0 110.295 179.746 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 95.1 m-20 -116.75 150.05 38.9 Favored 'General case' 0 N--CA 1.471 0.604 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.084 178.926 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 48.1 p -80.13 149.2 30.66 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 178.893 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.408 HG23 ' N ' ' A' ' 58' ' ' SER . 29.9 m -55.4 -37.87 46.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 120.858 0.361 . . . . 0.0 110.409 -179.796 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' SER . . . . . 0.408 ' N ' HG23 ' A' ' 57' ' ' VAL . 7.7 t -58.09 -44.86 87.83 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.669 179.878 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 50.7 tt0 -64.58 -49.57 70.65 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.836 0.35 . . . . 0.0 110.712 -179.686 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 66.2 mt -61.19 -42.2 92.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.205 -0.452 . . . . 0.0 109.95 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -51.42 -39.61 57.65 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.029 -179.541 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 92.2 mm-40 -63.22 -47.57 81.92 Favored 'General case' 0 C--N 1.327 -0.389 0 C-N-CA 120.7 -0.4 . . . . 0.0 110.135 179.524 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 69.9 mt -64.82 -48.94 82.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.626 -179.369 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 23.7 tp -68.65 -37.84 79.99 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.986 0.422 . . . . 0.0 110.478 -179.284 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.427 ' O ' ' N ' ' A' ' 69' ' ' ASP . . . -56.17 -41.78 86.74 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 -179.194 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 87.8 mt-30 -66.4 -31.79 72.77 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 121.06 -0.256 . . . . 0.0 110.522 179.834 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 21.5 m -62.33 -49.01 77.29 Favored 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 120.84 -0.344 . . . . 0.0 110.436 -179.756 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -95.14 -0.88 52.94 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.552 179.535 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' ASP . . . . . 0.427 ' N ' ' O ' ' A' ' 65' ' ' GLY . 50.2 t0 52.16 62.08 2.88 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.506 -0.315 . . . . 0.0 110.834 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -141.97 163.14 33.7 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.226 -179.78 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 72.3 m-20 -55.79 113.09 5.1 Favored Pre-proline 0 CA--C 1.543 0.683 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.46 -179.691 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 78.2 Cg_exo -49.35 -36.37 38.02 Favored 'Trans proline' 0 N--CA 1.5 1.891 0 C-N-CA 121.854 1.702 . . . . 0.0 112.68 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -52.85 -37.13 59.82 Favored 'General case' 0 C--N 1.326 -0.445 0 C-N-CA 120.864 -0.334 . . . . 0.0 111.091 -179.267 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 97.6 mt -67.02 -42.27 88.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.574 -179.77 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.516 ' N ' HD12 ' A' ' 75' ' ' ILE . 1.7 mp -55.09 -31.48 25.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 -178.403 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 23.2 mt-10 -61.8 -58.87 6.3 Favored 'General case' 0 C--N 1.324 -0.512 0 C-N-CA 120.373 -0.531 . . . . 0.0 110.428 -179.494 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.401 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -56.39 -20.18 18.26 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.16 -179.376 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 65.3 t0 -78.74 -55.55 5.09 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.554 -0.294 . . . . 0.0 110.789 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 21.7 pt -77.74 -32.22 17.83 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 N-CA-C 111.721 0.267 . . . . 0.0 111.721 -179.517 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 15.6 mt -44.92 -60.03 3.54 Favored Pre-proline 0 CA--C 1.545 0.769 0 CA-C-O 119.658 -0.211 . . . . 0.0 111.051 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.401 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 52.4 Cg_endo -63.04 -26.54 73.64 Favored 'Trans proline' 0 N--CA 1.499 1.845 0 C-N-CA 122.072 1.848 . . . . 0.0 112.142 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 43.1 tpp -65.79 -39.99 91.49 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.86 0.362 . . . . 0.0 110.265 -179.514 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 91.7 mt -62.34 -41.64 98.73 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.081 -179.558 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -63.8 -37.29 86.82 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.515 179.606 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -62.93 -37.75 95.44 Favored Glycine 0 CA--C 1.525 0.682 0 N-CA-C 111.031 -0.828 . . . . 0.0 111.031 -179.88 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 89.7 mt -67.41 -38.56 84.8 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.882 0.372 . . . . 0.0 110.243 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -54.86 -37.2 65.93 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.658 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 87.2 mt-30 -61.39 -23.66 65.95 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.584 -179.867 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -93.24 -6.7 47.05 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.311 -179.462 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 55.8 ttm-85 61.63 58.06 2.12 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.314 179.767 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 33.6 m -141.79 6.1 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.644 -179.867 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 55.2 tp -113.5 145.6 40.94 Favored 'General case' 0 N--CA 1.474 0.755 0 CA-C-O 121.306 0.574 . . . . 0.0 110.302 179.942 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 45.6 tp10 -153.27 127.98 9.45 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.054 -179.432 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 96.4 mtt180 . . . . . 0 C--N 1.325 -0.485 0 CA-C-O 118.143 -0.932 . . . . 0.0 110.368 179.856 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 71.7 mtm . . . . . 0 N--CA 1.49 1.561 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 9.4 tp10 -168.0 62.71 0.58 Allowed Pre-proline 0 CA--C 1.532 0.274 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.261 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_endo -76.02 -170.27 0.82 Allowed 'Trans proline' 0 N--CA 1.492 1.405 0 C-N-CA 122.268 1.979 . . . . 0.0 111.599 -179.648 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.461 ' OG1' ' CE1' ' A' ' 6' ' ' PHE . 48.8 p -77.14 -16.83 58.99 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.509 -179.425 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . 52.38 88.08 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.838 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.461 ' CE1' ' OG1' ' A' ' 4' ' ' THR . 76.0 m-85 -79.93 141.52 35.97 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.229 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 49.4 m -90.55 -177.62 5.09 Favored 'General case' 0 N--CA 1.47 0.535 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.463 -179.88 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -66.54 -35.0 89.36 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 111.388 -0.685 . . . . 0.0 111.388 179.858 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 33.9 t -71.36 -2.82 17.72 Favored 'General case' 0 C--N 1.329 -0.305 0 O-C-N 122.569 -0.371 . . . . 0.0 110.747 -179.453 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -66.66 135.6 54.31 Favored 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 120.746 -0.382 . . . . 0.0 110.037 179.749 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.519 ' O ' HG13 ' A' ' 11' ' ' VAL . 7.3 p -131.36 110.19 15.07 Favored Pre-proline 0 CA--C 1.539 0.551 0 N-CA-C 110.086 -0.338 . . . . 0.0 110.086 179.026 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -78.11 156.24 29.94 Favored 'Trans proline' 0 N--CA 1.489 1.216 0 C-N-CA 121.459 1.439 . . . . 0.0 111.891 -179.112 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 73.4 ttp85 -155.68 132.23 10.37 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 115.892 -0.594 . . . . 0.0 109.562 179.835 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 59.8 mt -67.92 115.41 27.89 Favored Pre-proline 0 CA--C 1.543 0.691 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.535 -179.642 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -78.93 167.23 22.38 Favored 'Trans proline' 0 N--CA 1.495 1.605 0 C-N-CA 121.84 1.693 . . . . 0.0 112.286 -179.671 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 62.1 ttp180 -54.66 139.87 37.36 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.396 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.76 3.63 73.8 Favored Glycine 0 N--CA 1.465 0.595 0 N-CA-C 110.971 -0.851 . . . . 0.0 110.971 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.476 ' CG1' HD11 ' A' ' 31' ' ' LEU . 62.0 t -127.06 127.29 69.46 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 CA-C-O 120.931 0.396 . . . . 0.0 109.971 179.596 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.419 ' HE ' ' CD2' ' A' ' 32' ' ' LEU . 34.7 ptt180 -144.38 161.49 38.87 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.19 179.902 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 25.0 mt -94.76 136.24 35.3 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.254 -179.608 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 83.5 mtp180 -139.86 144.76 37.39 Favored 'General case' 0 N--CA 1.469 0.496 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.233 179.914 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.473 ' O ' ' CD1' ' A' ' 22' ' ' PHE . 38.5 p90 -98.9 117.32 33.12 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.415 -179.718 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 29.5 m-20 -92.43 104.13 16.48 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.678 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 82.3 tt0 -64.22 -37.37 87.21 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.335 -179.941 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 1.5 m -63.31 -42.17 95.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.382 -179.732 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 75.0 mtp85 -81.43 -16.82 50.91 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 120.543 0.211 . . . . 0.0 110.622 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 61.4 t30 69.81 13.06 8.06 Favored 'General case' 0 N--CA 1.468 0.466 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.048 179.77 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 22.0 pttm -145.0 165.67 27.52 Favored 'General case' 0 N--CA 1.469 0.477 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.225 179.457 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.472 ' HD1' ' CG ' ' A' ' 42' ' ' ASP . 80.6 m80 -88.48 149.67 23.53 Favored 'General case' 0 CA--C 1.517 -0.31 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.152 179.892 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 31.0 m -137.68 158.82 34.32 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.103 -179.714 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.476 HD11 ' CG1' ' A' ' 18' ' ' VAL . 37.0 tp -97.54 120.97 38.89 Favored 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 109.651 -0.5 . . . . 0.0 109.651 179.837 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.419 ' CD2' ' HE ' ' A' ' 19' ' ' ARG . 34.3 tp -81.29 95.69 7.05 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 109.192 -0.669 . . . . 0.0 109.192 179.384 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -94.75 153.21 40.14 Favored Pre-proline 0 CA--C 1.535 0.369 0 N-CA-C 108.995 -0.742 . . . . 0.0 108.995 -179.869 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -63.66 -28.16 69.06 Favored 'Trans proline' 0 C--N 1.312 -1.382 0 C-N-CA 121.538 1.492 . . . . 0.0 111.206 -179.624 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 43.3 tp10 -78.78 -52.16 8.75 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.625 -179.93 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 61.1 ttp180 -176.32 149.07 0.81 Allowed 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.333 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 61.6 m -70.44 136.46 49.54 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.53 179.164 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -109.24 140.87 42.31 Favored 'General case' 0 N--CA 1.471 0.62 0 CA-C-O 120.909 0.385 . . . . 0.0 110.958 -179.647 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 39.5 p-10 -72.98 117.62 14.93 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.397 179.401 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 95.4 mt -135.53 155.93 49.7 Favored 'General case' 0 N--CA 1.47 0.556 0 CA-C-O 121.046 0.45 . . . . 0.0 110.313 -179.714 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 22.1 m-20 -86.58 163.07 17.66 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.145 -179.768 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.472 ' CG ' ' HD1' ' A' ' 29' ' ' HIS . 87.4 m-20 -60.92 -40.95 95.11 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 115.783 -0.644 . . . . 0.0 109.99 179.539 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 74.7 m-20 -63.4 -38.59 91.74 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.38 -179.574 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -67.96 -40.23 83.24 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.742 -179.524 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 58.7 t -80.42 -26.24 11.48 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 CA-C-O 120.748 0.309 . . . . 0.0 110.252 179.43 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.78 -39.96 75.03 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.032 0.444 . . . . 0.0 109.948 -179.846 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 87.2 t -61.01 -46.57 96.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.425 179.561 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 42.7 mt -76.08 -16.25 59.95 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.607 -179.161 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 36.7 ttmt -90.29 -34.7 15.64 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-O 120.904 0.383 . . . . 0.0 110.467 179.259 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 5.7 tp -70.37 -32.16 69.72 Favored 'General case' 0 N--CA 1.463 0.182 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.256 -179.306 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.4 HG13 ' O ' ' A' ' 51' ' ' VAL . 7.1 p -71.85 121.8 22.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 120.958 0.409 . . . . 0.0 110.62 -179.7 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 95.2 m-20 -70.08 -44.42 69.1 Favored 'General case' 0 CA--C 1.532 0.254 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.369 179.691 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -144.14 -98.38 0.26 Allowed Glycine 0 N--CA 1.472 1.077 0 N-CA-C 110.408 -1.077 . . . . 0.0 110.408 179.88 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' ARG . . . . . 0.443 ' HB3' HG21 ' A' ' 11' ' ' VAL . 89.3 mtm180 -114.73 104.3 11.83 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-N 116.747 0.273 . . . . 0.0 110.447 179.241 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.43 ' O ' HG23 ' A' ' 11' ' ' VAL . 98.3 m-20 -117.5 133.85 55.51 Favored 'General case' 0 N--CA 1.472 0.672 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.127 178.32 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 71.2 p -74.69 141.25 44.56 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.665 -0.494 . . . . 0.0 109.665 179.199 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.472 HG23 ' N ' ' A' ' 58' ' ' SER . 23.7 m -47.31 -40.35 6.21 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.248 0 CA-C-O 120.901 0.381 . . . . 0.0 110.702 -179.366 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 58' ' ' SER . . . . . 0.472 ' N ' HG23 ' A' ' 57' ' ' VAL . 58.0 m -58.42 -44.93 89.28 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.298 179.351 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 55.2 tt0 -65.94 -46.87 76.58 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.698 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 63.1 mt -60.96 -43.23 95.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.066 -179.654 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -53.33 -40.31 64.75 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.988 -179.365 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 26.4 mm100 -63.57 -54.31 38.05 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.524 -0.307 . . . . 0.0 110.971 179.897 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 73.7 mt -65.31 -48.5 83.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.819 0.342 . . . . 0.0 110.97 -179.069 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 26.0 tp -69.33 -37.6 77.8 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.657 -179.21 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -56.05 -41.96 86.26 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 110.94 -0.864 . . . . 0.0 110.94 -179.671 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 84.7 mt-30 -65.55 -31.16 72.06 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.601 0.239 . . . . 0.0 110.433 179.754 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 19.6 m -62.62 -46.68 87.15 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.704 0.287 . . . . 0.0 110.541 -179.734 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 88.1 m-85 -91.45 0.87 57.45 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.493 179.678 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 61.7 t0 51.98 53.19 12.96 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.482 -0.326 . . . . 0.0 110.838 179.585 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -139.93 162.6 34.78 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.182 -179.701 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -56.27 134.94 75.59 Favored Pre-proline 0 CA--C 1.545 0.787 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.725 -179.099 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -68.42 -29.27 31.53 Favored 'Trans proline' 0 N--CA 1.503 2.087 0 C-N-CA 122.523 2.149 . . . . 0.0 112.661 -179.387 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -55.34 -38.98 69.47 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.152 0.501 . . . . 0.0 110.865 -179.303 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 65.4 mt -71.1 -38.34 70.9 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.444 -179.884 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 37.3 mm -60.71 -46.2 96.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.07 -177.725 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -62.49 -45.34 93.47 Favored 'General case' 0 C--N 1.334 -0.101 0 C-N-CA 120.283 -0.567 . . . . 0.0 109.637 -179.614 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.421 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -65.56 -20.09 66.18 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.725 -0.67 . . . . 0.0 111.063 179.561 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 65.0 t0 -78.97 -50.01 11.82 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-O 120.813 0.339 . . . . 0.0 110.933 -179.466 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 25.5 pt -76.66 -37.81 29.59 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.515 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.468 -179.698 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 9.7 mt -43.06 -60.29 2.48 Favored Pre-proline 0 CA--C 1.548 0.9 0 CA-C-O 119.603 -0.237 . . . . 0.0 111.233 -179.65 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.421 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 36.7 Cg_endo -60.43 -32.2 93.54 Favored 'Trans proline' 0 N--CA 1.499 1.84 0 C-N-CA 121.847 1.698 . . . . 0.0 111.43 179.788 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 5.4 tpt -67.22 -43.14 82.8 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.786 0.327 . . . . 0.0 110.395 -179.937 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 78.1 mt -63.13 -39.63 95.24 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.411 -179.54 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.15 -38.72 87.45 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.144 179.904 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -65.5 -39.6 95.71 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.821 -0.911 . . . . 0.0 110.821 179.644 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 94.6 mt -68.12 -39.01 82.86 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.773 0.321 . . . . 0.0 110.422 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -53.29 -35.12 59.75 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.816 0.341 . . . . 0.0 110.754 -179.487 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 76.7 mt-30 -62.49 -20.28 64.42 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.828 179.692 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -93.46 -0.26 56.5 Favored 'General case' 0 N--CA 1.469 0.479 0 CA-C-O 120.86 0.362 . . . . 0.0 110.299 -179.451 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 16.2 tpp180 59.49 67.27 0.91 Allowed 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.614 179.739 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 7.5 m -139.78 6.62 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.476 -179.695 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 76.3 mt -138.04 141.18 40.35 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-O 121.03 0.443 . . . . 0.0 110.42 179.823 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -151.8 113.13 4.32 Favored 'General case' 0 CA--C 1.531 0.222 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.195 178.835 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 89.5 mtm180 . . . . . 0 C--O 1.22 -0.481 0 CA-C-O 117.975 -1.012 . . . . 0.0 110.353 179.521 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.1 mpt? . . . . . 0 N--CA 1.491 1.59 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 36.6 mt-10 48.16 55.76 17.26 Favored Pre-proline 0 CA--C 1.534 0.334 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.556 -179.642 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -70.1 153.33 67.45 Favored 'Trans proline' 0 N--CA 1.495 1.565 0 C-N-CA 122.607 2.205 . . . . 0.0 111.782 -179.528 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 59.8 p -152.87 34.59 0.48 Allowed 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.096 -179.929 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -163.72 -34.92 0.03 OUTLIER 'General case' 0 N--CA 1.463 0.175 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.419 179.79 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 50.7 m-85 50.7 -172.81 0.02 OUTLIER 'General case' 0 CA--C 1.531 0.225 0 CA-C-N 116.567 -0.288 . . . . 0.0 110.36 -179.714 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 17.3 m -133.57 -161.76 1.17 Allowed 'General case' 0 N--CA 1.468 0.464 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.304 -179.659 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -87.0 -28.38 25.95 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 111.161 -0.775 . . . . 0.0 111.161 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 67.6 m -76.92 -7.69 56.01 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-O 120.649 0.262 . . . . 0.0 110.714 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 42.8 p-10 -67.68 146.14 54.1 Favored 'General case' 0 C--N 1.331 -0.217 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 27.6 m -130.56 128.29 22.52 Favored Pre-proline 0 CA--C 1.542 0.662 0 CA-C-N 116.656 -0.247 . . . . 0.0 110.694 179.584 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_endo -77.43 145.57 23.82 Favored 'Trans proline' 0 N--CA 1.498 1.751 0 C-N-CA 121.795 1.663 . . . . 0.0 111.608 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.505 ' H ' HD11 ' A' ' 92' ' ' LEU . 78.5 ttt-85 -157.9 123.88 4.68 Favored 'General case' 0 N--CA 1.464 0.246 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.185 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 24.9 mt -68.9 119.59 70.55 Favored Pre-proline 0 CA--C 1.541 0.616 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.048 -179.322 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -76.86 162.0 32.74 Favored 'Trans proline' 0 N--CA 1.491 1.367 0 C-N-CA 121.783 1.655 . . . . 0.0 111.745 -179.78 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 77.4 ttt-85 -55.52 142.88 31.51 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.083 179.905 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 86.14 8.93 77.75 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 111.18 -0.768 . . . . 0.0 111.18 179.704 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.617 ' CG1' HD11 ' A' ' 31' ' ' LEU . 53.3 t -134.69 124.63 44.68 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 CA-C-O 120.893 0.378 . . . . 0.0 110.111 179.372 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 83.8 mtp180 -140.42 157.29 45.74 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.026 179.662 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 54.0 mt -91.55 138.47 31.54 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 116.043 -0.526 . . . . 0.0 109.915 -179.698 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 83.2 mtp180 -141.93 151.04 42.23 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.453 -179.488 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 72.4 t80 -100.89 114.33 28.09 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.977 179.606 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 13.5 m-20 -90.08 99.17 12.23 Favored 'General case' 0 N--CA 1.464 0.261 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 179.174 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -57.94 -31.61 67.01 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.038 179.962 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -65.55 -43.68 94.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.423 -179.341 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 88.9 mtt-85 -84.84 -16.41 41.44 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.304 -178.766 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 3.2 m120 69.5 15.4 8.29 Favored 'General case' 0 CA--C 1.531 0.214 0 CA-C-N 115.531 -0.758 . . . . 0.0 110.89 179.548 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 59.5 pttt -144.85 170.01 16.94 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 116.077 -0.51 . . . . 0.0 109.872 179.975 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 76.4 m80 -89.39 153.6 20.72 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.619 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 27.3 m -141.65 163.01 20.42 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.283 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.058 -179.853 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.617 HD11 ' CG1' ' A' ' 18' ' ' VAL . 34.1 tp -97.23 116.69 29.91 Favored 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 179.561 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 57.0 tp -80.01 92.73 5.62 Favored 'General case' 0 CA--C 1.517 -0.311 0 N-CA-C 109.211 -0.662 . . . . 0.0 109.211 178.886 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -96.83 154.9 38.17 Favored Pre-proline 0 CA--C 1.543 0.688 0 N-CA-C 110.007 -0.368 . . . . 0.0 110.007 -179.884 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -63.6 -29.75 70.25 Favored 'Trans proline' 0 N--CA 1.496 1.674 0 C-N-CA 122.46 2.107 . . . . 0.0 111.53 179.799 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 -80.4 -51.84 8.37 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 116.548 -0.296 . . . . 0.0 110.775 -179.582 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 61.7 ttp180 -173.46 148.68 1.61 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.269 -179.669 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 76.6 m -71.66 131.37 43.07 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.377 179.322 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 79.1 m-85 -100.92 137.85 38.76 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-O 120.935 0.397 . . . . 0.0 110.833 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 38.5 p-10 -74.7 116.63 15.62 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.424 179.32 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 81.4 mt -132.42 156.61 46.39 Favored 'General case' 0 N--CA 1.469 0.498 0 CA-C-O 121.076 0.465 . . . . 0.0 110.394 -179.63 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 95.9 m-20 -85.88 153.04 22.51 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.899 -179.847 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 68.3 t0 -58.23 -41.3 83.85 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.551 -179.429 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' ASN . . . . . 0.448 ' OD1' ' N ' ' A' ' 44' ' ' ALA . 21.0 p30 -64.2 -36.21 83.33 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.709 -179.767 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.448 ' N ' ' OD1' ' A' ' 43' ' ' ASN . . . -69.4 -41.07 76.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.341 -0.391 . . . . 0.0 111.053 -179.537 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 60.6 t -77.45 -27.71 15.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 N-CA-C 110.101 -0.333 . . . . 0.0 110.101 179.84 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.43 ' O ' ' N ' ' A' ' 50' ' ' LEU . . . -55.72 -39.02 70.52 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.33 -179.882 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 58.3 t -60.54 -45.1 97.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.136 179.739 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 49.6 mt -69.62 -32.12 70.63 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.457 -179.646 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 35.4 ttpt -82.93 -26.54 31.34 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.429 179.667 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.43 ' N ' ' O ' ' A' ' 46' ' ' ALA . 59.3 tp -72.19 -32.87 67.2 Favored 'General case' 0 N--CA 1.461 0.114 0 C-N-CA 120.429 -0.508 . . . . 0.0 110.353 -179.106 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.3 p -79.64 132.19 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.241 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.587 179.573 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 93.3 m-20 -73.34 -69.94 0.4 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.916 0.389 . . . . 0.0 109.985 179.63 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -114.31 -110.22 2.86 Favored Glycine 0 N--CA 1.474 1.198 0 N-CA-C 110.48 -1.048 . . . . 0.0 110.48 179.552 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 89.9 mtm180 -109.27 105.17 14.48 Favored 'General case' 0 N--CA 1.47 0.539 0 CA-C-O 120.864 0.364 . . . . 0.0 110.27 179.418 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 -116.68 150.24 38.48 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-N 115.828 -0.624 . . . . 0.0 109.923 178.801 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 35.7 p -78.24 139.68 38.91 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 179.214 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.415 HG23 ' N ' ' A' ' 58' ' ' SER . 32.0 m -53.82 -38.17 35.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.958 0.409 . . . . 0.0 110.323 -179.711 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 58' ' ' SER . . . . . 0.415 ' N ' HG23 ' A' ' 57' ' ' VAL . 53.4 m -58.69 -43.88 90.1 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.745 179.489 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 55.7 tt0 -64.8 -46.49 81.81 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.601 -179.556 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 65.0 mt -61.22 -42.93 95.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.228 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.443 ' O ' ' N ' ' A' ' 65' ' ' GLY . . . -53.68 -39.36 65.07 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.068 -179.258 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 92.2 mm-40 -63.7 -51.6 64.3 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.818 179.746 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 72.9 mt -65.21 -48.96 81.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 120.914 0.388 . . . . 0.0 110.862 -179.348 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 26.5 tp -70.31 -33.91 72.08 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.267 -179.349 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.443 ' N ' ' O ' ' A' ' 61' ' ' ALA . . . -57.72 -39.54 91.41 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 -179.391 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 -65.48 -32.0 73.37 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 121.001 -0.28 . . . . 0.0 110.339 179.706 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 19.7 m -62.58 -47.13 85.16 Favored 'General case' 0 C--N 1.329 -0.314 0 C-N-CA 120.755 -0.378 . . . . 0.0 110.57 -179.714 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -92.95 -2.41 55.82 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.441 179.817 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 49.4 t0 50.23 61.68 3.07 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.805 179.783 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -145.59 163.45 34.75 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 120.729 0.299 . . . . 0.0 110.352 -179.475 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 15.2 m-20 -55.65 112.88 4.76 Favored Pre-proline 0 CA--C 1.542 0.639 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.168 -179.074 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_exo -48.16 -35.02 25.4 Favored 'Trans proline' 0 N--CA 1.502 1.985 0 C-N-CA 121.964 1.776 . . . . 0.0 112.704 -179.492 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -51.45 -35.45 39.64 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-O 121.024 0.44 . . . . 0.0 110.885 -179.32 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 72.9 mt -72.11 -40.36 66.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.817 179.098 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.561 ' N ' HD12 ' A' ' 75' ' ' ILE . 1.7 mp -61.77 -47.9 91.14 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.134 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.006 -178.213 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -59.93 -45.47 92.48 Favored 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 120.385 -0.526 . . . . 0.0 110.461 -178.955 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.45 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -67.9 -20.44 65.11 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.037 179.729 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -80.52 -47.35 14.38 Favored 'General case' 0 CA--C 1.534 0.362 0 CA-C-N 116.55 -0.295 . . . . 0.0 111.004 -179.563 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 16.5 pt -72.61 -41.2 63.11 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.437 -179.765 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 6.9 mt -42.11 -60.72 1.88 Allowed Pre-proline 0 CA--C 1.546 0.801 0 CA-C-O 119.514 -0.279 . . . . 0.0 110.407 179.461 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.45 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 76.2 Cg_exo -41.12 -45.24 5.34 Favored 'Trans proline' 0 N--CA 1.494 1.529 0 C-N-CA 122.232 1.955 . . . . 0.0 111.815 177.522 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 13.2 tmm? -67.33 -42.76 83.06 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.018 -179.228 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 91.6 mt -63.55 -43.79 96.04 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.993 0.425 . . . . 0.0 110.215 -179.459 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -64.89 -35.98 82.89 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.592 179.74 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -61.8 -38.62 96.25 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.974 -0.85 . . . . 0.0 110.974 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 89.2 mt -66.9 -39.96 87.59 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 110.021 -0.363 . . . . 0.0 110.021 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -54.91 -39.09 68.42 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.314 179.852 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 78.3 mt-30 -63.12 -22.59 66.96 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.897 179.751 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 65.3 mttp -91.95 -3.89 55.34 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-O 120.784 0.326 . . . . 0.0 110.229 -179.548 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 59.7 ttm-85 62.39 55.07 2.39 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.597 179.583 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 32.4 m -141.47 5.91 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.206 179.855 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.505 HD11 ' H ' ' A' ' 13' ' ' ARG . 56.1 tp -139.87 131.01 26.43 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-O 121.144 0.497 . . . . 0.0 110.411 179.714 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 14.9 pt-20 -155.18 135.62 13.31 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.525 179.282 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 16.8 ptm180 . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 117.83 -1.081 . . . . 0.0 110.335 179.674 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 28.3 ttt . . . . . 0 N--CA 1.49 1.532 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 21.4 tp10 -169.35 72.36 0.71 Allowed Pre-proline 0 CA--C 1.531 0.244 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.881 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_exo -56.38 169.83 1.46 Allowed 'Trans proline' 0 N--CA 1.496 1.674 0 C-N-CA 122.467 2.111 . . . . 0.0 111.965 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 51.2 p -75.3 -19.9 59.41 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.344 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . 51.82 91.65 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.948 179.722 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -78.62 142.64 37.08 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 115.998 -0.546 . . . . 0.0 109.909 179.64 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 42.6 m -89.29 -178.66 5.68 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 115.694 -0.685 . . . . 0.0 110.057 179.753 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -78.73 -25.44 60.48 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 111.211 -0.756 . . . . 0.0 111.211 179.87 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 78.5 p -76.27 -4.81 44.0 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.619 0.247 . . . . 0.0 110.65 -179.497 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 41.1 p-10 -66.55 143.67 56.91 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 120.693 -0.403 . . . . 0.0 109.966 -179.834 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.578 HG23 ' O ' ' A' ' 11' ' ' VAL . 35.5 m -130.5 103.07 16.45 Favored Pre-proline 0 N--CA 1.47 0.528 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.647 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_endo -76.22 145.8 27.8 Favored 'Trans proline' 0 N--CA 1.488 1.149 0 C-N-CA 121.142 1.228 . . . . 0.0 111.986 -179.545 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 77.8 ttt-85 -155.16 144.07 20.78 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.797 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 60.4 mt -64.26 114.94 15.83 Favored Pre-proline 0 CA--C 1.541 0.624 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.828 -179.303 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -79.5 155.78 24.77 Favored 'Trans proline' 0 N--CA 1.49 1.286 0 C-N-CA 121.798 1.666 . . . . 0.0 111.705 -179.442 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 59.7 ttm-85 -57.75 139.25 54.36 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.172 179.683 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 90.81 2.63 71.85 Favored Glycine 0 CA--C 1.523 0.563 0 N-CA-C 110.956 -0.858 . . . . 0.0 110.956 179.657 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.442 ' CG1' HD11 ' A' ' 31' ' ' LEU . 49.4 t -131.13 129.84 63.22 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 179.548 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 83.3 mtp180 -136.91 155.86 49.21 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 115.943 -0.571 . . . . 0.0 109.965 179.811 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 30.7 mt -90.75 139.18 30.97 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.847 -0.615 . . . . 0.0 109.931 -179.596 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 75.6 mtp85 -137.26 138.62 40.29 Favored 'General case' 0 N--CA 1.466 0.372 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.717 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.47 ' O ' ' CD1' ' A' ' 22' ' ' PHE . 43.2 p90 -98.24 117.98 33.85 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.08 -179.863 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 87.0 m-20 -89.78 104.94 17.45 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.16 -0.473 . . . . 0.0 109.826 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -65.16 -36.29 83.78 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.161 179.882 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.413 HG22 ' H ' ' A' ' 25' ' ' VAL . 2.2 m -63.45 -42.8 97.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.645 -179.607 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 95.4 mtt-85 -83.08 -18.59 39.1 Favored 'General case' 0 N--CA 1.466 0.334 0 N-CA-C 110.406 -0.22 . . . . 0.0 110.406 -179.842 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 70.32 19.63 6.42 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.996 179.762 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -145.06 165.93 26.82 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.34 179.63 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 79.2 m80 -90.78 150.65 21.51 Favored 'General case' 0 CA--C 1.516 -0.343 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.307 179.889 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 33.7 m -139.86 160.05 26.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.153 -179.647 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.442 HD11 ' CG1' ' A' ' 18' ' ' VAL . 43.0 tp -102.38 121.58 42.59 Favored 'General case' 0 CA--C 1.517 -0.311 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 179.141 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 43.5 tp -79.7 100.59 7.96 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 178.852 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -96.55 146.36 31.17 Favored Pre-proline 0 CA--C 1.54 0.572 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -179.833 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_exo -47.17 -38.37 25.11 Favored 'Trans proline' 0 N--CA 1.495 1.615 0 C-N-CA 121.843 1.696 . . . . 0.0 112.67 178.907 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -74.07 -52.07 13.8 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.01 -178.579 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 58.5 ttt85 -175.32 152.17 1.35 Allowed 'General case' 0 C--N 1.333 -0.142 0 CA-C-O 120.89 0.376 . . . . 0.0 110.664 -179.784 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 37.9 m -68.18 133.92 49.66 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.547 179.456 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 78.5 m-85 -107.79 139.56 42.18 Favored 'General case' 0 N--CA 1.472 0.641 0 CA-C-O 120.977 0.418 . . . . 0.0 110.52 -179.624 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 36.6 p-10 -73.48 121.33 20.38 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.493 179.629 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 93.5 mt -136.09 158.12 45.17 Favored 'General case' 0 N--CA 1.471 0.583 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 179.738 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -85.16 163.14 18.91 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.405 -179.604 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 -60.59 -44.67 95.98 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.643 179.866 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' ASN . . . . . 0.518 ' O ' HG23 ' A' ' 47' ' ' VAL . 15.1 p-10 -65.54 -27.49 68.48 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.693 -179.417 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -72.52 -44.46 62.15 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.552 -0.295 . . . . 0.0 110.756 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 48.9 t -79.21 -35.72 17.54 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.629 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -51.83 -36.54 48.48 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.786 -179.101 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.518 HG23 ' O ' ' A' ' 43' ' ' ASN . 91.6 t -60.89 -47.57 92.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.606 179.677 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 45.1 mt -72.83 -24.06 60.85 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.435 -179.076 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 17.1 ttmm -84.44 -34.59 23.44 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.035 179.755 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 5.9 tp -71.16 -33.03 69.65 Favored 'General case' 0 N--CA 1.463 0.207 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.845 -178.464 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.2 p -76.68 126.11 37.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 121.01 0.433 . . . . 0.0 110.722 179.483 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 -78.6 -86.59 0.07 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.096 -0.502 . . . . 0.0 109.775 179.137 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -85.07 -116.55 0.79 Allowed Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.167 -1.173 . . . . 0.0 110.167 179.278 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 89.0 mtm180 -113.73 105.31 13.14 Favored 'General case' 0 N--CA 1.471 0.578 0 N-CA-C 110.037 -0.357 . . . . 0.0 110.037 179.484 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 88.3 m-20 -116.55 153.04 32.9 Favored 'General case' 0 N--CA 1.473 0.721 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.099 179.083 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 10.2 p -81.75 152.95 26.76 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.026 179.185 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.482 HG23 ' N ' ' A' ' 58' ' ' SER . 33.5 m -59.21 -43.15 89.0 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.309 179.953 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 58' ' ' SER . . . . . 0.482 ' N ' HG23 ' A' ' 57' ' ' VAL . 51.4 m -58.2 -43.77 87.78 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.719 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 57.6 tt0 -64.76 -46.13 83.49 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.54 -179.79 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 96.7 mt -61.76 -43.42 97.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 -179.92 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -52.97 -37.83 61.6 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.173 -179.011 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 27.8 mm100 -63.6 -52.95 58.67 Favored 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 120.588 -0.445 . . . . 0.0 110.776 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 68.0 mt -66.28 -46.82 86.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 C-N-CA 120.869 -0.332 . . . . 0.0 110.644 -179.906 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 34.7 tp -68.04 -37.67 81.6 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.417 -179.645 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.42 ' O ' ' N ' ' A' ' 69' ' ' ASP . . . -58.3 -41.0 94.78 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 111.018 -0.833 . . . . 0.0 111.018 -179.434 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 87.3 mt-30 -66.13 -30.88 71.45 Favored 'General case' 0 C--N 1.327 -0.408 0 C-N-CA 121.086 -0.245 . . . . 0.0 110.456 179.734 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 20.9 m -62.18 -48.71 78.82 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.799 -0.361 . . . . 0.0 110.531 -179.747 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -95.37 -2.14 49.72 Favored 'General case' 0 N--CA 1.469 0.51 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.565 179.489 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' ASP . . . . . 0.42 ' N ' ' O ' ' A' ' 65' ' ' GLY . 63.4 t0 53.86 62.19 2.73 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.809 179.792 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -138.53 160.63 39.08 Favored 'General case' 0 N--CA 1.469 0.491 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 -179.738 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 64.8 m-20 -55.8 114.06 6.77 Favored Pre-proline 0 CA--C 1.545 0.763 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.491 -179.201 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_exo -49.33 -36.89 39.33 Favored 'Trans proline' 0 N--CA 1.497 1.684 0 C-N-CA 121.725 1.617 . . . . 0.0 112.655 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -52.03 -39.31 59.36 Favored 'General case' 0 N--CA 1.464 0.227 0 CA-C-O 120.996 0.427 . . . . 0.0 111.158 -179.148 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 73.1 mt -71.96 -40.22 67.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.555 179.5 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 41.8 mm -59.56 -49.1 84.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.996 -178.225 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -63.08 -43.59 98.12 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 -179.859 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.445 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -66.04 -20.76 66.28 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.089 179.714 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 52.4 t0 -79.56 -48.22 14.19 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-O 120.642 0.258 . . . . 0.0 111.218 -179.418 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 34.4 pt -78.18 -35.01 19.41 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.575 0 CA-C-O 120.955 0.407 . . . . 0.0 111.496 -179.416 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 9.8 mt -45.74 -60.11 3.82 Favored Pre-proline 0 CA--C 1.544 0.747 0 CA-C-N 116.49 -0.323 . . . . 0.0 110.935 179.745 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.445 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 42.1 Cg_endo -61.97 -28.37 80.65 Favored 'Trans proline' 0 N--CA 1.497 1.703 0 C-N-CA 121.902 1.734 . . . . 0.0 111.713 179.814 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 40.8 tpp -65.89 -39.75 90.92 Favored 'General case' 0 CA--C 1.53 0.202 0 CA-C-O 120.811 0.339 . . . . 0.0 110.457 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 84.6 mt -62.13 -39.8 93.79 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.307 -179.522 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.03 -38.92 87.85 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.42 -0.354 . . . . 0.0 110.287 179.698 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -65.5 -40.96 96.48 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 111.146 -0.782 . . . . 0.0 111.146 179.777 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 92.1 mt -70.04 -35.53 74.35 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.785 0.326 . . . . 0.0 110.431 -179.865 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -54.86 -34.25 62.71 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.725 -179.883 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 87.5 mt-30 -56.21 -28.76 59.52 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.175 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -96.96 -7.99 31.72 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.253 179.795 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 18.6 tpt85 57.79 51.4 9.28 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.693 179.763 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 35.4 m -108.1 11.19 8.98 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.584 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.657 -179.58 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.47 HD12 ' C ' ' A' ' 92' ' ' LEU . 0.7 OUTLIER -138.37 179.71 6.3 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.478 -179.418 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 16.5 pt-20 -152.37 173.8 14.62 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.516 -179.875 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 8.9 ptm180 . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 117.905 -1.045 . . . . 0.0 110.49 -179.878 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 66.5 mtt . . . . . 0 N--CA 1.491 1.589 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 4.5 mp0 -71.62 148.87 93.09 Favored Pre-proline 0 CA--C 1.538 0.516 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.632 -178.96 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -71.7 42.88 0.51 Allowed 'Trans proline' 0 N--CA 1.499 1.796 0 C-N-CA 122.232 1.954 . . . . 0.0 111.514 179.518 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 13.1 p 52.58 68.57 0.8 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.042 0.449 . . . . 0.0 110.419 179.759 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.11 107.83 5.67 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.106 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 91.6 m-85 -79.38 138.46 37.66 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.154 -179.701 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.438 ' H ' ' CG ' ' A' ' 10' ' ' ASP . 15.4 m -93.65 -173.6 3.22 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 120.948 0.404 . . . . 0.0 110.814 -179.85 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -67.21 -35.49 88.39 Favored Glycine 0 CA--C 1.529 0.916 0 N-CA-C 111.379 -0.688 . . . . 0.0 111.379 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 33.6 t -69.08 -16.98 63.81 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.897 0.38 . . . . 0.0 110.897 -179.415 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.474 ' OD2' ' NH2' ' A' ' 94' ' ' ARG . 0.7 OUTLIER -68.79 149.7 48.69 Favored 'General case' 0 CA--C 1.515 -0.393 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 179.595 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 27.6 m -130.13 129.61 22.96 Favored Pre-proline 0 N--CA 1.472 0.644 0 CA-C-N 116.693 -0.23 . . . . 0.0 110.939 -179.835 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -77.6 151.79 29.03 Favored 'Trans proline' 0 N--CA 1.493 1.48 0 C-N-CA 121.637 1.558 . . . . 0.0 111.333 179.566 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 76.1 ttt180 -157.79 121.71 4.14 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 179.475 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 17.4 mt -69.77 121.96 84.32 Favored Pre-proline 0 CA--C 1.543 0.71 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.969 -179.133 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.413 ' CD ' ' O ' ' A' ' 91' ' ' VAL . 89.6 Cg_endo -75.07 157.4 42.49 Favored 'Trans proline' 0 N--CA 1.492 1.429 0 C-N-CA 121.805 1.67 . . . . 0.0 112.24 179.837 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 89.8 mtm180 -59.28 152.98 19.68 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.355 179.603 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 85.98 11.42 73.34 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 111.223 -0.751 . . . . 0.0 111.223 179.732 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 61.6 t -128.0 133.74 66.6 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 CA-C-O 120.871 0.367 . . . . 0.0 110.085 179.784 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 90.2 mtm180 -134.3 153.98 51.57 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.089 -179.819 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 31.0 mt -98.13 140.74 31.99 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.941 -179.776 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 84.3 mtp180 -140.34 144.76 36.48 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.117 -0.492 . . . . 0.0 109.933 -179.802 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 89.9 t80 -96.7 114.41 26.05 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.15 -0.477 . . . . 0.0 109.882 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 28.2 m-20 -90.05 99.17 12.23 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.919 179.776 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -64.74 -34.29 77.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.117 0.484 . . . . 0.0 109.879 179.83 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.423 ' H ' HG22 ' A' ' 25' ' ' VAL . 2.0 m -61.97 -40.88 88.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.86 -179.858 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 95.1 mtt-85 -87.82 -20.5 25.99 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.541 179.7 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 6.2 m-80 71.8 19.9 4.72 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.83 179.701 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -144.96 170.07 16.86 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.077 179.707 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 72.5 m80 -87.24 156.13 19.79 Favored 'General case' 0 CA--C 1.517 -0.289 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.536 179.828 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 34.4 m -140.26 158.11 25.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.818 -179.785 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 6.4 tp -103.21 107.92 18.92 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 179.727 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 53.4 tp -77.2 95.44 4.3 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 179.228 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -96.7 147.64 33.23 Favored Pre-proline 0 CA--C 1.54 0.571 0 N-CA-C 110.029 -0.359 . . . . 0.0 110.029 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 80.4 Cg_exo -44.99 -32.96 7.03 Favored 'Trans proline' 0 N--CA 1.496 1.62 0 C-N-CA 122.054 1.836 . . . . 0.0 112.267 178.716 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -72.52 -48.88 36.89 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.789 -179.014 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 51.3 ttp180 -171.81 -123.76 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.49 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.248 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 86.1 m -161.88 124.23 2.92 Favored 'General case' 0 N--CA 1.456 -0.142 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 -179.411 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -100.73 137.19 39.46 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.58 -179.809 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 38.1 p-10 -72.72 120.58 18.54 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.419 179.696 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 94.3 mt -133.0 158.49 42.57 Favored 'General case' 0 N--CA 1.469 0.51 0 CA-C-O 121.006 0.431 . . . . 0.0 110.073 -179.77 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 83.8 m-20 -82.84 159.95 22.31 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.009 -0.542 . . . . 0.0 110.084 -179.347 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.469 ' OD1' ' N ' ' A' ' 43' ' ' ASN . 35.7 p-10 -60.28 -41.91 94.3 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.852 -179.544 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' ASN . . . . . 0.499 ' OD1' ' N ' ' A' ' 44' ' ' ALA . 24.8 p30 -66.72 -28.41 68.4 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.691 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.499 ' N ' ' OD1' ' A' ' 43' ' ' ASN . . . -72.9 -42.59 63.4 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.893 -179.786 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 48.0 t -79.8 -34.53 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.494 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -53.76 -42.38 68.15 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.536 -179.654 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 74.1 t -60.32 -45.1 96.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.47 -0.332 . . . . 0.0 110.47 179.707 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 39.4 mt -71.62 -20.69 61.94 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.347 -179.225 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 35.8 ttpt -92.4 -29.38 16.33 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.734 179.559 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 5.3 tp -70.35 -32.32 69.97 Favored 'General case' 0 N--CA 1.462 0.155 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.953 -179.047 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.412 ' O ' HG13 ' A' ' 51' ' ' VAL . 7.5 p -72.15 120.77 21.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.547 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 95.0 m-20 -71.9 -44.54 63.53 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.185 179.643 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -142.58 -97.57 0.27 Allowed Glycine 0 N--CA 1.472 1.091 0 N-CA-C 110.261 -1.135 . . . . 0.0 110.261 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' ARG . . . . . 0.493 HH12 ' C ' ' A' ' 94' ' ' ARG . 95.2 mtt-85 -114.64 104.52 12.08 Favored 'General case' 0 N--CA 1.469 0.492 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 179.084 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 97.8 m-20 -117.42 145.59 44.02 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.866 178.632 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 18.2 p -80.83 137.11 36.2 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 179.092 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.446 HG23 ' N ' ' A' ' 58' ' ' SER . 30.0 m -55.61 -39.94 57.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.293 -179.753 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' SER . . . . . 0.446 ' N ' HG23 ' A' ' 57' ' ' VAL . 78.2 p -58.29 -43.52 88.08 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.53 179.697 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 55.4 tt0 -65.93 -44.28 85.59 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.889 -179.91 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 96.8 mt -61.39 -43.25 96.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 -179.412 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.422 ' O ' ' N ' ' A' ' 65' ' ' GLY . . . -50.7 -36.18 34.81 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.921 -179.072 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 25.2 mm100 -64.11 -49.96 70.16 Favored 'General case' 0 C--N 1.325 -0.485 0 C-N-CA 120.654 -0.418 . . . . 0.0 110.403 179.809 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 72.2 mt -65.2 -49.31 79.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.376 -0.374 . . . . 0.0 110.619 -179.661 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 31.3 tp -68.88 -36.24 77.84 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.284 -179.472 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.422 ' N ' ' O ' ' A' ' 61' ' ' ALA . . . -54.54 -39.54 66.58 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 111.114 -0.795 . . . . 0.0 111.114 -179.36 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 76.0 mt-30 -65.39 -32.34 73.92 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.665 0.269 . . . . 0.0 110.671 179.842 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 21.1 m -61.83 -48.46 80.46 Favored 'General case' 0 C--N 1.33 -0.264 0 C-N-CA 120.767 -0.373 . . . . 0.0 110.559 -179.774 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 95.5 m-85 -92.86 -3.14 55.14 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.43 179.6 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 61.8 t0 51.88 62.02 2.92 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.824 179.721 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -144.38 164.07 31.88 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-O 120.757 0.313 . . . . 0.0 110.282 -179.632 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 65.9 m-20 -55.8 113.65 6.07 Favored Pre-proline 0 CA--C 1.545 0.777 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.221 -179.408 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_exo -49.21 -36.79 37.89 Favored 'Trans proline' 0 N--CA 1.497 1.692 0 C-N-CA 121.937 1.758 . . . . 0.0 112.601 -179.739 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -52.23 -38.07 56.97 Favored 'General case' 0 C--N 1.323 -0.554 0 C-N-CA 120.806 -0.357 . . . . 0.0 111.076 -179.029 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 97.7 mt -66.7 -42.34 89.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.67 -179.481 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.51 ' N ' HD12 ' A' ' 75' ' ' ILE . 1.7 mp -54.67 -33.1 26.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 -178.394 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 21.9 mt-10 -61.37 -58.3 8.77 Favored 'General case' 0 C--N 1.321 -0.662 0 C-N-CA 120.302 -0.559 . . . . 0.0 110.4 -179.406 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.427 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -55.56 -19.9 11.56 Favored 'General case' 0 C--N 1.328 -0.328 0 O-C-N 123.543 0.527 . . . . 0.0 111.282 -179.375 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 58.3 t0 -79.23 -53.81 6.59 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-O 120.601 0.239 . . . . 0.0 111.02 -179.851 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 29.4 pt -80.29 -30.09 12.53 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 CA-C-O 121.146 0.498 . . . . 0.0 111.647 -179.452 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 13.2 mt -47.19 -59.71 5.03 Favored Pre-proline 0 CA--C 1.543 0.698 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.102 179.734 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.427 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 36.3 Cg_endo -61.84 -30.4 84.2 Favored 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 121.505 1.47 . . . . 0.0 111.216 179.293 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 38.6 tpp -65.0 -40.58 95.16 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.133 -179.859 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 83.9 mt -62.77 -41.76 99.39 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.22 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -63.84 -38.36 90.81 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.623 179.753 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -62.1 -38.86 96.83 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 111.004 -0.839 . . . . 0.0 111.004 -179.853 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 91.6 mt -66.8 -39.5 87.78 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 120.821 0.343 . . . . 0.0 110.551 -179.865 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -53.82 -38.43 64.59 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 120.758 0.313 . . . . 0.0 110.485 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 77.5 mt-30 -64.14 -20.24 65.85 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.024 179.864 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 64.4 mttp -92.22 -3.5 55.44 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-N 116.584 -0.28 . . . . 0.0 110.504 -179.199 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 32.3 ttm180 61.55 57.81 2.21 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.284 179.676 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 91' ' ' VAL . . . . . 0.413 ' O ' ' CD ' ' A' ' 15' ' ' PRO . 33.8 m -140.99 6.52 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.577 -179.886 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 45.9 tp -110.7 146.57 36.03 Favored 'General case' 0 N--CA 1.473 0.709 0 CA-C-O 121.109 0.481 . . . . 0.0 110.046 179.862 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 77.1 tt0 -146.85 162.24 39.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.276 -0.874 . . . . 0.0 110.459 -179.308 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 94' ' ' ARG . . . . . 0.493 ' C ' HH12 ' A' ' 54' ' ' ARG . 33.7 ptt180 . . . . . 0 C--O 1.22 -0.472 0 CA-C-O 118.008 -0.996 . . . . 0.0 110.371 -179.747 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 66.5 mtt . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.448 ' OE1' ' N ' ' A' ' 2' ' ' GLU . 1.1 mp0 49.5 63.0 11.01 Favored Pre-proline 0 CA--C 1.534 0.341 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.623 -179.996 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 86.8 Cg_endo -76.67 10.63 2.18 Favored 'Trans proline' 0 N--CA 1.495 1.561 0 C-N-CA 122.501 2.134 . . . . 0.0 111.72 -179.818 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 20.8 p -76.45 72.24 3.15 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.041 0.448 . . . . 0.0 110.18 -179.537 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.405 ' O ' ' O ' ' A' ' 6' ' ' PHE . . . -165.39 -84.13 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.802 179.641 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.405 ' O ' ' O ' ' A' ' 5' ' ' ALA . 6.2 m-85 55.62 110.51 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.324 0 CA-C-O 121.025 0.44 . . . . 0.0 110.116 -179.891 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 70.0 m -87.29 -177.9 6.07 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.203 179.647 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.06 -33.41 87.18 Favored Glycine 0 CA--C 1.527 0.841 0 N-CA-C 111.367 -0.693 . . . . 0.0 111.367 -179.76 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 22.9 t -71.65 -3.21 20.37 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.561 0.22 . . . . 0.0 111.072 -179.325 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 21.9 p-10 -67.18 147.92 52.46 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.685 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.456 HG23 ' O ' ' A' ' 11' ' ' VAL . 29.7 m -131.32 120.26 17.94 Favored Pre-proline 0 CA--C 1.542 0.647 0 N-CA-C 110.105 -0.331 . . . . 0.0 110.105 179.671 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 87.0 Cg_endo -76.57 148.26 29.2 Favored 'Trans proline' 0 N--CA 1.49 1.274 0 CA-C-N 120.371 1.168 . . . . 0.0 112.103 -179.822 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 73.0 ttp85 -154.58 121.51 5.55 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.556 179.888 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 89.2 mt -69.47 121.61 82.81 Favored Pre-proline 0 CA--C 1.543 0.676 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.781 -179.331 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_endo -76.3 159.84 36.3 Favored 'Trans proline' 0 N--CA 1.495 1.575 0 C-N-CA 121.557 1.505 . . . . 0.0 112.009 -179.802 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 90.9 mtt-85 -57.14 153.47 11.67 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.738 -179.828 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 80.49 16.5 75.69 Favored Glycine 0 CA--C 1.523 0.576 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 179.786 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.547 ' CG1' HD11 ' A' ' 31' ' ' LEU . 58.1 t -133.82 132.46 56.69 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 CA-C-O 120.849 0.357 . . . . 0.0 110.099 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 90.8 mtm180 -135.11 155.88 49.96 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.296 -179.703 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 25.0 mt -96.3 101.28 12.9 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.072 -179.835 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.472 ' NH1' ' OG1' ' A' ' 37' ' ' THR . 82.4 mtm180 -92.1 139.95 30.12 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.108 179.514 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.474 ' O ' ' CD1' ' A' ' 22' ' ' PHE . 44.2 p90 -105.0 118.09 35.65 Favored 'General case' 0 N--CA 1.469 0.48 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.129 179.751 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 93.7 m-20 -89.26 100.17 13.01 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.003 -179.768 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -63.9 -37.37 87.16 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.508 -179.885 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 3.1 m -62.9 -43.57 99.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.598 -179.484 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 96.5 mtt180 -90.33 -7.68 52.7 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-O 120.921 0.391 . . . . 0.0 110.403 179.68 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 49.2 t30 54.62 36.59 26.35 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.088 179.681 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 19.2 ptmt -145.12 158.47 43.81 Favored 'General case' 0 N--CA 1.468 0.442 0 N-CA-C 110.015 -0.365 . . . . 0.0 110.015 179.57 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 80.3 m80 -93.66 149.49 21.19 Favored 'General case' 0 C--N 1.329 -0.284 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 179.584 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 30.4 m -137.17 156.9 34.65 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-N 116.077 -0.51 . . . . 0.0 109.907 -179.911 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.547 HD11 ' CG1' ' A' ' 18' ' ' VAL . 37.9 tp -102.28 121.3 42.01 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.157 179.841 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 51.4 tp -76.87 99.85 5.34 Favored 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 179.226 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -96.52 144.84 28.53 Favored Pre-proline 0 CA--C 1.538 0.491 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.417 -179.489 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_exo -46.27 -37.46 18.74 Favored 'Trans proline' 0 N--CA 1.495 1.564 0 C-N-CA 121.26 1.307 . . . . 0.0 112.435 179.129 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -71.17 -42.64 68.83 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.887 -178.644 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 15.8 ptm180 -174.95 -120.03 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.504 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.536 -179.765 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.472 ' OG1' ' NH1' ' A' ' 21' ' ' ARG . 93.2 m -155.14 128.64 8.46 Favored 'General case' 0 C--N 1.333 -0.138 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 179.678 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -100.55 132.2 46.06 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.543 -179.355 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 40.3 p-10 -70.9 120.5 16.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.354 179.664 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 93.0 mt -133.67 159.52 40.26 Favored 'General case' 0 N--CA 1.472 0.673 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.261 -179.799 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -85.46 154.97 21.45 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.363 -179.66 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 48.9 t0 -57.98 -40.48 80.75 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.25 -179.847 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 97.6 m-20 -63.86 -39.32 93.93 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.39 -179.773 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.03 -40.16 78.78 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.66 -0.245 . . . . 0.0 111.307 -179.159 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 56.8 t -79.09 -29.94 14.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 CA-C-O 120.708 0.29 . . . . 0.0 110.662 -179.834 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -55.17 -35.67 65.04 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.388 -179.558 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 96.1 t -60.85 -46.57 96.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.528 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 42.6 mt -74.97 -17.87 60.47 Favored 'General case' 0 N--CA 1.462 0.152 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.633 -178.988 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 35.6 ttpt -90.54 -34.37 15.55 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.679 179.265 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 6.2 tp -70.35 -32.17 69.76 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.942 -178.753 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.408 HG13 ' O ' ' A' ' 51' ' ' VAL . 10.2 p -73.31 126.34 33.83 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-O 120.879 0.371 . . . . 0.0 110.583 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -71.77 -45.32 62.02 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.6 179.608 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -142.49 -102.73 0.45 Allowed Glycine 0 N--CA 1.472 1.048 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 89.6 mtm180 -114.63 105.01 12.56 Favored 'General case' 0 N--CA 1.471 0.585 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 179.052 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 96.4 m-20 -116.84 149.72 39.57 Favored 'General case' 0 N--CA 1.473 0.721 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.37 178.969 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 39.5 p -79.69 140.9 36.85 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 178.727 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.433 HG23 ' N ' ' A' ' 58' ' ' SER . 31.1 m -53.8 -38.8 36.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.755 0.312 . . . . 0.0 110.6 -179.765 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 58' ' ' SER . . . . . 0.433 ' N ' HG23 ' A' ' 57' ' ' VAL . 54.2 m -57.47 -44.39 84.8 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.719 179.706 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 50.7 tt0 -65.36 -47.38 76.61 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.695 -179.708 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 66.5 mt -60.78 -42.57 92.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.195 -0.457 . . . . 0.0 109.773 179.846 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -53.53 -41.99 66.96 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.272 -179.33 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 25.9 mm100 -63.29 -54.62 34.35 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 120.762 -0.375 . . . . 0.0 111.035 -179.742 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 69.3 mt -66.15 -49.04 79.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.767 0.318 . . . . 0.0 111.436 -179.03 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 24.8 tp -69.61 -37.72 76.98 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.903 -178.995 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -55.71 -42.12 84.38 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 110.796 -0.921 . . . . 0.0 110.796 -179.562 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 85.2 mt-30 -66.1 -30.19 70.65 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.605 0.24 . . . . 0.0 110.68 179.768 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 19.5 m -62.2 -45.35 93.75 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.758 0.313 . . . . 0.0 110.551 -179.644 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -90.26 1.96 55.95 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.541 179.674 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 66.1 t0 54.22 50.43 16.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.881 179.693 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -141.37 162.2 36.06 Favored 'General case' 0 N--CA 1.469 0.505 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.3 -179.729 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 72.7 m-20 -55.94 143.18 62.67 Favored Pre-proline 0 CA--C 1.54 0.583 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.555 -179.414 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -69.78 -31.58 20.17 Favored 'Trans proline' 0 N--CA 1.503 2.083 0 C-N-CA 122.51 2.14 . . . . 0.0 112.255 -179.603 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -53.74 -34.04 57.64 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.062 0.458 . . . . 0.0 110.613 -179.646 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 64.3 mt -68.58 -44.34 82.84 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.203 -179.569 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.561 ' N ' HD12 ' A' ' 75' ' ' ILE . 1.7 mp -62.07 -49.55 83.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 C-N-CA 120.933 -0.307 . . . . 0.0 111.26 -178.286 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -62.21 -45.59 92.67 Favored 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 120.143 -0.623 . . . . 0.0 110.225 -178.528 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.405 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -65.16 -24.07 67.29 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.36 179.55 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 65.8 t0 -78.41 -49.69 13.06 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-O 120.823 0.344 . . . . 0.0 111.157 -179.356 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 13.1 pt -74.31 -39.81 49.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.463 -179.407 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 9.1 mt -41.37 -60.41 1.82 Allowed Pre-proline 0 CA--C 1.549 0.919 0 CA-C-O 119.622 -0.228 . . . . 0.0 111.26 -179.693 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.405 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 46.8 Cg_endo -62.84 -29.98 77.07 Favored 'Trans proline' 0 N--CA 1.499 1.82 0 C-N-CA 122.0 1.8 . . . . 0.0 111.459 179.483 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 9.5 tpt -66.78 -40.6 88.24 Favored 'General case' 0 N--CA 1.462 0.168 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.483 -179.705 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 80.9 mt -62.2 -41.18 98.12 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.365 -179.129 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.22 -38.6 87.19 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 179.363 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -65.75 -40.22 95.6 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 111.166 -0.774 . . . . 0.0 111.166 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 92.6 mt -67.02 -38.59 86.2 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.843 0.354 . . . . 0.0 110.321 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -53.15 -35.91 60.27 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.839 0.352 . . . . 0.0 110.81 -179.671 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 86.9 mt-30 -61.73 -21.52 64.59 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.637 179.876 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 62.2 mttp -93.08 -5.17 50.99 Favored 'General case' 0 N--CA 1.467 0.419 0 CA-C-O 120.899 0.38 . . . . 0.0 110.048 -179.304 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 23.0 ttm180 65.54 22.46 11.79 Favored 'General case' 0 CA--C 1.531 0.229 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.597 179.5 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 19.5 m -96.1 -14.98 7.7 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.521 0 CA-C-O 120.777 0.322 . . . . 0.0 110.589 -179.748 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 39.6 tp -102.2 149.02 24.73 Favored 'General case' 0 N--CA 1.47 0.531 0 CA-C-O 121.253 0.549 . . . . 0.0 109.824 179.748 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -142.76 147.4 35.49 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.422 -0.808 . . . . 0.0 109.689 -178.829 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 7.8 tmm_? . . . . . 0 C--N 1.326 -0.451 0 CA-C-O 117.93 -1.033 . . . . 0.0 110.046 -179.407 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 15.6 ptt? . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -169.89 72.3 0.65 Allowed Pre-proline 0 C--N 1.326 -0.426 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.624 179.862 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.425 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 36.2 Cg_exo -59.82 155.21 44.85 Favored 'Trans proline' 0 N--CA 1.497 1.698 0 C-N-CA 122.544 2.163 . . . . 0.0 112.079 179.866 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.533 ' H ' ' HB1' ' A' ' 84' ' ' ALA . 14.6 t -76.17 -27.78 57.07 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.152 -179.87 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -162.55 -31.18 0.04 OUTLIER 'General case' 0 CA--C 1.528 0.114 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.419 -179.57 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.425 ' O ' ' CB ' ' A' ' 3' ' ' PRO . 36.0 m-85 -81.17 104.89 11.96 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-O 121.15 0.5 . . . . 0.0 110.653 -179.485 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 72.9 m -91.99 -172.89 3.31 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.581 179.417 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -66.83 -42.41 93.0 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 78.4 p -71.92 -21.21 61.66 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.78 0.324 . . . . 0.0 110.855 -179.691 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.466 ' OD2' ' NH2' ' A' ' 94' ' ' ARG . 91.3 m-20 -69.7 154.48 41.92 Favored 'General case' 0 C--O 1.233 0.188 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 179.863 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 28.6 m -128.82 128.63 23.46 Favored Pre-proline 0 N--CA 1.474 0.739 0 CA-C-O 119.67 -0.205 . . . . 0.0 110.728 -178.953 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -79.47 153.24 23.69 Favored 'Trans proline' 0 N--CA 1.494 1.528 0 C-N-CA 121.684 1.589 . . . . 0.0 111.81 179.743 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.421 ' NH1' ' OE2' ' A' ' 93' ' ' GLU . 60.8 ttp180 -154.28 128.55 9.06 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 116.037 -0.529 . . . . 0.0 109.707 178.95 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 93.0 mt -69.45 120.34 76.49 Favored Pre-proline 0 CA--C 1.545 0.77 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.205 -179.167 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.428 ' CD ' ' O ' ' A' ' 91' ' ' VAL . 95.1 Cg_endo -77.36 160.03 32.55 Favored 'Trans proline' 0 N--CA 1.498 1.75 0 C-N-CA 121.988 1.792 . . . . 0.0 112.074 179.444 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 43.1 ttm180 -57.31 151.57 15.76 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.132 179.276 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 82.59 14.79 75.12 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 111.108 -0.797 . . . . 0.0 111.108 179.719 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.2 t -133.2 131.16 58.26 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.444 0 CA-C-O 120.89 0.376 . . . . 0.0 109.998 179.682 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 81.3 mtm-85 -137.37 158.69 43.87 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.038 -179.651 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 15.1 mt -94.6 97.64 10.26 Favored 'General case' 0 N--CA 1.463 0.206 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.063 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 83.8 mtp180 -90.77 142.46 27.74 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.239 179.588 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 69.4 t80 -102.81 119.68 39.27 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.227 -0.442 . . . . 0.0 109.867 179.495 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.48 ' O ' ' N ' ' A' ' 27' ' ' ASN . 96.2 m-20 -86.72 96.28 10.1 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.998 -0.546 . . . . 0.0 109.712 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -62.65 -34.65 77.51 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.665 -179.76 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 1.7 p -60.63 -46.39 95.81 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.638 -179.361 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 94.3 mtt-85 -95.47 -6.17 41.29 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.69 -179.844 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.48 ' N ' ' O ' ' A' ' 23' ' ' ASP . 15.8 t-20 55.66 43.69 27.68 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.542 179.552 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -144.78 160.99 40.35 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-O 120.716 0.293 . . . . 0.0 110.571 178.905 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.452 ' HD1' ' CG ' ' A' ' 42' ' ' ASP . 77.2 m80 -94.12 143.85 26.01 Favored 'General case' 0 CA--C 1.519 -0.229 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 178.486 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 33.5 m -137.11 159.45 36.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.141 -0.481 . . . . 0.0 109.879 -179.447 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 6.0 tp -102.73 122.24 44.06 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 116.205 -0.452 . . . . 0.0 109.846 -179.902 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 44.4 tp -77.79 100.03 6.13 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 178.762 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -96.6 147.09 32.42 Favored Pre-proline 0 CA--C 1.539 0.532 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 -179.825 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_exo -48.62 -38.25 36.0 Favored 'Trans proline' 0 N--CA 1.497 1.682 0 C-N-CA 121.233 1.289 . . . . 0.0 112.743 179.217 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 79.3 tt0 -73.65 -52.15 14.33 Favored 'General case' 0 C--N 1.332 -0.186 0 C-N-CA 120.962 -0.295 . . . . 0.0 111.307 -178.394 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 43.6 ttm180 -175.87 151.99 1.18 Allowed 'General case' 0 N--CA 1.465 0.28 0 CA-C-O 120.964 0.412 . . . . 0.0 110.622 -179.788 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 58.0 m -68.79 133.34 48.19 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.407 179.267 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.404 ' CE2' ' NZ ' ' A' ' 89' ' ' LYS . 81.7 m-85 -106.49 137.62 44.15 Favored 'General case' 0 N--CA 1.472 0.629 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.596 -179.588 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 22.0 t0 -72.76 119.58 17.18 Favored 'General case' 0 C--N 1.333 -0.132 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.932 179.642 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 89.2 mt -134.53 157.37 46.7 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.007 -179.743 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 25.8 m-20 -84.86 161.41 19.9 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.421 -179.596 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.452 ' CG ' ' HD1' ' A' ' 29' ' ' HIS . 87.4 m-20 -60.59 -44.73 95.9 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.425 179.837 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 47.0 t30 -63.7 -35.66 81.28 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.625 -179.574 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -68.98 -44.86 72.04 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.185 -179.438 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 48.7 t -78.06 -25.32 14.2 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.197 0 CA-C-O 120.839 0.352 . . . . 0.0 110.333 -179.914 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.85 -31.55 64.9 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.194 -179.776 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 6.0 t -60.99 -46.34 96.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.893 -179.486 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 30.9 mt -76.37 -19.4 58.21 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.71 -179.027 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 33.6 ttpt -87.98 -34.54 18.03 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.671 179.509 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 5.4 tp -70.15 -32.55 70.58 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.03 -179.275 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 8.5 p -75.88 125.01 35.09 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-O 120.916 0.389 . . . . 0.0 110.696 179.849 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 97.5 m-20 -70.95 -45.64 63.81 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.384 179.579 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -139.89 -101.66 0.5 Allowed Glycine 0 N--CA 1.471 1.015 0 N-CA-C 110.448 -1.061 . . . . 0.0 110.448 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 90.7 mtm180 -115.02 104.69 12.15 Favored 'General case' 0 N--CA 1.47 0.572 0 CA-C-O 120.523 0.201 . . . . 0.0 110.527 179.252 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 96.7 m-20 -117.24 146.91 42.97 Favored 'General case' 0 N--CA 1.472 0.64 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 178.054 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 32.3 p -79.36 149.63 31.64 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 179.099 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.443 HG23 ' N ' ' A' ' 58' ' ' SER . 19.8 m -52.66 -40.32 33.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.829 0.347 . . . . 0.0 110.593 -179.559 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' SER . . . . . 0.443 ' N ' HG23 ' A' ' 57' ' ' VAL . 33.5 t -59.36 -45.16 92.17 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.886 179.891 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 50.5 tt0 -64.48 -48.13 76.36 Favored 'General case' 0 N--CA 1.463 0.182 0 CA-C-O 120.804 0.335 . . . . 0.0 110.894 -179.355 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 65.5 mt -61.09 -42.64 93.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.002 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -53.38 -40.39 64.98 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.932 -0.576 . . . . 0.0 111.224 -179.336 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 94.7 mm-40 -63.26 -55.39 25.2 Favored 'General case' 0 C--N 1.33 -0.275 0 C-N-CA 120.813 -0.355 . . . . 0.0 110.98 -179.541 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 66.1 mt -66.75 -45.13 88.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.843 0.354 . . . . 0.0 110.652 -179.267 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 36.0 tp -66.77 -38.6 86.9 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.445 -179.537 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.462 ' O ' ' N ' ' A' ' 69' ' ' ASP . . . -57.64 -39.22 90.74 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 111.103 -0.799 . . . . 0.0 111.103 -179.667 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 87.7 mt-30 -65.84 -33.14 75.16 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.972 -0.291 . . . . 0.0 110.408 179.688 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 25.2 m -62.24 -47.24 85.25 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 120.789 -0.364 . . . . 0.0 110.547 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -94.66 -3.58 49.2 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.565 179.45 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' ASP . . . . . 0.462 ' N ' ' O ' ' A' ' 65' ' ' GLY . 61.6 t0 51.51 62.12 2.87 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.972 179.726 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -141.35 160.96 39.04 Favored 'General case' 0 N--CA 1.467 0.408 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.103 -179.735 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 58.7 m-20 -55.79 113.42 5.66 Favored Pre-proline 0 CA--C 1.546 0.802 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.364 -179.37 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_exo -49.06 -32.42 23.76 Favored 'Trans proline' 0 N--CA 1.5 1.877 0 C-N-CA 121.807 1.671 . . . . 0.0 112.656 179.56 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -52.05 -37.82 54.92 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.934 0.397 . . . . 0.0 111.61 -178.793 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 19.9 mm -80.24 -34.59 14.98 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.609 -179.785 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 46.5 mm -62.01 -46.56 96.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.963 -179.396 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -62.89 -44.53 95.86 Favored 'General case' 0 C--N 1.333 -0.124 0 C-N-CA 120.547 -0.461 . . . . 0.0 109.783 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.431 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -67.32 -18.45 65.18 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.758 -0.655 . . . . 0.0 111.147 179.472 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 61.1 t0 -80.8 -46.84 14.75 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-O 120.753 0.311 . . . . 0.0 111.031 -179.709 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 22.0 pt -78.16 -34.12 18.59 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.434 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.017 -179.665 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 7.9 mt -46.07 -60.26 3.78 Favored Pre-proline 0 CA--C 1.547 0.839 0 C-N-CA 121.015 -0.274 . . . . 0.0 111.097 179.639 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.431 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 38.6 Cg_endo -61.92 -28.84 81.44 Favored 'Trans proline' 0 N--CA 1.499 1.812 0 C-N-CA 122.126 1.884 . . . . 0.0 111.845 179.516 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 45.1 ttp -66.15 -42.34 89.16 Favored 'General case' 0 C--N 1.333 -0.114 0 C-N-CA 120.858 -0.337 . . . . 0.0 110.14 -179.855 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 91.8 mt -63.06 -42.78 99.78 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.486 -179.742 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.533 ' HB1' ' H ' ' A' ' 4' ' ' THR . . . -62.82 -38.34 90.32 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.048 -0.524 . . . . 0.0 109.913 179.633 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -64.75 -41.01 97.82 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 111.206 -0.758 . . . . 0.0 111.206 -179.763 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 88.5 mt -68.4 -36.99 79.93 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.036 0.446 . . . . 0.0 110.128 179.788 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -53.1 -36.83 61.14 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.582 -179.785 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.5 mt-30 -61.23 -23.3 65.54 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.529 179.659 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' LYS . . . . . 0.404 ' NZ ' ' CE2' ' A' ' 38' ' ' PHE . 68.2 mttm -93.73 -3.89 51.42 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.086 -179.742 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 35.3 ttm180 57.14 67.97 0.92 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.568 179.909 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' VAL . . . . . 0.428 ' O ' ' CD ' ' A' ' 15' ' ' PRO . 33.4 m -136.7 -0.38 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.985 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 95.0 mt -106.66 173.47 6.31 Favored 'General case' 0 CA--C 1.511 -0.534 0 CA-C-O 121.413 0.625 . . . . 0.0 110.333 179.525 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.421 ' OE2' ' NH1' ' A' ' 13' ' ' ARG . 79.9 tt0 -149.09 145.8 27.41 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 114.852 -1.067 . . . . 0.0 110.653 179.873 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 94' ' ' ARG . . . . . 0.466 ' NH2' ' OD2' ' A' ' 10' ' ' ASP . 16.6 ptm180 . . . . . 0 C--N 1.324 -0.533 0 CA-C-O 118.1 -0.952 . . . . 0.0 110.059 179.777 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 4.3 mmt . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 109.063 -0.718 . . . . 0.0 109.063 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 54.6 tt0 50.44 64.15 8.8 Favored Pre-proline 0 CA--C 1.534 0.34 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.598 -179.571 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 77.1 Cg_endo -74.93 169.55 22.37 Favored 'Trans proline' 0 N--CA 1.495 1.59 0 C-N-CA 122.374 2.05 . . . . 0.0 111.928 -179.572 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 16.2 p -78.5 86.07 4.55 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.273 -179.668 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.21 100.96 4.47 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.463 -179.837 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -79.48 139.59 37.57 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.436 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 67.0 m -93.32 -175.12 3.72 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.696 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -68.41 -38.8 87.35 Favored Glycine 0 CA--C 1.528 0.876 0 N-CA-C 111.277 -0.729 . . . . 0.0 111.277 179.764 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 18.1 m -71.3 -17.04 62.48 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.75 0.31 . . . . 0.0 110.832 -179.48 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -66.93 142.71 57.19 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 179.573 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.463 HG23 ' O ' ' A' ' 55' ' ' ASN . 1.4 p -129.73 120.78 19.73 Favored Pre-proline 0 CA--C 1.547 0.828 0 O-C-N 123.167 0.292 . . . . 0.0 110.264 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_endo -77.31 150.2 28.56 Favored 'Trans proline' 0 N--CA 1.492 1.435 0 C-N-CA 121.389 1.393 . . . . 0.0 111.472 179.407 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.453 HH22 ' CA ' ' A' ' 53' ' ' GLY . 59.4 ttt85 -149.57 139.68 22.11 Favored 'General case' 0 N--CA 1.467 0.422 0 N-CA-C 109.624 -0.509 . . . . 0.0 109.624 179.085 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 65.6 mt -71.32 118.15 63.4 Favored Pre-proline 0 CA--C 1.541 0.633 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.78 -179.947 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo -77.12 160.66 33.05 Favored 'Trans proline' 0 N--CA 1.494 1.507 0 C-N-CA 121.633 1.555 . . . . 0.0 111.994 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 9.4 ptm180 -53.94 148.46 10.5 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.627 179.887 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 82.71 8.28 86.22 Favored Glycine 0 CA--C 1.521 0.444 0 N-CA-C 110.913 -0.875 . . . . 0.0 110.913 179.593 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.559 ' CG1' HD11 ' A' ' 31' ' ' LEU . 43.6 t -132.9 124.3 50.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.46 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.655 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 84.2 mtp180 -138.22 157.96 45.24 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.153 179.563 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 33.2 mt -94.36 109.16 21.02 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.222 -179.69 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.575 ' HE ' HD13 ' A' ' 32' ' ' LEU . 91.5 mtt-85 -90.89 137.76 32.11 Favored 'General case' 0 CA--C 1.52 -0.194 0 CA-C-N 116.114 -0.493 . . . . 0.0 109.888 179.786 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 35.0 t80 -95.99 100.06 11.77 Favored 'General case' 0 C--N 1.332 -0.187 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 94.5 m-20 -89.16 90.18 8.26 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.022 -179.904 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -61.77 -34.68 76.3 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.144 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 1.7 m -63.26 -41.22 91.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.285 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -80.68 -17.3 51.57 Favored 'General case' 0 N--CA 1.463 0.195 0 N-CA-C 110.222 -0.288 . . . . 0.0 110.222 -179.71 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 6.7 t-20 71.0 12.5 7.01 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.044 -0.526 . . . . 0.0 111.135 179.568 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 20.9 pttp -145.03 163.09 35.28 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-O 120.989 0.424 . . . . 0.0 110.187 179.461 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 62.1 m80 -89.14 160.55 16.95 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.053 179.865 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 27.7 m -141.91 156.83 20.28 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.1 179.846 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.559 HD11 ' CG1' ' A' ' 18' ' ' VAL . 44.5 tp -100.67 124.62 46.53 Favored 'General case' 0 N--CA 1.465 0.297 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 179.296 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.575 HD13 ' HE ' ' A' ' 21' ' ' ARG . 38.8 tp -79.65 96.27 6.15 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 179.031 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -94.08 147.67 33.83 Favored Pre-proline 0 CA--C 1.538 0.504 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.767 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 77.6 Cg_exo -50.05 -37.58 47.89 Favored 'Trans proline' 0 N--CA 1.496 1.652 0 C-N-CA 121.527 1.485 . . . . 0.0 112.721 179.143 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 47.6 tp10 -74.33 -52.14 13.09 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.409 -0.36 . . . . 0.0 111.117 -178.253 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 60.8 ttp180 -175.5 153.79 1.54 Allowed 'General case' 0 N--CA 1.462 0.155 0 CA-C-O 120.848 0.356 . . . . 0.0 110.608 -179.591 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 68.3 m -67.54 130.83 44.28 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.219 178.919 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 76.7 m-85 -105.53 142.55 35.08 Favored 'General case' 0 N--CA 1.471 0.578 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.522 -179.733 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 38.4 t0 -73.71 117.25 15.27 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.758 179.257 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 20.6 mt -131.8 155.85 47.04 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.189 -179.527 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 26.0 m-20 -83.72 147.06 27.86 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.216 -179.552 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.467 ' OD1' ' N ' ' A' ' 43' ' ' ASN . 36.8 p-10 -60.07 -35.79 75.95 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.744 -179.773 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' ASN . . . . . 0.467 ' N ' ' OD1' ' A' ' 42' ' ' ASP . 16.1 p30 -63.73 -40.85 97.75 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.776 -179.73 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.462 ' N ' ' OD1' ' A' ' 43' ' ' ASN . . . -70.96 -38.97 72.8 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.702 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 94.9 t -78.09 -28.96 15.34 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.157 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -55.81 -36.8 67.84 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.238 -179.65 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 65.8 t -59.71 -47.17 92.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.462 -179.671 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 47.6 mt -71.27 -28.71 64.34 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.682 -179.354 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 34.8 ttpt -82.16 -28.33 32.2 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.126 -179.678 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 7.0 tp -69.63 -32.53 71.26 Favored 'General case' 0 N--CA 1.463 0.19 0 C-N-CA 120.647 -0.421 . . . . 0.0 110.359 -179.005 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 2.6 p -76.33 129.27 37.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 121.122 0.487 . . . . 0.0 110.354 179.184 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -69.39 -43.96 72.42 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.374 179.049 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.453 ' CA ' HH22 ' A' ' 13' ' ' ARG . . . -145.48 -95.24 0.18 Allowed Glycine 0 N--CA 1.473 1.103 0 N-CA-C 110.511 -1.036 . . . . 0.0 110.511 179.632 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 82.7 mtm-85 -114.9 104.84 12.32 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-O 120.865 0.365 . . . . 0.0 110.256 179.347 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.463 ' O ' HG23 ' A' ' 11' ' ' VAL . 96.6 m-20 -117.51 142.75 46.79 Favored 'General case' 0 N--CA 1.472 0.633 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.214 177.348 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 65.2 p -78.78 141.58 37.68 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 178.548 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.438 HG23 ' N ' ' A' ' 58' ' ' SER . 28.3 m -51.09 -38.31 18.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.893 0.378 . . . . 0.0 110.671 -179.492 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 58' ' ' SER . . . . . 0.438 ' N ' HG23 ' A' ' 57' ' ' VAL . 60.2 m -58.47 -45.08 89.37 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.452 179.655 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 50.3 tt0 -66.21 -46.66 76.49 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.769 -179.777 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 66.7 mt -61.11 -42.91 95.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.058 -179.771 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.412 ' O ' ' N ' ' A' ' 65' ' ' GLY . . . -53.53 -39.19 64.48 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.206 -179.342 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 85.1 mm-40 -62.96 -53.44 54.05 Favored 'General case' 0 C--N 1.325 -0.467 0 C-N-CA 120.845 -0.342 . . . . 0.0 110.769 179.858 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 72.4 mt -65.16 -49.79 77.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.259 -179.203 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 23.3 tp -69.84 -37.06 76.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.691 -179.11 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.412 ' N ' ' O ' ' A' ' 61' ' ' ALA . . . -55.85 -42.2 85.42 Favored Glycine 0 CA--C 1.526 0.759 0 N-CA-C 110.945 -0.862 . . . . 0.0 110.945 -179.708 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 74.6 mt-30 -65.2 -31.0 71.95 Favored 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 121.106 -0.238 . . . . 0.0 110.535 179.711 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 19.4 m -62.27 -46.26 89.62 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.788 0.327 . . . . 0.0 110.544 -179.583 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -91.37 1.66 56.96 Favored 'General case' 0 N--CA 1.468 0.461 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.534 179.815 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 66.2 t0 53.94 51.97 13.76 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.784 179.689 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -142.19 159.0 43.1 Favored 'General case' 0 N--CA 1.468 0.459 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.212 -179.794 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 26.2 m-20 -55.95 143.83 60.31 Favored Pre-proline 0 CA--C 1.538 0.485 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.364 -179.321 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -66.34 -29.45 46.07 Favored 'Trans proline' 0 N--CA 1.502 1.971 0 C-N-CA 122.561 2.174 . . . . 0.0 112.307 -179.564 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -55.16 -36.41 65.8 Favored 'General case' 0 CA--C 1.515 -0.384 0 CA-C-O 121.218 0.533 . . . . 0.0 110.95 -179.106 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 34.5 mm -70.18 -44.26 78.09 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.868 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.157 -179.43 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.533 ' N ' HD12 ' A' ' 75' ' ' ILE . 1.7 mp -62.06 -51.89 67.07 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 CA-C-N 116.496 -0.32 . . . . 0.0 111.264 -178.704 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 15.9 pt-20 -59.49 -44.37 93.08 Favored 'General case' 0 C--N 1.326 -0.416 0 C-N-CA 120.402 -0.519 . . . . 0.0 110.079 -177.949 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.419 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -67.52 -23.26 65.44 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.992 179.577 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 66.0 t0 -80.1 -46.82 15.81 Favored 'General case' 0 N--CA 1.471 0.612 0 CA-C-N 116.587 -0.279 . . . . 0.0 111.741 -179.318 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 15.8 pt -71.32 -41.14 74.13 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.455 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.054 -179.15 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 7.0 mt -42.31 -60.98 1.78 Allowed Pre-proline 0 CA--C 1.55 0.955 0 CA-C-O 119.621 -0.228 . . . . 0.0 110.863 179.445 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.419 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 53.4 Cg_exo -40.22 -41.18 3.16 Favored 'Trans proline' 0 N--CA 1.491 1.374 0 C-N-CA 122.633 2.222 . . . . 0.0 112.204 177.773 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 10.8 tpt -65.37 -39.83 92.78 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.627 -178.986 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 41.6 mt -61.4 -39.44 90.72 Favored 'General case' 0 C--N 1.325 -0.499 0 C-N-CA 120.577 -0.449 . . . . 0.0 110.051 -179.303 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -63.31 -38.65 91.97 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.944 0.402 . . . . 0.0 110.063 179.211 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -69.07 -38.95 84.47 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 111.408 -0.677 . . . . 0.0 111.408 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 86.0 mt -66.42 -40.51 89.6 Favored 'General case' 0 C--N 1.326 -0.417 0 O-C-N 122.745 -0.268 . . . . 0.0 110.888 -179.668 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -53.74 -28.12 32.47 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.48 -0.327 . . . . 0.0 110.725 -179.768 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 94.7 mt-30 -63.08 -26.53 68.88 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.68 -179.858 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 46.1 mtmt -94.11 -1.98 53.47 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.497 -179.451 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 50.0 ttt180 65.29 23.01 12.13 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.567 179.385 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 23.8 m -95.18 -4.74 10.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.222 -179.891 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.524 HD13 ' N ' ' A' ' 93' ' ' GLU . 0.2 OUTLIER -109.06 121.58 45.44 Favored 'General case' 0 CA--C 1.533 0.324 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 -179.36 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.524 ' N ' HD13 ' A' ' 92' ' ' LEU . 12.8 pt-20 -101.31 174.49 5.96 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 115.869 -0.605 . . . . 0.0 109.992 179.539 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 73.1 ttp85 . . . . . 0 C--N 1.322 -0.592 0 CA-C-O 117.96 -1.019 . . . . 0.0 109.351 -179.853 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 72.3 mtm . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 17.7 tp10 -167.48 54.77 0.29 Allowed Pre-proline 0 CA--C 1.533 0.297 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.091 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 67.8 Cg_endo -68.01 -18.37 46.17 Favored 'Trans proline' 0 N--CA 1.497 1.706 0 C-N-CA 122.231 1.954 . . . . 0.0 111.73 -179.654 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 26.0 p -77.35 74.67 3.92 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.145 -179.542 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -165.78 62.72 0.11 Allowed 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 115.936 -0.574 . . . . 0.0 111.126 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 51.5 m-85 -89.85 117.59 28.8 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.065 179.482 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 50.9 m -94.18 -179.91 5.1 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.259 179.676 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -64.92 -40.08 96.96 Favored Glycine 0 CA--C 1.528 0.868 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 179.789 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 57.7 m -72.65 -16.57 61.7 Favored 'General case' 0 N--CA 1.462 0.16 0 CA-C-O 120.629 0.252 . . . . 0.0 110.89 -179.728 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 54.0 t0 -71.98 114.53 10.17 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.744 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.463 HG21 ' HE ' ' A' ' 54' ' ' ARG . 34.6 m -94.57 126.18 48.72 Favored Pre-proline 0 CA--C 1.548 0.902 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.979 -179.025 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 83.9 Cg_endo -78.82 151.78 24.82 Favored 'Trans proline' 0 N--CA 1.495 1.591 0 C-N-CA 121.27 1.313 . . . . 0.0 111.541 179.591 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 58.2 ttt85 -157.1 130.38 7.89 Favored 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 179.187 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 68.5 mt -70.62 128.62 90.85 Favored Pre-proline 0 CA--C 1.546 0.792 0 CA-C-O 119.245 -0.407 . . . . 0.0 110.674 -179.652 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -73.83 155.9 48.53 Favored 'Trans proline' 0 N--CA 1.496 1.628 0 C-N-CA 121.472 1.448 . . . . 0.0 111.945 179.827 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 35.4 ptt180 -54.26 151.65 7.11 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.832 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 80.55 18.19 71.5 Favored Glycine 0 CA--C 1.525 0.68 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.503 ' CG1' HD11 ' A' ' 31' ' ' LEU . 61.9 t -135.05 133.76 53.34 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 CA-C-O 120.877 0.37 . . . . 0.0 110.321 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 83.4 mtm-85 -136.68 155.78 49.41 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.262 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 41.5 mt -92.26 144.49 25.35 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.983 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 96.7 mtt180 -140.36 141.08 35.66 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.096 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.464 ' O ' ' CD1' ' A' ' 22' ' ' PHE . 50.2 p90 -106.81 121.45 44.42 Favored 'General case' 0 N--CA 1.469 0.495 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.742 -180.0 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.456 ' O ' ' N ' ' A' ' 27' ' ' ASN . 93.8 m-20 -90.19 103.43 16.11 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.042 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.2 tt0 -64.75 -37.88 89.09 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.531 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 3.2 m -63.15 -43.96 99.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.665 -179.487 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 96.5 mtt180 -92.61 -8.13 45.07 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-O 120.684 0.278 . . . . 0.0 110.953 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.456 ' N ' ' O ' ' A' ' 23' ' ' ASP . 15.6 t-20 54.86 37.69 29.03 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.57 179.519 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.439 ' NZ ' ' O ' ' A' ' 40' ' ' LEU . 11.6 ptmm? -145.04 158.51 43.79 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 110.036 -0.357 . . . . 0.0 110.036 179.512 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.4 ' O ' ' O ' ' A' ' 40' ' ' LEU . 69.9 m80 -92.58 148.75 21.83 Favored 'General case' 0 CA--C 1.517 -0.3 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.097 179.79 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 34.1 m -136.76 153.81 30.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.289 0 CA-C-N 116.093 -0.503 . . . . 0.0 109.813 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.503 HD11 ' CG1' ' A' ' 18' ' ' VAL . 41.3 tp -102.37 124.03 47.21 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.779 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 46.7 tp -77.7 101.48 6.65 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 179.046 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -97.27 140.95 22.34 Favored Pre-proline 0 CA--C 1.539 0.521 0 CA-C-O 119.308 -0.377 . . . . 0.0 110.093 -179.779 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 94.3 Cg_exo -43.93 -31.63 3.89 Favored 'Trans proline' 0 N--CA 1.496 1.654 0 C-N-CA 121.316 1.344 . . . . 0.0 112.467 179.029 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -71.36 -51.01 26.54 Favored 'General case' 0 C--N 1.33 -0.269 0 C-N-CA 120.807 -0.357 . . . . 0.0 110.221 -179.292 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 69.0 ttt-85 -172.89 -98.68 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.297 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.019 179.589 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 86.4 m -166.75 151.93 7.78 Favored 'General case' 0 C--N 1.333 -0.145 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 -179.61 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 68.1 m-85 -125.92 136.13 52.68 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-O 120.905 0.383 . . . . 0.0 110.344 -179.846 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 37.3 p-10 -72.07 119.15 15.85 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.943 -0.572 . . . . 0.0 110.194 179.607 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.439 ' O ' ' NZ ' ' A' ' 28' ' ' LYS . 95.4 mt -134.23 157.4 46.36 Favored 'General case' 0 N--CA 1.471 0.58 0 CA-C-O 121.029 0.443 . . . . 0.0 110.329 -179.491 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -84.94 157.43 20.82 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.214 -179.683 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.475 ' OD1' ' N ' ' A' ' 43' ' ' ASN . 38.5 p-10 -61.31 -35.8 78.35 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.757 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . 0.475 ' N ' ' OD1' ' A' ' 42' ' ' ASP . 48.6 t30 -63.04 -39.91 96.15 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.922 -179.507 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -68.75 -36.43 78.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.473 -0.331 . . . . 0.0 110.606 -179.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 46.8 t -87.65 -19.43 7.87 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 CA-C-O 120.726 0.298 . . . . 0.0 110.658 179.635 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.449 ' N ' ' O ' ' A' ' 42' ' ' ASP . . . -58.4 -49.95 75.44 Favored 'General case' 0 CA--C 1.52 -0.173 0 CA-C-O 120.803 0.335 . . . . 0.0 110.394 -179.704 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 30.7 m -62.43 -39.31 83.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.511 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 55.4 mt -69.33 -31.46 69.93 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.372 -0.377 . . . . 0.0 110.309 179.759 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 16.4 ttmm -86.72 -30.58 21.53 Favored 'General case' 0 CA--C 1.534 0.348 0 CA-C-O 120.56 0.219 . . . . 0.0 110.842 179.39 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 57.0 tp -72.47 -32.31 66.13 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 116.472 -0.331 . . . . 0.0 110.824 -179.105 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.6 p -74.86 127.24 36.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-O 121.009 0.433 . . . . 0.0 110.717 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -68.28 -42.68 79.19 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.12 179.371 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -145.97 -99.26 0.25 Allowed Glycine 0 N--CA 1.473 1.132 0 N-CA-C 110.617 -0.993 . . . . 0.0 110.617 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . 0.463 ' HE ' HG21 ' A' ' 11' ' ' VAL . 84.1 mtp180 -114.86 104.65 12.15 Favored 'General case' 0 N--CA 1.471 0.615 0 CA-C-N 116.6 0.2 . . . . 0.0 110.525 179.557 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 93.6 m-20 -117.3 155.79 28.91 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 122.684 0.394 . . . . 0.0 110.192 178.205 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 9.6 p -80.51 140.9 35.65 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 178.834 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.46 HG23 ' N ' ' A' ' 58' ' ' SER . 17.7 m -55.32 -41.93 64.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 C-N-CA 120.738 -0.385 . . . . 0.0 110.696 -179.537 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . 0.46 ' N ' HG23 ' A' ' 57' ' ' VAL . 67.1 m -57.71 -42.54 83.97 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.738 179.902 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 58.9 tt0 -63.84 -47.62 80.03 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.884 0.374 . . . . 0.0 110.497 -179.757 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 65.8 mt -60.96 -43.09 95.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.158 -0.474 . . . . 0.0 109.839 179.415 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.418 ' O ' ' N ' ' A' ' 65' ' ' GLY . . . -53.62 -38.19 63.8 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.702 -0.681 . . . . 0.0 111.006 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 93.8 mm-40 -64.14 -53.56 47.65 Favored 'General case' 0 C--N 1.331 -0.212 0 C-N-CA 120.694 -0.402 . . . . 0.0 110.582 179.739 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 75.2 mt -63.64 -48.84 84.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 C-N-CA 120.741 -0.383 . . . . 0.0 110.504 -179.255 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 40.3 tp -67.22 -38.91 86.06 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.01 0.433 . . . . 0.0 110.275 179.585 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.439 ' O ' ' N ' ' A' ' 69' ' ' ASP . . . -58.87 -42.17 96.52 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 111.233 -0.747 . . . . 0.0 111.233 -179.453 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 86.4 mt-30 -66.09 -30.37 70.86 Favored 'General case' 0 C--N 1.328 -0.352 0 C-N-CA 120.974 -0.29 . . . . 0.0 110.375 179.568 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 19.8 m -62.36 -49.13 76.78 Favored 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 120.627 -0.429 . . . . 0.0 110.226 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 95.3 m-85 -94.48 -2.43 51.78 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.562 179.301 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . 0.439 ' N ' ' O ' ' A' ' 65' ' ' GLY . 65.7 t0 52.52 62.12 2.85 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.763 0.316 . . . . 0.0 110.83 179.783 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -137.26 158.26 44.83 Favored 'General case' 0 N--CA 1.469 0.517 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.181 -179.652 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 85.6 m-20 -55.85 113.95 6.62 Favored Pre-proline 0 CA--C 1.546 0.798 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.18 -179.501 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 74.9 Cg_exo -48.56 -34.12 25.59 Favored 'Trans proline' 0 N--CA 1.501 1.913 0 C-N-CA 121.672 1.582 . . . . 0.0 112.195 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -52.08 -39.6 59.97 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.043 0.449 . . . . 0.0 110.609 -179.678 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 70.3 mt -71.74 -42.69 70.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.188 179.237 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 33.9 mm -61.35 -49.82 82.94 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.345 -178.616 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -65.0 -43.44 92.54 Favored 'General case' 0 C--O 1.232 0.176 0 C-N-CA 120.595 -0.442 . . . . 0.0 110.155 -179.684 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.418 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -63.9 -21.35 66.42 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.219 179.588 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 65.9 t0 -78.17 -51.91 9.5 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 120.742 0.306 . . . . 0.0 110.912 -179.531 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 30.3 pt -74.01 -37.79 47.98 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.498 -179.838 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 9.6 mt -42.88 -60.03 2.6 Favored Pre-proline 0 CA--C 1.551 1.017 0 N-CA-C 111.768 0.285 . . . . 0.0 111.768 -179.376 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.418 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 39.1 Cg_endo -61.96 -24.2 76.63 Favored 'Trans proline' 0 N--CA 1.501 1.947 0 C-N-CA 122.089 1.859 . . . . 0.0 112.057 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 9.3 tpt -66.19 -35.5 80.61 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 120.745 0.307 . . . . 0.0 110.659 -179.712 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 43.5 mt -61.19 -41.02 96.07 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.432 -178.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.35 -40.53 96.68 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.849 0.357 . . . . 0.0 110.077 179.469 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -64.31 -40.71 98.12 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 111.091 -0.804 . . . . 0.0 111.091 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 86.3 mt -66.74 -40.77 88.47 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.806 0.336 . . . . 0.0 110.676 -179.828 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -55.82 -37.13 68.27 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 120.824 -0.351 . . . . 0.0 110.977 -179.526 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 77.8 mt-30 -62.11 -21.43 65.0 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.05 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -91.73 -1.88 57.22 Favored 'General case' 0 N--CA 1.469 0.502 0 CA-C-N 116.476 -0.329 . . . . 0.0 110.549 -179.286 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 64.3 ttt-85 62.25 55.8 2.32 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.459 179.599 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 33.6 m -141.81 5.16 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.516 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.756 179.851 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 55.9 tp -141.81 138.04 31.93 Favored 'General case' 0 N--CA 1.47 0.555 0 CA-C-O 120.937 0.399 . . . . 0.0 110.294 179.673 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -150.77 135.91 17.65 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-N 116.036 -0.529 . . . . 0.0 109.873 179.395 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 60.3 ttp180 . . . . . 0 C--O 1.221 -0.429 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.162 -179.38 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 67.7 mtt . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 108.928 -0.768 . . . . 0.0 108.928 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -71.69 148.9 92.92 Favored Pre-proline 0 CA--C 1.54 0.56 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.466 -179.422 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 64.3 Cg_endo -69.04 -16.3 40.47 Favored 'Trans proline' 0 N--CA 1.495 1.617 0 C-N-CA 122.314 2.01 . . . . 0.0 112.108 179.718 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 19.4 p -75.92 70.11 2.61 Favored 'General case' 0 CA--C 1.52 -0.21 0 CA-C-O 121.057 0.456 . . . . 0.0 110.388 -179.139 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -166.23 53.31 0.09 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.8 179.825 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 75.6 m-85 -83.92 133.99 34.69 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-O 120.817 0.341 . . . . 0.0 110.203 179.818 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 47.8 m -92.58 -179.91 5.32 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.121 179.665 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -71.86 -30.1 66.33 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.176 -0.77 . . . . 0.0 111.176 179.738 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 34.8 t -69.75 -18.06 63.48 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.84 0.353 . . . . 0.0 110.824 -179.468 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 93.7 m-20 -69.0 150.34 47.78 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 179.756 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.534 HG21 ' HE ' ' A' ' 54' ' ' ARG . 19.7 m -129.41 130.47 23.31 Favored Pre-proline 0 N--CA 1.474 0.742 0 CA-C-N 116.568 -0.287 . . . . 0.0 110.786 -179.007 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -77.95 146.85 23.55 Favored 'Trans proline' 0 N--CA 1.49 1.306 0 C-N-CA 121.466 1.444 . . . . 0.0 111.64 179.632 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 62.1 ttp180 -158.12 124.04 4.62 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 179.206 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 72.4 mt -68.72 119.37 68.59 Favored Pre-proline 0 CA--C 1.543 0.707 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.935 -179.437 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.441 ' CD ' ' O ' ' A' ' 91' ' ' VAL . 98.4 Cg_endo -75.11 159.37 41.06 Favored 'Trans proline' 0 N--CA 1.493 1.452 0 C-N-CA 121.821 1.681 . . . . 0.0 112.112 -179.851 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 77.6 mtp85 -55.54 150.83 11.43 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.414 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 82.72 15.02 74.25 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.77 -0.932 . . . . 0.0 110.77 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.54 ' CG1' HD11 ' A' ' 31' ' ' LEU . 60.3 t -135.05 131.85 52.88 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.525 0 CA-C-O 120.869 0.366 . . . . 0.0 110.145 179.689 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 90.9 mtm180 -138.03 155.94 48.31 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.267 -179.795 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 29.2 mt -93.11 102.68 15.0 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 109.832 -0.432 . . . . 0.0 109.832 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 84.1 mtp180 -89.93 143.67 26.59 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 116.212 -0.449 . . . . 0.0 109.96 179.687 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 87.9 t80 -103.46 110.77 22.92 Favored 'General case' 0 N--CA 1.463 0.207 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.003 179.742 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 95.2 m-20 -89.66 92.97 9.29 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 116.034 -0.53 . . . . 0.0 109.879 179.706 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.5 tt0 -62.16 -33.16 73.98 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.184 -179.805 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.402 HG22 ' H ' ' A' ' 25' ' ' VAL . 3.0 m -63.19 -42.9 98.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.366 -179.809 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.469 ' NH2' ' OD1' ' A' ' 39' ' ' ASP . 99.8 mtt180 -90.9 -8.51 49.19 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-O 120.67 0.272 . . . . 0.0 110.525 179.693 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 17.0 t-20 55.66 33.36 21.12 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.028 179.737 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 18.2 ptmt -145.08 158.53 43.79 Favored 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 116.319 -0.4 . . . . 0.0 109.957 179.712 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.406 ' O ' ' O ' ' A' ' 40' ' ' LEU . 70.4 m80 -88.48 150.55 23.07 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 179.395 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 21.9 m -137.92 156.49 31.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -179.76 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.54 HD11 ' CG1' ' A' ' 18' ' ' VAL . 36.7 tp -104.53 123.82 48.2 Favored 'General case' 0 CA--C 1.517 -0.319 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.449 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 55.1 tp -78.78 97.16 5.81 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 179.205 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -95.32 147.32 32.84 Favored Pre-proline 0 CA--C 1.54 0.588 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 71.2 Cg_exo -48.24 -36.48 29.51 Favored 'Trans proline' 0 N--CA 1.497 1.724 0 C-N-CA 121.588 1.525 . . . . 0.0 112.557 178.62 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -73.95 -52.06 14.06 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.519 -0.31 . . . . 0.0 111.004 -178.596 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 17.6 ptm180 -176.12 161.69 2.4 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.712 -179.844 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 90.1 m -73.52 124.89 26.75 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.244 178.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 77.2 m-85 -101.5 133.65 45.83 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.156 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.469 ' OD1' ' NH2' ' A' ' 26' ' ' ARG . 82.7 m-20 -73.21 120.53 18.96 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.26 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.406 ' O ' ' O ' ' A' ' 29' ' ' HIS . 84.0 mt -133.16 158.96 41.53 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-O 121.062 0.458 . . . . 0.0 110.343 -179.701 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -82.9 152.14 25.67 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.048 -179.447 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 50.0 t0 -58.48 -37.8 76.27 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.27 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 98.1 m-20 -63.47 -38.96 93.16 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.352 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -68.71 -40.9 79.74 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.67 0.272 . . . . 0.0 110.857 -179.665 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 58.4 t -78.04 -31.45 16.68 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 N-CA-C 110.006 -0.368 . . . . 0.0 110.006 179.693 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -53.55 -38.16 63.58 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.235 -179.591 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 89.9 t -60.57 -46.6 95.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.657 179.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 40.3 mt -76.59 -16.9 59.47 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.842 -178.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 37.5 ttmt -92.37 -32.08 15.09 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.622 179.465 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 5.7 tp -72.51 -32.22 65.96 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.531 -179.123 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.409 HG13 ' O ' ' A' ' 51' ' ' VAL . 10.4 p -72.51 127.14 34.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 121.049 0.452 . . . . 0.0 110.458 -179.908 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 95.2 m-20 -69.59 -42.91 73.81 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.35 179.596 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -145.9 -102.47 0.34 Allowed Glycine 0 N--CA 1.472 1.038 0 N-CA-C 110.404 -1.078 . . . . 0.0 110.404 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . 0.534 ' HE ' HG21 ' A' ' 11' ' ' VAL . 84.3 mtp180 -114.79 104.98 12.49 Favored 'General case' 0 N--CA 1.471 0.586 0 CA-C-O 120.648 0.261 . . . . 0.0 110.321 179.512 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 97.6 m-20 -117.24 148.86 41.27 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.032 178.541 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 32.1 p -81.14 148.67 29.47 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 179.009 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.426 HG23 ' N ' ' A' ' 58' ' ' SER . 32.8 m -56.57 -39.08 60.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-N 116.374 -0.376 . . . . 0.0 110.361 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . 0.426 ' N ' HG23 ' A' ' 57' ' ' VAL . 69.5 m -57.68 -45.58 85.44 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.656 -179.678 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.3 tt0 -66.52 -45.73 78.55 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.603 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 96.6 mt -61.58 -43.21 96.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.141 -0.481 . . . . 0.0 109.762 -179.536 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.416 ' O ' ' N ' ' A' ' 65' ' ' GLY . . . -53.88 -42.04 68.2 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.9 -179.144 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 98.0 mm-40 -64.53 -56.08 16.36 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.083 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 69.9 mt -64.07 -48.92 83.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-O 120.846 0.355 . . . . 0.0 110.596 -179.096 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 30.6 tp -67.53 -36.53 81.19 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.252 -179.513 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.43 ' O ' ' N ' ' A' ' 69' ' ' ASP . . . -58.65 -39.46 93.45 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 111.011 -0.836 . . . . 0.0 111.011 -179.541 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 97.5 mt-30 -65.8 -34.65 78.66 Favored 'General case' 0 C--N 1.326 -0.434 0 C-N-CA 121.044 -0.262 . . . . 0.0 110.621 179.744 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 96.1 m -61.73 -47.43 85.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.767 0.318 . . . . 0.0 110.393 -179.674 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -93.92 -1.34 54.86 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.633 179.594 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . 0.43 ' N ' ' O ' ' A' ' 65' ' ' GLY . 51.5 t0 50.22 62.12 2.84 Favored 'General case' 0 C--N 1.332 -0.185 0 C-N-CA 120.92 -0.312 . . . . 0.0 110.878 179.756 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -140.45 161.54 37.47 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-N 116.484 -0.325 . . . . 0.0 110.255 -179.584 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 68.6 m-20 -55.85 114.5 7.58 Favored Pre-proline 0 CA--C 1.544 0.736 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.593 -179.193 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_exo -48.52 -35.71 29.54 Favored 'Trans proline' 0 N--CA 1.496 1.664 0 C-N-CA 121.793 1.662 . . . . 0.0 112.329 179.555 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -53.7 -39.97 65.63 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.342 -179.193 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 72.5 mt -72.63 -36.36 53.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.76 179.722 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 42.9 mm -61.01 -48.27 89.84 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.258 -178.506 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -61.71 -43.86 98.05 Favored 'General case' 0 CA--C 1.532 0.252 0 CA-C-O 120.856 0.36 . . . . 0.0 110.197 -179.619 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.454 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -66.85 -19.21 65.69 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.265 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 64.8 t0 -80.64 -46.13 16.13 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-O 120.683 0.278 . . . . 0.0 111.093 -179.637 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 34.0 pt -79.78 -33.88 15.16 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.566 0 CA-C-O 120.916 0.388 . . . . 0.0 111.369 -179.544 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.413 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 9.4 mt -47.66 -59.04 6.24 Favored Pre-proline 0 CA--C 1.545 0.768 0 CA-C-N 116.558 -0.292 . . . . 0.0 111.07 179.679 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.454 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 33.3 Cg_endo -60.0 -24.39 76.32 Favored 'Trans proline' 0 N--CA 1.497 1.726 0 C-N-CA 121.964 1.776 . . . . 0.0 111.749 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 13.2 tpt -65.45 -36.18 83.13 Favored 'General case' 0 CA--C 1.532 0.258 0 CA-C-O 120.805 0.335 . . . . 0.0 110.598 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 47.7 mt -61.56 -39.44 91.14 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.294 -179.652 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.0 -40.82 95.01 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 179.746 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -66.48 -40.56 94.38 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 111.51 -0.636 . . . . 0.0 111.51 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 87.2 mt -66.83 -40.59 88.02 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.852 0.358 . . . . 0.0 110.513 -179.601 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -54.73 -37.35 65.78 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.796 0.331 . . . . 0.0 110.542 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 86.7 mt-30 -62.57 -22.95 66.75 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.815 179.721 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 65.1 mttp -91.34 -6.76 52.55 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.199 -179.542 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 14.8 tpt180 62.35 53.13 2.86 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.914 -0.584 . . . . 0.0 110.17 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . 0.441 ' O ' ' CD ' ' A' ' 15' ' ' PRO . 30.2 m -133.09 -1.27 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.312 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.809 -179.619 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 35.1 tp -104.92 145.42 30.43 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-O 121.271 0.557 . . . . 0.0 109.989 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 45.8 tp10 -149.06 115.24 5.78 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.14 -0.936 . . . . 0.0 109.902 -179.302 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 61.3 ttp180 . . . . . 0 C--O 1.221 -0.436 0 CA-C-O 117.901 -1.047 . . . . 0.0 109.989 179.931 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 16.8 ptm . . . . . 0 N--CA 1.489 1.506 0 N-CA-C 109.268 -0.641 . . . . 0.0 109.268 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 52.46 63.76 8.4 Favored Pre-proline 0 CA--C 1.534 0.347 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.457 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -75.36 168.44 24.57 Favored 'Trans proline' 0 N--CA 1.493 1.456 0 C-N-CA 122.472 2.115 . . . . 0.0 111.869 -179.806 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 18.7 p -73.46 -35.28 65.7 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.123 -179.591 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . 45.76 93.12 0.01 OUTLIER 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.797 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 91.4 m-85 -80.01 133.83 36.18 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.378 -179.665 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 34.1 m -94.1 -175.43 3.69 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.506 -179.836 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -65.21 -37.47 94.07 Favored Glycine 0 CA--C 1.527 0.806 0 N-CA-C 111.348 -0.701 . . . . 0.0 111.348 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 15.5 m -72.81 -25.44 61.15 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.826 0.346 . . . . 0.0 110.734 -179.544 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -68.39 150.41 48.19 Favored 'General case' 0 CA--C 1.515 -0.369 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 -179.806 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.578 HG21 ' HE ' ' A' ' 54' ' ' ARG . 27.4 m -128.2 128.94 23.68 Favored Pre-proline 0 CA--C 1.54 0.565 0 CA-C-N 116.422 -0.353 . . . . 0.0 111.178 -179.192 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 95.1 Cg_endo -77.22 145.13 24.01 Favored 'Trans proline' 0 N--CA 1.494 1.551 0 C-N-CA 121.959 1.773 . . . . 0.0 111.742 179.377 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 71.1 ttt-85 -158.09 127.35 5.77 Favored 'General case' 0 C--N 1.332 -0.183 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.216 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 47.0 mt -68.2 131.59 91.99 Favored Pre-proline 0 CA--C 1.542 0.644 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.955 -179.381 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 81.2 Cg_endo -75.29 158.75 40.89 Favored 'Trans proline' 0 N--CA 1.491 1.354 0 C-N-CA 122.006 1.804 . . . . 0.0 111.938 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 60.4 ttt85 -55.95 144.44 28.4 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.074 179.556 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 87.36 12.39 67.51 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 179.679 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.519 ' CG1' HD11 ' A' ' 31' ' ' LEU . 59.9 t -132.83 130.28 58.76 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.52 0 CA-C-O 120.946 0.403 . . . . 0.0 110.155 179.344 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.598 HH11 ' NH1' ' A' ' 21' ' ' ARG . 81.2 mtm-85 -138.81 157.78 45.44 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.079 179.768 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 27.5 mt -92.03 139.9 30.18 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.715 179.846 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.598 ' NH1' HH11 ' A' ' 19' ' ' ARG . 81.7 mtt85 -139.47 146.71 40.38 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.002 -0.544 . . . . 0.0 109.948 -179.677 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 59.2 t80 -102.83 117.6 34.99 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 115.701 -0.682 . . . . 0.0 110.166 179.656 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -89.73 103.9 16.51 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.601 178.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 78.2 tt0 -63.76 -36.47 83.97 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.524 -179.828 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.418 HG22 ' H ' ' A' ' 25' ' ' VAL . 1.5 m -62.99 -42.67 97.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.342 -179.524 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 100.0 mtt180 -86.67 -18.6 30.88 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 120.743 0.306 . . . . 0.0 110.289 -179.629 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 12.2 m-80 68.03 23.66 8.08 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.116 179.502 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 14.6 ptpt -145.29 163.52 34.25 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.088 179.393 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 77.3 m80 -89.51 151.0 22.21 Favored 'General case' 0 CA--C 1.519 -0.247 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.934 179.67 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 34.7 m -140.74 158.07 23.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.007 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.519 HD11 ' CG1' ' A' ' 18' ' ' VAL . 34.1 tp -100.41 116.46 32.43 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.23 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 44.3 tp -77.02 99.35 5.27 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 179.285 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -97.38 147.27 32.73 Favored Pre-proline 0 CA--C 1.542 0.662 0 C-N-CA 121.107 -0.237 . . . . 0.0 110.395 179.782 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 77.3 Cg_exo -49.17 -37.84 39.78 Favored 'Trans proline' 0 N--CA 1.499 1.804 0 C-N-CA 122.073 1.849 . . . . 0.0 112.502 178.654 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 77.8 tt0 -74.28 -51.93 13.79 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.893 -178.72 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 59.4 ttm-85 -174.87 151.34 1.37 Allowed 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.954 0.407 . . . . 0.0 110.475 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 69.7 m -69.48 132.84 46.93 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.47 179.114 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 85.4 m-85 -103.4 133.99 47.53 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.458 179.895 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 38.5 p-10 -71.59 117.78 13.59 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.364 179.451 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 88.2 mt -133.45 157.48 45.49 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.392 -179.728 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 87.5 m-20 -86.7 152.49 22.5 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.045 -179.726 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 53.9 t0 -58.51 -39.47 80.2 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.716 -179.767 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 5.3 m120 -63.7 -39.97 95.63 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.704 -179.586 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.76 -40.19 76.26 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.865 -179.564 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 57.6 t -78.15 -29.94 15.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.398 -0.364 . . . . 0.0 110.258 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -54.11 -36.06 62.81 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.307 -179.68 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 60.1 t -60.71 -46.19 96.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.693 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 38.2 mt -75.76 -19.01 59.33 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.522 -179.024 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 15.2 ttmm -90.08 -29.42 18.37 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.546 179.639 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 9.0 tp -71.13 -32.7 69.31 Favored 'General case' 0 C--N 1.332 -0.178 0 C-N-CA 120.602 -0.439 . . . . 0.0 110.533 -178.522 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.1 p -74.46 127.37 36.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.456 179.75 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 95.2 m-20 -70.9 -43.75 67.67 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.376 179.536 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -143.51 -101.03 0.36 Allowed Glycine 0 N--CA 1.472 1.044 0 N-CA-C 110.458 -1.057 . . . . 0.0 110.458 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . 0.578 ' HE ' HG21 ' A' ' 11' ' ' VAL . 85.1 mtp180 -114.77 104.87 12.39 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-O 120.924 0.393 . . . . 0.0 110.265 179.232 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 97.2 m-20 -117.11 153.77 32.18 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.355 178.072 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 13.7 p -80.09 136.53 36.57 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 178.668 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 29.9 m -54.49 -38.98 43.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.481 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 12.0 t -60.12 -44.63 94.74 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.676 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 56.8 tt0 -64.41 -43.21 95.11 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.842 -179.461 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 96.6 mt -61.2 -43.15 95.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 -179.632 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -52.17 -35.42 48.74 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.164 -178.924 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 94.3 mm-40 -63.36 -53.85 46.08 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.674 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 70.2 mt -66.63 -48.43 80.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.924 0.392 . . . . 0.0 110.854 -179.503 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 21.8 tp -67.73 -39.21 84.29 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.545 -178.946 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -54.74 -41.0 73.55 Favored Glycine 0 CA--C 1.525 0.662 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 -179.319 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 87.7 mt-30 -65.85 -31.6 72.65 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.63 0.252 . . . . 0.0 110.557 179.706 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 18.8 m -61.99 -45.69 92.53 Favored 'General case' 0 C--N 1.329 -0.283 0 C-N-CA 120.872 -0.331 . . . . 0.0 110.546 -179.437 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -90.6 1.75 56.47 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.466 179.855 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 61.6 t0 54.74 48.65 19.72 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.564 179.767 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -140.94 160.56 39.81 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-O 120.915 0.388 . . . . 0.0 110.313 -179.68 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 95.0 m-20 -55.91 144.39 57.83 Favored Pre-proline 0 CA--C 1.54 0.566 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.678 -179.096 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -68.18 -33.76 23.85 Favored 'Trans proline' 0 N--CA 1.498 1.777 0 C-N-CA 122.462 2.108 . . . . 0.0 112.28 -179.533 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -54.41 -32.22 56.78 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.829 0.347 . . . . 0.0 110.861 -179.348 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 65.6 mt -68.46 -42.03 83.63 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.599 -179.856 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.544 ' N ' HD12 ' A' ' 75' ' ' ILE . 1.7 mp -60.82 -39.85 83.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 -179.182 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 7.0 mm-40 -57.31 -66.24 0.49 Allowed 'General case' 0 C--N 1.314 -0.977 0 C-N-CA 120.597 -0.441 . . . . 0.0 110.967 -178.337 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.402 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -55.34 -16.75 3.8 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.742 -178.69 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 58.5 t0 -80.65 -52.59 7.39 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.186 -179.713 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 18.4 pt -80.51 -33.5 13.84 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.425 0 CA-C-O 121.021 0.438 . . . . 0.0 111.485 -178.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.416 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 10.3 mt -44.94 -59.74 3.86 Favored Pre-proline 0 CA--C 1.54 0.578 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.611 179.844 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.416 ' HD2' ' N ' ' A' ' 80' ' ' LEU . 39.6 Cg_endo -61.73 -30.33 84.8 Favored 'Trans proline' 0 N--CA 1.493 1.444 0 C-N-CA 121.451 1.434 . . . . 0.0 111.751 179.793 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 15.1 tpt -65.85 -41.01 92.22 Favored 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 120.781 -0.367 . . . . 0.0 110.752 -179.367 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 82.9 mt -62.86 -41.41 99.37 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.243 -179.483 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.91 -37.87 88.71 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.384 179.647 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -62.43 -39.79 98.24 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 111.122 -0.791 . . . . 0.0 111.122 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 88.2 mt -67.67 -39.54 84.51 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.865 0.364 . . . . 0.0 110.491 -179.768 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -53.8 -36.94 63.01 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.886 0.374 . . . . 0.0 110.69 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 54.6 mt-30 -62.38 -21.76 65.6 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.886 179.734 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -92.26 -1.56 57.02 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 116.515 -0.312 . . . . 0.0 110.242 -179.261 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 63.2 ttt-85 61.56 57.11 2.37 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.345 179.525 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 34.8 m -141.71 11.82 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.216 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 55.3 tp -140.18 140.13 35.84 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.397 179.863 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 16.4 pt-20 -149.31 142.04 24.57 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 115.652 -0.703 . . . . 0.0 110.555 179.386 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 62.2 ttp180 . . . . . 0 C--O 1.22 -0.494 0 CA-C-O 118.057 -0.973 . . . . 0.0 110.263 179.727 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 48.4 ttp . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 26.4 mm-40 48.41 72.73 1.16 Allowed Pre-proline 0 CA--C 1.533 0.305 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.751 -179.81 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_exo -56.77 149.41 60.02 Favored 'Trans proline' 0 N--CA 1.496 1.631 0 C-N-CA 122.575 2.183 . . . . 0.0 111.942 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.429 HG22 ' H ' ' A' ' 4' ' ' THR . 0.0 OUTLIER -79.02 83.64 5.1 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.974 -179.78 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.405 ' O ' ' O ' ' A' ' 6' ' ' PHE . . . -76.21 -4.68 43.12 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.554 -179.906 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.558 ' CE2' ' NH2' ' A' ' 94' ' ' ARG . 97.0 m-85 58.67 146.56 0.01 OUTLIER 'General case' 0 N--CA 1.462 0.161 0 O-C-N 123.608 0.567 . . . . 0.0 110.515 -179.523 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 49.7 m -92.57 -177.57 4.62 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-O 120.833 0.349 . . . . 0.0 110.239 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -71.73 -32.07 64.44 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 110.926 -0.87 . . . . 0.0 110.926 179.604 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 37.1 t -69.41 -17.49 63.66 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.681 0.277 . . . . 0.0 110.841 -179.321 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -68.28 146.16 53.57 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.536 HG23 ' O ' ' A' ' 11' ' ' VAL . 30.0 m -128.96 102.83 18.94 Favored Pre-proline 0 CA--C 1.541 0.599 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.492 -179.861 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -55.71 143.49 79.86 Favored 'Trans proline' 0 N--CA 1.5 1.91 0 C-N-CA 122.082 1.855 . . . . 0.0 112.11 178.64 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.41 ' HD2' ' HE ' ' A' ' 54' ' ' ARG . 78.6 ttt-85 -151.33 122.65 7.8 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-O 120.814 0.34 . . . . 0.0 110.15 178.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 71.1 mt -69.61 118.73 65.51 Favored Pre-proline 0 CA--C 1.542 0.639 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.323 -179.265 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.46 ' CD ' ' O ' ' A' ' 91' ' ' VAL . 89.1 Cg_endo -78.61 166.49 23.78 Favored 'Trans proline' 0 N--CA 1.495 1.572 0 C-N-CA 122.257 1.971 . . . . 0.0 112.036 179.763 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 9.3 ptm180 -55.48 154.3 6.57 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.282 179.27 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 84.36 -14.83 43.43 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 111.211 -0.755 . . . . 0.0 111.211 179.442 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.587 ' CG1' HD11 ' A' ' 31' ' ' LEU . 41.4 t -104.65 127.8 58.78 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.498 0 CA-C-O 120.929 0.395 . . . . 0.0 110.06 179.743 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 81.8 mtm-85 -138.38 153.43 48.92 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.269 -179.732 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 19.0 mt -98.47 98.78 9.94 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.079 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.496 ' HE ' HD22 ' A' ' 32' ' ' LEU . 96.0 mtt-85 -93.07 143.2 26.47 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.194 179.596 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 82.1 t80 -102.21 119.16 38.34 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.581 179.408 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 88.5 m-20 -87.73 105.97 17.74 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.127 -179.772 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -64.92 -37.35 87.35 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.766 -179.796 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 3.0 m -62.64 -43.24 98.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.617 -179.223 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.431 ' CD ' ' HZ2' ' A' ' 28' ' ' LYS . 95.3 mtt-85 -90.76 -10.98 40.92 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-O 120.695 0.283 . . . . 0.0 110.589 179.844 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 61.1 t-20 56.36 37.11 28.53 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.591 179.768 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.623 ' HZ3' ' CG1' ' A' ' 30' ' ' VAL . 9.5 pttm -144.91 167.05 23.54 Favored 'General case' 0 N--CA 1.466 0.346 0 N-CA-C 109.648 -0.501 . . . . 0.0 109.648 179.809 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.471 ' ND1' ' OD1' ' A' ' 42' ' ' ASP . 73.9 m80 -93.32 149.9 20.88 Favored 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 109.652 -0.499 . . . . 0.0 109.652 178.467 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.623 ' CG1' ' HZ3' ' A' ' 28' ' ' LYS . 35.3 m -140.62 152.77 21.04 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.337 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.834 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.587 HD11 ' CG1' ' A' ' 18' ' ' VAL . 35.4 tp -100.56 117.68 35.19 Favored 'General case' 0 N--CA 1.465 0.289 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 179.567 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.496 HD22 ' HE ' ' A' ' 21' ' ' ARG . 56.9 tp -79.16 97.98 6.4 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 179.044 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -93.62 148.07 34.77 Favored Pre-proline 0 CA--C 1.543 0.688 0 C-N-CA 120.985 -0.286 . . . . 0.0 110.321 179.845 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -44.26 -34.75 7.39 Favored 'Trans proline' 0 N--CA 1.497 1.7 0 C-N-CA 122.19 1.927 . . . . 0.0 112.189 178.877 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 -76.17 -52.08 10.81 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-N 116.48 -0.327 . . . . 0.0 111.076 -178.787 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 37.5 ptt180 -176.39 165.75 2.73 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.672 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 61.3 m -77.24 127.86 33.35 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.39 178.845 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 65.1 m-85 -104.23 138.41 40.73 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-O 121.039 0.447 . . . . 0.0 110.074 179.682 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -74.15 119.87 18.95 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.506 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 92.8 mt -135.31 157.58 46.53 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.209 -0.45 . . . . 0.0 109.894 179.826 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 19.9 m-20 -85.05 161.58 19.66 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.973 -179.581 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.471 ' OD1' ' ND1' ' A' ' 29' ' ' HIS . 31.8 m-20 -61.15 -39.9 91.85 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.357 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . 0.403 ' O ' HG23 ' A' ' 47' ' ' VAL . 8.8 m120 -63.0 -36.8 84.76 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.578 -179.463 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.01 -43.44 74.78 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.468 -0.333 . . . . 0.0 111.119 -179.433 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 60.1 t -79.0 -31.83 15.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-O 120.741 0.305 . . . . 0.0 110.526 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -53.87 -35.84 61.98 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.537 -179.559 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.403 HG23 ' O ' ' A' ' 43' ' ' ASN . 93.1 t -61.32 -47.75 92.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.943 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 44.9 mt -77.61 -14.76 59.56 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.868 -178.833 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 37.4 ttmt -91.36 -30.66 16.41 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.88 0.371 . . . . 0.0 110.492 179.31 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 7.9 tp -71.15 -32.1 68.51 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.638 -178.451 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.6 p -73.51 125.01 31.85 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.602 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -73.35 -41.42 63.47 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.463 179.372 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -143.51 -99.58 0.31 Allowed Glycine 0 N--CA 1.471 0.968 0 N-CA-C 110.454 -1.059 . . . . 0.0 110.454 -179.635 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . 0.41 ' HE ' ' HD2' ' A' ' 13' ' ' ARG . 99.5 mtt180 -114.83 104.43 11.94 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 110.1 -0.333 . . . . 0.0 110.1 178.927 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 97.9 m-20 -117.36 146.09 43.63 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.005 178.207 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 42.3 p -79.69 141.43 36.42 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 178.776 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.442 HG23 ' N ' ' A' ' 58' ' ' SER . 27.8 m -54.19 -39.52 43.04 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.413 -179.667 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . 0.442 ' N ' HG23 ' A' ' 57' ' ' VAL . 67.0 m -58.64 -43.1 89.65 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.663 179.596 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 55.9 tt0 -64.97 -47.91 75.91 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.868 -179.701 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 65.2 mt -60.77 -43.04 94.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.307 179.913 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -53.24 -41.04 65.03 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.322 -0.399 . . . . 0.0 111.042 -179.286 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 96.0 mm-40 -63.59 -53.86 45.01 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.894 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 65.3 mt -66.06 -46.83 86.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-O 121.02 0.438 . . . . 0.0 110.604 -179.057 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 25.7 tp -68.58 -37.75 80.11 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.093 -179.419 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.433 ' O ' ' N ' ' A' ' 69' ' ' ASP . . . -57.14 -40.41 91.49 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 -179.537 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 73.1 mt-30 -66.03 -32.31 73.71 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.656 0.265 . . . . 0.0 110.46 179.545 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 19.5 m -62.66 -47.96 81.39 Favored 'General case' 0 C--N 1.329 -0.3 0 C-N-CA 120.722 -0.391 . . . . 0.0 110.634 -179.602 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -94.81 -3.04 49.7 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.47 179.73 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . 0.433 ' N ' ' O ' ' A' ' 65' ' ' GLY . 66.4 t0 54.25 62.26 2.66 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.798 179.654 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -140.99 160.52 39.9 Favored 'General case' 0 N--CA 1.469 0.523 0 CA-C-O 120.766 0.317 . . . . 0.0 110.434 -179.723 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 88.2 m-20 -55.73 114.21 7.0 Favored Pre-proline 0 CA--C 1.543 0.693 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.49 -178.774 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 81.9 Cg_exo -49.22 -36.5 37.1 Favored 'Trans proline' 0 N--CA 1.502 1.995 0 C-N-CA 122.099 1.866 . . . . 0.0 112.474 179.887 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -53.58 -38.58 64.06 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.053 0.454 . . . . 0.0 110.884 -179.274 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 67.4 mt -72.71 -38.2 57.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.53 179.409 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 43.6 mm -60.63 -49.14 85.65 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.122 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.12 -178.039 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -62.01 -44.56 96.45 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.888 0.375 . . . . 0.0 110.436 -179.914 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.449 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -66.31 -20.71 66.17 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.954 -0.567 . . . . 0.0 111.114 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 65.9 t0 -79.82 -46.39 16.99 Favored 'General case' 0 CA--C 1.533 0.297 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.255 -179.602 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 34.9 pt -79.26 -32.19 14.86 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 CA-C-O 121.074 0.464 . . . . 0.0 111.43 -179.124 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.438 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 8.3 mt -48.56 -59.63 5.82 Favored Pre-proline 0 CA--C 1.543 0.686 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.5 179.722 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.449 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 30.1 Cg_endo -59.22 -25.24 77.44 Favored 'Trans proline' 0 N--CA 1.494 1.523 0 C-N-CA 121.995 1.796 . . . . 0.0 111.988 -179.316 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 44.5 ttp -65.35 -36.39 83.89 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.843 0.354 . . . . 0.0 110.551 -179.7 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 52.2 mt -62.12 -39.32 92.15 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.892 -179.656 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.7 -37.3 83.62 Favored 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 120.763 -0.375 . . . . 0.0 110.376 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -65.47 -41.66 96.21 Favored Glycine 0 CA--C 1.526 0.781 0 N-CA-C 111.122 -0.791 . . . . 0.0 111.122 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.414 HD23 ' HZ1' ' A' ' 89' ' ' LYS . 84.6 mt -70.69 -38.36 73.7 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.902 0.382 . . . . 0.0 110.417 -179.714 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -52.68 -24.33 8.36 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.609 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 86.1 mt-30 -61.18 -30.85 70.65 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.566 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . 0.414 ' HZ1' HD23 ' A' ' 86' ' ' LEU . 25.6 mtmm -96.64 0.39 49.77 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-O 120.921 0.391 . . . . 0.0 110.462 -179.361 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 66.3 ttt180 56.52 47.73 18.09 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.295 179.588 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . 0.46 ' O ' ' CD ' ' A' ' 15' ' ' PRO . 24.5 m -105.85 2.2 10.26 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.504 0 CA-C-N 116.471 -0.332 . . . . 0.0 110.185 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.567 HD13 HH12 ' A' ' 94' ' ' ARG . 97.3 mt -102.31 164.84 11.46 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-O 121.23 0.538 . . . . 0.0 110.505 179.849 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 45.7 tp10 -154.33 129.19 9.43 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.185 -0.916 . . . . 0.0 110.243 -179.534 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . 0.567 HH12 HD13 ' A' ' 92' ' ' LEU . 73.2 mtt85 . . . . . 0 C--N 1.326 -0.449 0 CA-C-O 117.763 -1.113 . . . . 0.0 109.752 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 69.8 mtm . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 31.3 tt0 57.3 57.15 7.85 Favored Pre-proline 0 CA--C 1.533 0.314 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.376 -179.652 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.519 ' C ' ' H ' ' A' ' 5' ' ' ALA . 66.8 Cg_endo -70.56 -13.05 32.31 Favored 'Trans proline' 0 N--CA 1.496 1.658 0 C-N-CA 122.323 2.015 . . . . 0.0 111.536 -179.866 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.474 ' C ' ' H ' ' A' ' 6' ' ' PHE . 15.7 p 60.76 -4.13 0.13 Allowed 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.889 -179.312 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.519 ' H ' ' C ' ' A' ' 3' ' ' PRO . . . 69.63 -40.52 0.46 Allowed 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 116.476 -0.329 . . . . 0.0 110.907 179.886 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.474 ' H ' ' C ' ' A' ' 4' ' ' THR . 1.3 t80 56.74 107.72 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.111 -0.495 . . . . 0.0 109.928 -179.619 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 16.7 m -90.14 176.61 6.7 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.581 179.848 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -71.31 -27.16 72.11 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 111.125 -0.79 . . . . 0.0 111.125 179.763 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 15.4 m -70.44 -22.03 62.74 Favored 'General case' 0 C--O 1.232 0.156 0 CA-C-O 120.836 0.351 . . . . 0.0 110.522 -179.481 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 -69.09 149.75 48.36 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 179.232 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.479 ' CG2' ' HE ' ' A' ' 54' ' ' ARG . 20.9 m -128.17 127.44 23.78 Favored Pre-proline 0 CA--C 1.548 0.868 0 CA-C-O 119.744 -0.169 . . . . 0.0 110.783 -178.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -77.46 147.41 25.42 Favored 'Trans proline' 0 N--CA 1.494 1.538 0 C-N-CA 121.321 1.347 . . . . 0.0 112.279 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 56.7 ttt85 -158.1 124.85 4.88 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 115.728 -0.669 . . . . 0.0 109.364 178.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 67.6 mt -70.09 128.25 91.72 Favored Pre-proline 0 CA--C 1.544 0.743 0 CA-C-O 119.389 -0.339 . . . . 0.0 110.771 -179.531 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -73.33 158.78 47.98 Favored 'Trans proline' 0 N--CA 1.496 1.643 0 C-N-CA 121.748 1.632 . . . . 0.0 111.978 179.834 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 90.7 mtm180 -57.37 148.56 22.77 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.521 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 83.54 12.86 77.31 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 111.031 -0.827 . . . . 0.0 111.031 179.792 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.476 ' CG1' HD11 ' A' ' 31' ' ' LEU . 61.4 t -132.6 132.08 59.93 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.566 0 CA-C-O 121.037 0.446 . . . . 0.0 109.986 179.78 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 89.9 mtm180 -136.81 158.75 43.73 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.207 -179.82 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 47.6 mt -91.06 142.56 27.62 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.092 -179.698 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 83.6 mtp180 -137.58 139.86 40.66 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 121.052 0.453 . . . . 0.0 110.095 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 73.9 t80 -99.28 120.86 40.24 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.286 -179.855 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.481 ' O ' ' N ' ' A' ' 27' ' ' ASN . 94.6 m-20 -87.45 105.98 17.66 Favored 'General case' 0 N--CA 1.462 0.174 0 CA-C-N 116.031 -0.531 . . . . 0.0 109.638 179.84 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.478 ' O ' ' ND2' ' A' ' 27' ' ' ASN . 39.2 tt0 -64.85 -37.24 86.96 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.071 -179.531 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 1.5 p -62.18 -45.39 98.87 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.988 -179.275 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 94.6 mtt-85 -93.88 -9.25 37.85 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.689 -179.263 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.481 ' N ' ' O ' ' A' ' 23' ' ' ASP . 26.2 m120 54.18 41.39 32.03 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.216 179.352 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 13.9 pttm -144.45 163.58 33.4 Favored 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 109.457 -0.572 . . . . 0.0 109.457 179.768 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 78.2 m80 -94.26 148.29 22.35 Favored 'General case' 0 C--N 1.329 -0.284 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 179.158 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 27.4 m -139.6 158.87 27.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.246 -0.434 . . . . 0.0 109.836 -179.765 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.476 HD11 ' CG1' ' A' ' 18' ' ' VAL . 37.8 tp -103.07 120.15 40.16 Favored 'General case' 0 N--CA 1.468 0.467 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.241 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 58.5 tp -80.01 97.3 6.73 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 178.875 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -97.01 147.13 32.46 Favored Pre-proline 0 CA--C 1.538 0.518 0 N-CA-C 110.172 -0.307 . . . . 0.0 110.172 -179.546 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 80.8 Cg_exo -47.52 -37.75 26.74 Favored 'Trans proline' 0 N--CA 1.496 1.668 0 C-N-CA 121.419 1.412 . . . . 0.0 112.698 179.032 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 82.1 tt0 -72.84 -52.06 16.36 Favored 'General case' 0 C--N 1.331 -0.206 0 C-N-CA 120.785 -0.366 . . . . 0.0 111.205 -178.489 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 44.0 ttm180 -176.66 151.11 0.89 Allowed 'General case' 0 N--CA 1.465 0.295 0 O-C-N 123.462 0.476 . . . . 0.0 110.378 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 91.7 m -69.8 130.22 41.71 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.185 179.092 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.491 ' CD2' ' NZ ' ' A' ' 89' ' ' LYS . 95.5 m-85 -102.81 139.64 38.12 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-O 120.903 0.382 . . . . 0.0 110.504 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 95.4 m-20 -74.88 119.73 19.46 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.066 179.665 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 75.3 mt -131.38 158.66 40.16 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.364 -179.625 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -85.38 152.81 22.96 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.386 -179.727 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 68.2 t0 -58.95 -41.32 87.15 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.648 -179.711 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 43.8 t-20 -63.35 -37.59 87.85 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.537 -179.842 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -67.93 -37.84 82.15 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.75 -179.478 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 43.2 t -86.53 -19.32 8.25 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.344 0 CA-C-O 120.9 0.381 . . . . 0.0 110.543 179.529 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.73 -50.14 73.12 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.01 0.433 . . . . 0.0 110.321 -179.54 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 17.8 m -62.39 -38.06 80.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.714 179.742 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 47.9 mt -68.9 -32.5 72.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.914 0.387 . . . . 0.0 110.338 179.846 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 36.6 ttpt -87.63 -29.23 21.35 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 116.385 -0.371 . . . . 0.0 111.168 179.785 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 58.6 tp -71.47 -32.28 68.11 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-O 120.661 0.267 . . . . 0.0 110.717 -179.108 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.5 p -73.18 129.74 35.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 121.118 0.485 . . . . 0.0 110.644 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 86.6 m-20 -68.8 -43.18 76.19 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.282 179.45 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -145.36 -100.47 0.29 Allowed Glycine 0 N--CA 1.472 1.072 0 N-CA-C 110.493 -1.043 . . . . 0.0 110.493 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . 0.479 ' HE ' ' CG2' ' A' ' 11' ' ' VAL . 84.3 mtp180 -114.92 104.43 11.91 Favored 'General case' 0 N--CA 1.471 0.612 0 CA-C-N 116.897 0.349 . . . . 0.0 110.327 179.348 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 -117.6 152.13 35.77 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.05 178.07 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 71.2 p -79.18 140.32 37.75 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 178.682 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 29.6 m -54.0 -37.61 34.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 C-N-CA 120.725 -0.39 . . . . 0.0 110.456 -179.534 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 56.8 m -57.89 -43.96 86.44 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.772 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 50.6 tt0 -65.4 -46.3 80.56 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.824 0.345 . . . . 0.0 110.955 -179.534 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 66.8 mt -61.35 -42.63 94.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.312 -179.712 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.406 ' O ' ' N ' ' A' ' 65' ' ' GLY . . . -52.33 -38.44 58.58 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.893 -179.394 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 93.4 mm-40 -63.94 -49.57 72.08 Favored 'General case' 0 C--N 1.327 -0.392 0 C-N-CA 120.872 -0.331 . . . . 0.0 110.596 179.825 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 70.4 mt -64.32 -51.08 72.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.918 -179.252 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 30.0 tp -69.79 -35.63 75.04 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.028 0.442 . . . . 0.0 110.334 -179.606 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.406 ' N ' ' O ' ' A' ' 61' ' ' ALA . . . -54.22 -40.09 66.36 Favored Glycine 0 CA--C 1.525 0.698 0 N-CA-C 110.926 -0.87 . . . . 0.0 110.926 -179.487 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 51.6 mt-30 -66.15 -32.2 73.51 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.569 0.223 . . . . 0.0 110.642 179.598 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 20.8 m -62.45 -47.44 84.03 Favored 'General case' 0 C--N 1.33 -0.258 0 C-N-CA 120.752 -0.379 . . . . 0.0 110.654 -179.502 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 87.8 m-85 -92.33 -3.1 55.88 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.5 179.381 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 66.3 t0 51.6 60.96 3.48 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.996 179.649 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -144.65 164.58 30.54 Favored 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.224 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 76.6 m-20 -55.67 112.78 4.64 Favored Pre-proline 0 CA--C 1.545 0.787 0 CA-C-O 119.248 -0.406 . . . . 0.0 110.311 -179.509 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 80.0 Cg_exo -48.33 -34.74 25.8 Favored 'Trans proline' 0 N--CA 1.502 2.02 0 C-N-CA 121.926 1.751 . . . . 0.0 112.949 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -51.3 -36.54 42.94 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.954 0.407 . . . . 0.0 111.086 -179.352 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 67.8 mt -71.32 -40.44 73.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.806 179.747 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.558 ' N ' HD12 ' A' ' 75' ' ' ILE . 1.7 mp -60.66 -47.9 91.0 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.711 -178.6 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -61.81 -47.09 86.67 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 120.344 -0.542 . . . . 0.0 110.347 -179.162 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.428 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -65.07 -20.47 66.5 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.514 179.766 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 66.0 t0 -79.44 -52.19 8.38 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-O 120.716 0.293 . . . . 0.0 110.887 -179.628 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 13.2 pt -72.09 -40.62 67.12 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 116.299 -0.409 . . . . 0.0 111.256 -179.658 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 8.0 mt -41.19 -60.11 1.91 Allowed Pre-proline 0 CA--C 1.553 1.065 0 CA-C-O 119.586 -0.245 . . . . 0.0 111.056 -179.809 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.428 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 76.2 Cg_exo -39.53 -42.58 2.75 Favored 'Trans proline' 0 N--CA 1.493 1.471 0 C-N-CA 122.576 2.184 . . . . 0.0 112.363 177.824 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 36.2 tpp -65.76 -41.86 91.57 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.508 -179.496 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 44.7 mt -62.01 -41.71 98.37 Favored 'General case' 0 C--N 1.329 -0.283 0 C-N-CA 120.552 -0.459 . . . . 0.0 110.489 -179.031 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -63.5 -39.54 94.72 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.232 179.665 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -68.23 -40.53 87.62 Favored Glycine 0 CA--C 1.527 0.806 0 N-CA-C 111.512 -0.635 . . . . 0.0 111.512 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 66.7 mt -66.7 -39.86 88.26 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.709 0.29 . . . . 0.0 110.638 -179.608 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -52.67 -34.16 50.5 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.777 0.322 . . . . 0.0 110.516 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 77.2 mt-30 -62.87 -22.6 66.82 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.834 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . 0.491 ' NZ ' ' CD2' ' A' ' 38' ' ' PHE . 98.8 mttt -92.74 -3.75 54.27 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.412 -179.225 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 52.9 ttt180 64.43 26.94 13.56 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.549 179.327 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 26.1 m -100.23 0.58 10.39 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.492 179.795 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 45.8 tp -112.21 147.5 36.07 Favored 'General case' 0 N--CA 1.472 0.646 0 CA-C-O 121.215 0.531 . . . . 0.0 109.861 179.625 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -135.46 153.85 51.62 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.472 -0.786 . . . . 0.0 109.788 -179.307 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 50.5 ptt85 . . . . . 0 C--N 1.324 -0.516 0 CA-C-O 117.843 -1.075 . . . . 0.0 110.143 -179.298 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 81.6 mmm . . . . . 0 N--CA 1.492 1.642 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 8.3 mm-40 53.09 57.38 14.46 Favored Pre-proline 0 CA--C 1.532 0.26 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.424 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -71.23 159.67 51.26 Favored 'Trans proline' 0 N--CA 1.494 1.534 0 C-N-CA 122.317 2.011 . . . . 0.0 111.793 -179.8 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.528 ' C ' ' H ' ' A' ' 6' ' ' PHE . 5.2 p -81.3 -23.69 37.72 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.507 -179.521 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.413 ' HB3' ' O ' ' A' ' 4' ' ' THR . . . 69.56 -22.22 0.16 Allowed 'General case' 0 CA--C 1.532 0.266 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.04 -179.778 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.528 ' H ' ' C ' ' A' ' 4' ' ' THR . 96.0 m-85 52.26 175.46 0.02 OUTLIER 'General case' 0 CA--C 1.529 0.142 0 CA-C-N 116.476 -0.329 . . . . 0.0 110.394 -179.544 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 44.3 m -133.68 179.92 5.93 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-O 120.976 0.417 . . . . 0.0 110.526 -179.598 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -65.66 -32.9 84.55 Favored Glycine 0 CA--C 1.526 0.742 0 N-CA-C 110.84 -0.904 . . . . 0.0 110.84 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 78.2 p -70.76 -22.41 62.4 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 120.677 0.275 . . . . 0.0 111.102 -179.256 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 94.9 m-20 -68.85 145.75 53.45 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 179.855 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.499 ' CG2' ' HE ' ' A' ' 54' ' ' ARG . 16.5 m -122.8 125.0 26.49 Favored Pre-proline 0 CA--C 1.545 0.772 0 CA-C-N 116.572 -0.286 . . . . 0.0 110.493 -179.303 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 86.9 Cg_endo -77.96 151.13 27.29 Favored 'Trans proline' 0 N--CA 1.492 1.431 0 C-N-CA 121.161 1.241 . . . . 0.0 111.125 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 77.9 ttt180 -158.4 128.18 5.87 Favored 'General case' 0 N--CA 1.464 0.244 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 179.343 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 30.9 mt -68.53 120.68 77.01 Favored Pre-proline 0 CA--C 1.546 0.806 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.81 -179.414 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -75.55 164.52 32.19 Favored 'Trans proline' 0 N--CA 1.497 1.692 0 C-N-CA 121.678 1.585 . . . . 0.0 111.984 -179.762 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 17.0 ptm180 -53.62 143.53 19.88 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.661 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 85.86 6.41 82.56 Favored Glycine 0 CA--C 1.52 0.384 0 N-CA-C 110.713 -0.955 . . . . 0.0 110.713 179.718 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.5 ' CG1' HD11 ' A' ' 31' ' ' LEU . 42.9 t -132.55 128.84 58.35 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 CA-C-O 120.982 0.42 . . . . 0.0 110.326 179.925 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 39.3 ptt180 -145.15 164.72 30.41 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.362 179.679 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 46.0 mt -94.44 138.16 32.71 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.237 -179.737 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 76.6 mtp85 -139.62 148.14 42.06 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.127 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 88.3 t80 -97.17 119.71 36.17 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.266 -179.833 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.405 ' O ' ' N ' ' A' ' 27' ' ' ASN . 87.8 m-20 -90.5 105.85 18.1 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 116.021 -0.536 . . . . 0.0 109.689 179.258 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 82.6 tt0 -64.13 -37.94 89.28 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.321 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.461 HG22 ' H ' ' A' ' 25' ' ' VAL . 0.7 OUTLIER -63.43 -43.74 98.58 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.462 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.733 -179.389 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -89.09 -14.5 36.16 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-O 120.815 0.341 . . . . 0.0 110.201 -179.484 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.405 ' N ' ' O ' ' A' ' 23' ' ' ASP . 33.8 m-20 63.08 27.93 15.94 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.753 179.723 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.28 170.9 15.4 Favored 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 179.389 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 79.2 m80 -92.67 150.35 20.75 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.095 179.745 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 35.0 m -138.55 161.71 30.29 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.171 -179.462 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.5 HD11 ' CG1' ' A' ' 18' ' ' VAL . 32.4 tp -98.48 113.66 25.75 Favored 'General case' 0 N--CA 1.464 0.231 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 179.27 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 58.5 tp -77.83 95.07 4.63 Favored 'General case' 0 CA--C 1.517 -0.305 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 179.262 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -97.77 154.1 37.99 Favored Pre-proline 0 CA--C 1.537 0.473 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -63.7 -26.67 68.55 Favored 'Trans proline' 0 N--CA 1.495 1.599 0 C-N-CA 121.977 1.785 . . . . 0.0 111.673 179.789 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 42.2 tp10 -80.85 -51.98 7.99 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.699 -179.485 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 42.7 ttm180 -174.67 146.64 0.99 Allowed 'General case' 0 N--CA 1.463 0.22 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.54 -179.397 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 57.9 m -74.51 129.58 38.02 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.104 178.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 93.7 m-85 -102.79 140.2 37.37 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-N 116.515 -0.312 . . . . 0.0 110.744 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 30.8 t0 -73.89 118.47 16.88 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.288 -0.414 . . . . 0.0 109.926 179.49 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 63.2 mt -131.37 154.1 48.97 Favored 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 116.245 -0.434 . . . . 0.0 109.954 -179.755 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 80.8 m-20 -87.47 159.73 18.55 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.132 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.466 ' OD1' ' N ' ' A' ' 43' ' ' ASN . 36.6 p-10 -60.67 -39.87 90.04 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.693 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . 0.466 ' N ' ' OD1' ' A' ' 42' ' ' ASP . 50.4 t30 -64.02 -39.7 94.67 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.75 -179.747 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -68.63 -34.62 76.06 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.645 -179.671 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 59.9 t -88.83 -17.4 8.32 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 CA-C-O 120.765 0.317 . . . . 0.0 110.267 179.58 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.417 ' O ' ' N ' ' A' ' 50' ' ' LEU . . . -56.98 -47.21 81.33 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.382 -179.515 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.44 HG23 ' N ' ' A' ' 48' ' ' LEU . 35.0 m -61.42 -42.32 93.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.723 179.897 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.44 ' N ' HG23 ' A' ' 47' ' ' VAL . 56.5 mt -70.09 -30.52 67.76 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.455 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 36.7 ttmt -86.39 -28.85 23.34 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.884 179.778 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.417 ' N ' ' O ' ' A' ' 46' ' ' ALA . 59.3 tp -72.41 -32.43 66.35 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 116.485 -0.325 . . . . 0.0 110.593 -179.239 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.6 p -74.6 129.37 36.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 121.065 0.46 . . . . 0.0 110.654 179.884 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 -72.09 -41.11 67.69 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.204 178.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -144.66 -100.29 0.3 Allowed Glycine 0 N--CA 1.473 1.145 0 N-CA-C 110.605 -0.998 . . . . 0.0 110.605 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . 0.499 ' HE ' ' CG2' ' A' ' 11' ' ' VAL . 85.3 mtp180 -114.9 104.73 12.21 Favored 'General case' 0 N--CA 1.471 0.621 0 CA-C-O 120.583 0.23 . . . . 0.0 110.411 179.462 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 94.8 m-20 -117.41 154.61 31.05 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.137 178.024 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 35.3 p -79.89 136.86 36.77 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 178.626 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.407 HG23 ' N ' ' A' ' 58' ' ' SER . 29.8 m -54.31 -37.09 35.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-O 120.935 0.398 . . . . 0.0 110.482 -179.558 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . 0.407 ' N ' HG23 ' A' ' 57' ' ' VAL . 41.3 t -58.57 -44.54 89.79 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.599 179.808 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 49.4 tt0 -64.45 -44.68 90.35 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.785 -179.587 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 96.9 mt -62.12 -43.39 97.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -53.06 -36.73 60.93 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.148 -179.083 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 70.8 mm-40 -63.25 -52.79 60.67 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.723 -0.391 . . . . 0.0 110.596 179.803 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 73.2 mt -64.46 -49.97 78.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.925 -179.173 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 10.3 tp -67.06 -39.69 86.91 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.652 -179.391 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -56.39 -41.64 88.13 Favored Glycine 0 CA--C 1.526 0.746 0 N-CA-C 111.095 -0.802 . . . . 0.0 111.095 -179.192 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 86.4 mt-30 -65.29 -31.28 72.34 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.656 0.265 . . . . 0.0 110.46 179.511 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 20.3 m -62.16 -46.25 89.81 Favored 'General case' 0 C--N 1.331 -0.212 0 C-N-CA 120.813 -0.355 . . . . 0.0 110.476 -179.666 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -92.99 1.6 57.22 Favored 'General case' 0 N--CA 1.469 0.484 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.706 179.759 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 66.1 t0 54.79 53.23 10.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.506 -0.315 . . . . 0.0 110.961 179.707 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -141.19 159.57 41.94 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 110.122 -0.325 . . . . 0.0 110.122 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 69.6 m-20 -56.02 142.16 66.12 Favored Pre-proline 0 CA--C 1.541 0.622 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.392 -179.361 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -67.65 -30.26 35.06 Favored 'Trans proline' 0 N--CA 1.503 2.045 0 C-N-CA 122.426 2.084 . . . . 0.0 112.42 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -55.34 -34.87 64.6 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.2 0.524 . . . . 0.0 110.432 -179.621 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 63.7 mt -68.87 -44.62 81.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 115.813 -0.63 . . . . 0.0 111.252 -179.566 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.523 ' N ' HD12 ' A' ' 75' ' ' ILE . 1.6 mp -61.94 -52.1 64.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.425 0 CA-C-N 116.614 -0.266 . . . . 0.0 111.291 -178.505 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -60.54 -46.98 88.17 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 120.253 -0.579 . . . . 0.0 110.352 -178.048 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.429 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -63.89 -23.64 67.43 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.055 -0.521 . . . . 0.0 111.303 179.827 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 66.7 t0 -78.66 -52.17 8.81 Favored 'General case' 0 N--CA 1.469 0.508 0 CA-C-N 116.531 -0.304 . . . . 0.0 111.545 -179.502 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 12.6 pt -71.14 -41.92 75.75 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.188 -179.093 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 8.3 mt -40.64 -60.56 1.53 Allowed Pre-proline 0 CA--C 1.552 1.049 0 CA-C-O 119.314 -0.374 . . . . 0.0 110.983 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.429 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 50.8 Cg_exo -38.82 -42.71 2.01 Favored 'Trans proline' 0 N--CA 1.493 1.477 0 C-N-CA 122.511 2.141 . . . . 0.0 112.182 178.203 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 41.0 ttm -66.83 -41.64 87.11 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.846 -179.363 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 36.0 mt -62.23 -40.37 95.91 Favored 'General case' 0 C--N 1.328 -0.362 0 C-N-CA 120.689 -0.404 . . . . 0.0 109.987 -178.952 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -63.03 -40.77 98.72 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.916 -0.583 . . . . 0.0 110.362 179.608 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -66.81 -40.63 93.75 Favored Glycine 0 CA--C 1.526 0.767 0 N-CA-C 111.346 -0.702 . . . . 0.0 111.346 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 78.4 mt -66.34 -41.27 89.8 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.713 0.292 . . . . 0.0 110.808 -179.708 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -54.97 -38.56 67.95 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.969 0.414 . . . . 0.0 110.396 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 85.4 mt-30 -64.06 -22.05 66.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.041 179.477 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -91.27 -2.49 57.41 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-O 120.733 0.301 . . . . 0.0 110.439 -179.068 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 34.3 ttm180 62.14 55.5 2.44 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.656 179.542 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 33.0 m -140.84 3.77 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.472 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.498 179.761 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 54.2 tp -140.86 131.22 25.14 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-O 120.901 0.382 . . . . 0.0 110.067 179.588 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 18.8 pt-20 -153.43 148.22 26.42 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.911 179.164 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 90.6 mtm180 . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 117.968 -1.015 . . . . 0.0 110.399 179.842 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 70.2 mtm . . . . . 0 N--CA 1.489 1.478 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 92.0 mt-10 -71.73 148.12 92.33 Favored Pre-proline 0 CA--C 1.539 0.551 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.657 -179.276 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_exo -42.99 155.45 0.12 Allowed 'Trans proline' 0 N--CA 1.494 1.522 0 C-N-CA 122.045 1.83 . . . . 0.0 112.357 179.068 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 81.9 p -75.02 -27.62 60.16 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.402 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . 51.47 99.34 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.674 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 27.9 m-85 -79.39 128.47 33.38 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.045 -0.525 . . . . 0.0 109.755 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 28.1 m -95.34 177.42 5.84 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.206 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -64.92 -38.36 95.42 Favored Glycine 0 CA--C 1.527 0.817 0 N-CA-C 111.141 -0.784 . . . . 0.0 111.141 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 38.9 m -72.94 -18.23 61.41 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.689 0.281 . . . . 0.0 110.505 -179.738 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 48.5 t0 -71.45 116.24 11.55 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.492 HG23 ' O ' ' A' ' 11' ' ' VAL . 33.5 m -95.05 122.71 59.41 Favored Pre-proline 0 CA--C 1.54 0.587 0 CA-C-N 116.553 -0.294 . . . . 0.0 110.989 -179.32 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -77.58 154.52 31.13 Favored 'Trans proline' 0 N--CA 1.494 1.506 0 C-N-CA 121.531 1.487 . . . . 0.0 111.454 179.767 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 72.3 ttp85 -157.45 133.2 9.27 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 179.623 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 16.3 mt -67.17 123.04 85.37 Favored Pre-proline 0 CA--C 1.541 0.633 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.726 -178.899 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 92.7 Cg_endo -76.57 155.06 35.67 Favored 'Trans proline' 0 N--CA 1.492 1.397 0 C-N-CA 121.795 1.663 . . . . 0.0 111.99 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 58.4 ttt85 -57.17 151.2 15.97 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.04 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 84.31 15.79 68.28 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 111.047 -0.821 . . . . 0.0 111.047 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 62.0 t -135.55 133.92 51.91 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 CA-C-O 121.062 0.458 . . . . 0.0 110.213 179.66 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 89.5 mtm180 -136.23 153.24 51.27 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.119 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 31.9 mt -95.33 148.62 22.24 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.934 -179.836 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 86.5 mtm180 -140.09 142.61 36.08 Favored 'General case' 0 N--CA 1.463 0.218 0 CA-C-N 116.189 -0.459 . . . . 0.0 109.868 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 86.1 t80 -100.62 109.72 21.81 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.015 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -89.76 91.48 8.65 Favored 'General case' 0 N--CA 1.463 0.207 0 CA-C-N 116.077 -0.511 . . . . 0.0 109.697 179.59 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 42.3 tt0 -60.0 -33.67 72.29 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.162 -179.683 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.407 ' H ' HG22 ' A' ' 25' ' ' VAL . 1.7 m -64.02 -43.31 97.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.426 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.513 ' HD3' ' HZ2' ' A' ' 28' ' ' LYS . 99.9 mtt180 -86.46 -18.81 30.72 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-O 120.577 0.227 . . . . 0.0 110.522 179.941 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 60.8 t30 68.57 24.31 6.98 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.201 179.501 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.513 ' HZ2' ' HD3' ' A' ' 26' ' ' ARG . 2.7 ptmm? -145.17 167.62 22.32 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-O 121.094 0.474 . . . . 0.0 109.899 179.629 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 71.5 m80 -90.73 160.21 15.93 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.864 179.887 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 29.5 m -142.45 147.83 20.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.021 -0.536 . . . . 0.0 109.699 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 5.8 tp -102.01 111.87 24.29 Favored 'General case' 0 N--CA 1.463 0.207 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 179.487 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 55.9 tp -79.16 95.08 5.5 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 179.169 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -93.97 145.81 30.51 Favored Pre-proline 0 CA--C 1.538 0.502 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 179.864 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 70.9 Cg_exo -45.09 -36.45 11.76 Favored 'Trans proline' 0 N--CA 1.495 1.587 0 C-N-CA 122.03 1.82 . . . . 0.0 112.652 179.088 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 46.5 tp10 -74.81 -51.97 12.65 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.93 -178.755 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 75.2 ttt180 -174.48 150.95 1.47 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.798 -179.553 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 34.4 m -69.26 132.03 45.83 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.063 -0.517 . . . . 0.0 109.954 179.184 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -106.63 128.67 54.35 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.267 -179.473 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -72.8 115.14 11.72 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.167 -0.469 . . . . 0.0 109.914 179.73 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 95.9 mt -133.22 161.09 35.4 Favored 'General case' 0 N--CA 1.469 0.475 0 CA-C-O 121.051 0.453 . . . . 0.0 110.111 -179.58 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 81.6 m-20 -84.03 159.45 21.18 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.163 -179.421 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.464 ' OD1' ' N ' ' A' ' 43' ' ' ASN . 38.4 p-10 -61.55 -35.09 76.79 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.856 -179.694 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . 0.464 ' N ' ' OD1' ' A' ' 42' ' ' ASP . 88.4 m-20 -62.9 -39.92 95.99 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.64 -179.578 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -68.78 -35.51 77.15 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.729 -179.703 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 40.0 t -89.12 -20.04 7.3 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.451 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.77 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.46 ' N ' ' O ' ' A' ' 42' ' ' ASP . . . -58.33 -48.67 79.8 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.477 -179.583 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 35.4 m -61.78 -39.0 81.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.703 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 63.1 mt -69.53 -31.61 69.94 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.652 179.866 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 36.6 ttpt -88.68 -27.54 21.18 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.671 179.358 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.41 ' N ' ' O ' ' A' ' 46' ' ' ALA . 55.2 tp -73.1 -32.49 65.01 Favored 'General case' 0 N--CA 1.464 0.265 0 C-N-CA 120.862 -0.335 . . . . 0.0 110.563 -178.941 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.4 p -74.11 125.82 33.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.935 0.398 . . . . 0.0 110.671 -179.822 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 95.4 m-20 -72.92 -42.16 63.79 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.252 179.408 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -143.37 -98.95 0.29 Allowed Glycine 0 N--CA 1.472 1.048 0 N-CA-C 110.477 -1.049 . . . . 0.0 110.477 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . 0.508 HH22 ' C ' ' A' ' 94' ' ' ARG . 78.4 mtp85 -114.86 104.29 11.79 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-O 121.005 0.431 . . . . 0.0 110.389 179.533 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 97.0 m-20 -117.57 152.88 34.22 Favored 'General case' 0 N--CA 1.471 0.598 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.194 178.297 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 11.2 p -82.59 141.11 32.83 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 109.683 -0.488 . . . . 0.0 109.683 178.751 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.47 HG23 ' N ' ' A' ' 58' ' ' SER . 18.9 m -56.6 -41.23 73.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.349 -179.703 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . 0.47 ' N ' HG23 ' A' ' 57' ' ' VAL . 35.4 t -58.64 -44.18 89.96 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.716 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 57.4 tt0 -64.0 -44.39 92.79 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.501 -179.823 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 96.6 mt -62.1 -43.38 97.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.261 -0.427 . . . . 0.0 109.992 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.409 ' O ' ' N ' ' A' ' 65' ' ' GLY . . . -52.12 -38.16 56.56 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.876 -179.364 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 94.1 mm-40 -63.88 -51.18 65.77 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.492 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 69.2 mt -64.72 -49.0 82.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.497 -179.37 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 34.7 tp -68.69 -36.81 78.99 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.362 -179.629 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.455 ' O ' ' N ' ' A' ' 69' ' ' ASP . . . -59.14 -41.89 96.84 Favored Glycine 0 CA--C 1.526 0.754 0 N-CA-C 111.3 -0.72 . . . . 0.0 111.3 -179.206 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 86.4 mt-30 -65.12 -31.97 73.44 Favored 'General case' 0 C--N 1.326 -0.428 0 C-N-CA 121.025 -0.27 . . . . 0.0 110.423 179.751 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 22.1 m -61.94 -48.53 80.0 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 120.682 -0.407 . . . . 0.0 110.474 -179.879 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -94.62 -3.12 50.14 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.45 179.542 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . 0.455 ' N ' ' O ' ' A' ' 65' ' ' GLY . 65.8 t0 54.0 62.26 2.68 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.694 179.698 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -138.7 160.31 39.96 Favored 'General case' 0 N--CA 1.469 0.475 0 CA-C-O 120.897 0.379 . . . . 0.0 110.152 -179.591 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 74.0 m-20 -55.9 114.8 8.13 Favored Pre-proline 0 CA--C 1.543 0.675 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.532 -179.193 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_exo -48.41 -36.39 30.48 Favored 'Trans proline' 0 N--CA 1.497 1.716 0 C-N-CA 121.88 1.72 . . . . 0.0 112.714 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -52.6 -39.24 61.41 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-O 120.968 0.413 . . . . 0.0 111.157 -179.341 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 70.8 mt -71.5 -40.13 71.58 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.699 179.69 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 38.0 mm -59.92 -49.28 84.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.915 -178.374 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 15.6 pt-20 -65.13 -42.38 93.93 Favored 'General case' 0 C--N 1.333 -0.115 0 C-N-CA 120.765 -0.374 . . . . 0.0 110.055 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.457 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -65.92 -19.86 66.02 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.19 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 66.1 t0 -79.27 -48.59 13.89 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-O 120.875 0.369 . . . . 0.0 111.107 -179.566 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 28.5 pt -78.38 -36.47 20.59 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.525 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.235 -179.199 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 9.8 mt -43.99 -60.5 2.68 Favored Pre-proline 0 CA--C 1.543 0.688 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.782 179.857 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.457 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 39.5 Cg_endo -61.71 -31.56 86.21 Favored 'Trans proline' 0 N--CA 1.496 1.67 0 C-N-CA 121.762 1.641 . . . . 0.0 111.575 179.656 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 40.1 tpp -66.72 -42.67 85.97 Favored 'General case' 0 CA--C 1.529 0.166 0 CA-C-O 120.83 0.348 . . . . 0.0 110.775 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 74.7 mt -62.85 -41.9 99.54 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.246 -179.221 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -63.31 -38.85 92.76 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.54 179.779 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -64.62 -41.22 97.89 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 83.2 mt -68.22 -39.66 82.29 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.818 0.342 . . . . 0.0 110.465 -179.764 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -52.73 -35.08 55.34 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.84 0.352 . . . . 0.0 110.639 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 87.5 mt-30 -63.32 -21.09 66.04 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.755 179.775 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -92.58 0.29 57.41 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-O 120.702 0.287 . . . . 0.0 110.402 -179.42 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 33.8 ttm180 61.45 57.93 2.22 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.444 179.818 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 33.1 m -141.54 12.57 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.28 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 50.5 tp -134.26 147.0 50.58 Favored 'General case' 0 N--CA 1.473 0.706 0 CA-C-O 121.503 0.668 . . . . 0.0 110.618 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 44.2 tp10 -147.64 140.13 24.59 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.221 -179.619 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . 0.508 ' C ' HH22 ' A' ' 54' ' ' ARG . 88.2 mtm180 . . . . . 0 C--O 1.219 -0.506 0 CA-C-O 118.101 -0.952 . . . . 0.0 110.207 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.412 ' SD ' ' N ' ' A' ' 2' ' ' GLU . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.527 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 . . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.412 ' N ' ' SD ' ' A' ' 1' ' ' MET . 10.0 pt-20 -170.63 147.35 2.48 Favored Pre-proline 0 CA--C 1.537 0.462 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.504 179.913 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -70.9 161.59 45.57 Favored 'Trans proline' 0 N--CA 1.496 1.624 0 C-N-CA 122.203 1.935 . . . . 0.0 111.874 179.592 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 7.2 p -80.49 166.72 20.93 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.569 -0.741 . . . . 0.0 109.919 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -163.72 106.08 0.96 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.25 -179.726 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 66.6 m-85 -79.9 136.22 36.61 Favored 'General case' 0 N--CA 1.463 0.207 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.391 -179.717 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 63.7 m -93.14 -174.5 3.57 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.614 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -65.96 -40.25 95.23 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 111.18 -0.768 . . . . 0.0 111.18 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 78.2 p -70.95 -24.54 62.45 Favored 'General case' 0 C--O 1.233 0.198 0 CA-C-O 120.736 0.303 . . . . 0.0 110.803 -179.669 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 95.4 m-20 -68.26 148.19 51.14 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 179.676 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 30.1 m -128.99 127.27 23.37 Favored Pre-proline 0 CA--C 1.545 0.753 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.757 -178.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -77.02 155.05 33.63 Favored 'Trans proline' 0 N--CA 1.498 1.78 0 C-N-CA 121.732 1.621 . . . . 0.0 112.243 179.731 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 71.7 ttt-85 -156.0 131.11 9.31 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.285 179.261 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 55.1 mt -69.03 113.58 17.35 Favored Pre-proline 0 CA--C 1.538 0.517 0 CA-C-O 119.074 -0.489 . . . . 0.0 111.098 -179.455 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_exo -60.77 154.06 58.14 Favored 'Trans proline' 0 N--CA 1.507 2.278 0 C-N-CA 121.903 1.735 . . . . 0.0 113.799 179.493 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 68.5 ttt-85 -51.96 132.45 32.34 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.877 178.802 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.57 -6.34 67.77 Favored Glycine 0 N--CA 1.467 0.719 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.44 ' CG1' HD11 ' A' ' 31' ' ' LEU . 39.2 t -106.77 127.85 61.97 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.613 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 179.252 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.434 ' HE ' HD22 ' A' ' 32' ' ' LEU . 33.2 ptt180 -142.24 158.85 43.27 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.44 -0.8 . . . . 0.0 110.365 -179.299 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 15.9 mt -95.32 107.62 19.75 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.693 -179.109 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 84.6 mtp180 -98.46 137.97 36.36 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.406 179.23 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.468 ' O ' ' CD1' ' A' ' 22' ' ' PHE . 38.3 p90 -100.34 114.81 28.61 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.163 179.623 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -88.09 92.02 8.99 Favored 'General case' 0 N--CA 1.464 0.239 0 CA-C-N 116.207 -0.451 . . . . 0.0 109.914 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -60.56 -34.11 73.68 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.18 -179.796 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.455 HG22 ' H ' ' A' ' 25' ' ' VAL . 1.0 OUTLIER -63.5 -43.61 98.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.416 179.978 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -88.77 -7.43 56.24 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-O 120.776 0.322 . . . . 0.0 110.269 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 65.2 t30 60.3 30.32 19.73 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.83 179.645 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.494 ' NZ ' ' OD1' ' A' ' 39' ' ' ASP . 15.9 ptpt -145.34 168.74 19.76 Favored 'General case' 0 N--CA 1.47 0.553 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 178.774 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 69.8 m80 -99.39 150.15 22.44 Favored 'General case' 0 CA--C 1.518 -0.261 0 CA-C-N 116.017 -0.538 . . . . 0.0 109.829 178.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 34.2 m -137.66 155.46 30.89 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.206 -179.602 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.44 HD11 ' CG1' ' A' ' 18' ' ' VAL . 35.1 tp -102.47 121.94 43.34 Favored 'General case' 0 N--CA 1.468 0.447 0 CA-C-N 116.263 -0.426 . . . . 0.0 109.901 179.792 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.434 HD22 ' HE ' ' A' ' 19' ' ' ARG . 48.2 tp -77.26 100.5 5.87 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 179.151 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -95.7 145.21 29.15 Favored Pre-proline 0 CA--C 1.537 0.461 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_exo -47.17 -37.46 23.64 Favored 'Trans proline' 0 N--CA 1.493 1.447 0 C-N-CA 121.28 1.32 . . . . 0.0 112.243 179.183 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 9.5 tm-20 -74.62 -52.28 12.16 Favored 'General case' 0 N--CA 1.462 0.164 0 C-N-CA 120.812 -0.355 . . . . 0.0 111.863 -178.718 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 58.1 ttt85 -175.67 153.6 1.45 Allowed 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 120.798 0.332 . . . . 0.0 110.518 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 75.8 m -67.19 133.42 49.73 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.431 -0.35 . . . . 0.0 110.381 179.315 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 69.8 m-85 -108.84 141.43 40.89 Favored 'General case' 0 N--CA 1.472 0.642 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.954 -179.516 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.494 ' OD1' ' NZ ' ' A' ' 28' ' ' LYS . 37.1 t0 -73.18 121.01 19.59 Favored 'General case' 0 C--N 1.333 -0.13 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.148 179.144 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 72.3 mt -136.42 157.47 46.72 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-N 115.973 -0.558 . . . . 0.0 109.777 179.712 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 95.3 m-20 -85.47 154.06 22.05 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.382 -179.659 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 68.1 t0 -59.7 -38.4 81.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.982 -0.553 . . . . 0.0 110.545 -179.79 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 97.7 m-20 -63.1 -39.15 93.85 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.636 -179.687 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.26 -41.05 77.44 Favored 'General case' 0 C--N 1.329 -0.284 0 C-N-CA 120.899 -0.321 . . . . 0.0 110.886 -179.605 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 44.0 t -79.59 -27.87 12.83 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-O 120.714 0.293 . . . . 0.0 110.385 179.878 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.44 ' O ' ' N ' ' A' ' 50' ' ' LEU . . . -54.72 -39.1 67.88 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.016 -179.61 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 90.5 t -60.67 -48.07 90.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.355 179.824 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 49.7 mt -70.43 -29.54 66.16 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.234 -179.688 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . 0.437 ' HZ2' ' HB2' ' A' ' 49' ' ' LYS . 3.1 ttmp? -82.07 -29.05 32.04 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.701 179.933 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.44 ' N ' ' O ' ' A' ' 46' ' ' ALA . 50.2 tp -71.78 -32.61 67.83 Favored 'General case' 0 N--CA 1.465 0.276 0 C-N-CA 121.012 -0.275 . . . . 0.0 110.704 -178.926 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.7 p -77.55 128.47 38.06 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.345 0 CA-C-O 121.078 0.466 . . . . 0.0 110.604 179.567 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 -68.61 -43.12 77.08 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.351 179.218 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -146.84 -97.16 0.19 Allowed Glycine 0 N--CA 1.471 0.992 0 N-CA-C 110.488 -1.045 . . . . 0.0 110.488 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 89.2 mtm180 -114.9 104.86 12.35 Favored 'General case' 0 N--CA 1.471 0.6 0 CA-C-O 120.66 0.267 . . . . 0.0 110.658 179.286 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 93.9 m-20 -117.07 147.92 41.96 Favored 'General case' 0 N--CA 1.472 0.66 0 CA-C-N 116.156 -0.475 . . . . 0.0 109.862 177.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 15.3 p -78.74 142.15 37.27 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.057 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.406 HG23 ' N ' ' A' ' 58' ' ' SER . 33.0 m -55.76 -38.45 51.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.789 0.328 . . . . 0.0 110.461 -179.578 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . 0.406 ' N ' HG23 ' A' ' 57' ' ' VAL . 38.7 t -58.88 -44.83 91.19 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.691 179.789 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 10.6 tp-100 -65.32 -45.59 83.69 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.917 -179.588 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 85.3 mt -60.93 -42.65 93.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 121.062 0.458 . . . . 0.0 109.911 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.413 ' O ' ' N ' ' A' ' 65' ' ' GLY . . . -51.93 -40.06 60.17 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.249 -179.192 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 97.1 mm-40 -63.41 -51.38 66.02 Favored 'General case' 0 C--N 1.325 -0.469 0 C-N-CA 120.577 -0.449 . . . . 0.0 110.593 179.757 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 73.5 mt -65.09 -50.68 73.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.162 -179.312 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 23.9 tp -69.62 -34.74 74.5 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.095 0.474 . . . . 0.0 110.611 -179.061 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.413 ' N ' ' O ' ' A' ' 61' ' ' ALA . . . -58.54 -43.22 96.16 Favored Glycine 0 CA--C 1.527 0.824 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 -179.584 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 87.8 mt-30 -67.31 -38.66 85.3 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.664 0.269 . . . . 0.0 110.981 179.709 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 38.6 p -63.42 -38.29 90.57 Favored 'General case' 0 C--N 1.332 -0.188 0 C-N-CA 120.888 -0.325 . . . . 0.0 110.566 -179.411 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 30.4 m-85 -93.83 0.91 56.48 Favored 'General case' 0 N--CA 1.47 0.528 0 N-CA-C 110.057 -0.349 . . . . 0.0 110.057 179.515 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 66.6 t0 52.47 48.36 22.74 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.769 0.318 . . . . 0.0 110.881 179.556 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -140.86 158.49 43.87 Favored 'General case' 0 N--CA 1.469 0.502 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.43 -179.457 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 22.0 m-20 -56.07 144.14 60.29 Favored Pre-proline 0 CA--C 1.54 0.575 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.501 -179.374 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -67.82 -31.39 31.87 Favored 'Trans proline' 0 N--CA 1.501 1.937 0 C-N-CA 122.419 2.079 . . . . 0.0 112.097 -179.791 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -54.42 -33.67 59.89 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.076 0.465 . . . . 0.0 110.575 -179.712 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 65.4 mt -69.35 -43.45 81.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.423 -179.577 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.57 ' N ' HD12 ' A' ' 75' ' ' ILE . 1.7 mp -62.65 -48.34 88.65 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 C-N-CA 120.482 -0.487 . . . . 0.0 111.186 -178.131 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -60.61 -45.83 92.56 Favored 'General case' 0 C--N 1.325 -0.467 0 C-N-CA 119.94 -0.704 . . . . 0.0 110.097 -178.468 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.42 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -65.59 -23.44 66.84 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.25 179.445 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 64.2 t0 -78.5 -49.47 13.32 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.541 -0.3 . . . . 0.0 111.36 -179.301 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 15.3 pt -75.72 -37.27 35.54 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.41 0 CA-C-N 116.412 -0.358 . . . . 0.0 111.544 -179.224 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 8.9 mt -43.35 -59.74 3.04 Favored Pre-proline 0 CA--C 1.547 0.835 0 CA-C-O 119.748 -0.168 . . . . 0.0 111.137 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.42 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 43.0 Cg_endo -62.46 -31.46 80.66 Favored 'Trans proline' 0 N--CA 1.498 1.743 0 C-N-CA 121.954 1.769 . . . . 0.0 111.759 179.656 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 42.8 tpp -66.91 -43.1 84.22 Favored 'General case' 0 C--N 1.333 -0.112 0 C-N-CA 120.773 -0.371 . . . . 0.0 110.014 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 87.2 mt -62.67 -42.05 99.41 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.185 -179.547 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -63.78 -37.39 87.19 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.36 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -64.19 -38.35 95.81 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 111.089 -0.805 . . . . 0.0 111.089 -179.871 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 87.3 mt -68.07 -36.65 80.19 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.787 0.327 . . . . 0.0 110.291 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -53.29 -27.41 22.77 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.827 -179.672 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 86.2 mt-30 -61.89 -26.24 68.04 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.491 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 46.7 mtmt -94.08 -1.87 53.7 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.092 -179.672 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 59.7 ttt180 60.24 38.92 19.68 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.783 -0.644 . . . . 0.0 109.911 179.638 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 31.7 m -109.86 -3.75 10.58 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.585 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.354 179.858 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 38.3 tp -113.95 143.68 44.33 Favored 'General case' 0 N--CA 1.475 0.814 0 CA-C-O 121.274 0.559 . . . . 0.0 110.775 -179.369 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 40.1 tp10 -151.67 150.11 29.88 Favored 'General case' 0 CA--C 1.519 -0.245 0 CA-C-N 115.231 -0.895 . . . . 0.0 109.731 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 91.4 mtm180 . . . . . 0 C--N 1.314 -0.971 0 CA-C-O 118.062 -0.97 . . . . 0.0 110.284 179.011 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 72.2 mtm . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 57.8 mm-40 45.5 73.58 0.95 Allowed Pre-proline 0 CA--C 1.533 0.293 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.952 -179.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_exo -57.81 142.48 96.23 Favored 'Trans proline' 0 N--CA 1.497 1.681 0 C-N-CA 122.333 2.022 . . . . 0.0 112.009 -179.739 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.459 ' OG1' ' CE1' ' A' ' 6' ' ' PHE . 24.5 p -84.52 112.6 20.55 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.061 179.722 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -76.16 108.33 9.01 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.62 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.459 ' CE1' ' OG1' ' A' ' 4' ' ' THR . 95.4 m-85 -81.72 135.6 35.49 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.284 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 44.3 m -91.87 178.57 5.86 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.693 -179.904 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -65.8 -33.12 84.95 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 111.157 -0.777 . . . . 0.0 111.157 179.799 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 31.7 t -71.22 -20.57 62.24 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.7 0.286 . . . . 0.0 111.427 -178.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.412 ' CG ' ' NH2' ' A' ' 94' ' ' ARG . 92.6 m-20 -71.67 124.97 25.92 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 -179.732 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.472 ' CG2' ' HE ' ' A' ' 54' ' ' ARG . 27.4 m -101.69 116.32 63.63 Favored Pre-proline 0 CA--C 1.56 1.351 0 N-CA-C 113.525 0.935 . . . . 0.0 113.525 -177.523 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_endo -58.79 143.31 99.14 Favored 'Trans proline' 0 N--CA 1.511 2.508 0 C-N-CA 121.52 1.48 . . . . 0.0 113.595 178.186 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.457 ' NH1' ' OE2' ' A' ' 93' ' ' GLU . 70.0 ttp85 -158.27 121.77 3.95 Favored 'General case' 0 N--CA 1.47 0.539 0 CA-C-N 115.637 -0.711 . . . . 0.0 109.559 177.074 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 53.1 mt -66.82 122.04 80.49 Favored Pre-proline 0 CA--C 1.543 0.708 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.594 -179.523 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 96.9 Cg_endo -78.11 160.8 29.8 Favored 'Trans proline' 0 N--CA 1.491 1.374 0 C-N-CA 121.893 1.729 . . . . 0.0 111.743 -179.554 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 17.2 ptm180 -53.54 150.98 6.23 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.759 179.571 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 82.15 6.41 88.84 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.975 -0.85 . . . . 0.0 110.975 179.562 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.511 ' CG1' HD11 ' A' ' 31' ' ' LEU . 45.8 t -129.48 126.05 62.7 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.582 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 83.5 mtp180 -138.24 158.18 44.81 Favored 'General case' 0 N--CA 1.468 0.436 0 CA-C-N 116.085 -0.507 . . . . 0.0 109.939 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 21.9 mt -94.15 103.35 15.4 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.139 -179.653 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 96.8 mtt180 -92.81 139.69 30.28 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.122 179.456 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.472 ' O ' ' CD1' ' A' ' 22' ' ' PHE . 38.3 p90 -102.85 116.19 32.08 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.024 179.635 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.454 ' O ' ' N ' ' A' ' 27' ' ' ASN . 87.9 m-20 -87.5 95.04 9.89 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 116.234 -0.439 . . . . 0.0 109.896 -179.816 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 42.0 tt0 -61.21 -35.59 77.61 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.414 -179.634 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 3.4 m -63.77 -43.35 97.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.556 -179.788 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -92.1 -7.43 48.61 Favored 'General case' 0 N--CA 1.469 0.484 0 CA-C-O 120.742 0.306 . . . . 0.0 110.493 179.735 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.454 ' N ' ' O ' ' A' ' 23' ' ' ASP . 18.3 t-20 55.42 37.17 28.51 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.3 179.638 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -145.14 158.03 43.93 Favored 'General case' 0 N--CA 1.469 0.519 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 179.55 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 77.9 m80 -94.06 148.69 21.92 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.121 179.637 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 33.6 m -136.89 157.19 35.8 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.247 -179.857 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.511 HD11 ' CG1' ' A' ' 18' ' ' VAL . 41.0 tp -100.36 123.44 44.59 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.16 -179.828 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 38.9 tp -77.36 98.99 5.41 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 179.067 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -93.89 148.18 34.82 Favored Pre-proline 0 CA--C 1.54 0.56 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 -179.601 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_exo -46.74 -33.64 14.15 Favored 'Trans proline' 0 N--CA 1.497 1.73 0 C-N-CA 121.551 1.501 . . . . 0.0 112.292 179.013 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -71.24 -51.68 23.21 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.772 -179.086 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 60.3 ttt85 -172.26 -96.64 0.01 OUTLIER 'General case' 0 CA--C 1.531 0.245 0 CA-C-N 116.598 -0.273 . . . . 0.0 110.543 179.827 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 90.1 m -165.95 151.81 9.05 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.292 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 53.2 m-85 -125.99 137.7 53.69 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-O 120.967 0.413 . . . . 0.0 110.593 -179.641 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 38.8 p-10 -71.04 117.92 13.15 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.357 179.643 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 89.1 mt -134.25 155.98 49.2 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.021 -179.769 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 86.2 m-20 -85.09 154.78 21.83 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.976 0.417 . . . . 0.0 110.201 -179.74 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.462 ' OD1' ' N ' ' A' ' 43' ' ' ASN . 36.6 p-10 -59.96 -37.66 80.23 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.64 -179.867 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . 0.462 ' N ' ' OD1' ' A' ' 42' ' ' ASP . 5.4 m120 -64.2 -39.63 94.39 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.472 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.06 -39.99 78.78 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.468 -0.333 . . . . 0.0 110.917 -179.457 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 66.0 t -78.7 -26.52 13.68 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.239 0 CA-C-O 120.74 0.305 . . . . 0.0 110.271 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.428 ' O ' ' N ' ' A' ' 50' ' ' LEU . . . -58.1 -36.08 72.35 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.355 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 84.0 t -59.93 -47.71 90.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.42 -179.684 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 47.2 mt -70.95 -29.53 65.57 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.373 -179.634 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 36.0 ttpt -83.38 -23.5 32.4 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.651 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.428 ' N ' ' O ' ' A' ' 46' ' ' ALA . 60.4 tp -70.4 -32.55 70.24 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-O 120.735 0.302 . . . . 0.0 110.586 -179.477 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 2.4 p -75.17 130.1 36.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-O 121.047 0.451 . . . . 0.0 110.638 179.78 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 -70.12 -44.86 68.07 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.612 179.291 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -143.32 -96.96 0.24 Allowed Glycine 0 N--CA 1.473 1.152 0 N-CA-C 110.341 -1.104 . . . . 0.0 110.341 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . 0.472 ' HE ' ' CG2' ' A' ' 11' ' ' VAL . 83.9 mtp180 -114.85 104.68 12.18 Favored 'General case' 0 N--CA 1.472 0.661 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 179.06 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 96.9 m-20 -117.28 145.49 43.94 Favored 'General case' 0 N--CA 1.476 0.86 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.16 178.465 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 48.4 p -78.3 140.18 38.83 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 178.528 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.4 HG23 ' N ' ' A' ' 58' ' ' SER . 33.0 m -53.44 -38.22 32.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 120.837 0.351 . . . . 0.0 110.325 -179.358 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . 0.4 ' N ' HG23 ' A' ' 57' ' ' VAL . 38.5 t -59.93 -44.3 94.42 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.892 179.395 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 50.8 tt0 -64.69 -45.88 84.75 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.534 -0.303 . . . . 0.0 110.862 -179.266 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 66.5 mt -60.76 -42.73 93.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 120.88 0.372 . . . . 0.0 110.021 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.432 ' O ' ' N ' ' A' ' 65' ' ' GLY . . . -52.71 -38.41 60.69 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.679 -179.585 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 98.4 mm-40 -63.7 -51.13 66.38 Favored 'General case' 0 C--N 1.329 -0.297 0 C-N-CA 120.583 -0.447 . . . . 0.0 110.683 179.816 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 73.7 mt -64.63 -48.84 83.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.776 0.322 . . . . 0.0 110.677 -179.396 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . 0.416 ' O ' ' OG1' ' A' ' 67' ' ' THR . 28.7 tp -69.95 -32.49 70.77 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.169 0.509 . . . . 0.0 110.19 -179.771 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.451 ' O ' ' N ' ' A' ' 69' ' ' ASP . . . -61.84 -41.64 99.65 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.871 -0.892 . . . . 0.0 110.871 -179.719 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 93.8 mt-30 -66.74 -38.43 86.64 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 121.049 -0.26 . . . . 0.0 110.339 179.551 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.416 ' OG1' ' O ' ' A' ' 64' ' ' LEU . 37.3 p -64.05 -39.9 95.11 Favored 'General case' 0 C--N 1.329 -0.283 0 C-N-CA 120.779 -0.368 . . . . 0.0 110.361 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 40.3 m-85 -95.97 -1.3 49.35 Favored 'General case' 0 N--CA 1.472 0.651 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 179.359 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . 0.451 ' N ' ' O ' ' A' ' 65' ' ' GLY . 50.7 t0 47.97 61.85 2.78 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.737 0.304 . . . . 0.0 111.159 179.749 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -144.24 160.49 40.89 Favored 'General case' 0 N--CA 1.468 0.425 0 CA-C-N 116.378 -0.373 . . . . 0.0 110.484 -179.762 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 56.2 m-20 -55.37 113.99 6.47 Favored Pre-proline 0 CA--C 1.542 0.646 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.578 -179.708 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_exo -48.76 -37.61 35.86 Favored 'Trans proline' 0 N--CA 1.5 1.889 0 C-N-CA 121.784 1.656 . . . . 0.0 112.928 179.765 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -52.8 -39.99 62.85 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.817 0.342 . . . . 0.0 111.244 -179.104 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 75.0 mt -70.65 -39.31 75.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-O 120.796 0.331 . . . . 0.0 110.315 179.378 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 42.9 mm -60.31 -48.57 87.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.351 -178.638 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -62.21 -45.21 94.36 Favored 'General case' 0 C--N 1.331 -0.201 0 C-N-CA 120.083 -0.647 . . . . 0.0 109.77 -179.776 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.437 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -65.76 -20.7 66.36 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.261 179.584 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 65.6 t0 -79.74 -49.58 11.84 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-O 120.823 0.344 . . . . 0.0 111.551 -179.396 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 17.1 pt -72.17 -39.27 64.67 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.483 -179.423 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 6.8 mt -43.93 -59.68 3.39 Favored Pre-proline 0 CA--C 1.545 0.762 0 CA-C-O 119.509 -0.281 . . . . 0.0 111.039 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.437 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 62.3 Cg_exo -39.82 -42.81 3.18 Favored 'Trans proline' 0 N--CA 1.493 1.444 0 C-N-CA 122.451 2.101 . . . . 0.0 112.186 177.901 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 40.3 tpp -64.77 -41.21 96.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.191 -179.277 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 44.5 mt -62.5 -40.75 97.71 Favored 'General case' 0 C--N 1.327 -0.392 0 C-N-CA 120.585 -0.446 . . . . 0.0 110.027 -179.609 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -63.57 -40.92 98.21 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.325 179.542 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -67.54 -41.75 89.63 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 111.125 -0.79 . . . . 0.0 111.125 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 76.5 mt -66.89 -39.82 87.56 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.673 0.273 . . . . 0.0 110.618 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -52.58 -35.94 55.04 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 120.785 -0.366 . . . . 0.0 110.746 -179.771 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 86.5 mt-30 -63.28 -19.14 64.31 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.78 179.831 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 61.0 mttp -93.65 1.28 56.66 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.41 -179.12 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 65.8 ttt-85 60.23 58.74 2.53 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.542 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 35.4 m -141.78 16.42 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.156 179.71 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 42.6 tp -139.64 143.54 37.24 Favored 'General case' 0 N--CA 1.471 0.578 0 CA-C-O 120.988 0.423 . . . . 0.0 110.218 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.457 ' OE2' ' NH1' ' A' ' 13' ' ' ARG . 20.9 pt-20 -148.42 173.6 12.92 Favored 'General case' 0 N--CA 1.462 0.16 0 CA-C-N 115.626 -0.715 . . . . 0.0 110.312 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . 0.412 ' NH2' ' CG ' ' A' ' 10' ' ' ASP . 0.3 OUTLIER . . . . . 0 C--O 1.22 -0.466 0 CA-C-O 118.025 -0.988 . . . . 0.0 110.573 -179.46 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 72.2 mtm . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 109.091 -0.707 . . . . 0.0 109.091 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 -166.53 62.04 0.69 Allowed Pre-proline 0 CA--C 1.533 0.316 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.236 179.631 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 75.8 Cg_endo -74.13 165.77 31.17 Favored 'Trans proline' 0 N--CA 1.494 1.522 0 C-N-CA 122.389 2.059 . . . . 0.0 111.877 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 11.2 p -79.05 90.09 4.81 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.27 -179.689 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.51 120.57 21.11 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.046 -179.834 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -80.67 144.84 31.96 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.33 -0.396 . . . . 0.0 110.022 -179.89 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 16.5 m -88.58 175.04 7.73 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-O 120.85 0.357 . . . . 0.0 110.469 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -66.5 -37.89 92.99 Favored Glycine 0 CA--C 1.527 0.813 0 N-CA-C 111.272 -0.731 . . . . 0.0 111.272 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 74.6 m -71.77 -16.75 62.2 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.729 0.299 . . . . 0.0 110.479 -179.661 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 17.6 t70 -66.85 152.66 45.18 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 179.633 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 28.9 m -129.15 123.56 21.77 Favored Pre-proline 0 N--CA 1.474 0.757 0 CA-C-O 119.607 -0.235 . . . . 0.0 110.716 -179.731 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_endo -76.94 150.5 30.15 Favored 'Trans proline' 0 N--CA 1.494 1.5 0 C-N-CA 121.39 1.393 . . . . 0.0 111.578 -179.882 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 72.7 ttp85 -158.12 130.94 7.3 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.467 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 61.8 mt -68.0 121.68 80.86 Favored Pre-proline 0 CA--C 1.544 0.738 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.913 -179.222 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 91.3 Cg_endo -76.42 160.96 35.09 Favored 'Trans proline' 0 N--CA 1.493 1.456 0 C-N-CA 121.757 1.638 . . . . 0.0 112.028 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 9.5 ptm180 -54.83 153.35 6.22 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.513 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 79.31 12.91 83.39 Favored Glycine 0 CA--C 1.523 0.545 0 N-CA-C 111.218 -0.753 . . . . 0.0 111.218 179.609 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.557 ' CG1' HD11 ' A' ' 31' ' ' LEU . 46.4 t -134.05 130.06 54.7 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.593 0 CA-C-O 120.927 0.394 . . . . 0.0 110.173 179.655 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 83.5 mtm-85 -140.12 157.2 46.0 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.097 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 23.4 mt -95.79 104.96 16.91 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.215 -0.448 . . . . 0.0 109.866 179.864 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 85.1 mtp180 -90.48 141.35 28.84 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 116.095 -0.502 . . . . 0.0 109.931 179.777 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 78.4 t80 -98.95 104.04 16.05 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.236 -0.438 . . . . 0.0 109.875 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 86.8 m-20 -88.81 93.3 9.53 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-N 115.964 -0.562 . . . . 0.0 109.922 179.742 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -62.38 -34.13 76.1 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.226 -179.913 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.433 HG22 ' H ' ' A' ' 25' ' ' VAL . 1.8 m -63.81 -42.05 94.6 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.366 -179.853 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 99.9 mtt180 -82.24 -16.63 48.9 Favored 'General case' 0 N--CA 1.465 0.296 0 N-CA-C 110.276 -0.268 . . . . 0.0 110.276 -179.792 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 64.8 t30 66.72 19.78 10.72 Favored 'General case' 0 N--CA 1.467 0.387 0 O-C-N 123.56 0.537 . . . . 0.0 111.014 179.685 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 14.8 ptpt -145.03 165.13 29.09 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-O 121.019 0.438 . . . . 0.0 110.097 179.331 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 79.7 m80 -87.89 154.32 20.61 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.808 -0.633 . . . . 0.0 109.502 179.382 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 25.8 m -137.9 157.34 32.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.083 -0.508 . . . . 0.0 109.865 -179.625 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.557 HD11 ' CG1' ' A' ' 18' ' ' VAL . 37.7 tp -109.48 120.84 43.72 Favored 'General case' 0 N--CA 1.467 0.399 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 178.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 61.4 tp -78.26 95.78 5.09 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 178.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -94.66 146.37 31.31 Favored Pre-proline 0 CA--C 1.54 0.586 0 N-CA-C 109.673 -0.491 . . . . 0.0 109.673 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 78.8 Cg_exo -46.34 -35.7 16.25 Favored 'Trans proline' 0 N--CA 1.497 1.702 0 C-N-CA 121.784 1.656 . . . . 0.0 112.658 179.068 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -74.56 -52.04 12.93 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.638 -0.255 . . . . 0.0 111.069 -178.451 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 17.7 ptp180 -176.59 162.72 2.3 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-O 120.861 0.362 . . . . 0.0 110.646 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 58.2 m -73.67 125.16 27.42 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.171 179.048 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 78.6 m-85 -103.54 130.01 50.86 Favored 'General case' 0 N--CA 1.472 0.647 0 CA-C-O 120.864 0.364 . . . . 0.0 110.099 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -71.71 120.3 17.11 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.138 179.82 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 90.2 mt -130.52 158.96 38.52 Favored 'General case' 0 N--CA 1.468 0.464 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.042 -179.532 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 16.7 m-20 -84.22 160.03 20.88 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.165 -179.518 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 84.8 m-20 -61.32 -40.71 95.2 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.529 -179.847 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 49.9 t30 -62.38 -37.61 86.39 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.789 -179.249 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -68.64 -41.91 78.76 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.497 -0.32 . . . . 0.0 110.963 -179.51 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 49.0 t -80.4 -27.12 11.63 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.183 0 CA-C-O 120.678 0.275 . . . . 0.0 110.423 179.803 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.459 ' O ' ' N ' ' A' ' 50' ' ' LEU . . . -57.31 -41.47 79.97 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.436 -179.85 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 94.5 t -60.62 -47.34 93.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.367 -179.824 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 49.5 mt -70.16 -32.2 70.05 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.508 -179.612 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 37.9 ttmt -82.17 -26.22 33.62 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.458 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.459 ' N ' ' O ' ' A' ' 46' ' ' ALA . 53.6 tp -69.29 -32.92 72.4 Favored 'General case' 0 N--CA 1.462 0.171 0 C-N-CA 120.531 -0.468 . . . . 0.0 110.08 -179.299 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 2.7 p -76.92 129.72 37.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.99 0.424 . . . . 0.0 110.501 179.803 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -72.98 -45.49 57.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.112 179.258 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -140.23 -99.21 0.4 Allowed Glycine 0 N--CA 1.473 1.146 0 N-CA-C 110.633 -0.987 . . . . 0.0 110.633 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 95.2 mtt180 -114.87 104.82 12.31 Favored 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 179.147 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 -116.95 144.51 44.47 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.002 178.68 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 21.6 p -79.15 141.3 37.37 Favored 'General case' 0 C--N 1.327 -0.398 0 N-CA-C 109.664 -0.495 . . . . 0.0 109.664 179.05 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.417 HG23 ' N ' ' A' ' 58' ' ' SER . 34.1 m -53.95 -37.68 34.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.252 -179.66 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . 0.417 ' N ' HG23 ' A' ' 57' ' ' VAL . 69.9 m -58.38 -44.64 88.99 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.639 179.704 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 54.0 tt0 -65.08 -46.99 78.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.518 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 66.1 mt -61.91 -43.06 96.93 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.192 179.801 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.443 ' O ' ' N ' ' A' ' 65' ' ' GLY . . . -53.39 -38.39 63.35 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.143 -179.204 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 80.6 mm-40 -63.51 -52.34 61.64 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.637 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 70.0 mt -64.67 -50.67 74.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.941 -179.046 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 20.9 tp -69.37 -38.46 78.07 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.596 -179.334 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.443 ' N ' ' O ' ' A' ' 61' ' ' ALA . . . -54.71 -42.19 77.09 Favored Glycine 0 CA--C 1.524 0.612 0 N-CA-C 111.131 -0.788 . . . . 0.0 111.131 -179.279 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 87.0 mt-30 -64.65 -31.85 73.25 Favored 'General case' 0 C--N 1.327 -0.37 0 C-N-CA 120.984 -0.286 . . . . 0.0 110.546 179.656 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 19.4 m -62.04 -46.52 88.78 Favored 'General case' 0 C--N 1.33 -0.25 0 C-N-CA 120.764 -0.374 . . . . 0.0 110.627 -179.835 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 90.7 m-85 -91.08 -0.6 57.76 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.451 179.652 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 64.8 t0 54.26 51.85 13.64 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.744 179.687 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -140.13 157.29 45.86 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.18 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 16.6 m-20 -56.77 141.96 73.02 Favored Pre-proline 0 CA--C 1.545 0.771 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.078 -178.846 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -66.46 -28.46 45.97 Favored 'Trans proline' 0 N--CA 1.503 2.072 0 C-N-CA 122.618 2.212 . . . . 0.0 112.752 -179.171 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -54.93 -29.51 56.56 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.945 0.402 . . . . 0.0 110.748 -179.242 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.688 ' N ' HD12 ' A' ' 74' ' ' ILE . 1.6 mp -78.58 -44.61 26.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.111 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.551 ' N ' HD12 ' A' ' 75' ' ' ILE . 1.7 mp -62.46 -47.72 91.69 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.641 -178.046 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 14.9 pt-20 -60.34 -46.35 90.22 Favored 'General case' 0 C--N 1.324 -0.526 0 C-N-CA 120.416 -0.514 . . . . 0.0 110.443 -178.502 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.44 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -67.6 -20.6 65.38 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.096 179.759 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 66.0 t0 -80.74 -47.59 13.73 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 120.727 0.298 . . . . 0.0 111.508 -179.47 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 18.0 pt -71.46 -41.03 72.94 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 CA-C-N 116.385 -0.371 . . . . 0.0 111.136 -179.117 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 7.2 mt -43.0 -61.13 1.89 Allowed Pre-proline 0 CA--C 1.548 0.894 0 CA-C-N 116.522 -0.308 . . . . 0.0 110.843 179.544 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.44 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 61.9 Cg_exo -38.94 -41.54 1.79 Allowed 'Trans proline' 0 N--CA 1.492 1.435 0 C-N-CA 122.707 2.272 . . . . 0.0 112.264 177.845 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 14.2 tpt -65.63 -40.71 92.85 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.6 -179.191 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 47.2 mt -61.42 -40.41 94.32 Favored 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 120.59 -0.444 . . . . 0.0 110.3 -179.293 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -63.71 -40.02 95.73 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 120.839 0.352 . . . . 0.0 110.335 179.469 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -67.82 -39.78 89.74 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 111.405 -0.678 . . . . 0.0 111.405 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 73.8 mt -67.01 -38.51 86.11 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.752 0.311 . . . . 0.0 110.525 -179.605 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -53.93 -36.3 62.63 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.89 0.376 . . . . 0.0 110.459 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 83.7 mt-30 -63.06 -23.9 67.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.795 179.764 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -90.7 -3.18 57.67 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-O 120.684 0.278 . . . . 0.0 110.342 -179.382 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 14.5 tpt180 63.97 51.35 2.31 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.992 179.498 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 30.8 m -139.29 10.53 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.283 179.889 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.569 HD13 ' N ' ' A' ' 93' ' ' GLU . 0.2 OUTLIER -141.53 123.23 15.18 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-O 121.14 0.495 . . . . 0.0 109.755 -179.901 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.569 ' N ' HD13 ' A' ' 92' ' ' LEU . 11.4 pt-20 -153.29 137.93 16.92 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.24 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 49.0 ptt85 . . . . . 0 C--N 1.325 -0.48 0 CA-C-O 117.901 -1.047 . . . . 0.0 110.597 179.787 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.418 ' SD ' ' N ' ' A' ' 1' ' ' MET . 2.0 mpt? . . . . . 0 N--CA 1.491 1.593 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -168.24 71.6 0.85 Allowed Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.28 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -54.07 165.37 2.08 Favored 'Trans proline' 0 N--CA 1.495 1.566 0 C-N-CA 122.574 2.183 . . . . 0.0 111.885 179.523 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 5.2 t -149.9 178.0 9.32 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.111 -179.626 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -158.15 120.11 3.64 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.059 -179.483 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 64.1 m-85 -77.58 139.02 39.47 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.175 179.866 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 15.9 m -94.41 179.48 5.27 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-O 120.786 0.327 . . . . 0.0 110.228 179.888 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -65.0 -43.06 96.4 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.691 -0.963 . . . . 0.0 110.691 179.761 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 27.9 t -72.84 -25.39 61.1 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.864 0.364 . . . . 0.0 110.605 179.826 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.44 ' OD1' ' N ' ' A' ' 11' ' ' VAL . 60.5 t0 -67.82 135.95 53.37 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 179.848 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.44 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 15.5 m -117.59 129.6 25.24 Favored Pre-proline 0 CA--C 1.546 0.822 0 CA-C-O 119.621 -0.228 . . . . 0.0 111.123 -179.091 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -79.56 157.58 25.17 Favored 'Trans proline' 0 N--CA 1.493 1.494 0 C-N-CA 121.899 1.733 . . . . 0.0 111.133 179.005 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 58.3 ttt85 -157.99 127.52 5.9 Favored 'General case' 0 N--CA 1.466 0.346 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 179.162 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 58.9 mt -67.39 118.21 54.35 Favored Pre-proline 0 CA--C 1.541 0.61 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.937 -179.328 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -76.58 160.68 34.79 Favored 'Trans proline' 0 N--CA 1.49 1.292 0 C-N-CA 121.731 1.621 . . . . 0.0 111.789 -179.723 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 78.3 ttt180 -54.52 141.0 32.8 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.423 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 92.96 6.29 63.53 Favored Glycine 0 N--CA 1.465 0.585 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 179.896 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.532 ' CG1' HD11 ' A' ' 31' ' ' LEU . 51.2 t -130.63 129.76 64.4 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.535 0 CA-C-O 120.915 0.388 . . . . 0.0 110.0 179.505 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 63.3 mtt-85 -143.42 155.93 44.52 Favored 'General case' 0 N--CA 1.462 0.131 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.064 -179.568 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 16.2 mt -94.67 100.13 12.12 Favored 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.582 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.486 ' HE ' HD22 ' A' ' 32' ' ' LEU . 96.2 mtt-85 -93.82 139.47 30.83 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.134 179.821 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.468 ' O ' ' CD1' ' A' ' 22' ' ' PHE . 41.9 p90 -100.11 117.43 34.34 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.331 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 86.0 m-20 -89.74 99.44 12.45 Favored 'General case' 0 N--CA 1.463 0.218 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 179.729 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 82.9 tt0 -63.38 -35.22 79.69 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.323 -179.782 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.433 ' H ' HG22 ' A' ' 25' ' ' VAL . 1.6 m -63.4 -42.9 97.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.61 -179.776 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -84.09 -16.04 45.15 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 110.383 -0.229 . . . . 0.0 110.383 -179.847 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 57.6 t30 68.77 21.53 7.7 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 115.945 -0.571 . . . . 0.0 111.094 179.714 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -145.05 164.68 30.46 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 116.124 -0.489 . . . . 0.0 109.93 179.396 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 73.2 m80 -92.49 152.9 19.41 Favored 'General case' 0 CA--C 1.514 -0.42 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.281 179.855 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 30.2 m -139.33 154.1 24.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.837 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.532 HD11 ' CG1' ' A' ' 18' ' ' VAL . 50.7 tp -98.89 116.14 30.44 Favored 'General case' 0 CA--C 1.517 -0.314 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 179.216 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.486 HD22 ' HE ' ' A' ' 21' ' ' ARG . 57.8 tp -79.11 102.06 8.23 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 179.21 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -97.65 142.03 23.91 Favored Pre-proline 0 CA--C 1.538 0.503 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.858 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_exo -43.37 -34.55 4.87 Favored 'Trans proline' 0 N--CA 1.495 1.614 0 C-N-CA 121.898 1.732 . . . . 0.0 112.569 179.297 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.445 ' CG ' ' N ' ' A' ' 36' ' ' ARG . 14.2 pt-20 -75.66 -51.61 12.4 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.393 -178.673 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.445 ' N ' ' CG ' ' A' ' 35' ' ' GLU . 77.0 ttt-85 -177.16 151.59 0.82 Allowed 'General case' 0 C--N 1.332 -0.193 0 O-C-N 123.293 0.371 . . . . 0.0 110.124 -179.368 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 51.6 m -69.32 135.11 49.95 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.661 179.106 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 78.1 m-85 -108.58 137.41 46.57 Favored 'General case' 0 N--CA 1.472 0.636 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.288 179.857 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 38.8 p-10 -72.69 117.71 14.71 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.352 179.698 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 83.8 mt -134.71 157.38 46.83 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-O 121.042 0.448 . . . . 0.0 110.153 -179.594 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 95.0 m-20 -86.07 155.22 20.9 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.942 -179.691 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -59.39 -37.74 78.75 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.564 -179.614 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -62.98 -39.78 95.75 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.542 -179.765 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.26 -41.74 76.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.554 -0.294 . . . . 0.0 110.882 -179.659 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 44.6 t -78.79 -26.2 13.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 120.856 0.36 . . . . 0.0 110.141 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.65 -35.61 68.57 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.088 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 66.8 t -60.47 -47.45 92.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.67 -179.685 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 41.4 mt -77.61 -16.48 58.56 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.856 -179.239 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 2.8 ttmp? -89.08 -32.17 17.68 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.593 179.224 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 5.6 tp -71.06 -32.25 68.88 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.791 -178.557 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.5 p -73.55 126.02 33.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 121.001 0.429 . . . . 0.0 110.375 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 94.5 m-20 -71.04 -41.13 71.19 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.259 179.475 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -147.68 -97.8 0.2 Allowed Glycine 0 N--CA 1.471 0.998 0 N-CA-C 110.578 -1.009 . . . . 0.0 110.578 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 83.4 mtp180 -114.77 104.84 12.36 Favored 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 110.16 -0.311 . . . . 0.0 110.16 179.78 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 92.6 m-20 -117.12 148.86 41.18 Favored 'General case' 0 N--CA 1.473 0.696 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.156 178.429 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 41.3 p -81.04 139.95 35.43 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.73 178.836 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.461 HG23 ' N ' ' A' ' 58' ' ' SER . 19.5 m -54.81 -39.75 49.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.385 -179.657 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . 0.461 ' N ' HG23 ' A' ' 57' ' ' VAL . 70.9 m -57.17 -43.95 83.04 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.521 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 49.2 tt0 -65.55 -47.93 74.16 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.825 0.345 . . . . 0.0 110.593 -179.839 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 66.5 mt -59.63 -40.75 83.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.14 179.488 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.419 ' O ' ' N ' ' A' ' 65' ' ' GLY . . . -55.36 -42.95 74.58 Favored 'General case' 0 C--N 1.325 -0.492 0 C-N-CA 120.664 -0.414 . . . . 0.0 110.612 -179.778 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 90.4 mm-40 -64.13 -55.99 17.99 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.034 179.902 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 72.5 mt -64.41 -48.94 83.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.829 -179.141 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 28.0 tp -67.83 -36.96 81.28 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.407 -179.528 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.419 ' N ' ' O ' ' A' ' 61' ' ' ALA . . . -56.93 -40.72 91.1 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -179.645 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 75.5 mt-30 -64.4 -31.67 72.97 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 121.011 -0.275 . . . . 0.0 110.35 179.797 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 20.5 m -63.08 -46.59 86.69 Favored 'General case' 0 C--N 1.331 -0.198 0 C-N-CA 120.842 -0.343 . . . . 0.0 110.526 -179.749 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -91.13 -1.08 57.81 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.324 179.782 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 55.6 t0 53.17 54.06 10.9 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.464 -0.335 . . . . 0.0 110.65 179.605 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -140.44 162.48 35.23 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.11 -179.65 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 79.0 m-20 -56.7 134.89 78.28 Favored Pre-proline 0 CA--C 1.541 0.629 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.307 -179.098 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -66.35 -31.25 43.65 Favored 'Trans proline' 0 N--CA 1.502 1.989 0 C-N-CA 122.456 2.104 . . . . 0.0 112.659 -179.309 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -55.25 -37.76 67.66 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.04 0.448 . . . . 0.0 110.785 -179.368 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 64.8 mt -70.92 -39.54 75.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.48 179.938 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 36.9 mm -59.74 -48.79 86.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.981 -177.896 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -62.13 -45.26 94.25 Favored 'General case' 0 N--CA 1.461 0.094 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.132 -179.673 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.452 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -66.63 -19.02 65.67 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.166 179.779 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 64.7 t0 -80.64 -47.54 13.94 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 116.617 -0.265 . . . . 0.0 111.03 -179.525 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 33.5 pt -79.6 -33.24 14.97 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.624 0 CA-C-O 121.054 0.454 . . . . 0.0 111.251 -179.399 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.405 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 9.7 mt -47.38 -59.63 5.23 Favored Pre-proline 0 CA--C 1.545 0.76 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.836 179.719 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.452 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 39.8 Cg_endo -61.39 -29.38 85.46 Favored 'Trans proline' 0 N--CA 1.496 1.64 0 C-N-CA 121.988 1.792 . . . . 0.0 111.612 179.86 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 40.2 ttm -67.07 -39.31 86.82 Favored 'General case' 0 N--CA 1.461 0.125 0 CA-C-O 120.772 0.32 . . . . 0.0 110.784 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 84.5 mt -62.56 -39.92 95.2 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.396 -179.714 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -60.91 -38.6 86.3 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.256 179.808 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -65.2 -40.81 96.99 Favored Glycine 0 CA--C 1.527 0.812 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 88.1 mt -69.74 -35.34 74.9 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.799 0.333 . . . . 0.0 110.583 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -52.68 -38.12 59.98 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.886 0.374 . . . . 0.0 110.443 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 87.6 mt-30 -61.45 -21.18 63.92 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.432 179.564 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 62.9 mttp -95.05 -1.44 52.22 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.109 -179.47 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 67.3 ttp85 55.83 67.82 0.95 Allowed 'General case' 0 N--CA 1.453 -0.318 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.73 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 24.4 m -141.46 16.2 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.507 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 95.1 mt -129.83 155.96 45.14 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-O 121.311 0.577 . . . . 0.0 110.251 179.629 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 80.2 tt0 -146.19 113.69 6.33 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.08 -0.964 . . . . 0.0 110.497 -179.228 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 90.3 mtm180 . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 118.159 -0.924 . . . . 0.0 110.218 179.32 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 79.0 mmm . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.454 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 0.0 OUTLIER -166.86 51.14 0.22 Allowed Pre-proline 0 CA--C 1.536 0.408 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.321 -179.885 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.454 ' CD ' ' N ' ' A' ' 2' ' ' GLU . 55.8 Cg_endo -66.81 -19.03 53.31 Favored 'Trans proline' 0 N--CA 1.497 1.685 0 C-N-CA 122.236 1.957 . . . . 0.0 111.785 179.781 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 81.6 p 49.13 94.16 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.229 0 CA-C-O 120.788 0.327 . . . . 0.0 110.643 -179.392 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.61 -11.09 60.31 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.562 -179.641 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 69.2 m-85 52.44 174.96 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.813 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 69.5 m -133.58 -171.88 2.82 Favored 'General case' 0 N--CA 1.471 0.6 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.63 -179.515 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -66.16 -38.39 93.85 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 95.0 p -71.75 -14.0 61.88 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-O 120.614 0.245 . . . . 0.0 111.099 -179.492 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -66.2 136.69 56.25 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.745 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.432 HG23 ' O ' ' A' ' 55' ' ' ASN . 1.0 OUTLIER -130.13 114.63 17.45 Favored Pre-proline 0 CA--C 1.545 0.78 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.069 -179.736 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -79.27 144.01 17.96 Favored 'Trans proline' 0 N--CA 1.489 1.264 0 C-N-CA 121.001 1.134 . . . . 0.0 111.492 179.805 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 76.2 ttt180 -153.14 139.3 18.34 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.758 -0.655 . . . . 0.0 109.722 179.348 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 52.6 mt -69.33 123.91 89.35 Favored Pre-proline 0 CA--C 1.545 0.78 0 CA-C-N 115.655 -0.702 . . . . 0.0 111.35 -179.239 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_endo -73.57 159.47 45.99 Favored 'Trans proline' 0 N--CA 1.497 1.708 0 C-N-CA 121.842 1.695 . . . . 0.0 111.902 179.341 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 78.7 ttt180 -54.81 150.5 9.75 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.337 179.728 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 81.7 18.69 67.52 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.837 -0.905 . . . . 0.0 110.837 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.578 ' CG1' HD11 ' A' ' 31' ' ' LEU . 58.7 t -133.98 133.65 56.08 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 CA-C-O 120.931 0.396 . . . . 0.0 110.183 179.831 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 89.6 mtm-85 -136.82 155.91 49.18 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.244 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 44.5 mt -92.81 138.0 31.87 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.742 179.853 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 25.2 mtp-105 -135.46 142.45 45.55 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.121 -179.601 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 43.4 t80 -101.53 115.71 31.14 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.203 179.739 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 87.6 m-20 -91.65 94.4 9.38 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.485 178.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -60.45 -35.17 75.21 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.193 -179.682 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.402 ' H ' HG22 ' A' ' 25' ' ' VAL . 0.6 OUTLIER -63.13 -42.96 98.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.285 179.977 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 76.1 mtp180 -84.24 -13.54 52.35 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-O 120.767 0.318 . . . . 0.0 110.482 -179.873 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 58.1 t30 66.19 19.84 11.11 Favored 'General case' 0 CA--C 1.532 0.278 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.366 179.639 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.512 ' HZ1' ' HA ' ' A' ' 39' ' ' ASP . 20.8 pttp -145.1 162.58 36.66 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-O 120.679 0.276 . . . . 0.0 110.282 179.184 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 78.4 m80 -90.5 153.13 20.6 Favored 'General case' 0 N--CA 1.464 0.238 0 N-CA-C 109.622 -0.51 . . . . 0.0 109.622 178.932 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 27.4 m -140.26 156.75 24.61 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.359 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.214 -179.721 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.578 HD11 ' CG1' ' A' ' 18' ' ' VAL . 34.5 tp -100.63 118.22 36.33 Favored 'General case' 0 N--CA 1.467 0.409 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 179.496 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 50.5 tp -78.22 97.27 5.46 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 179.276 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -96.05 145.01 28.81 Favored Pre-proline 0 CA--C 1.539 0.551 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.097 -179.506 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_exo -46.23 -37.08 18.05 Favored 'Trans proline' 0 N--CA 1.493 1.449 0 C-N-CA 121.266 1.311 . . . . 0.0 112.517 179.319 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 41.2 tp10 -72.66 -52.04 16.97 Favored 'General case' 0 C--N 1.331 -0.201 0 C-N-CA 120.986 -0.286 . . . . 0.0 111.204 -178.444 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 9.0 ptm180 -176.59 161.2 2.1 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.863 0.363 . . . . 0.0 110.603 -179.732 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 59.3 m -74.87 128.75 36.31 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.374 178.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -100.82 140.64 34.82 Favored 'General case' 0 N--CA 1.472 0.652 0 CA-C-O 120.943 0.401 . . . . 0.0 110.666 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.512 ' HA ' ' HZ1' ' A' ' 28' ' ' LYS . 36.4 p-10 -72.84 115.13 11.77 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.25 179.243 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 41.1 mt -131.05 152.41 50.39 Favored 'General case' 0 N--CA 1.472 0.657 0 CA-C-O 120.939 0.4 . . . . 0.0 110.198 -179.478 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 29.6 m-20 -88.2 165.87 14.76 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.121 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -60.7 -43.58 97.6 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.247 179.783 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . 0.464 ' OD1' ' N ' ' A' ' 44' ' ' ALA . 23.6 p30 -65.02 -32.83 74.74 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.053 -0.522 . . . . 0.0 110.663 -179.705 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.464 ' N ' ' OD1' ' A' ' 43' ' ' ASN . . . -69.87 -42.71 73.14 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 120.853 -0.339 . . . . 0.0 111.014 -179.601 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 58.9 t -80.32 -33.53 14.13 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 CA-C-N 116.533 -0.303 . . . . 0.0 110.779 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -53.29 -44.86 68.62 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.863 0.363 . . . . 0.0 110.565 -179.432 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 96.4 t -61.01 -45.66 98.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.318 179.629 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 50.4 mt -73.2 -17.87 61.31 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.102 -179.282 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 36.5 ttpt -91.18 -27.94 18.18 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.567 179.312 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 36.1 tp -71.15 -32.22 68.68 Favored 'General case' 0 N--CA 1.461 0.113 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.547 -179.198 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.3 p -73.74 120.34 22.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-O 121.122 0.487 . . . . 0.0 110.561 179.824 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 95.2 m-20 -71.12 -44.05 66.4 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.48 179.553 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -141.8 -98.31 0.31 Allowed Glycine 0 N--CA 1.472 1.053 0 N-CA-C 110.2 -1.16 . . . . 0.0 110.2 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 90.2 mtm180 -114.8 104.78 12.29 Favored 'General case' 0 N--CA 1.472 0.652 0 CA-C-O 120.734 0.302 . . . . 0.0 110.21 179.003 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.432 ' O ' HG23 ' A' ' 11' ' ' VAL . 99.3 m-20 -117.27 138.2 51.89 Favored 'General case' 0 N--CA 1.473 0.706 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.199 178.17 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 44.0 p -78.07 141.65 38.67 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 178.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.439 HG23 ' N ' ' A' ' 58' ' ' SER . 28.7 m -51.26 -39.42 21.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-O 120.886 0.374 . . . . 0.0 110.557 -179.536 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . 0.439 ' N ' HG23 ' A' ' 57' ' ' VAL . 55.9 m -58.62 -44.94 90.13 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.54 179.223 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 44.7 tt0 -65.18 -46.7 79.72 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.789 -179.783 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 67.0 mt -61.23 -42.91 95.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.173 -0.467 . . . . 0.0 109.861 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.409 ' O ' ' N ' ' A' ' 65' ' ' GLY . . . -53.69 -41.63 67.13 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.829 -179.317 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 95.9 mm-40 -63.81 -52.88 58.21 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.823 179.855 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 72.9 mt -64.0 -49.77 80.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.822 0.344 . . . . 0.0 110.967 -178.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 25.3 tp -69.95 -36.19 75.07 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.967 0.413 . . . . 0.0 110.477 -179.414 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.409 ' N ' ' O ' ' A' ' 61' ' ' ALA . . . -55.58 -40.23 77.74 Favored Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.985 -0.846 . . . . 0.0 110.985 -179.65 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 85.0 mt-30 -65.6 -32.08 73.47 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.717 0.294 . . . . 0.0 110.338 179.727 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 19.5 m -62.71 -47.03 85.37 Favored 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 120.816 -0.354 . . . . 0.0 110.331 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 90.5 m-85 -92.68 -2.3 56.17 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.565 179.591 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 65.5 t0 49.25 61.23 3.24 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.801 0.334 . . . . 0.0 111.135 179.666 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -144.31 164.5 30.6 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.126 -179.68 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 81.7 m-20 -55.65 112.79 4.65 Favored Pre-proline 0 CA--C 1.545 0.76 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.234 -179.667 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 76.3 Cg_exo -48.37 -36.33 30.12 Favored 'Trans proline' 0 N--CA 1.503 2.038 0 C-N-CA 121.995 1.797 . . . . 0.0 112.94 -179.746 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -50.68 -35.9 33.17 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.869 0.366 . . . . 0.0 111.011 -179.489 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 68.5 mt -70.92 -41.44 77.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.646 179.473 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.555 ' N ' HD12 ' A' ' 75' ' ' ILE . 1.7 mp -60.61 -47.81 91.28 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.698 -178.336 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 8.6 pt-20 -61.82 -45.78 92.35 Favored 'General case' 0 C--N 1.329 -0.322 0 C-N-CA 120.164 -0.614 . . . . 0.0 109.993 -179.222 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.427 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -66.51 -20.54 66.06 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.17 179.771 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 65.7 t0 -80.97 -48.9 11.64 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-O 120.775 0.321 . . . . 0.0 111.275 -179.529 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 14.8 pt -71.08 -40.72 75.85 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.279 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.889 -179.525 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 6.6 mt -42.55 -60.8 1.97 Allowed Pre-proline 0 CA--C 1.549 0.933 0 CA-C-O 119.487 -0.292 . . . . 0.0 111.113 -179.884 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.427 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 59.4 Cg_exo -39.88 -41.5 2.86 Favored 'Trans proline' 0 N--CA 1.495 1.609 0 C-N-CA 122.617 2.211 . . . . 0.0 112.286 178.01 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 13.0 tpt -65.61 -39.53 91.63 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.506 -179.038 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 45.0 mt -61.83 -36.64 81.77 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.117 -179.437 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -60.9 -42.14 97.45 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.318 179.574 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -70.56 -39.88 67.69 Favored Glycine 0 CA--C 1.529 0.956 0 N-CA-C 111.73 -0.548 . . . . 0.0 111.73 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 79.4 mt -67.6 -39.98 84.76 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.887 0.375 . . . . 0.0 110.573 -179.268 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -54.56 -40.02 68.33 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.666 -179.723 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 78.4 mt-30 -61.69 -22.26 65.17 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.545 179.874 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -94.24 -3.78 50.06 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.076 -179.662 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 36.7 ttm180 55.83 68.03 0.92 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.343 179.937 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 33.7 m -140.07 16.61 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.667 -179.755 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 78.0 mt -122.18 159.67 26.76 Favored 'General case' 0 N--CA 1.471 0.6 0 CA-C-O 121.51 0.672 . . . . 0.0 110.582 179.853 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 79.6 tt0 -140.93 144.97 35.47 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 114.651 -1.159 . . . . 0.0 110.326 179.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 52.6 ptt85 . . . . . 0 C--N 1.324 -0.54 0 CA-C-N 115.07 -0.968 . . . . 0.0 110.397 179.733 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.536 ' SD ' ' N ' ' A' ' 1' ' ' MET . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.619 0 CA-C-O 121.236 0.541 . . . . 0.0 109.936 . . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.451 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 5.9 tp10 -176.91 -57.92 0.0 OUTLIER Pre-proline 0 CA--C 1.54 0.585 0 CA-C-N 115.265 -0.88 . . . . 0.0 110.109 -179.484 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.451 ' HD2' ' N ' ' A' ' 2' ' ' GLU . 32.7 Cg_endo -58.07 -86.85 0.01 OUTLIER 'Trans proline' 0 N--CA 1.5 1.897 0 C-N-CA 121.935 1.757 . . . . 0.0 111.81 -179.858 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -161.92 67.32 0.26 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.058 -179.542 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -72.94 111.28 7.91 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.158 -179.685 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 62.8 m-85 -78.13 139.98 39.02 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.405 -179.323 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.431 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 17.5 m -88.29 175.01 7.85 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.469 179.9 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -65.17 -31.36 80.44 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 111.231 -0.748 . . . . 0.0 111.231 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 68.8 m -72.0 -6.75 44.42 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.495 0.188 . . . . 0.0 111.303 -179.249 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.431 ' OD2' ' O ' ' A' ' 7' ' ' SER . 0.2 OUTLIER -68.42 153.09 44.43 Favored 'General case' 0 C--N 1.332 -0.192 0 N-CA-C 109.587 -0.523 . . . . 0.0 109.587 179.798 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.521 HG23 ' O ' ' A' ' 11' ' ' VAL . 33.0 m -131.21 116.89 16.72 Favored Pre-proline 0 CA--C 1.54 0.574 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 179.266 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -77.02 151.3 30.6 Favored 'Trans proline' 0 N--CA 1.492 1.438 0 C-N-CA 121.114 1.209 . . . . 0.0 111.958 -178.828 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 72.5 ttp85 -154.97 133.94 12.26 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.615 -0.721 . . . . 0.0 109.631 179.7 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 65.7 mt -67.68 115.25 25.45 Favored Pre-proline 0 CA--C 1.542 0.636 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.776 -179.57 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -78.75 159.65 27.98 Favored 'Trans proline' 0 N--CA 1.494 1.515 0 C-N-CA 121.682 1.588 . . . . 0.0 111.827 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 85.3 mtp180 -57.93 148.54 25.41 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.76 179.68 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 82.21 13.23 79.42 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 179.669 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 61.9 t -134.32 132.11 55.14 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 CA-C-O 120.966 0.412 . . . . 0.0 110.167 179.697 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 90.0 mtm180 -136.66 153.44 50.91 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.233 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 19.2 mt -98.81 97.67 8.86 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.173 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 84.2 mtp180 -96.18 139.63 32.05 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.12 179.611 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.481 ' O ' ' CD1' ' A' ' 22' ' ' PHE . 38.7 p90 -97.71 115.22 27.54 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-O 121.001 0.429 . . . . 0.0 110.161 179.873 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -89.86 96.72 10.81 Favored 'General case' 0 N--CA 1.464 0.268 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.736 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -61.82 -34.11 75.35 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.212 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.434 ' H ' HG22 ' A' ' 25' ' ' VAL . 2.4 m -63.63 -40.95 90.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.359 -179.854 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -84.43 -15.9 44.55 Favored 'General case' 0 N--CA 1.467 0.402 0 CA-C-O 120.692 0.282 . . . . 0.0 110.439 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.4 ' O ' ' ND2' ' A' ' 27' ' ' ASN . 0.1 OUTLIER 71.96 12.85 6.05 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.773 179.69 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 47.2 pttt -144.83 161.01 40.34 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 121.071 0.462 . . . . 0.0 109.885 179.731 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 72.0 m80 -86.88 154.48 20.82 Favored 'General case' 0 CA--C 1.513 -0.462 0 CA-C-N 115.717 -0.674 . . . . 0.0 109.989 -179.888 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 34.5 m -136.6 157.25 36.58 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.257 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.108 -179.632 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 6.7 tp -98.95 110.23 22.87 Favored 'General case' 0 N--CA 1.464 0.256 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 179.612 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 55.9 tp -75.32 101.3 4.67 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 109.222 -0.659 . . . . 0.0 109.222 179.479 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -94.62 144.48 27.98 Favored Pre-proline 0 CA--C 1.537 0.48 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.031 -179.619 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 89.3 Cg_exo -45.05 -38.28 13.62 Favored 'Trans proline' 0 N--CA 1.495 1.575 0 C-N-CA 121.494 1.463 . . . . 0.0 112.315 179.313 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 -71.72 -44.32 64.36 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.951 -178.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 50.4 ttp180 -171.51 -122.28 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.523 0 N-CA-C 110.083 -0.34 . . . . 0.0 110.083 -179.64 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 91.8 m -161.05 153.09 19.89 Favored 'General case' 0 C--O 1.232 0.167 0 N-CA-C 109.508 -0.552 . . . . 0.0 109.508 -179.523 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 -126.2 139.84 53.03 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.441 -179.432 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -72.32 115.57 11.73 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.129 -0.487 . . . . 0.0 109.872 179.791 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 16.0 mt -128.52 156.88 42.58 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.117 -179.422 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -84.67 153.73 22.94 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.077 -179.716 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 68.1 t0 -59.01 -36.72 75.41 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.189 -179.613 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -63.59 -38.48 91.29 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.322 179.934 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -68.01 -40.39 82.99 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.724 -179.437 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 49.1 t -79.64 -28.15 12.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 120.809 0.338 . . . . 0.0 110.153 179.793 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.45 ' O ' ' N ' ' A' ' 50' ' ' LEU . . . -57.58 -41.63 81.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.365 -179.671 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 97.3 t -61.03 -47.15 94.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.482 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 38.6 mt -70.0 -30.46 67.78 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.022 -179.589 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 36.9 ttmt -82.66 -29.41 30.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.687 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.45 ' N ' ' O ' ' A' ' 46' ' ' ALA . 58.8 tp -72.49 -32.74 66.44 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 120.984 -0.286 . . . . 0.0 110.661 -179.121 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.5 p -79.25 128.67 38.4 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.251 0 CA-C-O 120.966 0.413 . . . . 0.0 110.592 179.676 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 94.8 m-20 -76.43 -86.81 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.166 -0.47 . . . . 0.0 109.738 179.343 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -88.56 -117.08 1.4 Allowed Glycine 0 CA--C 1.524 0.633 0 N-CA-C 110.332 -1.107 . . . . 0.0 110.332 179.328 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 83.2 mtm-85 -111.37 105.3 13.89 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-O 120.802 0.334 . . . . 0.0 110.295 179.746 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 95.1 m-20 -116.75 150.05 38.9 Favored 'General case' 0 N--CA 1.471 0.604 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.084 178.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 48.1 p -80.13 149.2 30.66 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 178.893 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.408 HG23 ' N ' ' A' ' 58' ' ' SER . 29.9 m -55.4 -37.87 46.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 120.858 0.361 . . . . 0.0 110.409 -179.796 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . 0.408 ' N ' HG23 ' A' ' 57' ' ' VAL . 7.7 t -58.09 -44.86 87.83 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.669 179.878 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 50.7 tt0 -64.58 -49.57 70.65 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.836 0.35 . . . . 0.0 110.712 -179.686 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 66.2 mt -61.19 -42.2 92.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.205 -0.452 . . . . 0.0 109.95 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -51.42 -39.61 57.65 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.029 -179.541 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 92.2 mm-40 -63.22 -47.57 81.92 Favored 'General case' 0 C--N 1.327 -0.389 0 C-N-CA 120.7 -0.4 . . . . 0.0 110.135 179.524 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 69.9 mt -64.82 -48.94 82.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.626 -179.369 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 23.7 tp -68.65 -37.84 79.99 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.986 0.422 . . . . 0.0 110.478 -179.284 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.427 ' O ' ' N ' ' A' ' 69' ' ' ASP . . . -56.17 -41.78 86.74 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 -179.194 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 87.8 mt-30 -66.4 -31.79 72.77 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 121.06 -0.256 . . . . 0.0 110.522 179.834 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 21.5 m -62.33 -49.01 77.29 Favored 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 120.84 -0.344 . . . . 0.0 110.436 -179.756 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -95.14 -0.88 52.94 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.552 179.535 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . 0.427 ' N ' ' O ' ' A' ' 65' ' ' GLY . 50.2 t0 52.16 62.08 2.88 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.506 -0.315 . . . . 0.0 110.834 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -141.97 163.14 33.7 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.226 -179.78 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 72.3 m-20 -55.79 113.09 5.1 Favored Pre-proline 0 CA--C 1.543 0.683 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.46 -179.691 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 78.2 Cg_exo -49.35 -36.37 38.02 Favored 'Trans proline' 0 N--CA 1.5 1.891 0 C-N-CA 121.854 1.702 . . . . 0.0 112.68 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -52.85 -37.13 59.82 Favored 'General case' 0 C--N 1.326 -0.445 0 C-N-CA 120.864 -0.334 . . . . 0.0 111.091 -179.267 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 97.6 mt -67.02 -42.27 88.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.574 -179.77 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.516 ' N ' HD12 ' A' ' 75' ' ' ILE . 1.7 mp -55.09 -31.48 25.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 -178.403 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 23.2 mt-10 -61.8 -58.87 6.3 Favored 'General case' 0 C--N 1.324 -0.512 0 C-N-CA 120.373 -0.531 . . . . 0.0 110.428 -179.494 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.401 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -56.39 -20.18 18.26 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.16 -179.376 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 65.3 t0 -78.74 -55.55 5.09 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.554 -0.294 . . . . 0.0 110.789 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 21.7 pt -77.74 -32.22 17.83 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 N-CA-C 111.721 0.267 . . . . 0.0 111.721 -179.517 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 15.6 mt -44.92 -60.03 3.54 Favored Pre-proline 0 CA--C 1.545 0.769 0 CA-C-O 119.658 -0.211 . . . . 0.0 111.051 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.401 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 52.4 Cg_endo -63.04 -26.54 73.64 Favored 'Trans proline' 0 N--CA 1.499 1.845 0 C-N-CA 122.072 1.848 . . . . 0.0 112.142 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 43.1 tpp -65.79 -39.99 91.49 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.86 0.362 . . . . 0.0 110.265 -179.514 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 91.7 mt -62.34 -41.64 98.73 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.081 -179.558 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -63.8 -37.29 86.82 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.515 179.606 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -62.93 -37.75 95.44 Favored Glycine 0 CA--C 1.525 0.682 0 N-CA-C 111.031 -0.828 . . . . 0.0 111.031 -179.88 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 89.7 mt -67.41 -38.56 84.8 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.882 0.372 . . . . 0.0 110.243 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -54.86 -37.2 65.93 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.658 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 87.2 mt-30 -61.39 -23.66 65.95 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.584 -179.867 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -93.24 -6.7 47.05 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.311 -179.462 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 55.8 ttm-85 61.63 58.06 2.12 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.314 179.767 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 33.6 m -141.79 6.1 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.644 -179.867 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 55.2 tp -113.5 145.6 40.94 Favored 'General case' 0 N--CA 1.474 0.755 0 CA-C-O 121.306 0.574 . . . . 0.0 110.302 179.942 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 45.6 tp10 -153.27 127.98 9.45 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.054 -179.432 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 96.4 mtt180 . . . . . 0 C--N 1.325 -0.485 0 CA-C-O 118.143 -0.932 . . . . 0.0 110.368 179.856 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 71.7 mtm . . . . . 0 N--CA 1.49 1.561 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 9.4 tp10 -168.0 62.71 0.58 Allowed Pre-proline 0 CA--C 1.532 0.274 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.261 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_endo -76.02 -170.27 0.82 Allowed 'Trans proline' 0 N--CA 1.492 1.405 0 C-N-CA 122.268 1.979 . . . . 0.0 111.599 -179.648 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.461 ' OG1' ' CE1' ' A' ' 6' ' ' PHE . 48.8 p -77.14 -16.83 58.99 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.509 -179.425 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . 52.38 88.08 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.838 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.461 ' CE1' ' OG1' ' A' ' 4' ' ' THR . 76.0 m-85 -79.93 141.52 35.97 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.229 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 49.4 m -90.55 -177.62 5.09 Favored 'General case' 0 N--CA 1.47 0.535 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.463 -179.88 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -66.54 -35.0 89.36 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 111.388 -0.685 . . . . 0.0 111.388 179.858 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 33.9 t -71.36 -2.82 17.72 Favored 'General case' 0 C--N 1.329 -0.305 0 O-C-N 122.569 -0.371 . . . . 0.0 110.747 -179.453 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -66.66 135.6 54.31 Favored 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 120.746 -0.382 . . . . 0.0 110.037 179.749 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.519 ' O ' HG13 ' A' ' 11' ' ' VAL . 7.3 p -131.36 110.19 15.07 Favored Pre-proline 0 CA--C 1.539 0.551 0 N-CA-C 110.086 -0.338 . . . . 0.0 110.086 179.026 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -78.11 156.24 29.94 Favored 'Trans proline' 0 N--CA 1.489 1.216 0 C-N-CA 121.459 1.439 . . . . 0.0 111.891 -179.112 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 73.4 ttp85 -155.68 132.23 10.37 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 115.892 -0.594 . . . . 0.0 109.562 179.835 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 59.8 mt -67.92 115.41 27.89 Favored Pre-proline 0 CA--C 1.543 0.691 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.535 -179.642 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -78.93 167.23 22.38 Favored 'Trans proline' 0 N--CA 1.495 1.605 0 C-N-CA 121.84 1.693 . . . . 0.0 112.286 -179.671 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 62.1 ttp180 -54.66 139.87 37.36 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.396 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.76 3.63 73.8 Favored Glycine 0 N--CA 1.465 0.595 0 N-CA-C 110.971 -0.851 . . . . 0.0 110.971 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.476 ' CG1' HD11 ' A' ' 31' ' ' LEU . 62.0 t -127.06 127.29 69.46 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 CA-C-O 120.931 0.396 . . . . 0.0 109.971 179.596 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.419 ' HE ' ' CD2' ' A' ' 32' ' ' LEU . 34.7 ptt180 -144.38 161.49 38.87 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.19 179.902 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 25.0 mt -94.76 136.24 35.3 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.254 -179.608 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 83.5 mtp180 -139.86 144.76 37.39 Favored 'General case' 0 N--CA 1.469 0.496 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.233 179.914 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.473 ' O ' ' CD1' ' A' ' 22' ' ' PHE . 38.5 p90 -98.9 117.32 33.12 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.415 -179.718 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 29.5 m-20 -92.43 104.13 16.48 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.678 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 82.3 tt0 -64.22 -37.37 87.21 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.335 -179.941 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 1.5 m -63.31 -42.17 95.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.382 -179.732 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 75.0 mtp85 -81.43 -16.82 50.91 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 120.543 0.211 . . . . 0.0 110.622 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 61.4 t30 69.81 13.06 8.06 Favored 'General case' 0 N--CA 1.468 0.466 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.048 179.77 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 22.0 pttm -145.0 165.67 27.52 Favored 'General case' 0 N--CA 1.469 0.477 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.225 179.457 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.472 ' HD1' ' CG ' ' A' ' 42' ' ' ASP . 80.6 m80 -88.48 149.67 23.53 Favored 'General case' 0 CA--C 1.517 -0.31 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.152 179.892 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 31.0 m -137.68 158.82 34.32 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.103 -179.714 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.476 HD11 ' CG1' ' A' ' 18' ' ' VAL . 37.0 tp -97.54 120.97 38.89 Favored 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 109.651 -0.5 . . . . 0.0 109.651 179.837 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.419 ' CD2' ' HE ' ' A' ' 19' ' ' ARG . 34.3 tp -81.29 95.69 7.05 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 109.192 -0.669 . . . . 0.0 109.192 179.384 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -94.75 153.21 40.14 Favored Pre-proline 0 CA--C 1.535 0.369 0 N-CA-C 108.995 -0.742 . . . . 0.0 108.995 -179.869 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -63.66 -28.16 69.06 Favored 'Trans proline' 0 C--N 1.312 -1.382 0 C-N-CA 121.538 1.492 . . . . 0.0 111.206 -179.624 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 43.3 tp10 -78.78 -52.16 8.75 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.625 -179.93 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 61.1 ttp180 -176.32 149.07 0.81 Allowed 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.333 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 61.6 m -70.44 136.46 49.54 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.53 179.164 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -109.24 140.87 42.31 Favored 'General case' 0 N--CA 1.471 0.62 0 CA-C-O 120.909 0.385 . . . . 0.0 110.958 -179.647 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 39.5 p-10 -72.98 117.62 14.93 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.397 179.401 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 95.4 mt -135.53 155.93 49.7 Favored 'General case' 0 N--CA 1.47 0.556 0 CA-C-O 121.046 0.45 . . . . 0.0 110.313 -179.714 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 22.1 m-20 -86.58 163.07 17.66 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.145 -179.768 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.472 ' CG ' ' HD1' ' A' ' 29' ' ' HIS . 87.4 m-20 -60.92 -40.95 95.11 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 115.783 -0.644 . . . . 0.0 109.99 179.539 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 5.5 m120 -63.4 -38.59 91.74 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.38 -179.574 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -67.96 -40.23 83.24 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.742 -179.524 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 58.7 t -80.42 -26.24 11.48 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 CA-C-O 120.748 0.309 . . . . 0.0 110.252 179.43 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.78 -39.96 75.03 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.032 0.444 . . . . 0.0 109.948 -179.846 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 87.2 t -61.01 -46.57 96.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.425 179.561 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 42.7 mt -76.08 -16.25 59.95 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.607 -179.161 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 36.7 ttmt -90.29 -34.7 15.64 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-O 120.904 0.383 . . . . 0.0 110.467 179.259 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 5.7 tp -70.37 -32.16 69.72 Favored 'General case' 0 N--CA 1.463 0.182 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.256 -179.306 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.4 HG13 ' O ' ' A' ' 51' ' ' VAL . 7.1 p -71.85 121.8 22.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 120.958 0.409 . . . . 0.0 110.62 -179.7 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 95.2 m-20 -70.08 -44.42 69.1 Favored 'General case' 0 CA--C 1.532 0.254 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.369 179.691 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -144.14 -98.38 0.26 Allowed Glycine 0 N--CA 1.472 1.077 0 N-CA-C 110.408 -1.077 . . . . 0.0 110.408 179.88 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . 0.443 ' HB3' HG21 ' A' ' 11' ' ' VAL . 89.3 mtm180 -114.73 104.3 11.83 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-N 116.747 0.273 . . . . 0.0 110.447 179.241 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.43 ' O ' HG23 ' A' ' 11' ' ' VAL . 98.3 m-20 -117.5 133.85 55.51 Favored 'General case' 0 N--CA 1.472 0.672 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.127 178.32 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 71.2 p -74.69 141.25 44.56 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.665 -0.494 . . . . 0.0 109.665 179.199 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.472 HG23 ' N ' ' A' ' 58' ' ' SER . 23.7 m -47.31 -40.35 6.21 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.248 0 CA-C-O 120.901 0.381 . . . . 0.0 110.702 -179.366 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . 0.472 ' N ' HG23 ' A' ' 57' ' ' VAL . 58.0 m -58.42 -44.93 89.28 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.298 179.351 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 55.2 tt0 -65.94 -46.87 76.58 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.698 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 63.1 mt -60.96 -43.23 95.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.066 -179.654 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -53.33 -40.31 64.75 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.988 -179.365 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 95.7 mm-40 -63.57 -54.31 38.05 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.524 -0.307 . . . . 0.0 110.971 179.897 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 73.7 mt -65.31 -48.5 83.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.819 0.342 . . . . 0.0 110.97 -179.069 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 26.0 tp -69.33 -37.6 77.8 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.657 -179.21 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -56.05 -41.96 86.26 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 110.94 -0.864 . . . . 0.0 110.94 -179.671 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 84.7 mt-30 -65.55 -31.16 72.06 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.601 0.239 . . . . 0.0 110.433 179.754 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 19.6 m -62.62 -46.68 87.15 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.704 0.287 . . . . 0.0 110.541 -179.734 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 88.1 m-85 -91.45 0.87 57.45 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.493 179.678 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 61.7 t0 51.98 53.19 12.96 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.482 -0.326 . . . . 0.0 110.838 179.585 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -139.93 162.6 34.78 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.182 -179.701 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -56.27 134.94 75.59 Favored Pre-proline 0 CA--C 1.545 0.787 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.725 -179.099 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -68.42 -29.27 31.53 Favored 'Trans proline' 0 N--CA 1.503 2.087 0 C-N-CA 122.523 2.149 . . . . 0.0 112.661 -179.387 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -55.34 -38.98 69.47 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.152 0.501 . . . . 0.0 110.865 -179.303 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 65.4 mt -71.1 -38.34 70.9 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.444 -179.884 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 37.3 mm -60.71 -46.2 96.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.07 -177.725 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -62.49 -45.34 93.47 Favored 'General case' 0 C--N 1.334 -0.101 0 C-N-CA 120.283 -0.567 . . . . 0.0 109.637 -179.614 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.421 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -65.56 -20.09 66.18 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.725 -0.67 . . . . 0.0 111.063 179.561 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 65.0 t0 -78.97 -50.01 11.82 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-O 120.813 0.339 . . . . 0.0 110.933 -179.466 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 25.5 pt -76.66 -37.81 29.59 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.515 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.468 -179.698 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 9.7 mt -43.06 -60.29 2.48 Favored Pre-proline 0 CA--C 1.548 0.9 0 CA-C-O 119.603 -0.237 . . . . 0.0 111.233 -179.65 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.421 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 36.7 Cg_endo -60.43 -32.2 93.54 Favored 'Trans proline' 0 N--CA 1.499 1.84 0 C-N-CA 121.847 1.698 . . . . 0.0 111.43 179.788 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 5.4 tpt -67.22 -43.14 82.8 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.786 0.327 . . . . 0.0 110.395 -179.937 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 78.1 mt -63.13 -39.63 95.24 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.411 -179.54 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.15 -38.72 87.45 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.144 179.904 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -65.5 -39.6 95.71 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.821 -0.911 . . . . 0.0 110.821 179.644 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 94.6 mt -68.12 -39.01 82.86 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.773 0.321 . . . . 0.0 110.422 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -53.29 -35.12 59.75 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.816 0.341 . . . . 0.0 110.754 -179.487 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 76.7 mt-30 -62.49 -20.28 64.42 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.828 179.692 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -93.46 -0.26 56.5 Favored 'General case' 0 N--CA 1.469 0.479 0 CA-C-O 120.86 0.362 . . . . 0.0 110.299 -179.451 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 16.2 tpp180 59.49 67.27 0.91 Allowed 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.614 179.739 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 7.5 m -139.78 6.62 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.476 -179.695 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 76.3 mt -138.04 141.18 40.35 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-O 121.03 0.443 . . . . 0.0 110.42 179.823 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -151.8 113.13 4.32 Favored 'General case' 0 CA--C 1.531 0.222 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.195 178.835 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 89.5 mtm180 . . . . . 0 C--O 1.22 -0.481 0 CA-C-O 117.975 -1.012 . . . . 0.0 110.353 179.521 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.1 mpt? . . . . . 0 N--CA 1.491 1.59 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 36.6 mt-10 48.16 55.76 17.26 Favored Pre-proline 0 CA--C 1.534 0.334 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.556 -179.642 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -70.1 153.33 67.45 Favored 'Trans proline' 0 N--CA 1.495 1.565 0 C-N-CA 122.607 2.205 . . . . 0.0 111.782 -179.528 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 59.8 p -152.87 34.59 0.48 Allowed 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.096 -179.929 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -163.72 -34.92 0.03 OUTLIER 'General case' 0 N--CA 1.463 0.175 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.419 179.79 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 50.7 m-85 50.7 -172.81 0.02 OUTLIER 'General case' 0 CA--C 1.531 0.225 0 CA-C-N 116.567 -0.288 . . . . 0.0 110.36 -179.714 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 17.3 m -133.57 -161.76 1.17 Allowed 'General case' 0 N--CA 1.468 0.464 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.304 -179.659 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -87.0 -28.38 25.95 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 111.161 -0.775 . . . . 0.0 111.161 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 67.6 m -76.92 -7.69 56.01 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-O 120.649 0.262 . . . . 0.0 110.714 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 42.8 p-10 -67.68 146.14 54.1 Favored 'General case' 0 C--N 1.331 -0.217 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 27.6 m -130.56 128.29 22.52 Favored Pre-proline 0 CA--C 1.542 0.662 0 CA-C-N 116.656 -0.247 . . . . 0.0 110.694 179.584 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_endo -77.43 145.57 23.82 Favored 'Trans proline' 0 N--CA 1.498 1.751 0 C-N-CA 121.795 1.663 . . . . 0.0 111.608 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.505 ' H ' HD11 ' A' ' 92' ' ' LEU . 78.5 ttt-85 -157.9 123.88 4.68 Favored 'General case' 0 N--CA 1.464 0.246 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.185 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 24.9 mt -68.9 119.59 70.55 Favored Pre-proline 0 CA--C 1.541 0.616 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.048 -179.322 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -76.86 162.0 32.74 Favored 'Trans proline' 0 N--CA 1.491 1.367 0 C-N-CA 121.783 1.655 . . . . 0.0 111.745 -179.78 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 77.4 ttt-85 -55.52 142.88 31.51 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.083 179.905 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 86.14 8.93 77.75 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 111.18 -0.768 . . . . 0.0 111.18 179.704 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.617 ' CG1' HD11 ' A' ' 31' ' ' LEU . 53.3 t -134.69 124.63 44.68 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 CA-C-O 120.893 0.378 . . . . 0.0 110.111 179.372 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 83.8 mtp180 -140.42 157.29 45.74 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.026 179.662 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 54.0 mt -91.55 138.47 31.54 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 116.043 -0.526 . . . . 0.0 109.915 -179.698 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 83.2 mtp180 -141.93 151.04 42.23 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.453 -179.488 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 72.4 t80 -100.89 114.33 28.09 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.977 179.606 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 13.5 m-20 -90.08 99.17 12.23 Favored 'General case' 0 N--CA 1.464 0.261 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 179.174 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -57.94 -31.61 67.01 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.038 179.962 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -65.55 -43.68 94.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.423 -179.341 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 88.9 mtt-85 -84.84 -16.41 41.44 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.304 -178.766 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 3.2 m120 69.5 15.4 8.29 Favored 'General case' 0 CA--C 1.531 0.214 0 CA-C-N 115.531 -0.758 . . . . 0.0 110.89 179.548 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 59.5 pttt -144.85 170.01 16.94 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 116.077 -0.51 . . . . 0.0 109.872 179.975 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 76.4 m80 -89.39 153.6 20.72 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.619 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 27.3 m -141.65 163.01 20.42 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.283 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.058 -179.853 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.617 HD11 ' CG1' ' A' ' 18' ' ' VAL . 34.1 tp -97.23 116.69 29.91 Favored 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 179.561 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 57.0 tp -80.01 92.73 5.62 Favored 'General case' 0 CA--C 1.517 -0.311 0 N-CA-C 109.211 -0.662 . . . . 0.0 109.211 178.886 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -96.83 154.9 38.17 Favored Pre-proline 0 CA--C 1.543 0.688 0 N-CA-C 110.007 -0.368 . . . . 0.0 110.007 -179.884 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -63.6 -29.75 70.25 Favored 'Trans proline' 0 N--CA 1.496 1.674 0 C-N-CA 122.46 2.107 . . . . 0.0 111.53 179.799 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 -80.4 -51.84 8.37 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 116.548 -0.296 . . . . 0.0 110.775 -179.582 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 61.7 ttp180 -173.46 148.68 1.61 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.269 -179.669 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 76.6 m -71.66 131.37 43.07 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.377 179.322 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 79.1 m-85 -100.92 137.85 38.76 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-O 120.935 0.397 . . . . 0.0 110.833 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 38.5 p-10 -74.7 116.63 15.62 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.424 179.32 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 81.4 mt -132.42 156.61 46.39 Favored 'General case' 0 N--CA 1.469 0.498 0 CA-C-O 121.076 0.465 . . . . 0.0 110.394 -179.63 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 95.9 m-20 -85.88 153.04 22.51 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.899 -179.847 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 68.3 t0 -58.23 -41.3 83.85 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.551 -179.429 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . 0.448 ' OD1' ' N ' ' A' ' 44' ' ' ALA . 21.0 p30 -64.2 -36.21 83.33 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.709 -179.767 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.448 ' N ' ' OD1' ' A' ' 43' ' ' ASN . . . -69.4 -41.07 76.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.341 -0.391 . . . . 0.0 111.053 -179.537 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 60.6 t -77.45 -27.71 15.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 N-CA-C 110.101 -0.333 . . . . 0.0 110.101 179.84 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.43 ' O ' ' N ' ' A' ' 50' ' ' LEU . . . -55.72 -39.02 70.52 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.33 -179.882 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 58.3 t -60.54 -45.1 97.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.136 179.739 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 49.6 mt -69.62 -32.12 70.63 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.457 -179.646 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 35.4 ttpt -82.93 -26.54 31.34 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.429 179.667 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.43 ' N ' ' O ' ' A' ' 46' ' ' ALA . 59.3 tp -72.19 -32.87 67.2 Favored 'General case' 0 N--CA 1.461 0.114 0 C-N-CA 120.429 -0.508 . . . . 0.0 110.353 -179.106 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.3 p -79.64 132.19 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.241 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.587 179.573 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 93.3 m-20 -73.34 -69.94 0.4 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.916 0.389 . . . . 0.0 109.985 179.63 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -114.31 -110.22 2.86 Favored Glycine 0 N--CA 1.474 1.198 0 N-CA-C 110.48 -1.048 . . . . 0.0 110.48 179.552 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 89.9 mtm180 -109.27 105.17 14.48 Favored 'General case' 0 N--CA 1.47 0.539 0 CA-C-O 120.864 0.364 . . . . 0.0 110.27 179.418 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 -116.68 150.24 38.48 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-N 115.828 -0.624 . . . . 0.0 109.923 178.801 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 35.7 p -78.24 139.68 38.91 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 179.214 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.415 HG23 ' N ' ' A' ' 58' ' ' SER . 32.0 m -53.82 -38.17 35.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.958 0.409 . . . . 0.0 110.323 -179.711 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . 0.415 ' N ' HG23 ' A' ' 57' ' ' VAL . 53.4 m -58.69 -43.88 90.1 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.745 179.489 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 55.7 tt0 -64.8 -46.49 81.81 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.601 -179.556 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 65.0 mt -61.22 -42.93 95.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.228 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.443 ' O ' ' N ' ' A' ' 65' ' ' GLY . . . -53.68 -39.36 65.07 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.068 -179.258 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 92.2 mm-40 -63.7 -51.6 64.3 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.818 179.746 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 72.9 mt -65.21 -48.96 81.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 120.914 0.388 . . . . 0.0 110.862 -179.348 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 26.5 tp -70.31 -33.91 72.08 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.267 -179.349 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.443 ' N ' ' O ' ' A' ' 61' ' ' ALA . . . -57.72 -39.54 91.41 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 -179.391 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 -65.48 -32.0 73.37 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 121.001 -0.28 . . . . 0.0 110.339 179.706 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 19.7 m -62.58 -47.13 85.16 Favored 'General case' 0 C--N 1.329 -0.314 0 C-N-CA 120.755 -0.378 . . . . 0.0 110.57 -179.714 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -92.95 -2.41 55.82 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.441 179.817 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 49.4 t0 50.23 61.68 3.07 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.805 179.783 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -145.59 163.45 34.75 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 120.729 0.299 . . . . 0.0 110.352 -179.475 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 15.2 m-20 -55.65 112.88 4.76 Favored Pre-proline 0 CA--C 1.542 0.639 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.168 -179.074 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_exo -48.16 -35.02 25.4 Favored 'Trans proline' 0 N--CA 1.502 1.985 0 C-N-CA 121.964 1.776 . . . . 0.0 112.704 -179.492 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -51.45 -35.45 39.64 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-O 121.024 0.44 . . . . 0.0 110.885 -179.32 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 72.9 mt -72.11 -40.36 66.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.817 179.098 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.561 ' N ' HD12 ' A' ' 75' ' ' ILE . 1.7 mp -61.77 -47.9 91.14 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.134 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.006 -178.213 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -59.93 -45.47 92.48 Favored 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 120.385 -0.526 . . . . 0.0 110.461 -178.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.45 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -67.9 -20.44 65.11 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.037 179.729 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -80.52 -47.35 14.38 Favored 'General case' 0 CA--C 1.534 0.362 0 CA-C-N 116.55 -0.295 . . . . 0.0 111.004 -179.563 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 16.5 pt -72.61 -41.2 63.11 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.437 -179.765 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 6.9 mt -42.11 -60.72 1.88 Allowed Pre-proline 0 CA--C 1.546 0.801 0 CA-C-O 119.514 -0.279 . . . . 0.0 110.407 179.461 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.45 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 76.2 Cg_exo -41.12 -45.24 5.34 Favored 'Trans proline' 0 N--CA 1.494 1.529 0 C-N-CA 122.232 1.955 . . . . 0.0 111.815 177.522 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 13.2 tmm? -67.33 -42.76 83.06 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.018 -179.228 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 91.6 mt -63.55 -43.79 96.04 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.993 0.425 . . . . 0.0 110.215 -179.459 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -64.89 -35.98 82.89 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.592 179.74 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -61.8 -38.62 96.25 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.974 -0.85 . . . . 0.0 110.974 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 89.2 mt -66.9 -39.96 87.59 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 110.021 -0.363 . . . . 0.0 110.021 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -54.91 -39.09 68.42 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.314 179.852 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 78.3 mt-30 -63.12 -22.59 66.96 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.897 179.751 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 65.3 mttp -91.95 -3.89 55.34 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-O 120.784 0.326 . . . . 0.0 110.229 -179.548 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 59.7 ttm-85 62.39 55.07 2.39 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.597 179.583 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 32.4 m -141.47 5.91 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.206 179.855 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.505 HD11 ' H ' ' A' ' 13' ' ' ARG . 56.1 tp -139.87 131.01 26.43 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-O 121.144 0.497 . . . . 0.0 110.411 179.714 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 14.9 pt-20 -155.18 135.62 13.31 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.525 179.282 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 16.8 ptm180 . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 117.83 -1.081 . . . . 0.0 110.335 179.674 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 28.3 ttt . . . . . 0 N--CA 1.49 1.532 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 21.4 tp10 -169.35 72.36 0.71 Allowed Pre-proline 0 CA--C 1.531 0.244 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.881 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_exo -56.38 169.83 1.46 Allowed 'Trans proline' 0 N--CA 1.496 1.674 0 C-N-CA 122.467 2.111 . . . . 0.0 111.965 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 51.2 p -75.3 -19.9 59.41 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.344 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . 51.82 91.65 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.948 179.722 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -78.62 142.64 37.08 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 115.998 -0.546 . . . . 0.0 109.909 179.64 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 42.6 m -89.29 -178.66 5.68 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 115.694 -0.685 . . . . 0.0 110.057 179.753 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -78.73 -25.44 60.48 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 111.211 -0.756 . . . . 0.0 111.211 179.87 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 78.5 p -76.27 -4.81 44.0 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.619 0.247 . . . . 0.0 110.65 -179.497 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 41.1 p-10 -66.55 143.67 56.91 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 120.693 -0.403 . . . . 0.0 109.966 -179.834 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.578 HG23 ' O ' ' A' ' 11' ' ' VAL . 35.5 m -130.5 103.07 16.45 Favored Pre-proline 0 N--CA 1.47 0.528 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.647 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_endo -76.22 145.8 27.8 Favored 'Trans proline' 0 N--CA 1.488 1.149 0 C-N-CA 121.142 1.228 . . . . 0.0 111.986 -179.545 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 77.8 ttt-85 -155.16 144.07 20.78 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.797 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 60.4 mt -64.26 114.94 15.83 Favored Pre-proline 0 CA--C 1.541 0.624 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.828 -179.303 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -79.5 155.78 24.77 Favored 'Trans proline' 0 N--CA 1.49 1.286 0 C-N-CA 121.798 1.666 . . . . 0.0 111.705 -179.442 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 59.7 ttm-85 -57.75 139.25 54.36 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.172 179.683 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 90.81 2.63 71.85 Favored Glycine 0 CA--C 1.523 0.563 0 N-CA-C 110.956 -0.858 . . . . 0.0 110.956 179.657 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.442 ' CG1' HD11 ' A' ' 31' ' ' LEU . 49.4 t -131.13 129.84 63.22 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 179.548 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 83.3 mtp180 -136.91 155.86 49.21 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 115.943 -0.571 . . . . 0.0 109.965 179.811 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 30.7 mt -90.75 139.18 30.97 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.847 -0.615 . . . . 0.0 109.931 -179.596 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 75.6 mtp85 -137.26 138.62 40.29 Favored 'General case' 0 N--CA 1.466 0.372 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.717 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.47 ' O ' ' CD1' ' A' ' 22' ' ' PHE . 43.2 p90 -98.24 117.98 33.85 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.08 -179.863 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 87.0 m-20 -89.78 104.94 17.45 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.16 -0.473 . . . . 0.0 109.826 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -65.16 -36.29 83.78 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.161 179.882 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.413 HG22 ' H ' ' A' ' 25' ' ' VAL . 2.2 m -63.45 -42.8 97.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.645 -179.607 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 95.4 mtt-85 -83.08 -18.59 39.1 Favored 'General case' 0 N--CA 1.466 0.334 0 N-CA-C 110.406 -0.22 . . . . 0.0 110.406 -179.842 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 70.32 19.63 6.42 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.996 179.762 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -145.06 165.93 26.82 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.34 179.63 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 79.2 m80 -90.78 150.65 21.51 Favored 'General case' 0 CA--C 1.516 -0.343 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.307 179.889 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 33.7 m -139.86 160.05 26.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.153 -179.647 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.442 HD11 ' CG1' ' A' ' 18' ' ' VAL . 43.0 tp -102.38 121.58 42.59 Favored 'General case' 0 CA--C 1.517 -0.311 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 179.141 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 43.5 tp -79.7 100.59 7.96 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 178.852 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -96.55 146.36 31.17 Favored Pre-proline 0 CA--C 1.54 0.572 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -179.833 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_exo -47.17 -38.37 25.11 Favored 'Trans proline' 0 N--CA 1.495 1.615 0 C-N-CA 121.843 1.696 . . . . 0.0 112.67 178.907 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -74.07 -52.07 13.8 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.01 -178.579 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 58.5 ttt85 -175.32 152.17 1.35 Allowed 'General case' 0 C--N 1.333 -0.142 0 CA-C-O 120.89 0.376 . . . . 0.0 110.664 -179.784 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 37.9 m -68.18 133.92 49.66 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.547 179.456 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 78.5 m-85 -107.79 139.56 42.18 Favored 'General case' 0 N--CA 1.472 0.641 0 CA-C-O 120.977 0.418 . . . . 0.0 110.52 -179.624 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 36.6 p-10 -73.48 121.33 20.38 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.493 179.629 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 93.5 mt -136.09 158.12 45.17 Favored 'General case' 0 N--CA 1.471 0.583 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 179.738 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -85.16 163.14 18.91 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.405 -179.604 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 -60.59 -44.67 95.98 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.643 179.866 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . 0.518 ' O ' HG23 ' A' ' 47' ' ' VAL . 15.1 p-10 -65.54 -27.49 68.48 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.693 -179.417 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -72.52 -44.46 62.15 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.552 -0.295 . . . . 0.0 110.756 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 48.9 t -79.21 -35.72 17.54 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.629 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -51.83 -36.54 48.48 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.786 -179.101 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.518 HG23 ' O ' ' A' ' 43' ' ' ASN . 91.6 t -60.89 -47.57 92.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.606 179.677 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 45.1 mt -72.83 -24.06 60.85 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.435 -179.076 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 17.1 ttmm -84.44 -34.59 23.44 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.035 179.755 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 5.9 tp -71.16 -33.03 69.65 Favored 'General case' 0 N--CA 1.463 0.207 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.845 -178.464 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.2 p -76.68 126.11 37.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 121.01 0.433 . . . . 0.0 110.722 179.483 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 -78.6 -86.59 0.07 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.096 -0.502 . . . . 0.0 109.775 179.137 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -85.07 -116.55 0.79 Allowed Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.167 -1.173 . . . . 0.0 110.167 179.278 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 89.0 mtm180 -113.73 105.31 13.14 Favored 'General case' 0 N--CA 1.471 0.578 0 N-CA-C 110.037 -0.357 . . . . 0.0 110.037 179.484 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 88.3 m-20 -116.55 153.04 32.9 Favored 'General case' 0 N--CA 1.473 0.721 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.099 179.083 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 10.2 p -81.75 152.95 26.76 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.026 179.185 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.482 HG23 ' N ' ' A' ' 58' ' ' SER . 33.5 m -59.21 -43.15 89.0 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.309 179.953 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . 0.482 ' N ' HG23 ' A' ' 57' ' ' VAL . 51.4 m -58.2 -43.77 87.78 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.719 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 57.6 tt0 -64.76 -46.13 83.49 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.54 -179.79 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 96.7 mt -61.76 -43.42 97.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 -179.92 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -52.97 -37.83 61.6 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.173 -179.011 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 97.4 mm-40 -63.6 -52.95 58.67 Favored 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 120.588 -0.445 . . . . 0.0 110.776 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 68.0 mt -66.28 -46.82 86.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 C-N-CA 120.869 -0.332 . . . . 0.0 110.644 -179.906 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 34.7 tp -68.04 -37.67 81.6 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.417 -179.645 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.42 ' O ' ' N ' ' A' ' 69' ' ' ASP . . . -58.3 -41.0 94.78 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 111.018 -0.833 . . . . 0.0 111.018 -179.434 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 87.3 mt-30 -66.13 -30.88 71.45 Favored 'General case' 0 C--N 1.327 -0.408 0 C-N-CA 121.086 -0.245 . . . . 0.0 110.456 179.734 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 20.9 m -62.18 -48.71 78.82 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.799 -0.361 . . . . 0.0 110.531 -179.747 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -95.37 -2.14 49.72 Favored 'General case' 0 N--CA 1.469 0.51 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.565 179.489 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . 0.42 ' N ' ' O ' ' A' ' 65' ' ' GLY . 63.4 t0 53.86 62.19 2.73 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.809 179.792 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -138.53 160.63 39.08 Favored 'General case' 0 N--CA 1.469 0.491 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 -179.738 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 64.8 m-20 -55.8 114.06 6.77 Favored Pre-proline 0 CA--C 1.545 0.763 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.491 -179.201 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_exo -49.33 -36.89 39.33 Favored 'Trans proline' 0 N--CA 1.497 1.684 0 C-N-CA 121.725 1.617 . . . . 0.0 112.655 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -52.03 -39.31 59.36 Favored 'General case' 0 N--CA 1.464 0.227 0 CA-C-O 120.996 0.427 . . . . 0.0 111.158 -179.148 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 73.1 mt -71.96 -40.22 67.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.555 179.5 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 41.8 mm -59.56 -49.1 84.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.996 -178.225 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -63.08 -43.59 98.12 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 -179.859 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.445 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -66.04 -20.76 66.28 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.089 179.714 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 52.4 t0 -79.56 -48.22 14.19 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-O 120.642 0.258 . . . . 0.0 111.218 -179.418 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 34.4 pt -78.18 -35.01 19.41 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.575 0 CA-C-O 120.955 0.407 . . . . 0.0 111.496 -179.416 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 9.8 mt -45.74 -60.11 3.82 Favored Pre-proline 0 CA--C 1.544 0.747 0 CA-C-N 116.49 -0.323 . . . . 0.0 110.935 179.745 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.445 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 42.1 Cg_endo -61.97 -28.37 80.65 Favored 'Trans proline' 0 N--CA 1.497 1.703 0 C-N-CA 121.902 1.734 . . . . 0.0 111.713 179.814 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 40.8 tpp -65.89 -39.75 90.92 Favored 'General case' 0 CA--C 1.53 0.202 0 CA-C-O 120.811 0.339 . . . . 0.0 110.457 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 84.6 mt -62.13 -39.8 93.79 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.307 -179.522 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.03 -38.92 87.85 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.42 -0.354 . . . . 0.0 110.287 179.698 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -65.5 -40.96 96.48 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 111.146 -0.782 . . . . 0.0 111.146 179.777 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 92.1 mt -70.04 -35.53 74.35 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.785 0.326 . . . . 0.0 110.431 -179.865 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -54.86 -34.25 62.71 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.725 -179.883 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 87.5 mt-30 -56.21 -28.76 59.52 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.175 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -96.96 -7.99 31.72 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.253 179.795 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 18.6 tpt85 57.79 51.4 9.28 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.693 179.763 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 35.4 m -108.1 11.19 8.98 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.584 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.657 -179.58 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.47 HD12 ' C ' ' A' ' 92' ' ' LEU . 0.7 OUTLIER -138.37 179.71 6.3 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.478 -179.418 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 16.5 pt-20 -152.37 173.8 14.62 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.516 -179.875 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 8.9 ptm180 . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 117.905 -1.045 . . . . 0.0 110.49 -179.878 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 66.5 mtt . . . . . 0 N--CA 1.491 1.589 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 4.5 mp0 -71.62 148.87 93.09 Favored Pre-proline 0 CA--C 1.538 0.516 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.632 -178.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -71.7 42.88 0.51 Allowed 'Trans proline' 0 N--CA 1.499 1.796 0 C-N-CA 122.232 1.954 . . . . 0.0 111.514 179.518 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 13.1 p 52.58 68.57 0.8 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.042 0.449 . . . . 0.0 110.419 179.759 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.11 107.83 5.67 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.106 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 91.6 m-85 -79.38 138.46 37.66 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.154 -179.701 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.438 ' H ' ' CG ' ' A' ' 10' ' ' ASP . 15.4 m -93.65 -173.6 3.22 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 120.948 0.404 . . . . 0.0 110.814 -179.85 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -67.21 -35.49 88.39 Favored Glycine 0 CA--C 1.529 0.916 0 N-CA-C 111.379 -0.688 . . . . 0.0 111.379 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 33.6 t -69.08 -16.98 63.81 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.897 0.38 . . . . 0.0 110.897 -179.415 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.474 ' OD2' ' NH2' ' A' ' 94' ' ' ARG . 0.7 OUTLIER -68.79 149.7 48.69 Favored 'General case' 0 CA--C 1.515 -0.393 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 179.595 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 27.6 m -130.13 129.61 22.96 Favored Pre-proline 0 N--CA 1.472 0.644 0 CA-C-N 116.693 -0.23 . . . . 0.0 110.939 -179.835 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -77.6 151.79 29.03 Favored 'Trans proline' 0 N--CA 1.493 1.48 0 C-N-CA 121.637 1.558 . . . . 0.0 111.333 179.566 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 76.1 ttt180 -157.79 121.71 4.14 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 179.475 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 17.4 mt -69.77 121.96 84.32 Favored Pre-proline 0 CA--C 1.543 0.71 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.969 -179.133 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.413 ' CD ' ' O ' ' A' ' 91' ' ' VAL . 89.6 Cg_endo -75.07 157.4 42.49 Favored 'Trans proline' 0 N--CA 1.492 1.429 0 C-N-CA 121.805 1.67 . . . . 0.0 112.24 179.837 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 89.8 mtm180 -59.28 152.98 19.68 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.355 179.603 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 85.98 11.42 73.34 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 111.223 -0.751 . . . . 0.0 111.223 179.732 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 61.6 t -128.0 133.74 66.6 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 CA-C-O 120.871 0.367 . . . . 0.0 110.085 179.784 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 90.2 mtm180 -134.3 153.98 51.57 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.089 -179.819 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 31.0 mt -98.13 140.74 31.99 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.941 -179.776 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 84.3 mtp180 -140.34 144.76 36.48 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.117 -0.492 . . . . 0.0 109.933 -179.802 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 89.9 t80 -96.7 114.41 26.05 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.15 -0.477 . . . . 0.0 109.882 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 28.2 m-20 -90.05 99.17 12.23 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.919 179.776 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -64.74 -34.29 77.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.117 0.484 . . . . 0.0 109.879 179.83 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.423 ' H ' HG22 ' A' ' 25' ' ' VAL . 2.0 m -61.97 -40.88 88.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.86 -179.858 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 95.1 mtt-85 -87.82 -20.5 25.99 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.541 179.7 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 6.2 m-80 71.8 19.9 4.72 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.83 179.701 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -144.96 170.07 16.86 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.077 179.707 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 72.5 m80 -87.24 156.13 19.79 Favored 'General case' 0 CA--C 1.517 -0.289 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.536 179.828 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 34.4 m -140.26 158.11 25.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.818 -179.785 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 6.4 tp -103.21 107.92 18.92 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 179.727 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 53.4 tp -77.2 95.44 4.3 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 179.228 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -96.7 147.64 33.23 Favored Pre-proline 0 CA--C 1.54 0.571 0 N-CA-C 110.029 -0.359 . . . . 0.0 110.029 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 80.4 Cg_exo -44.99 -32.96 7.03 Favored 'Trans proline' 0 N--CA 1.496 1.62 0 C-N-CA 122.054 1.836 . . . . 0.0 112.267 178.716 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -72.52 -48.88 36.89 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.789 -179.014 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 51.3 ttp180 -171.81 -123.76 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.49 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.248 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 86.1 m -161.88 124.23 2.92 Favored 'General case' 0 N--CA 1.456 -0.142 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 -179.411 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -100.73 137.19 39.46 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.58 -179.809 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 38.1 p-10 -72.72 120.58 18.54 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.419 179.696 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 94.3 mt -133.0 158.49 42.57 Favored 'General case' 0 N--CA 1.469 0.51 0 CA-C-O 121.006 0.431 . . . . 0.0 110.073 -179.77 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 83.8 m-20 -82.84 159.95 22.31 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.009 -0.542 . . . . 0.0 110.084 -179.347 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.469 ' OD1' ' N ' ' A' ' 43' ' ' ASN . 35.7 p-10 -60.28 -41.91 94.3 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.852 -179.544 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . 0.499 ' OD1' ' N ' ' A' ' 44' ' ' ALA . 24.8 p30 -66.72 -28.41 68.4 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.691 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.499 ' N ' ' OD1' ' A' ' 43' ' ' ASN . . . -72.9 -42.59 63.4 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.893 -179.786 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 48.0 t -79.8 -34.53 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.494 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -53.76 -42.38 68.15 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.536 -179.654 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 74.1 t -60.32 -45.1 96.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.47 -0.332 . . . . 0.0 110.47 179.707 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 39.4 mt -71.62 -20.69 61.94 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.347 -179.225 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 35.8 ttpt -92.4 -29.38 16.33 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.734 179.559 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 5.3 tp -70.35 -32.32 69.97 Favored 'General case' 0 N--CA 1.462 0.155 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.953 -179.047 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.412 ' O ' HG13 ' A' ' 51' ' ' VAL . 7.5 p -72.15 120.77 21.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.547 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 95.0 m-20 -71.9 -44.54 63.53 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.185 179.643 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -142.58 -97.57 0.27 Allowed Glycine 0 N--CA 1.472 1.091 0 N-CA-C 110.261 -1.135 . . . . 0.0 110.261 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . 0.493 HH12 ' C ' ' A' ' 94' ' ' ARG . 95.2 mtt-85 -114.64 104.52 12.08 Favored 'General case' 0 N--CA 1.469 0.492 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 179.084 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 97.8 m-20 -117.42 145.59 44.02 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.866 178.632 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 18.2 p -80.83 137.11 36.2 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 179.092 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.446 HG23 ' N ' ' A' ' 58' ' ' SER . 30.0 m -55.61 -39.94 57.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.293 -179.753 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . 0.446 ' N ' HG23 ' A' ' 57' ' ' VAL . 78.2 p -58.29 -43.52 88.08 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.53 179.697 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 55.4 tt0 -65.93 -44.28 85.59 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.889 -179.91 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 96.8 mt -61.39 -43.25 96.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 -179.412 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.422 ' O ' ' N ' ' A' ' 65' ' ' GLY . . . -50.7 -36.18 34.81 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.921 -179.072 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 96.6 mm-40 -64.11 -49.96 70.16 Favored 'General case' 0 C--N 1.325 -0.485 0 C-N-CA 120.654 -0.418 . . . . 0.0 110.403 179.809 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 72.2 mt -65.2 -49.31 79.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.376 -0.374 . . . . 0.0 110.619 -179.661 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 31.3 tp -68.88 -36.24 77.84 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.284 -179.472 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.422 ' N ' ' O ' ' A' ' 61' ' ' ALA . . . -54.54 -39.54 66.58 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 111.114 -0.795 . . . . 0.0 111.114 -179.36 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 76.0 mt-30 -65.39 -32.34 73.92 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.665 0.269 . . . . 0.0 110.671 179.842 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 21.1 m -61.83 -48.46 80.46 Favored 'General case' 0 C--N 1.33 -0.264 0 C-N-CA 120.767 -0.373 . . . . 0.0 110.559 -179.774 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 95.5 m-85 -92.86 -3.14 55.14 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.43 179.6 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 61.8 t0 51.88 62.02 2.92 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.824 179.721 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -144.38 164.07 31.88 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-O 120.757 0.313 . . . . 0.0 110.282 -179.632 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 65.9 m-20 -55.8 113.65 6.07 Favored Pre-proline 0 CA--C 1.545 0.777 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.221 -179.408 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_exo -49.21 -36.79 37.89 Favored 'Trans proline' 0 N--CA 1.497 1.692 0 C-N-CA 121.937 1.758 . . . . 0.0 112.601 -179.739 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -52.23 -38.07 56.97 Favored 'General case' 0 C--N 1.323 -0.554 0 C-N-CA 120.806 -0.357 . . . . 0.0 111.076 -179.029 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 97.7 mt -66.7 -42.34 89.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.67 -179.481 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.51 ' N ' HD12 ' A' ' 75' ' ' ILE . 1.7 mp -54.67 -33.1 26.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 -178.394 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 21.9 mt-10 -61.37 -58.3 8.77 Favored 'General case' 0 C--N 1.321 -0.662 0 C-N-CA 120.302 -0.559 . . . . 0.0 110.4 -179.406 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.427 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -55.56 -19.9 11.56 Favored 'General case' 0 C--N 1.328 -0.328 0 O-C-N 123.543 0.527 . . . . 0.0 111.282 -179.375 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 58.3 t0 -79.23 -53.81 6.59 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-O 120.601 0.239 . . . . 0.0 111.02 -179.851 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 29.4 pt -80.29 -30.09 12.53 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 CA-C-O 121.146 0.498 . . . . 0.0 111.647 -179.452 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 13.2 mt -47.19 -59.71 5.03 Favored Pre-proline 0 CA--C 1.543 0.698 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.102 179.734 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.427 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 36.3 Cg_endo -61.84 -30.4 84.2 Favored 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 121.505 1.47 . . . . 0.0 111.216 179.293 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 38.6 tpp -65.0 -40.58 95.16 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.133 -179.859 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 83.9 mt -62.77 -41.76 99.39 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.22 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -63.84 -38.36 90.81 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.623 179.753 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -62.1 -38.86 96.83 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 111.004 -0.839 . . . . 0.0 111.004 -179.853 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 91.6 mt -66.8 -39.5 87.78 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 120.821 0.343 . . . . 0.0 110.551 -179.865 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -53.82 -38.43 64.59 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 120.758 0.313 . . . . 0.0 110.485 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 77.5 mt-30 -64.14 -20.24 65.85 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.024 179.864 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 64.4 mttp -92.22 -3.5 55.44 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-N 116.584 -0.28 . . . . 0.0 110.504 -179.199 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 32.3 ttm180 61.55 57.81 2.21 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.284 179.676 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . 0.413 ' O ' ' CD ' ' A' ' 15' ' ' PRO . 33.8 m -140.99 6.52 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.577 -179.886 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 45.9 tp -110.7 146.57 36.03 Favored 'General case' 0 N--CA 1.473 0.709 0 CA-C-O 121.109 0.481 . . . . 0.0 110.046 179.862 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 77.1 tt0 -146.85 162.24 39.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.276 -0.874 . . . . 0.0 110.459 -179.308 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . 0.493 ' C ' HH12 ' A' ' 54' ' ' ARG . 33.7 ptt180 . . . . . 0 C--O 1.22 -0.472 0 CA-C-O 118.008 -0.996 . . . . 0.0 110.371 -179.747 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 66.5 mtt . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.448 ' OE1' ' N ' ' A' ' 2' ' ' GLU . 1.1 mp0 49.5 63.0 11.01 Favored Pre-proline 0 CA--C 1.534 0.341 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.623 -179.996 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 86.8 Cg_endo -76.67 10.63 2.18 Favored 'Trans proline' 0 N--CA 1.495 1.561 0 C-N-CA 122.501 2.134 . . . . 0.0 111.72 -179.818 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 20.8 p -76.45 72.24 3.15 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.041 0.448 . . . . 0.0 110.18 -179.537 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.405 ' O ' ' O ' ' A' ' 6' ' ' PHE . . . -165.39 -84.13 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.802 179.641 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.405 ' O ' ' O ' ' A' ' 5' ' ' ALA . 6.2 m-85 55.62 110.51 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.324 0 CA-C-O 121.025 0.44 . . . . 0.0 110.116 -179.891 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 70.0 m -87.29 -177.9 6.07 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.203 179.647 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.06 -33.41 87.18 Favored Glycine 0 CA--C 1.527 0.841 0 N-CA-C 111.367 -0.693 . . . . 0.0 111.367 -179.76 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 22.9 t -71.65 -3.21 20.37 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.561 0.22 . . . . 0.0 111.072 -179.325 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 21.9 p-10 -67.18 147.92 52.46 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.685 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.456 HG23 ' O ' ' A' ' 11' ' ' VAL . 29.7 m -131.32 120.26 17.94 Favored Pre-proline 0 CA--C 1.542 0.647 0 N-CA-C 110.105 -0.331 . . . . 0.0 110.105 179.671 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 87.0 Cg_endo -76.57 148.26 29.2 Favored 'Trans proline' 0 N--CA 1.49 1.274 0 CA-C-N 120.371 1.168 . . . . 0.0 112.103 -179.822 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 73.0 ttp85 -154.58 121.51 5.55 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.556 179.888 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 89.2 mt -69.47 121.61 82.81 Favored Pre-proline 0 CA--C 1.543 0.676 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.781 -179.331 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_endo -76.3 159.84 36.3 Favored 'Trans proline' 0 N--CA 1.495 1.575 0 C-N-CA 121.557 1.505 . . . . 0.0 112.009 -179.802 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 90.9 mtt-85 -57.14 153.47 11.67 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.738 -179.828 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 80.49 16.5 75.69 Favored Glycine 0 CA--C 1.523 0.576 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 179.786 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.547 ' CG1' HD11 ' A' ' 31' ' ' LEU . 58.1 t -133.82 132.46 56.69 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 CA-C-O 120.849 0.357 . . . . 0.0 110.099 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 90.8 mtm180 -135.11 155.88 49.96 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.296 -179.703 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 25.0 mt -96.3 101.28 12.9 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.072 -179.835 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.472 ' NH1' ' OG1' ' A' ' 37' ' ' THR . 82.4 mtm180 -92.1 139.95 30.12 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.108 179.514 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.474 ' O ' ' CD1' ' A' ' 22' ' ' PHE . 44.2 p90 -105.0 118.09 35.65 Favored 'General case' 0 N--CA 1.469 0.48 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.129 179.751 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 93.7 m-20 -89.26 100.17 13.01 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.003 -179.768 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -63.9 -37.37 87.16 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.508 -179.885 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 3.1 m -62.9 -43.57 99.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.598 -179.484 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 96.5 mtt180 -90.33 -7.68 52.7 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-O 120.921 0.391 . . . . 0.0 110.403 179.68 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 54.62 36.59 26.35 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.088 179.681 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 19.2 ptmt -145.12 158.47 43.81 Favored 'General case' 0 N--CA 1.468 0.442 0 N-CA-C 110.015 -0.365 . . . . 0.0 110.015 179.57 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 80.3 m80 -93.66 149.49 21.19 Favored 'General case' 0 C--N 1.329 -0.284 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 179.584 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 30.4 m -137.17 156.9 34.65 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-N 116.077 -0.51 . . . . 0.0 109.907 -179.911 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.547 HD11 ' CG1' ' A' ' 18' ' ' VAL . 37.9 tp -102.28 121.3 42.01 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.157 179.841 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 51.4 tp -76.87 99.85 5.34 Favored 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 179.226 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -96.52 144.84 28.53 Favored Pre-proline 0 CA--C 1.538 0.491 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.417 -179.489 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_exo -46.27 -37.46 18.74 Favored 'Trans proline' 0 N--CA 1.495 1.564 0 C-N-CA 121.26 1.307 . . . . 0.0 112.435 179.129 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -71.17 -42.64 68.83 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.887 -178.644 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 15.8 ptm180 -174.95 -120.03 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.504 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.536 -179.765 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.472 ' OG1' ' NH1' ' A' ' 21' ' ' ARG . 93.2 m -155.14 128.64 8.46 Favored 'General case' 0 C--N 1.333 -0.138 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 179.678 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -100.55 132.2 46.06 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.543 -179.355 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 40.3 p-10 -70.9 120.5 16.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.354 179.664 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 93.0 mt -133.67 159.52 40.26 Favored 'General case' 0 N--CA 1.472 0.673 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.261 -179.799 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -85.46 154.97 21.45 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.363 -179.66 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 48.9 t0 -57.98 -40.48 80.75 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.25 -179.847 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 97.6 m-20 -63.86 -39.32 93.93 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.39 -179.773 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.03 -40.16 78.78 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.66 -0.245 . . . . 0.0 111.307 -179.159 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 56.8 t -79.09 -29.94 14.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 CA-C-O 120.708 0.29 . . . . 0.0 110.662 -179.834 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -55.17 -35.67 65.04 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.388 -179.558 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 96.1 t -60.85 -46.57 96.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.528 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 42.6 mt -74.97 -17.87 60.47 Favored 'General case' 0 N--CA 1.462 0.152 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.633 -178.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 35.6 ttpt -90.54 -34.37 15.55 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.679 179.265 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 6.2 tp -70.35 -32.17 69.76 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.942 -178.753 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.408 HG13 ' O ' ' A' ' 51' ' ' VAL . 10.2 p -73.31 126.34 33.83 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-O 120.879 0.371 . . . . 0.0 110.583 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -71.77 -45.32 62.02 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.6 179.608 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -142.49 -102.73 0.45 Allowed Glycine 0 N--CA 1.472 1.048 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 89.6 mtm180 -114.63 105.01 12.56 Favored 'General case' 0 N--CA 1.471 0.585 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 179.052 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 96.4 m-20 -116.84 149.72 39.57 Favored 'General case' 0 N--CA 1.473 0.721 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.37 178.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 39.5 p -79.69 140.9 36.85 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 178.727 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.433 HG23 ' N ' ' A' ' 58' ' ' SER . 31.1 m -53.8 -38.8 36.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.755 0.312 . . . . 0.0 110.6 -179.765 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . 0.433 ' N ' HG23 ' A' ' 57' ' ' VAL . 54.2 m -57.47 -44.39 84.8 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.719 179.706 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 50.7 tt0 -65.36 -47.38 76.61 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.695 -179.708 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 66.5 mt -60.78 -42.57 92.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.195 -0.457 . . . . 0.0 109.773 179.846 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -53.53 -41.99 66.96 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.272 -179.33 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 96.4 mm-40 -63.29 -54.62 34.35 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 120.762 -0.375 . . . . 0.0 111.035 -179.742 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 69.3 mt -66.15 -49.04 79.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.767 0.318 . . . . 0.0 111.436 -179.03 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 24.8 tp -69.61 -37.72 76.98 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.903 -178.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -55.71 -42.12 84.38 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 110.796 -0.921 . . . . 0.0 110.796 -179.562 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 85.2 mt-30 -66.1 -30.19 70.65 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.605 0.24 . . . . 0.0 110.68 179.768 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 19.5 m -62.2 -45.35 93.75 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.758 0.313 . . . . 0.0 110.551 -179.644 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -90.26 1.96 55.95 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.541 179.674 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 66.1 t0 54.22 50.43 16.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.881 179.693 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -141.37 162.2 36.06 Favored 'General case' 0 N--CA 1.469 0.505 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.3 -179.729 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 72.7 m-20 -55.94 143.18 62.67 Favored Pre-proline 0 CA--C 1.54 0.583 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.555 -179.414 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -69.78 -31.58 20.17 Favored 'Trans proline' 0 N--CA 1.503 2.083 0 C-N-CA 122.51 2.14 . . . . 0.0 112.255 -179.603 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -53.74 -34.04 57.64 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.062 0.458 . . . . 0.0 110.613 -179.646 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 64.3 mt -68.58 -44.34 82.84 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.203 -179.569 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.561 ' N ' HD12 ' A' ' 75' ' ' ILE . 1.7 mp -62.07 -49.55 83.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 C-N-CA 120.933 -0.307 . . . . 0.0 111.26 -178.286 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -62.21 -45.59 92.67 Favored 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 120.143 -0.623 . . . . 0.0 110.225 -178.528 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.405 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -65.16 -24.07 67.29 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.36 179.55 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 65.8 t0 -78.41 -49.69 13.06 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-O 120.823 0.344 . . . . 0.0 111.157 -179.356 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 13.1 pt -74.31 -39.81 49.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.463 -179.407 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 9.1 mt -41.37 -60.41 1.82 Allowed Pre-proline 0 CA--C 1.549 0.919 0 CA-C-O 119.622 -0.228 . . . . 0.0 111.26 -179.693 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.405 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 46.8 Cg_endo -62.84 -29.98 77.07 Favored 'Trans proline' 0 N--CA 1.499 1.82 0 C-N-CA 122.0 1.8 . . . . 0.0 111.459 179.483 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 9.5 tpt -66.78 -40.6 88.24 Favored 'General case' 0 N--CA 1.462 0.168 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.483 -179.705 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 80.9 mt -62.2 -41.18 98.12 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.365 -179.129 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.22 -38.6 87.19 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 179.363 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -65.75 -40.22 95.6 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 111.166 -0.774 . . . . 0.0 111.166 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 92.6 mt -67.02 -38.59 86.2 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.843 0.354 . . . . 0.0 110.321 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -53.15 -35.91 60.27 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.839 0.352 . . . . 0.0 110.81 -179.671 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 86.9 mt-30 -61.73 -21.52 64.59 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.637 179.876 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 62.2 mttp -93.08 -5.17 50.99 Favored 'General case' 0 N--CA 1.467 0.419 0 CA-C-O 120.899 0.38 . . . . 0.0 110.048 -179.304 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 23.0 ttm180 65.54 22.46 11.79 Favored 'General case' 0 CA--C 1.531 0.229 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.597 179.5 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 19.5 m -96.1 -14.98 7.7 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.521 0 CA-C-O 120.777 0.322 . . . . 0.0 110.589 -179.748 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 39.6 tp -102.2 149.02 24.73 Favored 'General case' 0 N--CA 1.47 0.531 0 CA-C-O 121.253 0.549 . . . . 0.0 109.824 179.748 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -142.76 147.4 35.49 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.422 -0.808 . . . . 0.0 109.689 -178.829 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 7.8 tmm_? . . . . . 0 C--N 1.326 -0.451 0 CA-C-O 117.93 -1.033 . . . . 0.0 110.046 -179.407 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 15.6 ptt? . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -169.89 72.3 0.65 Allowed Pre-proline 0 C--N 1.326 -0.426 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.624 179.862 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.425 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 36.2 Cg_exo -59.82 155.21 44.85 Favored 'Trans proline' 0 N--CA 1.497 1.698 0 C-N-CA 122.544 2.163 . . . . 0.0 112.079 179.866 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.533 ' H ' ' HB1' ' A' ' 84' ' ' ALA . 14.6 t -76.17 -27.78 57.07 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.152 -179.87 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -162.55 -31.18 0.04 OUTLIER 'General case' 0 CA--C 1.528 0.114 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.419 -179.57 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.425 ' O ' ' CB ' ' A' ' 3' ' ' PRO . 36.0 m-85 -81.17 104.89 11.96 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-O 121.15 0.5 . . . . 0.0 110.653 -179.485 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 72.9 m -91.99 -172.89 3.31 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.581 179.417 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -66.83 -42.41 93.0 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 78.4 p -71.92 -21.21 61.66 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.78 0.324 . . . . 0.0 110.855 -179.691 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.466 ' OD2' ' NH2' ' A' ' 94' ' ' ARG . 91.3 m-20 -69.7 154.48 41.92 Favored 'General case' 0 C--O 1.233 0.188 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 179.863 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 28.6 m -128.82 128.63 23.46 Favored Pre-proline 0 N--CA 1.474 0.739 0 CA-C-O 119.67 -0.205 . . . . 0.0 110.728 -178.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -79.47 153.24 23.69 Favored 'Trans proline' 0 N--CA 1.494 1.528 0 C-N-CA 121.684 1.589 . . . . 0.0 111.81 179.743 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.421 ' NH1' ' OE2' ' A' ' 93' ' ' GLU . 60.8 ttp180 -154.28 128.55 9.06 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 116.037 -0.529 . . . . 0.0 109.707 178.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 93.0 mt -69.45 120.34 76.49 Favored Pre-proline 0 CA--C 1.545 0.77 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.205 -179.167 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.428 ' CD ' ' O ' ' A' ' 91' ' ' VAL . 95.1 Cg_endo -77.36 160.03 32.55 Favored 'Trans proline' 0 N--CA 1.498 1.75 0 C-N-CA 121.988 1.792 . . . . 0.0 112.074 179.444 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 43.1 ttm180 -57.31 151.57 15.76 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.132 179.276 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 82.59 14.79 75.12 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 111.108 -0.797 . . . . 0.0 111.108 179.719 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.2 t -133.2 131.16 58.26 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.444 0 CA-C-O 120.89 0.376 . . . . 0.0 109.998 179.682 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 81.3 mtm-85 -137.37 158.69 43.87 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.038 -179.651 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 15.1 mt -94.6 97.64 10.26 Favored 'General case' 0 N--CA 1.463 0.206 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.063 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 83.8 mtp180 -90.77 142.46 27.74 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.239 179.588 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 69.4 t80 -102.81 119.68 39.27 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.227 -0.442 . . . . 0.0 109.867 179.495 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.48 ' O ' ' N ' ' A' ' 27' ' ' ASN . 96.2 m-20 -86.72 96.28 10.1 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.998 -0.546 . . . . 0.0 109.712 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -62.65 -34.65 77.51 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.665 -179.76 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 1.7 p -60.63 -46.39 95.81 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.638 -179.361 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 94.3 mtt-85 -95.47 -6.17 41.29 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.69 -179.844 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.48 ' N ' ' O ' ' A' ' 23' ' ' ASP . 15.8 t-20 55.66 43.69 27.68 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.542 179.552 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -144.78 160.99 40.35 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-O 120.716 0.293 . . . . 0.0 110.571 178.905 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.452 ' HD1' ' CG ' ' A' ' 42' ' ' ASP . 77.2 m80 -94.12 143.85 26.01 Favored 'General case' 0 CA--C 1.519 -0.229 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 178.486 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 33.5 m -137.11 159.45 36.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.141 -0.481 . . . . 0.0 109.879 -179.447 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 6.0 tp -102.73 122.24 44.06 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 116.205 -0.452 . . . . 0.0 109.846 -179.902 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 44.4 tp -77.79 100.03 6.13 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 178.762 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -96.6 147.09 32.42 Favored Pre-proline 0 CA--C 1.539 0.532 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 -179.825 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_exo -48.62 -38.25 36.0 Favored 'Trans proline' 0 N--CA 1.497 1.682 0 C-N-CA 121.233 1.289 . . . . 0.0 112.743 179.217 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 79.3 tt0 -73.65 -52.15 14.33 Favored 'General case' 0 C--N 1.332 -0.186 0 C-N-CA 120.962 -0.295 . . . . 0.0 111.307 -178.394 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 43.6 ttm180 -175.87 151.99 1.18 Allowed 'General case' 0 N--CA 1.465 0.28 0 CA-C-O 120.964 0.412 . . . . 0.0 110.622 -179.788 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 58.0 m -68.79 133.34 48.19 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.407 179.267 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.404 ' CE2' ' NZ ' ' A' ' 89' ' ' LYS . 81.7 m-85 -106.49 137.62 44.15 Favored 'General case' 0 N--CA 1.472 0.629 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.596 -179.588 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 22.0 t0 -72.76 119.58 17.18 Favored 'General case' 0 C--N 1.333 -0.132 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.932 179.642 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 89.2 mt -134.53 157.37 46.7 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.007 -179.743 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 25.8 m-20 -84.86 161.41 19.9 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.421 -179.596 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.452 ' CG ' ' HD1' ' A' ' 29' ' ' HIS . 87.4 m-20 -60.59 -44.73 95.9 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.425 179.837 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 47.0 t30 -63.7 -35.66 81.28 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.625 -179.574 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -68.98 -44.86 72.04 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.185 -179.438 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 48.7 t -78.06 -25.32 14.2 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.197 0 CA-C-O 120.839 0.352 . . . . 0.0 110.333 -179.914 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.85 -31.55 64.9 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.194 -179.776 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 6.0 t -60.99 -46.34 96.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.893 -179.486 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 30.9 mt -76.37 -19.4 58.21 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.71 -179.027 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 33.6 ttpt -87.98 -34.54 18.03 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.671 179.509 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 5.4 tp -70.15 -32.55 70.58 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.03 -179.275 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 8.5 p -75.88 125.01 35.09 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-O 120.916 0.389 . . . . 0.0 110.696 179.849 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 97.5 m-20 -70.95 -45.64 63.81 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.384 179.579 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -139.89 -101.66 0.5 Allowed Glycine 0 N--CA 1.471 1.015 0 N-CA-C 110.448 -1.061 . . . . 0.0 110.448 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 90.7 mtm180 -115.02 104.69 12.15 Favored 'General case' 0 N--CA 1.47 0.572 0 CA-C-O 120.523 0.201 . . . . 0.0 110.527 179.252 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 96.7 m-20 -117.24 146.91 42.97 Favored 'General case' 0 N--CA 1.472 0.64 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 178.054 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 32.3 p -79.36 149.63 31.64 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 179.099 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.443 HG23 ' N ' ' A' ' 58' ' ' SER . 19.8 m -52.66 -40.32 33.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.829 0.347 . . . . 0.0 110.593 -179.559 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . 0.443 ' N ' HG23 ' A' ' 57' ' ' VAL . 33.5 t -59.36 -45.16 92.17 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.886 179.891 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 50.5 tt0 -64.48 -48.13 76.36 Favored 'General case' 0 N--CA 1.463 0.182 0 CA-C-O 120.804 0.335 . . . . 0.0 110.894 -179.355 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 65.5 mt -61.09 -42.64 93.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.002 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -53.38 -40.39 64.98 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.932 -0.576 . . . . 0.0 111.224 -179.336 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 94.7 mm-40 -63.26 -55.39 25.2 Favored 'General case' 0 C--N 1.33 -0.275 0 C-N-CA 120.813 -0.355 . . . . 0.0 110.98 -179.541 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 66.1 mt -66.75 -45.13 88.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.843 0.354 . . . . 0.0 110.652 -179.267 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 36.0 tp -66.77 -38.6 86.9 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.445 -179.537 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.462 ' O ' ' N ' ' A' ' 69' ' ' ASP . . . -57.64 -39.22 90.74 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 111.103 -0.799 . . . . 0.0 111.103 -179.667 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 87.7 mt-30 -65.84 -33.14 75.16 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.972 -0.291 . . . . 0.0 110.408 179.688 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 25.2 m -62.24 -47.24 85.25 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 120.789 -0.364 . . . . 0.0 110.547 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -94.66 -3.58 49.2 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.565 179.45 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . 0.462 ' N ' ' O ' ' A' ' 65' ' ' GLY . 61.6 t0 51.51 62.12 2.87 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.972 179.726 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -141.35 160.96 39.04 Favored 'General case' 0 N--CA 1.467 0.408 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.103 -179.735 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 58.7 m-20 -55.79 113.42 5.66 Favored Pre-proline 0 CA--C 1.546 0.802 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.364 -179.37 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_exo -49.06 -32.42 23.76 Favored 'Trans proline' 0 N--CA 1.5 1.877 0 C-N-CA 121.807 1.671 . . . . 0.0 112.656 179.56 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -52.05 -37.82 54.92 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.934 0.397 . . . . 0.0 111.61 -178.793 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 19.9 mm -80.24 -34.59 14.98 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.609 -179.785 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 46.5 mm -62.01 -46.56 96.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.963 -179.396 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -62.89 -44.53 95.86 Favored 'General case' 0 C--N 1.333 -0.124 0 C-N-CA 120.547 -0.461 . . . . 0.0 109.783 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.431 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -67.32 -18.45 65.18 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.758 -0.655 . . . . 0.0 111.147 179.472 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 61.1 t0 -80.8 -46.84 14.75 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-O 120.753 0.311 . . . . 0.0 111.031 -179.709 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 22.0 pt -78.16 -34.12 18.59 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.434 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.017 -179.665 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 7.9 mt -46.07 -60.26 3.78 Favored Pre-proline 0 CA--C 1.547 0.839 0 C-N-CA 121.015 -0.274 . . . . 0.0 111.097 179.639 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.431 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 38.6 Cg_endo -61.92 -28.84 81.44 Favored 'Trans proline' 0 N--CA 1.499 1.812 0 C-N-CA 122.126 1.884 . . . . 0.0 111.845 179.516 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 45.1 ttp -66.15 -42.34 89.16 Favored 'General case' 0 C--N 1.333 -0.114 0 C-N-CA 120.858 -0.337 . . . . 0.0 110.14 -179.855 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 91.8 mt -63.06 -42.78 99.78 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.486 -179.742 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.533 ' HB1' ' H ' ' A' ' 4' ' ' THR . . . -62.82 -38.34 90.32 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.048 -0.524 . . . . 0.0 109.913 179.633 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -64.75 -41.01 97.82 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 111.206 -0.758 . . . . 0.0 111.206 -179.763 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 88.5 mt -68.4 -36.99 79.93 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.036 0.446 . . . . 0.0 110.128 179.788 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -53.1 -36.83 61.14 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.582 -179.785 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 26.5 mt-30 -61.23 -23.3 65.54 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.529 179.659 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . 0.404 ' NZ ' ' CE2' ' A' ' 38' ' ' PHE . 68.2 mttm -93.73 -3.89 51.42 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.086 -179.742 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 35.3 ttm180 57.14 67.97 0.92 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.568 179.909 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . 0.428 ' O ' ' CD ' ' A' ' 15' ' ' PRO . 33.4 m -136.7 -0.38 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.985 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 95.0 mt -106.66 173.47 6.31 Favored 'General case' 0 CA--C 1.511 -0.534 0 CA-C-O 121.413 0.625 . . . . 0.0 110.333 179.525 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.421 ' OE2' ' NH1' ' A' ' 13' ' ' ARG . 79.9 tt0 -149.09 145.8 27.41 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 114.852 -1.067 . . . . 0.0 110.653 179.873 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . 0.466 ' NH2' ' OD2' ' A' ' 10' ' ' ASP . 16.6 ptm180 . . . . . 0 C--N 1.324 -0.533 0 CA-C-O 118.1 -0.952 . . . . 0.0 110.059 179.777 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 4.3 mmt . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 109.063 -0.718 . . . . 0.0 109.063 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 54.6 tt0 50.44 64.15 8.8 Favored Pre-proline 0 CA--C 1.534 0.34 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.598 -179.571 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 77.1 Cg_endo -74.93 169.55 22.37 Favored 'Trans proline' 0 N--CA 1.495 1.59 0 C-N-CA 122.374 2.05 . . . . 0.0 111.928 -179.572 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 16.2 p -78.5 86.07 4.55 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.273 -179.668 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.21 100.96 4.47 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.463 -179.837 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -79.48 139.59 37.57 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.436 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 67.0 m -93.32 -175.12 3.72 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.696 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -68.41 -38.8 87.35 Favored Glycine 0 CA--C 1.528 0.876 0 N-CA-C 111.277 -0.729 . . . . 0.0 111.277 179.764 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 18.1 m -71.3 -17.04 62.48 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.75 0.31 . . . . 0.0 110.832 -179.48 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -66.93 142.71 57.19 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 179.573 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.463 HG23 ' O ' ' A' ' 55' ' ' ASN . 1.4 p -129.73 120.78 19.73 Favored Pre-proline 0 CA--C 1.547 0.828 0 O-C-N 123.167 0.292 . . . . 0.0 110.264 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_endo -77.31 150.2 28.56 Favored 'Trans proline' 0 N--CA 1.492 1.435 0 C-N-CA 121.389 1.393 . . . . 0.0 111.472 179.407 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.453 HH22 ' CA ' ' A' ' 53' ' ' GLY . 59.4 ttt85 -149.57 139.68 22.11 Favored 'General case' 0 N--CA 1.467 0.422 0 N-CA-C 109.624 -0.509 . . . . 0.0 109.624 179.085 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 65.6 mt -71.32 118.15 63.4 Favored Pre-proline 0 CA--C 1.541 0.633 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.78 -179.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo -77.12 160.66 33.05 Favored 'Trans proline' 0 N--CA 1.494 1.507 0 C-N-CA 121.633 1.555 . . . . 0.0 111.994 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 9.4 ptm180 -53.94 148.46 10.5 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.627 179.887 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 82.71 8.28 86.22 Favored Glycine 0 CA--C 1.521 0.444 0 N-CA-C 110.913 -0.875 . . . . 0.0 110.913 179.593 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.559 ' CG1' HD11 ' A' ' 31' ' ' LEU . 43.6 t -132.9 124.3 50.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.46 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.655 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 84.2 mtp180 -138.22 157.96 45.24 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.153 179.563 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 33.2 mt -94.36 109.16 21.02 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.222 -179.69 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.575 ' HE ' HD13 ' A' ' 32' ' ' LEU . 91.5 mtt-85 -90.89 137.76 32.11 Favored 'General case' 0 CA--C 1.52 -0.194 0 CA-C-N 116.114 -0.493 . . . . 0.0 109.888 179.786 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 35.0 t80 -95.99 100.06 11.77 Favored 'General case' 0 C--N 1.332 -0.187 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 94.5 m-20 -89.16 90.18 8.26 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.022 -179.904 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -61.77 -34.68 76.3 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.144 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 1.7 m -63.26 -41.22 91.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.285 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -80.68 -17.3 51.57 Favored 'General case' 0 N--CA 1.463 0.195 0 N-CA-C 110.222 -0.288 . . . . 0.0 110.222 -179.71 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 6.7 t-20 71.0 12.5 7.01 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.044 -0.526 . . . . 0.0 111.135 179.568 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 20.9 pttp -145.03 163.09 35.28 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-O 120.989 0.424 . . . . 0.0 110.187 179.461 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 62.1 m80 -89.14 160.55 16.95 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.053 179.865 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 27.7 m -141.91 156.83 20.28 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.1 179.846 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.559 HD11 ' CG1' ' A' ' 18' ' ' VAL . 44.5 tp -100.67 124.62 46.53 Favored 'General case' 0 N--CA 1.465 0.297 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 179.296 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.575 HD13 ' HE ' ' A' ' 21' ' ' ARG . 38.8 tp -79.65 96.27 6.15 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 179.031 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -94.08 147.67 33.83 Favored Pre-proline 0 CA--C 1.538 0.504 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.767 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 77.6 Cg_exo -50.05 -37.58 47.89 Favored 'Trans proline' 0 N--CA 1.496 1.652 0 C-N-CA 121.527 1.485 . . . . 0.0 112.721 179.143 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 47.6 tp10 -74.33 -52.14 13.09 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.409 -0.36 . . . . 0.0 111.117 -178.253 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 60.8 ttp180 -175.5 153.79 1.54 Allowed 'General case' 0 N--CA 1.462 0.155 0 CA-C-O 120.848 0.356 . . . . 0.0 110.608 -179.591 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 68.3 m -67.54 130.83 44.28 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.219 178.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 76.7 m-85 -105.53 142.55 35.08 Favored 'General case' 0 N--CA 1.471 0.578 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.522 -179.733 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 38.4 t0 -73.71 117.25 15.27 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.758 179.257 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 20.6 mt -131.8 155.85 47.04 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.189 -179.527 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 26.0 m-20 -83.72 147.06 27.86 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.216 -179.552 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.467 ' OD1' ' N ' ' A' ' 43' ' ' ASN . 36.8 p-10 -60.07 -35.79 75.95 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.744 -179.773 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . 0.467 ' N ' ' OD1' ' A' ' 42' ' ' ASP . 16.1 p30 -63.73 -40.85 97.75 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.776 -179.73 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.462 ' N ' ' OD1' ' A' ' 43' ' ' ASN . . . -70.96 -38.97 72.8 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.702 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 94.9 t -78.09 -28.96 15.34 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.157 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -55.81 -36.8 67.84 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.238 -179.65 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 65.8 t -59.71 -47.17 92.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.462 -179.671 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 47.6 mt -71.27 -28.71 64.34 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.682 -179.354 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 34.8 ttpt -82.16 -28.33 32.2 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.126 -179.678 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 7.0 tp -69.63 -32.53 71.26 Favored 'General case' 0 N--CA 1.463 0.19 0 C-N-CA 120.647 -0.421 . . . . 0.0 110.359 -179.005 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 2.6 p -76.33 129.27 37.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 121.122 0.487 . . . . 0.0 110.354 179.184 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -69.39 -43.96 72.42 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.374 179.049 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.453 ' CA ' HH22 ' A' ' 13' ' ' ARG . . . -145.48 -95.24 0.18 Allowed Glycine 0 N--CA 1.473 1.103 0 N-CA-C 110.511 -1.036 . . . . 0.0 110.511 179.632 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 82.7 mtm-85 -114.9 104.84 12.32 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-O 120.865 0.365 . . . . 0.0 110.256 179.347 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.463 ' O ' HG23 ' A' ' 11' ' ' VAL . 96.6 m-20 -117.51 142.75 46.79 Favored 'General case' 0 N--CA 1.472 0.633 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.214 177.348 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 65.2 p -78.78 141.58 37.68 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 178.548 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.438 HG23 ' N ' ' A' ' 58' ' ' SER . 28.3 m -51.09 -38.31 18.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.893 0.378 . . . . 0.0 110.671 -179.492 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . 0.438 ' N ' HG23 ' A' ' 57' ' ' VAL . 60.2 m -58.47 -45.08 89.37 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.452 179.655 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 50.3 tt0 -66.21 -46.66 76.49 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.769 -179.777 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 66.7 mt -61.11 -42.91 95.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.058 -179.771 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.412 ' O ' ' N ' ' A' ' 65' ' ' GLY . . . -53.53 -39.19 64.48 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.206 -179.342 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 85.1 mm-40 -62.96 -53.44 54.05 Favored 'General case' 0 C--N 1.325 -0.467 0 C-N-CA 120.845 -0.342 . . . . 0.0 110.769 179.858 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 72.4 mt -65.16 -49.79 77.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.259 -179.203 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 23.3 tp -69.84 -37.06 76.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.691 -179.11 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.412 ' N ' ' O ' ' A' ' 61' ' ' ALA . . . -55.85 -42.2 85.42 Favored Glycine 0 CA--C 1.526 0.759 0 N-CA-C 110.945 -0.862 . . . . 0.0 110.945 -179.708 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 74.6 mt-30 -65.2 -31.0 71.95 Favored 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 121.106 -0.238 . . . . 0.0 110.535 179.711 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 19.4 m -62.27 -46.26 89.62 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.788 0.327 . . . . 0.0 110.544 -179.583 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -91.37 1.66 56.96 Favored 'General case' 0 N--CA 1.468 0.461 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.534 179.815 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 66.2 t0 53.94 51.97 13.76 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.784 179.689 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -142.19 159.0 43.1 Favored 'General case' 0 N--CA 1.468 0.459 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.212 -179.794 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 26.2 m-20 -55.95 143.83 60.31 Favored Pre-proline 0 CA--C 1.538 0.485 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.364 -179.321 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -66.34 -29.45 46.07 Favored 'Trans proline' 0 N--CA 1.502 1.971 0 C-N-CA 122.561 2.174 . . . . 0.0 112.307 -179.564 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -55.16 -36.41 65.8 Favored 'General case' 0 CA--C 1.515 -0.384 0 CA-C-O 121.218 0.533 . . . . 0.0 110.95 -179.106 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 34.5 mm -70.18 -44.26 78.09 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.868 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.157 -179.43 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.533 ' N ' HD12 ' A' ' 75' ' ' ILE . 1.7 mp -62.06 -51.89 67.07 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 CA-C-N 116.496 -0.32 . . . . 0.0 111.264 -178.704 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 15.9 pt-20 -59.49 -44.37 93.08 Favored 'General case' 0 C--N 1.326 -0.416 0 C-N-CA 120.402 -0.519 . . . . 0.0 110.079 -177.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.419 ' O ' ' CD ' ' A' ' 81' ' ' PRO . . . -67.52 -23.26 65.44 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.992 179.577 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 66.0 t0 -80.1 -46.82 15.81 Favored 'General case' 0 N--CA 1.471 0.612 0 CA-C-N 116.587 -0.279 . . . . 0.0 111.741 -179.318 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 15.8 pt -71.32 -41.14 74.13 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.455 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.054 -179.15 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 7.0 mt -42.31 -60.98 1.78 Allowed Pre-proline 0 CA--C 1.55 0.955 0 CA-C-O 119.621 -0.228 . . . . 0.0 110.863 179.445 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.419 ' CD ' ' O ' ' A' ' 77' ' ' ALA . 53.4 Cg_exo -40.22 -41.18 3.16 Favored 'Trans proline' 0 N--CA 1.491 1.374 0 C-N-CA 122.633 2.222 . . . . 0.0 112.204 177.773 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 10.8 tpt -65.37 -39.83 92.78 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.627 -178.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 41.6 mt -61.4 -39.44 90.72 Favored 'General case' 0 C--N 1.325 -0.499 0 C-N-CA 120.577 -0.449 . . . . 0.0 110.051 -179.303 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -63.31 -38.65 91.97 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.944 0.402 . . . . 0.0 110.063 179.211 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -69.07 -38.95 84.47 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 111.408 -0.677 . . . . 0.0 111.408 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 86.0 mt -66.42 -40.51 89.6 Favored 'General case' 0 C--N 1.326 -0.417 0 O-C-N 122.745 -0.268 . . . . 0.0 110.888 -179.668 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -53.74 -28.12 32.47 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.48 -0.327 . . . . 0.0 110.725 -179.768 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 94.7 mt-30 -63.08 -26.53 68.88 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.68 -179.858 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 46.1 mtmt -94.11 -1.98 53.47 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.497 -179.451 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 50.0 ttt180 65.29 23.01 12.13 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.567 179.385 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 23.8 m -95.18 -4.74 10.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.222 -179.891 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.524 HD13 ' N ' ' A' ' 93' ' ' GLU . 0.2 OUTLIER -109.06 121.58 45.44 Favored 'General case' 0 CA--C 1.533 0.324 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 -179.36 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.524 ' N ' HD13 ' A' ' 92' ' ' LEU . 12.8 pt-20 -101.31 174.49 5.96 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 115.869 -0.605 . . . . 0.0 109.992 179.539 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 73.1 ttp85 . . . . . 0 C--N 1.322 -0.592 0 CA-C-O 117.96 -1.019 . . . . 0.0 109.351 -179.853 . . . . . . . . 0 0 . 1 stop_ save_